Elucidation of the genetic etiology of hemostasis and thrombosis through family-based studies by Hinckley, Jesse
ELUCIDATION OF THE GENETIC ETIOLOGY OF HEMOSTASIS AND THROMBOSIS 
THROUGH FAMILY-BASED STUDIES 
By 
JESSE DARRELL HINCKLEY 















A thesis submitted to the 
Faculty of the Graduate School of the 
University of Colorado in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 




This thesis for the Doctor of Philosophy degree by 
Jesse Darrell Hinckley 
has been approved for the 







Tasha Fingerlin, Chair 













Hinckley, Jesse Darrell (Ph.D., Human Medical Genetics) 
Elucidation of the Genetic Etiology of Hemostasis and Thrombosis through Family-
Based Studies 




 Von Willebrand Factor (VWF) plays a key role in primary hemostasis by initiating 
platelet recruitment and adhesion and an indirect role in secondary hemostasis as the 
noncovalent chaperone of coagulation factor VIII (FVIII) in circulation. Larger blood 
components such as erythrocytes and leukocytes contribute to the etiology of 
hemostasis and thrombosis by displacing platelets and VWF toward the endothelium. 
 I first characterized an Amish pedigree with VWD type 2. Genome-wide linkage 
analyses identified candidate quantitative trait loci (QTL) of VWF and FVIII levels on 
chromosomes 6p22, 9q34 (ABO), and 16q11. I also replicated previously reported 
associations confirming STXBP5, SCARA5, STAB2, and TC2N as candidate QTL. 
 Secondly, I evaluated VWF single nucleotide polymorphisms (SNPs) as sources 
of genetic variation of VWF levels in the Amish pedigree. I replicated association with 
two SNPs in three replication cohorts (n=3,316). I also found significant differences of 
the minor allele frequency of five SNPs between VWD type 1 index cases (n=310) and a 
control cohort.  
 Thirdly, I mapped candidate QTL of complete blood count traits by genome-wide 
quantitative trait linkage analysis in the Amish pedigree. I identified four candidate loci 
with LOD scores above 2.0: 6q25, 9q33, 10p12, and 20q13. I also demonstrated that the 
most common causal variant of hereditary hemochromatosis was associated with 
common variation of complex erythrocyte traits. 
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 Fourthly, I characterized the novel VWF c.3911T>G mutation in a family that 
demonstrated phenotypic variability. Results demonstrated the extent of mutant VWF 
peptide incorporation into multimers may explain phenotypic variability in VWD patients. 
 Fifthly, I studied two families with inherited thrombocytopenias. Homozygosity 
mapping and analysis of platelet mRNA in a large Native American kindred identified 
NBEAL2 as the most likely cause of gray platelet syndrome. Whole genome sequence 
analysis in a family with autosomal dominant thrombocytopenia (THC2) identified 
MASTL and ANKRD26 as the most likely causal genes. 
 Taken together, these findings demonstrate the importance of multiple family-
based study strategies in elucidating the genetic etiology of hemostasis and thrombosis. 
The genes and candidate QTL reported herein provide the foundation for molecular 
biology experiments to further characterize the complex pathways that mediate 
hemostasis and thrombosis. 
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CHAPTER I 
HEMOSTASIS AND THROMBOSIS 
 
Significance 
Hemostasis and thrombosis are important physiologic processes that maintain 
the integrity of the circulatory system through multiple interacting pathways. Excessive 
bleeding and pathologic thromboembolism, dichotomous presentations of abnormalities 
in hemostasis and thrombosis, respectively, are significant medical issues worldwide, 
including in the United States. In addition to posing a significant financial burden on the 
healthcare system, both hemostasis and thrombosis may be permanently debilitating or 
fatal. In the United States approximately 14 million blood transfusions are administered 
each year, with subsequent risk of transfusion-related reactions such as anaphylaxis and 
sepsis. Menorrhagia (heavy menstrual bleeding), in particular, represents a significant 
cause of morbidity, with approximately 100,000 admissions per year to acute-care 
hospitals. Of those admissions, 82% result in hysterectomy, yet 50% of patients have no 
identified cause of bleeding1,2. Post-partum bleeding is a leading cause of maternal 
mortality and causes serious morbidity in developing countries3. Furthermore, mild 
bleeding and bruising are common in the general population in the absence of an 
identifiable bleeding disorder, and some symptoms overlap between patients with a 
bleeding disorder and normal controls4.  
Pathologic thrombotic events are also a common clinical presentation and a 
leading cause of death in the United States.  Venous thromboembolism (VTE), 
encompassing deep-vein thrombosis (DVT) and pulmonary embolism (PE), and 
myocardial infarction (MI) are two of the three most common presentations of 
cardiovascular disease (CVD). CVD affects an estimated 82.6 million American adults, 
and it is the most common cited underlying cause (32.8%) and contributing to cause 
1
(55.0%) of deaths reviewed in 20085. The estimated prevalence of coronary heart 
disease in the United States is 7.0%, with an incidence of 610,000 new MI and of 
325,000 recurrent MI annually. Approximately 15% of patients with MI will die due to the 
event. Furthermore, an estimated 1 million patients present each year with VTE, and 
approximately two-thirds of VTE-related deaths have an iatrogenic component, making 
VTE the most common preventable cause of death during hospitalization6. The overall 
stroke prevalence (hemorrhagic and ischemic) is an estimated 3%, with a prevalence of 
silent cerebral infarction ranging from 6 to 28%; approximately 795,000 individuals 
present with new or recurrent strokes annually5. Therefore, due to the prevalence of 
hemostatic and thrombotic pathology in our population, it is vital to better characterize 
the genetic etiology of key components of hemostasis and thrombosis in order to 
improve risk assessment and provide new hypotheses related to pathogenesis of 
excessive bleeding and pathologic thromboembolism. Furthermore, understanding the 
genetic basis of defects in hemostasis and thrombosis may yield new treatment insights. 
 
Background 
 The circulatory system consists of the cardiovascular and the lymphatic systems. 
The cardiovascular system is a closed system with regions of specialized endothelium 
that create zones of exchange between the blood and interstitial fluid. Blood is 
composed of various circulating cells, organic molecules, proteins, and salt suspended 
in aqueous plasma7. Cell types include erythrocytes which carry oxygen to and carbon 
dioxide from tissues, leukocytes which participate in the immune system, and platelets 
which function primarily to maintain vascular integrity. Complete blood counts (CBC) are 
one of the most commonly ordered clinical tests and are used to provide a global 
evaluation of the patient’s cellular blood components and to assess overall wellbeing. 
2
Standard CBC assays evaluate the quantification and size of erythrocytes, leukocytes, 
and platelets as well as several other erythrocyte traits. 
The integrity of the cardiovascular system is maintained by complex interactions 
of multiple biologic pathways that mediate a balance between hemostasis and 
thrombosis (Figure 1.1). At the site of endothelial damage, a thrombus is formed through 
platelet plug formation (primary hemostasis) and deposition of cross-linked fibrin fibrils 
as the result of the coagulation cascade (secondary hemostasis) to strengthen the 
platelet plug8. Von Willebrand factor (VWF) plays a key role in primary hemostasis by 
recruiting and activating platelets at the site of endothelial damage and by functioning as 
the noncovalent chaperone of coagulation factor VIII (FVIII), thus participating indirectly 
in secondary hemostasis. Additionally, hemostasis is tempered by multiple regulatory 
pathways to allow the circulatory system to be fluid yet dynamically primed to respond to 
hemostatic challenges. Each pathway is affected by environmental and genetic factors 
as well as by vascular and endothelial physiology. The convergence of these various 
pathways and components produces a finely balanced system that, when altered or 
deficient, results in excessive bleeding or pathologic thrombosis. 
 
Figure 1.1: Hemostasis and thrombosis 
Hemostasis and thrombosis are complex physiologic endpoints that result from the 
interaction of multiple biologic processes tempered by regulatory pathways. Each 




















Thrombus formation: VWF, FVIII, and platelets 
The main role of VWF in thrombogenesis is thought to be initiation of platelet 
adhesion as the foundation of the platelet plug9. At the site of endothelial damage, 
increased shear stress induces a conformational change in VWF from a globular state to 
an extended chain conformation that exposes intracellular domains essential for platelet 
plug formation10 (Figure 1.2). VWF binds exposed collagen in the extracellular matrix via 
the A3 domain11.  Immobilized VWF then transiently interacts with platelet glycoprotein 
Ibα (GPIbα) via the A1 domain to mediate platelet rolling and tethering12,13.  
GPIbα is part of the GPIB-IX-V membrane complex and is extended from the 
platelet surface by an O-glycosylated stalk, making it accessible for transient interactions 
with VWF14,15. However, VWF-GPIbα interactions do not occur at detectable levels in 
static conditions, as shear stress-induced unfolding of VWF occurs only under flofw 
conditions16,17. Though transient, the VWF-GPIbα interaction is able to withstand the 
high shear stresses of arterial flow18,19. This shear stress-induced activation of VWF 
localizes VWF-mediated thrombogenesis to regions of vascular injury. 
The VWF-GPIBα interaction stimulates platelet activation via protein kinase C 
and tyrosine kinases, resulting in elevated levels of cytosolic calcium and activation of 
phospholipase A2
18,20,21. Platelet rolling increases contact time with reactive components 
of the cellular matrix, leading to further platelet activation and integrin-mediated 
adhesion of platelets to form the base of the platelet plug12,16. Platelet activation and 
signal transduction in turn trigger activation of platelet GPIIb/IIIa. Fibrinogen, and to 
some degree VWF, act as ligands to bridge platelets via GPIIb/IIIa, forming platelet 
aggregates22. 
Native VWF is a globular protein in circulation and functions as a noncovalent 
chaperone for coagulation FVIII, protecting FVIII from rapid inactivation by activated 
protein C (APC) and FXa10,22. While FVIII levels are influenced by VWF levels, there is 
4
 
Figure 1.2: VWF, FVIII, and platelets in thrombogenesis 
VWF circulates in a globular form and chaperones coagulation FVIII. Platelets circulate 
in an inactive state with membrane-bound GPIbα extended to interact with VWF. VWF is 
also stored in platelet α-granules as well as endothelial Weibel-Palade bodies. At a site 
of endothelial damage, higher shear rates unfold and activate VWF, exposing domains 
that bind exposed collagen and platelet GPIbα. Unfolding also releases FVIII to 
participate in the coagulation cascade. Activated platelets and endothelial cells secrete 
VWF, increasing the local concentration. Adapted and reprinted from Clinics in 
Laboratory Medicine, Vol 29, Torres and Fedoriw, Laboratory Testing for von Willebrand 
Disease: Toward a Mechanism-Based Classification, Pages 193-228, Copyright (2009), 
with permission from Elsevier23.  
 
not a reciprocal dependency for the stability of VWF levels24. VWF may also traffic FVIII 
into storage vesicles to allow for rapid local increases in concentration to participate in 
hemostasis25. It is hypothesized that VWF may participate in the activation of FVIII by 
thrombin26. Upon VWF unfolding, released FVIII is able to participate in the coagulation 
cascade to organize a cross-linked fibrin clot in conjunction with the platelet plug. 
Though not directly involved in hemostasis and thrombosis, the viscosity of the 
blood and number of erythrocytes in circulation affect the extent of platelet adhesion to 
the vessel wall26. Erythrocytes contribute to the central layer of circulating blood, 
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displacing platelets and the VWF-FVIII complex to the boundary layer near the vessel 
wall. This hemorheologic effect is more pronounced at increased erythrocyte counts and 
at higher shear rates in arterial flow. Blood viscosity is also inversely proportional to 
shear stress, an important stimulus of VWF activation18. Given these unique interactions 
between VWF, FVIII, and common CBC traits, the work presented herein focuses on 
elucidating the genetic etiology of variation in VWF and FVIII levels as well as CBC traits 
including platelet count and erythrocyte count. Extremes in variation of each trait are 
causes of or risk factors for excessive bleeding or pathologic thromboembolism. Hence, 
a more complete understanding of the genetic etiology underlying trait variability will 
allow improved diagnostics and risk assessment. 
 
Von Willebrand factor 
 VWF is a large multimeric protein synthesized exclusively by endothelial cells 
and megakaryocytes27.  The VWF gene (MIM: 613160) spans 178 kilobases (kb) on 
chromosome 12p13 and is composed of 52 exons ranging from 40 base pairs (bp; exon 
50) to 1.3 kb (exon 28)28-30. Exon 1 encodes a signal peptide, exons 2-17 encode the 
VWF propeptide, and exons 18-52 encode the VWF monomer (P04275). The propeptide 
is composed of 741 amino acids and demonstrates internal homologies24. The VWF 
monomer also consists of four types of repeating domains that make up over 80% of the 
2,050 amino acid sequence: NH2-D1-D2-D’-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK-
COOH18,31,32. This suggests the VWF gene evolved from a series of gene segment 
duplications and exon shuffling. Genetic analysis of VWF is complicated by an 
unprocessed pseudogene located on chromosome 22 that duplicates the VWF gene 
sequence for exons 23-34 with 97% sequence homology (See Appendix A)33.  
Cell-specific expression of VWF is regulated by positive and negative regulatory 
elements spanning the transcription start site (TSS)34. Deletion analysis identified a 724-
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bp fragment spanning from -487 to +247, relative to the TSS of VWF, as the cell-specific 
promoter of VWF in endothelial cells. The minimal core promoter consists of bases -90 
to +22 and is not cell-specific. A strong negative regulatory element common to all cell 
types was mapped from bases -500 to -300. Downstream of the core promoter, 
mutational analysis of the positive regulatory region identified a GATA binding element 
that relieves inhibition only in endothelial cells, resulting in endothelial-specific 
expression of VWF. The VWF promoter also contains a GT repeat segment 2 kb 
upstream of the TSS that encodes a shear stress response element responsible for 
mediating an increase in gene expression in regions of high shear stress35. Thus, 
endothelial expression of VWF is not uniform throughout the vasculature with highest 
levels in regions of disturbed blood flow or steep shear stress gradients. Regulation of 
VWF expression in megakaryocytes is less understood. 
 In cell culture, COS-1 and CHO cells transfected with VWF expression constructs 
synthesize and process VWF, including dimerization, proteolytic processing of the 
propeptide, polymerization, and secretion via the constitutive pathway, suggesting VWF 
synthesis occurs by common cellular mechanisms26. Cysteine-rich domains at the amino 
and carboxy-terminal ends of the VWF monomer participate in formation of head-to-
head dimerization and tail-to-tail polymerization36. Within the endoplasmic reticulum, the 
VWF signal peptide is cleaved and VWF undergoes initial glycosylation events and 
dimerization24. These early glycosylation events are required for VWF dimerization and 
may protect VWF from degradation26,37. VWF is further processed in the Golgi apparatus 
by multiple glycosylation events. Carbohydrate moieties consistent with H antigens 
processed by the ABO blood system are also present on mature VWF37. Cleavage of the 
propeptide occurs in the trans-Golgi and secretory granules, though it is not required 
before multimerization of VWF.32 Glycosylated VWF dimers polymerize within the trans-
Golgi and secretory granules, and polymerization is arrested after secretion32. 
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 VWF is synthesized via constitutive and secretory pathways, generating 
monomers ranging in size from 0.5 to 20 million daltons32. The largest (high molecular 
weight) VWF multimers are the most biologically active, suggesting multivalency of 
binding sites is optimal for adhesion and bridging function of VWF in homeostasis22,38. 
High molecular weight VWF multimers are stored in specialized intracellular granules in 
endothelial cells and platelets (Weibel Palade bodies and α-granules, respectively) 
whereas constitutively secreted multimers have undergone less polymerization36. 
However, VWF released through the constitutive pathway consists of multimers of all 
molecular weights and contributes 95% of plasma VWF levels measured by laboratory 
assays32,39. Storage granule release is stimulated by endothelial stress, increasing the 
local concentration of high molecular weight VWF multimers40-42. VWF undergoes 
proteolytic cleavage in circulation under physiologic conditions, which is mediated in part 
by the metalloproteinase ADAMTS1322,36. As a result of cleavage, VWF multimer 
analysis by electrophoresis produces a characteristic banding pattern that distinguishes 
the most active high molecular weight multimers from smaller, less- effective multimers. 
 VWF protein domains exhibit specific binding activity that characterize their 
recognized functions: the D’ domain binds FVIII and heparin, the A1 domain binds 
platelet GPIbα and mimetic molecules such as botrocetin and ristocetin, the A3 domain 
binds fibril forms of collagen, and the C1 domain binds platelet GPIIb/IIIa18,23. Thus, VWF 
bridges the pathways of hemostasis and thrombosis as a noncovalent chaperone of 
FVIII and the initial binding partner of platelets to exposed subendothelial cellular matrix 
collagen (Figure 1.2). The D3 domain contains cysteine residues that participate in 
multimerization and the CK domain contains cysteine residues that participate in 
dimerization23. The A2 domain is the target cleavage site for ADAMTS1318. 
 In the clinical setting, VWF levels are assessed by an enzyme-linked 
immunosorbent assay (ELISA; VWF:Ag)43. The FVIII coagulation assay (FVIII:C) 
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contributes to the understanding of VWF levels in the clinical context due to their 
noncovalent relationship. The interaction of VWF with platelet GPIbα can be simulated 
using the antibiotic ristocetin which agglutinates formalin-fixed platelets in the presence 
of VWF (VWF:RCo). The VWF:RCo/VWF:Ag ratio is used to evaluate qualitative vs. 
quantitative VWF defects. Multimer distribution is analyzed by low-resolution agarose gel 
electrophoresis in order to evaluate the banding pattern for presence or loss of high 
molecular weight VWF multimers. 
Von Willebrand disease (VWD) is the most common inherited bleeding disorder 
with an estimated prevalence ranging from 0.8 to 1.3%44. The clinical presentation of 
VWD is characterized by mucocutaneous bleeding symptoms including epistaxis, 
gingival bleeding, and menorrhagia as well as easy bruising and bleeding upon 
significant challenge including tooth extraction, vaginal live births, surgeries, and minor 
traumas26. VWD is classified as quantitative (type 1 and 3) or qualitative (type 2) 
abnormalities of VWF (Table 1.1)45.   
VWD type 1 (OMIM: 193400) is characterized by mild deficiencies in VWF levels 
that may or may not result in a clinical phenotype. More than 100 mutations have been 
reported throughout the VWF promoter and coding region. The International Society on 










Type 1 ↓ ↓ ↓ Normal VWF transcription or transcript 
processing, secretion, clearance 
Type 2A ↓ ↓↓ ↓ Abnormal Dimerization or multimerization, 
secretion, increased ADAMTS13-
mediated cleavage 
Type 2B ↓ ↓↓ ↓ Abnormal Increased affinity for platelet 
GPIbα 
Type 2M ↓ ↓↓↓ ↓ Normal Decreased affinity for platelet 
GPIbα 
Type 2N ↓ ↓ ↓↓↓ Normal Decreased affinity for FVIII 
Type 3 ↓↓↓ ↓↓↓ ↓↓↓ Absent Null mutations 
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Thrombosis and Hemostasis Scientific Standardization Committee maintains a 
comprehensive database of VWF variants (http://www.VWF.group.shef.ac.uk). Proposed 
disease mechanisms include disruption of gene transcription or transcript processing, 
inefficient VWF secretion, and accelerated VWF clearance.  
VWD type 1 is a challenging diagnosis in the clinical setting because two-thirds 
of patients with moderately low VWF levels are asymptomatic or have minimal bleeding 
symptoms that are indistinguishable from the general population46. Though classically 
considered “monogenic,” type 1 mutations commonly exhibit incomplete penetrance and 
variable expressivity, even in families with a causal VWF mutation47. The majority of type 
1 mutations are inherited in an autosomal dominant pattern and have an estimated 
penetrance of 60%47. Approximately 37-45% of patients with mild VWD have no putative 
mutation in VWF48,49. Cases with no identifiable VWF mutation are likely due to 
previously unreported mutations or modifier gene variants (quantitative trait loci, QTL) 
involved in VWF biosynthesis and processing50. VWF mutations are likely to be found in 
cases with VWF:Ag <30IU/mL50. Mutations in VWF are also more likely to be found in 
patients with abnormal VWF multimer patterns51. 
VWD type 3 (OMIM: 277480) is a more severe quantitative deficiency, in which 
patients have markedly decreased or immeasurable VWF levels. Whereas type 1 
mutations demonstrate variable expressivity and incomplete penetrance, type 3 VWF 
mutations tend to generate null alleles that result in clinically significant bleeding47. 
Mutations are typically nonsense or frameshift mutations or large deletions that are 
inherited in an autosomal recessive pattern47,52. Of note, heterozygosity for type 3 
mutations is typically asymptomatic, and type 3 mutations are rarely if ever found in 
cases of VWD type 146,47,53.  Patients with VWD type 1 typically have VWF levels less 
than 50 IU/dL, whereas obligate carriers of type 3 mutations often have normal VWF 
levels53. Because VWF functions to chaperone FVIII in circulation, VWD type 3 patients 
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also have decreased FVIII levels and present with hemophilia-like muscle and joint 
hemorrhages in addition to classical VWD mucocutaneous bleeding46.  
Qualitative defects in VWF comprise VWD type 2 (OMIM: 613554). Mutations are 
typically missense mutations inherited in an autosomal dominant pattern46. Penetrance 
for the biochemical phenotype of low VWF levels is typically 100%, whereas penetrance 
for the clinical phenotype of bleeding is commonly much less with variable expressivity, 
even in families with a unifying causal VWF mutation. Pathomechanisms of mutations 
include defective dimerization and multimerization, impaired secretion of high molecular 
weight VWF multimers, increased ADAMTS13-mediated clearance, altered VWF-GPIbα 
or VWF-collagen interactions, and altered VWF-FVIII interactions54,55. VWD type 2 
mutations are further subdivided into types 2A, 2B, 2M, and 2N. Type 2A is 
characterized by selective loss of intermediate and high molecular weight multimers 
caused by defective dimerization or multimerization, impaired secretion, or increased 
clearance54-56. Type 2B mutations are generally gain-of-function mutations in the A1 
domain that increase the affinity of VWF for platelet GPIbα54,55,57,58. The gain-of-function 
A1 mutations result in increased clearance of high molecular weight VWF multimers 
bound to platelets at otherwise physiologic conditions. Conversely, type 2M mutations in 
the A1 domain result in decreased affinity or disruption of the GPIbα binding site leading 
to defective recruitment of platelets to the site of endothelial damage54,55. Type 2N 
mutations consist of mutations in the D’ and D3 domains of VWF and disrupt the FVIII 
binding domain54,55,59. 
 Recombination between the VWF pseudogene and VWF locus has been 
implicated as a source of pathogenic alleles in VWD60-66. Gene conversion is a form of 
homologous recombination where a donor sequence transfers genetic material to a 
highly homologous acceptor sequence in a unidirectional manner67. Evidence of multiple 
genetic changes within an exon consistent with the pseudogene sequence has 
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implicated gene conversion in familial cases of all VWD types, with an apparent 
pathogenic preference of conversion events encompassing exon 2862,65. Additionally, 
multiple genetic changes consistent with gene conversion have been identified in both 
patients and unaffected relatives, suggesting gene conversion is not always 
pathogenic66. 
The role of VWF in thrombogenesis is well-characterized. However, the 
significance of elevations in VWF levels in pathologic thromboembolic events is currently 
a topic of clinical interest.  Numerous studies reported high VWF levels in patients 
presenting with acute MI and established associations between elevated VWF levels 
and future risk of MI, as well as reinfarction and higher mortality rates68-74. At the time of 
clinical presentation, VWF levels are associated with increased incidence of major 
adverse cardiac events, including death75. High levels of VWF (VWF:Ag and VWF:RCo) 
are associated with lacunar infarct and ischemic stroke76-78. In patients with atrial 
fibrillation or acute coronary syndrome, elevated VWF levels are predictive of clinical 
outcome. Furthermore, elevated VWF levels are a risk factor for stroke and vascular 
events in patients with atrial fibrillation79. In the general population associations have 
been reported between VWF levels and the risk of future cardiovascular events and 
stroke as well as future coronary artery disease75,79. The role of VWF in vascular disease 
may be amplified by other disease, including type 2 diabetes mellitus80. VWF levels are 
also associated with cardiovascular disease and are an independent risk factor of CVD 
in patients with insulin resistance or type 2 diabetes mellitus80,81. 
 
FVIII and the coagulation cascade 
 Coagulation factors are circulating zymogens activated by a cascade of stepwise 
limited proteolysis events to serine proteases that ultimately result in deposition of a 
cross-linked fibrin clot (Figure 1.3)82. The penultimate step activates prothrombin to 
12
thrombin, and thrombin then coverts fibrinogen, a soluble protein, into fibrin monomers 
that polymerize to form an insoluble clot. By convention the coagulation cascade divided 
into the intrinsic pathway, extrinsic pathway, and common pathway. Many zymogen 
activations require cell membrane phospholipids as a cofactor. This brings activated 
coagulation factors into close proximity to form complexes such as TF-FVIIa, FXa-FVIIIa, 
and FXa-FVa (prothrombinase). 
Tissue factor (TF) is a type I integral membrane receptor that is expressed 
constitutively on several cell types83. At the site of vascular injury, TF binds circulating 
 
Figure 1.3: The coagulation cascade 
The coagulation cascade is a series of stepwise limited proteolysis events that convert 
inactive circulating zymogens to serine proteases. Inactive isoforms are traditionally 
denoted by Roman numerals and active isoforms are denoted by “a” following the 
Roman numeral. By convention, the coagulation cascade is divided into the intrinsic 
pathway consisting of FXII, FXI, FIX, and FVIII; the extrinsic pathway consisting of tissue 
factor (TF) and FVII; and the common pathway consisting of FX and FV which form the 
prothrombinase complex, prothrombin (FII), fibrinogen, and FXIII. Cleavage of fibrinogen 
by thrombin releases fibrin monomers that are covalently cross-linked by FXIIIa to form 
an insoluble clot. 
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FVII in a one-to-one complex and functions as a cofactor in the activation of FVII by 
limited proteolysis in a calcium-dependent manner82,84. The TF-FVIIa complex then 
activates FX, the first zymogen in the common pathway82. TF is an important cofactor for 
the activation of both FVII and FX and accelerates both cascade steps85. FXa forms a 
one-to-one complex with FVa, constituting the prothrombinase complex with calcium 
ions and phospholipids82,86. FVa increases the Vmax of prothrombin activation by 1,000-
fold and the phospholipid component reduces the Km 1,400-fold
82,87. In addition to 
activating fibrinogen to free fibrin monomers, thrombin also activates FV, FVIII, and FXIII 
as well as regulatory protein C and protein S82. Thrombin cleaves fibrinogen to generate 
fibrin monomers A and B which cross-link through side-to-side overlapping88-90. When 
activated, fibrin acts as a cofactor with thrombin to activate FXIII82,91. FXIIIa then forms 
covalent cross-links between overlapping fibrin monomers82. 
 At low concentrations TF-FVIIa complex also activates FIX, a component of the 
intrinsic or contact pathway82,92,93. FIXa complexes with FVIIIa, calcium ions, and 
phospholipids to activate FX82. The FVIII zymogen circulates in complex with VWF and 
is released upon VWF unfolding at the site of endothelial damage94. As are other 
coagulation zymogens, FVIII is activated by limited proteolysis, initially by FXa95-97. 
Thrombin also acts to cleave FVIII, generating a positive feedback loop to accelerate FX 
activation and thereby prothrombin activation82. FVIIIa functions as a cofactor for FIXa in 
a similar manner to FVa in the prothrombinase complex and increases the Vmax of FX 
activation by 200,000 fold82,98.  
 Fibrinolysis is a complementary cascade of zymogen activations that culminates 
in the activation of plasminogen to the serine protease plasmin82. Thrombin stimulates 
endothelial cells to secrete tissue-type plasminogen activator (tPA)99. Fibrin binds tPA 
and plasminogen and functions as the cofactor in the activation of plasminogen to 
plasmin100. Plasmin then functions to dissolve fibrin clots. Furthermore, there are several 
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inhibitors of coagulation that localize clot formation to the site of damage: tissue factor 
pathway inhibitor (TFPI) inhibits the TF-FVIIa complex and FXa101,102, FXII is inhibited by 
C1 inhibitor103, FXI is inhibited by α1-antitrypsin
104, and FX is inhibited by Z protease 
inhibitor105. Antithrombin III inhibits thrombin, FIXa, FXa, and FXIa by forming one-to-one 
complexes of the inhibitor and serine protease82. The rate of sequestration is effectively 
immediate in the presence of the drug heparin. Thrombin substrate specificity is altered 
by thrombomodulin, an endothelial cell membrane protein, from procoagulant proteins 
fibrinogen and FX to anticoagulant proteins C and S82. APC complexes with protein S, 
calcium ions, and phospholipids and inactivates cofactors FVa and FVIIIa by proteolysis 
to significantly slow the activation of FX and prothrombin97,106,107. 
 F8 (MIM: 300841), which encodes the FVIII zymogen, is 186 kb in length, 
consists of 26 exons, and maps to chromosome Xq28108. F8 mRNA has been detected 
in multiple tissues, but liver transplant cures FVIII deficiency, indicating the importance of 
the liver as the primary site of FVIII synthesis109. The 9,000 nucleotide transcript 
encodes a 2,332 amino acid peptide with a 19 amino acid leader sequence 
(P00451)110,111. The resulting peptide is cleaved a second time during processing and 
circulates as a two-chain molecule. FVIII has two types of internal homology in triplicated 
repeats that are also homologous to FV and ceruloplasmin97,108,111,112. As with 
ceruloplasmin, copper is bound to processed and secreted FVIII, but the role of copper 
remains unclear113,114.  
Hemophilia A, which accounts for 80% of hemophilia cases, is diagnosed in 1 in 
5,000 live male births115. Most cases of hemophilia A are caused by single-base 
mutations in F8 that result in impaired biosynthesis, secretion, or stability, resulting in 
quantitative deficiencies of FVIII116. Additional mutations have been reported that result 
in functional or qualitative defects of FVIII116-120. Approximately one-third of cases are 
sporadic and caused by de novo mutations121,122. Less than 5% of cases are caused by 
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large indels or rearrangements123-125. However, approximately 50% of all cases of severe 
hemophilia A are caused by an inversion in intron 22. Most deletions are thought to be 
caused by nonhomologous recombination126. Unlike the discrepancy between VWF 
levels and bleeding in VWD, bleeding severity usually correlates well with FVIII levels in 
hemophilia127. In addition to hemophilia, combined FV-FVIII deficiency (OMIM: 613625) 
causes low FVIII levels in an autosomal recessive pattern. The first mutations described 
were identified in the gene LMAN1 (MIM: 601567), previously called endoplasmic 
reticulum intermediate Golgi compartment-53 (ERGIC53)128. Additional mutations in 
MCFD2 (MIM: 607788), an ERGIC component that associates with LMAN1, have also 
been identified as putative causes of combined FV-FVIII deficiency. 
While low levels of FVIII cause excessive bleeding, elevated levels of FVIII are 
associated with increased risk and recurrence of pathologic thromboembolic events 
including VTE129,130. Elevated FVIII:C is also associated with higher incidence of arterial 
thrombotic events as well as with incidence of ischemic stroke77,81,131. In women with 
type 2 diabetes mellitus, elevated FVIII levels were associated with cardiovascular 
disease132. However, this association may be due to the role of FVIII as an acute phase 
reactant and the significance of elevated FVIII levels as a risk factor for thrombotic 
events remains unclear. In a large Austrian cohort, FVIII:C levels were associated with 
all-cause mortality with a stronger association in women133. 
 
Environmental and genetic etiology of VWF and FVIII 
Among the general population VWF levels exhibit a high degree of variability, 
ranging from 50 to 200 IU/dL134-136. Even in families with a single VWF mutation that 
causes VWD, variable expressivity and incomplete penetrance are often noted, but the 
mechanism of variation has yet to be elucidated47. Furthermore, normal variation of 
VWF:Ag overlaps with the distribution of VWF:Ag in patients with VWD, which 
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complicates diagnosis and risk stratification. Elucidation of the environmental and 
genetic etiology underlying VWF and FVIII variation may provide clinical insight for the 
diagnosis of VWD, as well as risk stratification for excessive bleeding and pathologic 
thrombosis47. Identification of genetic risk factors will allow classification of individuals as 
high-risk due to persistently elevated levels as opposed to individuals with 
environmentally-acquired elevations in VWF:Ag or FVIII:C137. Genetic variants may also 
explain incomplete penetrance and variable expressivity of VWF mutations138-143. 
VWF:Ag and FVIII:C are highly correlated traits144; thus, it is feasible that environmental 
and genetic components may modify both traits through their noncovalent relationship. 
Several environmental modifiers have been described that influence hemostasis 
and thrombosis. Diet is an important environmental factor that affects both platelet plug 
formation and the coagulation cascade145. FVIII and VWF levels also differ by ethnicity 
and gender, with higher FVIII and VWF levels in African Americans than 
Caucasians144,146-148. FVIII levels are higher in women than men in both ethnic groups, 
whereas VWF level gender differences were demonstrated only in African-American 
individuals144. Age and body mass index are also strong covariates of VWF levels149. It is 
thought that age mediates a secondary effect of FVIII:C through its interaction with 
VWF150. 
A significant genetic variance component has been reported for both VWF:Ag 
and FVIII:C. Twin studies demonstrate that an estimated 66-75% of the variability in 
VWF levels is heritable, whereas pedigree analyses estimate a genetic variance 
component of 0.25-0.32150-153. Similarly, twin studies report a heritability estimate of 0.57-
0.61 for FVIII:C, whereas pedigree analyses report a more conservative estimate of 
0.40150,151,153. Though heritability calculations are population-specific, pedigree studies 
consistently generate lower heritability estimates for hemostatic proteins than twin 
studies, which is more pronounced for heritability estimates of VWF antigen levels137. 
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Elucidating QTL that influence VWF and FVIII levels is important to understand the 
underlying physiology of phenotypic variation. 
 VWF is a highly polymorphic gene with over 1,100 single nucleotide 
polymorphisms (SNPs), of which more than 150 are exonic or in closely flanking intronic 
sequence154. The contribution of these SNPs in isolation or as part of a functional allelic 
unit remains to be elucidated. Because sequencing VWF would be cost-prohibitive, we 
proposed to study VWF haplotypes as a functional unit to evaluate the contribution of 
allelic heterogeneity to the variability of VWF levels. Recently, apparently silent 
polymorphisms have been demonstrated to affect VWF levels and even to cause VWD 
type 1155. Allelic variants in VWF which are not sufficient to cause VWD but can 
modulate VWF levels and activity have also been reported156.  
The ABO locus, which determines blood type, is the best-characterized QTL of 
VWF levels, accounting for up to 30% of the genetic variability of VWF and, by 
extension, FVIII levels37,136,150. The effect of blood type is large enough to mitigate known 
variants within the VWF gene previously associated with VWF:Ag levels157. Individuals 
with type O blood have the lowest mean VWF:Ag level (74.8 IU/dL) and individuals with 
type AB blood have the highest mean VWF:Ag level (123.3 IU/dL)136. Type O blood is 
overrepresented in cohorts with VWD type 1 and other blood types are 
underrepresented. ABO genotyping provides a more accurate representation of the 
influence of ABO on VWF:Ag by identifying individuals heterozygous for the inactive 
(type O) H transferase allele158.  Multimeric analysis of VWF indicated that subjects with 
type O blood exhibited higher rates of proteolysis than for non-O blood types 
(O≥B>A≥AB) with preferential loss of high molecular weight VWF multimers, suggesting 
that processed H antigens protect VWF from rapid clearance37. Other components of the 
ABO system have been implicated as QTL that affect VWF and FVIII levels, including 
the secretor locus and the Bombay blood group159-165.  
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Agnostic genome-wide linkage and association analyses have been published 
reporting multiple QTL that affect VWF and FVIII levels, including the Genetic Analysis of 
Idiopathic Thrombophilia (GAIT) study linkage analysis134, the Framingham Heart Study 
(FHS) linkage and association studies166, the Cohorts for Heart and Aging Research in 
Genome Epidemiology (CHARGE) Consortium meta-analysis167, and a meta-analysis of 
3 French-Canadian cohorts (MARTHA)168. Candidate QTL identified by association and 
by linkage are presented in Table 1.2 and in Table 1.3, respectively. 
Table 1.2: VWF and FVIII candidate QTL by association 
Chr. Phenotype SNP P-value Gene Study 
2p23.1 FVIII rs6708166 1.30x10-6  MARTHA 
3q27.2 VWF rs4686760 1.08x10-6 VPS8 (intergenic) MARTHA 
5q22.2 VWF rs13361927 4.51x10-6 EPB41L4A MARTHA 
5q22.2 VWF rs379440 9.82x10-7 EPB41L4A MARTHA 
6p22.1 VWF rs9295740 2.8x10-5  FHS 
6p22.1 VWF rs202906 2.1x10-5  FHS 
6q14.1 FVIII rs1321761 9.54x10-6  MARTHA 
6q15 VWF rs6454764 5.12x10-6 ANKRD6 MARTHA 
6q24 VWF rs9390459 1.2x10-22 STXBP5 CHARGE 
6q24 FVIII rs9390459 6.7x10-10 STXBP5 CHARGE 
8p21 VWF rs2726953 1.3x10-16 SCARA5 CHARGE 
8p21 FVIII rs9644133 4.4x10-15 SCARA5 CHARGE 
9q21.31 VWF rs1757948 7.37x10-6  MARTHA 
9q34.2 VWF rs687621 <5.0x10-324 ABO CHARGE 
9q34.2 FVIII rs687249 <5.0x10-324 ABO CHARGE 
9q34.2 FVIII rs12344583 7.92x10-6 VAV2 MARTHA 
12p13 VWF rs1063857 1.7x10-32 VWF CHARGE 
12p13 FVIII rs1063856 3.6x20-9 VWF CHARGE 
12q21.33 VWF rs1438993 6.25x10-6  MARTHA 
12q21.33 VWF rs10745527 5.43x10-6  MARTHA 
12q21.33 VWF rs2579103 7.61x10-6  MARTHA 
12q23 VWF rs4981022 7.3x10-10 STAB2 CHARGE 
12q23 FVIII rs122299292 7.2x10-9 STAB2 CHARGE 
12q23.3 FVIII rs7306642 2.95x10-6 STAB2 MARTHA 
12q24.3 VWF rs7978987 3.8x10-11 STX2 CHARGE 
12q24.33 VWF rs708356 1.5x10-5  FHS 
13q13.3 VWF rs7319671 3.6x10-5  FHS 
14q32 VWF rs10133762 2.3x10-10 TC2N CHARGE 
17q11.2 FVIII rs1354492 2.41x10-6 ACCN1 MARTHA 
17q11.2 FVIII rs12941510 5.67x10-6 ACCN1 MARTHA 
18q12.1 VWF rs1954971 1.0x10-5  FHS 
18q12.1 VWF rs2298574 5.67x10-6 CDH2 MARTHA 
19p13.2 VWF rs868875 1.3x10-9 CLEC4M CHARGE 
19p13.3 VWF rs732505 9.38x10-6  MARTHA 
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             Table 1.3: VWF candidate QTL by linkage 
Chromosome Phenotype LOD Gene Study 
1p36.13 VWF 1.48  GAIT 
3p25.3-p24.2 VWF 2.1  FHS 
2q23.2 VWF 1.84  GAIT 
5q31.1 VWF 1.27  GAIT 
6p22.3 VWF 1.4  GAIT 
9q34.2 VWF 3.46 ABO GAIT 




 First described in the late 1800s, platelets are small discoid subcellular fragments 
that circulate in a resting state169. At the site of vascular injury, platelets activate, 
undergoing a dynamic transformation, and form the bulk of the thrombus to stop 
bleeding. Platelets are derived from megakaryocytes by thrombopoiesis at a rate of 
approximately 1011 platelets per day and have a circulating lifespan of about 7-10 
days170-172. The small size and high concentration results in platelets being displaced in 
circulatory flow (hemorheologic effect) to patrol the cardiovascular endothelium 
efficiently throughout the body. 
 Megakaryocytes are polyploid myeloid cells that each give rise to hundreds of 
platelets173-177. Thrombopoietin, a glycoprotein produced primarily in the bone marrow, 
liver, and kidneys, is the most potent regulator of thrombopoiesis and promotes the 
expansion of all hematopoietic stem cells and progenitor cells with megakaryocytic 
potential178. Thrombopoietin-induced thrombopoiesis is autoregulated by high-affinity 
platelet receptors that sequester the hormone178,179. Hence, when platelet counts are 
low, more thrombopoietin is available to stimulate megakaryocytes and when platelet 
counts are replenished, thrombopoietin is sequestered and thrombopoiesis slows.  
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The process of platelet formation and release is complex and many steps remain 
unclear. Megakaryocytes extend long intermediate proplatelet formations that are 
continuous with the megakaryocyte cytoplasm in a microtubule-dependent manner180-182. 
Mature platelets are found only at the ends of protruding proplatelet formations, and the 
proplatelet microtubule network functions to traffic granules and organelles to nascent 
platelet buds182. Repeated bending and bifurcation of the proplatelet projection 
generates proplatelet ends in an actin-dependent manner. Filamin, a protein that 
crosslinks actin filaments, also connects the actin cytoskeleton with platelet GPIbα. 
Filamin-GPIbα complexes are abundant within the platelet and each actin filament is 
linked an average of six times to GPIbα170. Based on clinical observation in patients with 
Bernard-Soulier syndrome, these filamin-GPIbα complexes appear to be necessary for 
normal platelet formation170,183,184. When bound to VWF, this actin-filamin-GPIbα 
interaction initiates intracellular signaling and platelet activation185,186.  
Early observations by electron microscopy noted the ability of platelets to 
radically change shape187,188. Platelet activation is a dynamic process that includes rapid 
shape change, translocation of proteins to the cell membrane, and degranulation and 
exocytosis of cellular vesicles189. Actin is an abundant platelet protein that forms a 
complex network connected to the plasma membrane throughout the platelet170. In the 
resting state, actin polymerization is restricted by sequestration of the assembly ends of 
the filaments by capping proteins170,190. Upon activation, assembly ends are exposed 
and dynamic actin nucleation sites are organized191. Platelet activation also results in 
exocytosis of vesicles, α-granules (procoagulant proteins including VWF, fibrinolytic 
regulators, and other proteins), and dense granules (cell activating agents including ADP 
and calcium)189,192. Activated platelets release microvesicles that contain platelet 
transmembrane proteins including GPIbα and GPIIb/IIIa. Platelet degranulation releases 
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proteins and agents that amplify and regulate thrombotic response, recruit and activate 
cells, and initiate tissue remodeling and healing192. 
Congenital platelet disorders are classified as thrombocytopenias with otherwise 
normal platelet function and thrombocytopenias with thrombocytopathy193-200. 
Thrombocytopenias are caused by mutations in several genes that encode components 
of platelet structure and function (Figure 1.4). Thrombocytopenias with normal platelet 
function include autosomal dominant thrombocytopenia which demonstrates linkage to 
chromosome 10 (the THC2 locus; OMIM: 188000)201. Thrombocytopenias with  
 
Figure 1.4: Congenital thrombocytopenias 
Congenital thrombocytopenias are caused by mutations in genes that encode 
components underlying platelet structure and function. α:α-granules; δ: dense granules; 
L: lysosomes; G: G-protein coupled receptor; TxA2: thromboxane A2; GPS: gray platelet 
syndrome; QPD: Quebec platelet disorder; ARC: arthrogryposis, renal dysfunction, 
cholestasis syndrome; SPD: storage pool deficiency; CHS: Chediak-Higashi syndrome; 
HPS: Hermansky-Pudlak syndrome; VWD: von Willebrand disease; WASP: Wiskott-




thrombocytopathy include platelet storage pool disorders. The classic α-granule storage 
pool disorder gray platelet syndrome (OMIM: 139090) demonstrates little phenotypic 
variation, whereas dense granule storage pool disorders are heterogeneous192. Dense 
storage pool disorders may also present as part of syndromes, including Chediak-
Higashi syndrome (OMIM: 214500) and Hermansky-Pudlak syndrome (OMIM: 
203300)192,202,203.  
Platelets play an important role in atherosclerotic disease, including acute MI, 
peripheral artery disease, and stroke204. Baseline platelet count at the time of diagnosis 
is a strong predictor of reocclusion, reinfarction, and mortality even one year post-
infarct205. Elevated platelet counts are also associated with increased risk of  
fatal coronary heart disease206.  Both platelet count and mean platelet volume are 
independent risk factors for ischemic stroke, and platelet count demonstrates a 
significant negative correlation with hemorrhagic stroke207. Both low and high platelet 
counts are associated with non-cardiovascular mortality208. In certain cancers including 
breast and ovarian, higher platelet counts are associated with worse prognosis209. 
 Though platelet counts demonstrate a large range in the general population, the 
degree of intra-individual variation is much more modest, suggesting that platelet count 
is under strong genetic influence210-214. The largest study of serial platelet counts to date 
reported that the repeatability of platelet counts was 0.871 in male subjects and 0.849 in 
female subjects214. Twin studies estimate that the heritability of platelet count is as high 
as 0.80212,215-217. However, heritability estimates are population-specific, and some 
studies do not establish a significant genetic component216. Multiple studies also report 
that platelet function is a heritable trait, as evaluated by in vitro aggregation218-220. 
Several genome-wide studies have been conducted to map candidate QTL of CBC traits 
including platelet count. Table 1.4 presents candidate QTL reported for platelet count. 
For a comprehensive review of candidate QTL of other CBC traits, see Appendix B. 
23
      Table 1.4: Candidate QTL for platelet count 
Chromosome P-value Gene Study 
3q27.1 5.38x10-11 THPO-CHRD Kamatani et al. 2010221 
6p21.3 3.70x10-10 BAK1 Soranzo et al. 2009222 
6p21.31 6.66x10-11 BAK1 Kamatani et al. 2010221 
6p21.31 6.20x10-8 BAK1 Lo et al. 2011223 
6p21.31 7.60x10-73 BAK1 Lo et al. 2011223 
6q23.3 2.54x10-14 HBS1L-MYB Kamatani et al. 2010221 
9p24.1 2.95x10-13 RCL1 Kamatani et al. 2010221 
9p24.1 –p24.3 8.50x10-17 AK3 Soranzo et al. 2009222 
12q13.13 1.60x10-6 NFE2-COPZI Lo et al. 2011223 
12q24 2.20x10-13 ATXN2 Soranzo et al. 2009222 
12q24 7.70x10-12 PTPN11 Soranzo et al. 2009222 
12q24.12 4.75x10-19 SH2B3 Kamatani et al. 2010221 
17p13.2 2.13x10-12 GP1BA Kamatani et al. 2010221 
19p13.12 3.00x10-7 TPM4 Lo et al. 2011223 
19p13.12 3.00x10-7 TPM4 Lo et al. 2011223 
 
Objective 
 The objective of this dissertation is to further elucidate the genetic etiology of 
VWF, FVIII, and platelets through the study of human pedigrees. The first aim was to 
further characterize allelic variation of VWF. Subsequent chapters report identification 
and characterization of a novel VWF mutation (M1304R) and haplotype analysis of 
common variants in VWF. The second aim was to map candidate QTL of VWF and FVIII 
levels and CBC traits including platelet count in a large Amish pedigree. One approach 
to identifying QTL for complex traits like the aforementioned is to focus on a single large, 
culturally-isolated pedigree, in which it is reasonable to assume that the genetic 
component represents the common variation of an outbred population while being under 
the control of fewer QTL224,225. Thus, it is anticipated that related individuals with similar 
trait values will share a higher amount of genetic material identical by descent near the 
gene or genes that contribute to the quantitative trait. Additionally, genetic isolates 
demonstrate a more homogenous environmental component, whereas a collection of 
ancestrally unrelated smaller pedigrees tend to have more variable lifestyles. The third 
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aim was to identify genes involved in platelet biogenesis by mapping the putative 






ANALYSIS IN A MULTIGENERATIONAL AMISH PEDIGREE IDENTIFIES NOVEL 
CANDIDATE QTL THAT AFFECT VWF AND FVIII LEVELS AND REPLICATES 
GWAS QTL ASSOCIATIONS1  
 
Abstract 
 Von Willebrand disease (VWD) is the most common heritable bleeding disorder 
and is characterized by incomplete penetrance and variable expressivity. It is highly 
likely that modifier genes influence phenotypic variability.  We phenotypically and 
genetically characterized a 2,000-member Amish pedigree with VWD type 2. Sequence 
analysis of the VWF gene demonstrated heterozygosity for a missense mutation at 
position c.4120 (C>T) in 74 individuals that predicts an arginine to cysteine amino acid 
change at position 1374 (R1374C). The R1374C mutation disrupts the VWF A1 domain, 
resulting in defective binding to platelet glycoprotein 1bα. Distribution of VWF levels 
among pedigree members with the familial VWF mutation ranges three-fold between 
the maximum and minimum observation. Bleeding patterns also vary significantly. A 
primary genetic screen at an average interval of 10 cM was performed to search for 
candidate modifier loci. Genome-wide linkage analyses of VWF antigen levels 
(VWF:Ag), VWF ristocetin cofactor activity (VWF:RCo), and coagulation factor VIII 
(FVIII:C) levels were performed using SOLAR and MORGAN. Dichotomous multipoint 
linkage analysis of the bleeding score was performed using MORGAN. We 
                                                            
1 The Sandy Haberichter laboratory conducted all cell culture data. The in silico modeling 
of the R1374C mutation was completed by Daniel Ferraro. STRP genotyping and 
Illumina VeraCode and GoldenGate genotyping were conducted by third party facilities. 
Statistical genetics software packages were operated by Kai Wang and Trudy Burns. 
Jesse Hinckley designed and/or conducted all other aspects and experiments presented 
herein including subject recruitment clinics, scoring all bleeding score surveys, VWF and 
ABO sequencing, Illumina custom array design and quality control analysis of 
genotypes, and analysis of results provided by aforementioned individuals.  
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independently confirmed a previously reported candidate QTL that maps to chromosme 
6q22. Additionally, we identified a novel candidate QTL on chromosome 16q11. Fine-
mapping of the chromosome 9q34 QTL established significant associations between 
tagging SNPs in ABO and VWF levels whereas no significant associations were 
established with tagging SNPs in ADAMTS13, confirming ABO is the primary 9q34 QTL 
gene modulating VWF levels. We also independently replicated previously reported 
associations with VWF and FVIII levels, confirming STXBP5, SCARA5, STAB2, and 
TC2N as candidate QTL. 
 
Introduction 
Von Willebrand disease (VWD) is one of the most common congenital bleeding 
disorders. Qualitative defects of von Willebrand factor (VWF) comprise VWD type 2, 
whereas mild and severe quantitative deficiencies comprise VWD types 1 and 3, 
respectively45. Alternatively, elevated levels of VWF have been associated with 
cardiovascular disease, specifically with acute coronary syndromes226.  
Though considered “monogenic,” VWD, particularly type 1, is characterized by 
incomplete penetrance and variable expressivity, even in families with a unifying causal 
VWF mutation47. Individuals with very low levels of VWF antigen (VWF:Ag; < 30 IU/dL) 
or abnormal VWF multimer patterns typically have mutations in the VWF gene50,63. 
However, a large number of VWD patients who have VWF:Ag levels greater than 30 
IU/dL do not demonstrate linkage to VWF, suggesting the involvement of other 
genes48,227. Recent studies have shown that approximately 40% of patients with mild 
VWD have no presently identifiable putative mutation in VWF48,49. The complexity of 
VWD is underscored by the variability observed in the clinical phenotype (bleeding) as 
well as the biochemical phenotype (VWF levels). Furthermore, the extent of clinical 
bleeding in patients with VWD does not always correlate with VWF levels. Patients with 
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mild or moderate deficiencies (types 1 and 2) may show considerable variation in 
bleeding tendency even within the same family. Conversely, mild bleeding and bruising 
are common in the general population without an identifiable bleeding disorder and 
some symptoms may overlap between “bleeders” and healthy controls4. 
 VWF levels are also highly variable in the general population, ranging between 
50 and 200 IU/dL134-136. VWF levels also increase with age. While a percentage of that 
variation can be attributed to environmental factors such as stress, exercise, and 
hormonal status, twin and family studies have estimated that 25 to 75% of the variation 
in VWF levels may be genetically determined137,150,151,228. Family-based genetic study 
designs have been used to conduct linkage analysis of VWF levels in individuals 
without VWD, and genetic linkage of VWF levels to VWF has been difficult to 
demonstrate134,229. 
 The best-characterized quantitative trait locus (QTL) of VWF levels is that 
encoding the ABO blood group136. However, ABO accounts for no more than 30% of the 
genetic component of VWF:Ag levels150. In terms of bleeding severity, it is likely that 
other modifiers may explain the significant disparity in bleeding tendencies observed 
between patients with similar laboratory profiles and levels of VWF. Variants in the 
ITGA2B, GP6 and ITGA2 genes have been identified by association studies as 
candidate modifiers of disease severity230,231. These genetic factors may also contribute 
to the incomplete penetrance and variable expressivity observed in VWD. 
 One approach to identify QTL of complex traits such as VWF levels is to focus 
on a single large, culturally isolated pedigree in which it is reasonable to assume that 
trait variability is under the control of fewer genes and environmental influences than 
would be found in a collection of ancestrally unrelated smaller pedigrees with more 
variable life styles224,225. We identified, characterized, and collected blood samples from 
a single Amish pedigree diagnosed with VWD that shows significant variability in VWF 
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levels and bleeding severity among both the individuals with a familial VWF mutation 
and unaffected relatives. In addition to identifying a novel candidate QTL on 
chromosome 16q11, we also replicated candidate QTL mapping to chromosomes 6p22 
and 9q34. Additionally, we report replication of meta-analyses associations with VWF 
levels to seven SNPs in six genes: STXBP5, SCARA5, ABO, VWF, STAB2, and TC2N. 
Elucidation of the genetic etiology of the variability of VWF and FVIII levels will provide 
further insight into the phenotypic variability of VWD and the underlying cause of cases 





The Amish pedigree is composed of over 2,000 individuals, of whom 788 
provided blood samples. Eleven pedigree members were excluded because of their 
uncertain position in the pedigree. Although this is a community with limited outbreeding, 
no consanguineous marriages were identified. The bleeding phenotype was assessed 
by survey and blood was drawn, processed, and immediately frozen for DNA extraction 
and laboratory evaluation of VWF and FVIII levels. The number of examined pedigree 
members included in the genome-wide linkage analysis presented herein is 384. 
Additional samples were collected after the initial mapping study, increasing the sample 
resource from 395 samples to 788. The number of Amish pedigree members included in 
fine-mapping assays is 460. Informed consent was obtained following institutional 
guidelines and according to the Declaration of Helsinki. 
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VWF:Ag, VWF:RCo and FVIII:C levels  
Testing for VWF and FVIII:C levels was performed at the Blood Center of 
Wisconsin (Milwaukee, WI). VWF:Ag and VWF:RCo levels were measured for all 
recruited pedigree members who provided a blood sample. VWF:Ag was measured on 
standard enzyme-linked immunosorbent assay (ELISA) plates coated with a combination 
of two monoclonal antibodies. Plasma samples were plated into duplicate wells for three 
different dilutions per sample. Captured VWF was detected with polyclonal rabbit 
antibody with an enzyme conjugate reaction. Agreement between dilutions (and 
observed ristocetin cofactor [RCo] level – see below) was evaluated as a measure of 
quality.  VWF:RCo was measured by automated analysis of formalin-fixed platelet 
agglutination on the Dade-Behring BCS analyzer (Dade Behring Inc. Newark, DE). Data 
were analyzed using the manufacturer’s end-point based software package. To 
investigate intra-individual variability in VWF:Ag, VWF:RCo, and FVIII:C, 15 pedigree 
members were re-sampled at the time of the second enrollment clinic.  
 
Bleeding score 
To characterize the bleeding phenotype of pedigree members, a modified 
bleeding questionnaire was employed that was originally designed and validated by the 
Epidemiology Branch of the Centers for Disease Control and Prevention (CDC) to 
screen women with VWD232. The questionnaire consists of 10 questions selected from a 
more extensive set of questions on the basis of their positive predictive value. Questions 
focused on nosebleeds, minor injury (cuts), bruising, gingival bleeding, bleeding after 
challenges dental and surgical procedures, and transfusion requirements. 
Questionnaires were graded on a Likert scale with the lowest (no bleeding phenotype) 
possible score being zero and the highest (most severe) score being seven. To evaluate 
sensitivity and specificity, the questionnaire was also given to a group of unrelated 
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patients with VWD recruited from the Bleeding Disorders Clinic at the University of Iowa 
and a group of unrelated controls (data not shown). All questionnaires were 
administered to pedigree members by clinical personnel to increase accuracy, and they 
were evaluated by one individual to standardize scoring and implementation of clinical 
judgment233. 
 
ABO blood group 
DNA was extracted with the Gentra Puregene Kit (Qiagen Valencia, CA) and 
sequencing of exons 6 and 7 of the ABO gene was performed in all collected samples. 
Blood type determination was made based on haplotypes formed by sequence variants 
at positions 261, 802, 803 and 1,069234. Although this is not a standard technique for 
ABO determination, the advantage of DNA sequencing over serum antibody detection 
includes the ability to distinguish individuals heterozygous for an O allele (inactive 
glycosyltransferase; AO and BO) from individuals with no O allele (AA, BB, and AB). 
Genotyping of ABO was validated by sequencing samples from the University of Iowa 
Blood Bank with known serologic ABO status (data not shown).  
 
VWF sequencing 
Low VWF:RCo and VWF:Ag levels in several pedigree members suggested the 
diagnosis of VWD type 2. Thus, a sequencing strategy for VWF was initiated in exon 28, 
which harbors the majority of type 2 mutations. Exon 28 of VWF was sequenced for all 
pedigree members who provided a blood sample. PCR and sequencing primers were 
designed for selective amplification of VWF in order to avoid amplification of the VWF 
pseudogene located on chromosome 2233. Targeted sequence analysis identified a C>T 
mutation at position c.4120 that segregated with VWF:RCo < 25 IU/dL. To rule out 
additional mutations, the entire VWF sequence, including introns, was analyzed in three 
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pedigree members: two VWD patients and one unaffected relative. Sequencing was 
performed at the Partners Healthcare Center for Genetics and Genomics (Harvard 
Medical School, Boston, MA). A 5’ allelic discrimination high-throughput fluorescent 
genotyping assay (TaqMan)235  was designed to determine the population frequency of 
the c.4120C>T mutation in a group of individuals with European ancestry (n=358) from 
different populations included in the Centre d’Etude du Polymorphisme Humain (CEPH) 
diversity panel236.  
 
In silico modeling 
The R1374C amino acid substitution was modeled using the structure of the 
wild-type VWF A1 domain bound to platelet glycoprotein Ibα, 1SQ0237. The arginine 
side chain of reside 1374 (residue 611 using the numbering from 1SQ0) was replaced 
with a cysteine side chain using the program COOT238. The most common protomer 
was selected for the position of the side chain. In this position, the alpha and beta 
carbons of the arginine and cysteine residues were in the same position. There was no 
steric clash with any of the cysteine atoms and any other atoms in the model. Images 
were rendered using the program PyMol239. 
 
Cell culture, transfection, and multimer analysis 
The human VWF expression vector, pCIneo-VWF-WT, has been previously 
described240. The c.4120C>T mutation was introduced into the full-length VWF 
expression vector to create pCIneo-VWF-R1374C. Human embryonic kidney cells 
(HEK293T, D. Ginsburg, University of Michigan, Ann Arbor, MI) and mouse pituitary 
tumor cells (AtT-20/D16v-F2, CRL 1795, American Type Culture Collection) were 
cultured at 37°C in an atmosphere of 5% CO2 as previously described
240. The variant 
pCIneo-VWF-R1374C was expressed alone or co-expressed with pCIneo-VWF-WT. 
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Conditioned media were harvested from the cells 72 hours after transfection and 
centrifuged to remove debris. Transfected HEK293T cells were washed twice with PBS 
(phosphate buffered saline) and lysed in Reporter Lysis Buffer (Promega, Madison, WI). 
The concentration of VWF:Ag in conditioned media and in cell lysate was determined by 
ELISA. VWF multimer structure was analyzed by electrophoresis through a 0.8% (w/v) 
HGT(P) agarose (FMC Bioproducts, Rockland, ME) stacking gel and 2% (w/v) HGT(P) 
agarose running gel containing 0.1% SDS for 16 hours at 40 V using the Laemmli buffer 
system and Western blotting as previously described240. Binding of expressed VWF to 
platelets in the presence or absence of either ristocetin or botrocetin was determined 
using a modification of the platelet-binding assay previously described. Briefly, 
conditioned media from transfected cells was incubated with Alexa-647 labeled rabbit-
anti-human VWF (DAKO, Carpintera, CA), and then added to formalin-fixed platelets. 
Ristocetin or botrocetin was added to the VWF-antibody-platelet mixture and labeled 
cells were analyzed using a BD LSRII flow cytometer. 
 
Genome-wide scan 
Genotyping was completed by the NHLBI Mammalian Genotyping Service at 
Marshfield, WI (http://research.marshfieldclinic.org/genetics/home/index.asp), using the 
Screening Set 16 with 400 short tandem repeat polymorphic (STRP) markers. For a 
complete list of Screening Set 16 STRP markers, refer to Appendix C. This generated a 
total of approximately 160,000 genotypes for the 384 samples. Data were processed 
and linkage analysis data files were created. Mendelian inconsistencies were evaluated 
using the computer program PEDCHECK and resolved241.  
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SNP selection and genotyping 
For all candidate QTL intervals, tagging SNPs were selected using the Tagger 
algorithm, implemented in Haploview using pairwise tagging with an r2 threshold of 0.80 
(http://www.broadinstitute.org/scientific-community/science/programs/medical-and-
population-genetics/haploview/haploview)242,243. Centre d’Etude du Polymorphisme 
Humain from Utah (CEU) data downloaded from the HapMap Genome Browser Release 
#28 (http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse /hapmap28_B36/) were used to 
evaluate linkage disequilibrium (LD) patterns and pairwise r2 of tagging SNPs for the 
candidate intervals. All coordinates were based on the NCBI36/hg18 build. In addition to 
fine-mapping tagging SNPs, we also genotyped 14 SNPs identified as candidate QTL of 
VWF and/or FVIII levels by previously reported meta-analyses (rs10133762, rs1063857, 
rs12229292, rs12941510, rs13361927, rs1354492, rs2726953, rs379440, rs4981022, 
rs687289, rs7978987, rs868875, rs9390459, and rs9644133)167,168. Chromosome 6 
tagging SNPs and genome-wide association study (GWAS) replication SNPs were 
genotyped using an Illumina VeraCode assay by BodySync (Aurora, CO). Chromosome 
9 and chromosome 16 tagging SNPs were genotyped using an Illumina GoldenGate 
assay by the University of Colorado Denver Genomics and Microarray Core (Aurora, 
CO). All SNPs were filtered per manufacturer’s quality control recommendations using 
GenomeStudio. Mendelian inconsistencies were evaluated using PEDCHECK and 
inconsistent genotypes were zeroed out241. 
 
Heritability, linkage, and association analyses 
VWF:Ag, VWF:RCo, and FVIII:C are quantitative traits that demonstrate high 
kurtosis (data not shown). Hence, VWF:Ag, VWF:RCo and FVIII:C were transformed by 
taking the natural logarithm to better meet model assumptions. Heritability estimates 
were obtained using the SOLAR (Sequential Oligogenic Linkage Analysis Routines, 
34
version 4.2.7) program assuming a polygenic model244. All individuals in the pedigree 
were included in the analysis, and STRP genotypes were provided for the original 384 
samples genotyped by the NHLBI Mammalian Genotyping Service. Multipoint variance 
components linkage analysis of quantitative traits was also performed in SOLAR. 
Because of the large size of this pedigree, the multipoint estimates of pairwise identity by 
descent (IBD) status that is required for SOLAR computation were obtained using the 
software package Loki (version 2.4.5)245. Parametric multipoint linkage analysis of 
dichotomized bleeding score (2,  3) and VWF:RCo (≤ 25 IU/dL) were performed using 
the program lm_markers in MORGAN (version 2.9, 
http://www.stat.washington.edu/thompson/Genepi/genepi.shtml). Association analyses 
were also conducted in SOLAR. Multiple testing corrections were implemented using the 
Holm-Bonferroni method246. For analysis of bleeding scores with VWF levels, the PROC 
LOGISTIC procedure in SAS (version 9.2) was used to fit a multivariable logistic 
regression model; pedigree members were treated as independent. 
 
STXBP5 and STAB2 sequencing 
 Candidate gene primers were designed covering all exons and exon/intron 
boundaries of the genomic sequence of STXBP5 and STAB2 using Primer3 
(http://frodo.wi.mit.edu/). PCR was performed on genomic DNA and Sanger sequencing 
was performed using BigDye V3.1 on an ABI3730xl DNA analyzer247. Analysis of 
sequence was conducted using Sequencher V4.9. 
 
Results 
VWF and FVIII levels are variable yet reproducible 
VWF:Ag, VWF:RCo, and FVIII:C were measured and analyzed in the 384 Amish 
pedigree members included in the genome-wide linkage analysis. VWF:RCo levels were 
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reported as < 10 IU/dL (lower limit of detection) for 21 pedigree members. For analysis, 
a value of 5 IU/dL was assigned for these individuals. As the biochemical measures 
were not normally distributed based on the Kolmogorov-Smirnov test (p < 0.01), log-
transformed values were used for subsequent analyses. The VWF c.4120C>T mutation 
(detailed below) was present in 74 of the pedigree members, including all pedigree 
members with VWF:RCo < 10 IU/dL. Of the pedigree members analyzed, males were 
younger overall, and male unaffected relatives had lower levels of VWF:Ag, VWF:RCo, 
and FVIII:C than female unaffected relatives (Table 2.1). There was a very strong 
association between log-transformed VWF:Ag and FVIII:C, VWF:Ag and VWF:RCo, and 
VWF:RCo and FVIII:C within unaffected relatives (Spearman rank correlation 
coefficients = 0.74, 0.88, and 0.69, respectively; all p<0.0001) as well as within VWD 
patients (Spearman rank correlation coefficients = 0.90, 0.61, and 0.60, respectively; all 
p<0.0001). 
 The intra-individual variability was minimal, with intraclass correlation coefficient 
(ICC) of 0.94 for VWF:Ag; 0.98 for VWF:RCo (when individuals with VWF:RCo <10, 
were excluded from the analysis the ICC = 0.97), and 0.95 for FVIII:C. It could be 
argued that measures for the 11 pedigree members from this subset who carry the 
VWF c.4120C>T mutation were less likely to vary. However, four of the 15 pedigree 
members were non-carriers, and their levels also showed minimal variability. 
Table 2.1: Description of the 384 examined pedigree members by gender 
 
All Examined 
N = 384 
Females 
N = 195 
Males 
N = 189 p-value† 
Mean Age (Range) 21.5 (0.2, 86.1) 24.1 (0.2, 86.1) 18.9 (0.2, 76.7) < 0.005 
Unaffected Relatives* N = 310 N = 159 N = 151  
Mean VWF:Ag IU/dL (Range) 102.7 (26, 483) 108.0 (26, 483) 97.0 (42, 239) > 0.10‡ 
Mean VWF:RCo IU/dL 
(Range) 
115.9 (43, 508) 121.4 (46, 508) 110.1 (43, 263) > 0.20‡ 
Mean FVIII:C IU/dL (Range) 115.8 (64, 290) 119.3 (64, 290) 112.1 (65, 232) < 0.10‡ 
* Pedigree members without the VWF c.4120C>T mutation 
† Wilcoxon Rank Sum Test (two-tailed) 
‡ Analysis of log-transformed traits corrected by age 
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       Table 2.2: Heritability estimates of log-transformed biochemical phenotypes 
Trait Heritability estimate p-value 
VWF:Ag 0.30 p < 610-7 
VWF:RCo 0.39 p < 210-6 
FVIII:C 0.30 p < 210-8 
 
VWF:Ag, VWF:RCo, and FVIII:C are heritable traits in the pedigree 
To investigate the heritability of biochemical phenotypes, a polygenic model 
was assumed with VWF c.4120C>T mutation status included as a covariate. Gender  
was initially considered as a possible covariate; however, its effect was not 
significant, and gender was excluded from the final models. There was strong 
evidence that each phenotype is influenced by genetic factors (Table 2.2). 
Interestingly, when age was included as a covariate, heritability for VWF:Ag 
significantly decreased to h2 = 0.11 (p < 0.0005) due to a reduced variance 
component while heritability for VWF:RCo remained stable (h2 = 0.37, p < 2  10-8), 
underscoring the previously described effect of age on VWF:Ag136. 
 
A c.4120C>T missense mutation in the A1 domain of VWF underlies familial VWD 
Sequence analysis of VWF exon 28 identified a missense mutation at position 
c.4120, represented by a single C>T base substitution (c.4120C>T) that segregated with 
all pedigree members found to have VWF:RCo < 25 IU/dL. The c.4120C>T mutation 
predicts an arginine to cysteine change at amino acid position 1374 (R1374C) in the A1 
domain of the mature VWF molecule (Figure 2.1A). The A1 domain has been well 
characterized and consists of six β-sheets surrounded by six -helices forming a typical 
β structure248. This domain represents the main binding site for the platelet glycoprotein 
1b (GPIbα), and mutations in this particular region increase or impair binding of VWF to  
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Figure 2.1: VWF c.4120C>T mutation 
The c.4120C>T mutation predicts an arginine to cysteine change at position 1374 in the 
A1 domain of the mature VWF molecule. A) Sequence chromatograms demonstrate a 
heterozygous C>T change in individuals with VWF:RCo < 25 IU/dL at position c.4120 
compared to a homozygous CC4120 signal in WT individuals. B) VWF A1 domain 
(orange)-GPIbα (dark grey) complex modeled with the WT arginine and mutant cysteine 
amino acids. As seen in the magnified area, the R1374C mutation appears to cause a 
conformational change causing disruption in the A1 domain. C) Ristocetin-induced 
platelet binding to recombinant WT VWF (•), R1374C-VWF (■), and co-expressed alleles 
R1374C/WT (○). Co-expression of the WT VWF expression vector partially rescues 
ristocetin-induced platelet binding activity. 
 
platelets resulting in VWD types 2B and 2M, respectively. VWD type 2M is characterized 
by VWF:RCo < 25 IU/dL, consistent with reduced VWF binding to GPIbα, yet an 
apparently normal VWF multimer pattern16. All 358 CEPH samples evaluated by 
TaqMan assay were homozygous for the wild-type (WT) C nucleotide at position c.4120.  
Full length sequence of VWF in three pedigree members, two VWD patients and one 
unaffected relative, did not identify any additional mutations (data not shown). 
This R1374C amino acid change was modeled using the structure of the WT 
VWF A1 domain bound to GPIbα, 1SQ0237. Molecular modeling demonstrated that the 
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R1374C substitution affects a salt bridge interaction between the arginine side chain and 
three residues in the 1-2 loop of the A1 domain: the carbonyl oxygen of residues 
K1312 and W1313 and the arginine side chain of residue R1315 (Figure 2.1B). 
Disruption of the A1 domain has been shown to cause VWD type 2M54,249-251. Though 
R1374 is not located in the 1-2 loop, it most likely helps stabilize the loop 
conformation. A loss of this salt-bridge in the R1374C mutant was predicted to result in a 
conformational change in the 1-2 loop, altering the functionality of the A1 domain237. 
Expression of the VWF R1374C variant alone and co-expressed with WT VWF 
showed impaired secretion, which resolves as the WT/R1374C mutant ratio increased. 
Confocal microscopic imaging of transfected HEK293 and AtT-20 cells demonstrated 
granular storage of VWF when R1374C-VWF was expressed alone, or co-expressed 
with wild-type VWF (data not shown). Multimer analysis of R1374C-VWF demonstrates 
a smeared pattern compared to the WT (see Appendix D). Functional analysis of 
ristocetin-induced platelet binding showed markedly decreased binding of R1374C-VWF 
that was partially corrected with the co-expression of the wild-type allele (Figure 2.1C; 
also see Appendix D).  
 
c.4120C>T demonstrates complete penetrance for VWF levels but incomplete 
penetrance for bleeding scores 
VWF:RCo levels for all of the pedigree members heterozygous for the 
c.4120C>T mutation were  25 U/dL, indicating 100% penetrance for the biochemical 
phenotype. Among these individuals, all but one exhibited VWF:Ag levels below 33 
IU/dL (Table 2.3). Of the 74 members who heterozygous for the c.4120C>T mutation, 38 
have bleeding scores  3, estimating penetrance for the bleeding phenotype is 51%. 
Among individuals older than 12 years-old, penetrance for the bleeding phenotype was  
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Table 2.3: VWF:Ag, VWF:RCo, and FVIII:C and the bleeding score by age group 
and VWF mutation status 
Age Group < 12 years*  12 years* 
Mutation Status VWF C4120T VWF CC4120 VWF C4120T VWF CC4120
Gender (Males/ Females) 16 / 8 75 / 51 20 / 28 77 / 108 
Mean Age† 5.1 (0.3, 11.2) 4.9 (0.2, 11.7) 35.4 (16.6, 86.1) 31.5 (12.0, 73.7) 
Mean VWF:Ag IU/dL† 22.2 (13, 33) 99.6 (44, 239) 27.9 (9, 76§) 104.8 (26, 483) 
Mean VWF:RCo IU/dL†,‡ 14.0 (10, 21) 113.5 (43, 263) 13.5 (10, 25) 117.6 (43, 508) 
Mean FVIII:C IU/dL† 47.9 (31, 82) 117.3 (76, 232) 53.6 (25, 108) 114.7 (64, 290) 
Bleeding Score N (%)     
0-1 16 (66.7) 102 (81.6) 6 (12.5) 80 (43.7) 
2 3 (12.5) 15 (12.0) 12 (25.0) 53 (29.0) 
3 4 (16.6) 6 (4.8) 15 (31.2) 30 (16.4) 
 4 1 (4.2) 2 (1.6) 15 (31.2) 20 (10.9) 
* Bleeding score distribution < 12 years of age Fisher’s Exact Test p < 0.10;  12 years of age Pearson chi-
square test p < 0.000025 
† Mean (Range) 
‡Lower limit of measurement: 10 IU/dL 
§ Only one individual with the VWF c.4120C>T mutation exhibited a VWF:Ag level  > 35 IU/dL. This value of 
76 is likely a lab error the test could not be repeated. 
 
62% (33 of 53). Nineteen (49%) of 39 pedigree members with the c.4120C>T mutation 
and a bleeding score  2 are children under the age of 12. The distribution of bleeding 
scores for individuals with the c.4120C>T mutation compared with unaffected relatives 
was significantly different among pedigree members  12 years of age (p<5.0x10-6) but 
not for members younger than 12 years of age (p<0.10). This is consistent with the 
progression of clinical symptoms as patients reach menarche and begin to experience 
hemostatic challenges such as menstruation, tooth extraction, surgery, and parturition. 
In all pedigree members ≥ 12 years of age, the odds of having a bleeding score < 3 were 
1.78 (95% CI 1.19-2.65; p<0.005) times higher for each unit increase in log(VWF:Ag), 
and the odds of having a bleeding score < 3 were 1.78 (95% CI 1.36-2.34; p<0.0001) 
times higher for each unit increase in log(VWF:RCo). When c.4120C>T mutation status 
was added to each of the models, neither VWF:Ag nor VWF:RCo were able to predict 
the bleeding score with any accuracy in individuals with the c.4120C>T mutation (data 
not shown).  
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The ABO blood group is a modifier of VWF levels in the Amish pedigree 
ABO genotypes were available in 382 pedigree members. Approximately 60% of 
pedigree members were found to have type A blood:  8% A1A1, 45% A1O1, and 7% A2O1. 
Type O was the second most common blood type: 24% O1O1 and 7% O1O2. Type B 
blood, type AB blood, and other type A and type O blood genotypes were rare in the 
Amish pedigree (0.3 to 4%). Age-gender-adjusted least squares VWF:RCo, VWF:Ag,  
and FVIII:C levels are displayed in Table 2.4 by copy number of an inactive 
glycosyltransferase allele (type O) and by VWF c.4120 genotype. The general linear 
models analysis identified a significant age-gender-adjusted ABO type  VWF C4120T 
genotype interaction effect for log-transformed VWF:Ag, VWF:RCo, and FVIII:C levels. 
Among unaffected relatives, those with type O blood had significantly lower mean 
levels of VWF:Ag, VWF:RCo, and FVIII:C than did individuals with type A blood (AA and 
AO) as has previously been reported136. Interestingly, among unaffected relatives, 
individuals with type A or type B blood that were heterozygous for an inactive 
glycosyltransferase allele (AO, BO) had lower VWF:RCo levels than individuals with two 
copies of the type A allele or with type AB blood. Among unaffected relatives, ABO  
Table 2.4: Least squares mean VWF:Ag, VWF:RCo, and FVIII:C by ABO blood 
group and VWF 4120 genotype 
 
VWF C4120T * VWF CC4120 
p-value 
OO 
N = 24 
AO+BO 
N = 40 
AA+AB 
N = 8 
OO 
N = 95 
AO+BO 
N = 174 
AA+AB 
N = 41 
VWF:Ag† 25.11 21.99 26.34 83.49 100.48 111.88 < 0.01 
VWF:RCo‡ 12.03 12.50 11.64 90.29 112.38 134.56 < 0.025 
FVIII:C§ 48.58 47.84 52.47 103.27 115.46 116.55 NS 
* No significant age-gender-adjusted ABO type pairwise differences for VWF:Ag or 
VWF:RCo or FVIII:C or Platelet Count within VWF C4120T 
† Age-gender-adjusted VWF:Ag within VWF CC4120:  OO vs. AO+BO p<0.001; OO vs. 
AA+AB p<0.001; AO+BO vs. AA+AB NS, adjusted for multiple comparisons 
‡ Age-gender-adjusted VWF:RCo within VWF CC4120:  OO vs. AO+BO p<0.001; OO vs. 
AA+AB p<0.001; AO+BO vs. AA+AB p<0.05, adjusted for multiple comparisons 
§ Age-gender-adjusted FVIII:C within VWF CC4120 ABO type p<0.001:  OO vs. AO+BO 
p<0.0025; OO vs. AA+AB p<0.10; AO+BO vs. AA+AB NS, adjusted for multiple 
comparisons 
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genotypes explained an additional 8, 12, and 7% of the variability in log-transformed 
VWF:Ag, VWF:RCo, and FVIII:C levels, respectively. There were no significant age-
adjusted pairwise ABO type differences among individuals with the c.4120C>T mutation, 
which is consistent with the impact the c.4120C>T mutation has on VWF levels.  
 
Linkage analysis identifies candidate QTL for VWF:Ag and VWF:RCo 
Given the significant heritability of the biochemical phenotypes, a genome-wide 
QTL linkage analysis was conducted in an attempt to identify new candidate modifier loci 
(Figure 2.2). The highest LOD score from the QTL analysis of log- transformed VWF:Ag, 
VWF:RCo, and FVIII:C levels corresponded to chromosome 12p13 where VWF has  
 
Figure 2.2: SOLAR genome-wide QTL scans for VWF:Ag, VWF:RCo, and FVIII:C 
Chromosomes are represented along the x-axis with an estimated LOD score (y-axis) 
plotted at every 1 cM interval. Chromosome numbers  correspond to the middle of the 
respective region. The y-axis scales with the maximum LOD score for the linkage model. 
A) VWF:Ag, B) VWF:RCo, C) FVIII:C.  
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Figure 2.3: SOLAR QTL chromosome scans for VWF:Ag and VWF:RCo 
CentiMorgan (cM) distance is mapped along the x-axis with a LOD score estimate (y-
axis) plotted every 1 cM interval to generate a continuous linkage estimate. The y-axis 
scales with the maximum LOD score for the linkage model. Marshfield Map STRP 
markers are listed vertically. A) VWF:Ag chromosome 3 scan (3q28, LOD=1.93). B) 
VWF:Ag chromosome 9 scan (LOD=2.85). C) VWF:RCo chromosome 9 scan (LOD-




been physically mapped. The maximum LOD score of 64.73 corresponds to linkage with 
VWF:RCo levels, the phenotype most directly affected by the VWF c.4120C>T mutation. 
A LOD score of 47.12 was obtained in the same region for VWF:Ag. The next highest 
LOD scores were established for linkage of VWF:Ag and VWF:RCo to chromosome 
9q34 (LOD=2.85 and 2.79, respectively; Figure 2.3). Chromosome 9q34 is the physical 
location of the ABO gene that determines the ABO blood type as well as ADAMTS13, 
which encodes the metalloproteinase that cleaves VWF in circulation. We also identified 
novel candidate QTL of VWF:Ag and VWF:RCo that map to chromosome 16q11 
(LOD=1.56 and 2.79, respectively; Figure 2.3) and to chromosome 3q28 (VWF:Ag, 
LOD=1.93; Figure 2.3). 
 Prior to implementation of SOLAR, the pedigree size limited genome-wide 
linkage analyses to multipoint parametric analysis of dichotomous traits. We 
dichotomized VWF:RCo levels at < 25 IU/dL. Among candidate QTL identified, we 
established a LOD score of 2.18 to a previously reported QTL on chromosome 6p22. 
Outside of chromosome 12p13 (VWF) and 9q34 (ABO), this is the first QTL reported 
concomitantly in multiple studies including the Genetic Analysis of Idiopathic 
Thrombophilia (GAIT) Project genome-wide linkage analysis and  the Framingham 
Heart Study genome-wide association study (GWAS) 134,166,252. While linkage was not 
replicated by SOLAR, multiple independent studies validate the chromosome 6p22 
candidate QTL. 
 
Common variants in ABO, but not ADAMTS13, contribute to the chromosome 
9q34 QTL 
Previous reports demonstrated tagging SNPs selected from the HapMap Project 
are applicable to other Caucasian populations and capture a majority of the genetic 
variation253,254. As an isolated founder population, the Amish have a more uniform 
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genetic background with wider intervals of LD than outbred Caucasian populations255. 
However, the Amish demonstrate similar mean heterozygosity of HapMap tagging SNPs 
to the CEU dataset, HapMap tagging SNPs capture much of the same variation in the 
Amish, and the Amish demonstrate similar LD patterns compared with the CEU 
dataset256. The chromosome 9 candidate interval was defined as 135,119,000-
135,315,000 and encompasses both ABO (135,120,384-135,140,451) and ADAMTS13 
(135,284,856-135,314,329). We and others have established evidence of ABO as a QTL 
of VWF levels. The role of ADAMTS13, which encodes the metalloproteinase that 
cleaves VWF in circulation under physiologic conditions, as a candidate QTL is largely 
uninvestigated22,36. Fifty-eight tagging SNPs were required to capture both genes in a 
continuous interval. Of the 58 tagging SNPs, 11 SNPs were excluded due to low signal 
intensity, low cluster separation or low minor allele frequency in the Amish pedigree, 
resulting in a total of 47 SNPs used in the analysis. 
Analysis of the Amish pedigree revealed evidence of strong LD corresponding to 
each ABO and ADAMTS13 and evidence of pockets of long-range LD (Figure 2.4). 
There is no evidence of strong pairwise correlations (r2 ≥ 0.80) between tagging SNPs in 
ABO and tagging SNPs in ADAMTS13. Three tagging SNPs within ABO and one 
intergenic tagging SNP approximately 3.5 kb telomeric to ABO demonstrated significant 
associations with VWF:Ag and VWF:RCo (Figure 2.5; Table 2.5). Additionally, we 
established significant associations between VWF:Ag and three additional SNPs in ABO 
and one additional intergenic SNP approximately 6.5 kb telomeric to ABO. All eight 
tagging SNPs to which significant associations were established demonstrate moderate 
to high pairwise correlation (r2=0.34-0.81). Intergenic SNPs rs579459 and rs558240 
demonstrate high pairwise correlations with ABO SNPs (rs657152 [r2=0.73] and 
rs500498 [r2=0.70], respectively). Prior to multiple testing corrections, one SNP in 




Figure 2.4: Haploview LD and r2 patterns demonstrate distinct blocks of LD 
corresponding to ABO and ADAMTS13 
LD (A) and r2 (B) patterns were visualized using Haploview. Haplotype blocks were 
generated by Haploview using the confidence intervals function242. The ABO and 
ADAMTS13 genes are represented by blue and green boxes, respectively. Lines 
radiating from the boxes represent tagging SNPs within the respective gene. A) There is 
evidence strong local LD with pockets of long-range LD within the pedigree. B) Strong 




  Table 2.5: SNPs associated with VWF levels 
SNP Gene Phenotype p-value 
rs2073824 ABO VWF:Ag 2.7x10-4 
rs8176694 ABO VWF:Ag 1.9 x10-4 
rs657152 ABO VWF:Ag 1.8 x10-7 
VWF:RCo 9.9x x10-7 
rs474279 ABO VWF:Ag 6.7 x10-6 
VWF:RCo 3.4 x10-5 
rs500498 ABO VWF:Ag 5.5 x10-4 
rs630014 ABO VWF:Ag 2.4 x10-7 
VWF:RCo 1.8 x10-6 
rs579459 Intergenic VWF:Ag 6.3 x10-6 
VWF:RCo 4.3 x10-5 
rs558240 Intergenic VWF:Ag 5.1 x10-4 
 
 
Figure 2.5: P-values of association between VWF:Ag and individual SNPs on 9q34 
Association between individual tagging SNPs mapping to chromosome 9q34 and log-
transformed VWF:Ag adjusting for age was evaluated using SOLAR. The data show one 
cluster of SNP associations that reach study-wide significance (dashed line) 




and 0.025, respectively; Appendix E). Within the Amish pedigree, rs1055432 is not 
correlated with ABO tagging SNPs (highest r2=0.12). When ABO is considered as a 
covariate, no significant associations were established with SNPs in ADAMTS13 (p-
values: 0.17-0.96). Taken together, these data suggest common variants (MAF ≥ 0.01) 
in ABO contribute to variation in VWF levels whereas common variants in ADAMTS13 
were not found to be associated with VWF levels. 
 
Chromosome 6p22 and 16q11 candidate QTL fine-mapping is ongoing 
For the chromosome 6p22 candidate QTL, we narrowed the candidate interval to 
27,700,000-28,200,000 based on fine-mapping inferred from the resolution of the 
Framingham Heart Study GWAS.  In addition to 52 tagging SNPs required to capture the 
interval, we also genotyped 2 SNPs within the candidate interval (rs9295740 and 
rs202906) to which associations with VWF:Ag were reported166. All tagging SNPs 
passed quality control standards and no Mendelian inconsistencies were identified. The 
chromosome 16q11 candidate QTL 1-LOD confidence interval is 39 Mb in size 
(19,400,000-58,451,000) and contains 264 reported genes. To analyze the CEU 
HapMap data in Haploview for tagging SNP selection, it was necessary to divide this 
interval into four regions. A total of 6,211 tagging SNPs are required to capture this 
candidate interval. However, due to GoldenGate platform limitations, we were limited to 
3,009 SNPs. To determine SNP coverage by region we multiplied the percentage of total 
SNPs required to completely capture the region by 3,009 and limited Tagger to select 
the most informative SNPs based on that constraint. Of 3,009 tagging SNPs, 473 were 
eliminated for low signal intensity or low cluster separation. An additional 9 SNPs were 
eliminated for more than 3 genotype clusters or one genotype cluster for a common 
variant (minor allele frequency > 0.15). In the Amish pedigree 10 SNPs were not 
informative and were eliminated from further analysis. Association analyses of VWF:Ag 
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and VWF:RCo are ongoing to fine-map candidate QTL on chromosomes 6p22 and 
16q11. 
 
STXBP5, SCARA5, STAB2, and TC2N are confirmed as candidate QTL  
To date, two meta-analyses of genome-wide association studies of VWF and 
FVIII levels have been reported by the Cohorts for Heart and Aging in Genomic 
Epidemiology (CHARGE) consortium and the Marseille Thrombosis Association 
(MARTHA)167,168. We evaluated association of 14 previously reported SNPs: 10 SNPs in 
eight genes selected from the CHARGE consortium meta-analysis and 4 SNPs in two 
genes selected from the MARTHA meta-analysis, with VWF levels and FVIII levels 
based on previously reports (Table 2.6).  For SNPs previously associated with VWF 
levels, we evaluated association with VWF:Ag and VWF:RCo. Of the 14 SNPs we 
evaluated, association with VWF or FVIII levels were replicated for seven SNPs in six 
genes: STXBP5, SCARA5, ABO, VWF, STAB2, and TC2N. P-values are reported for all 
SNPs evaluated by VWF:Ag and FVIII:C and for SNPs. P-values are only provided for 
SNPs to which significant associations were established with VWF:RCo. Additionally, 
where significant associations were established, we report the percent of the trait 
genetic variance component explained by the test SNP.  
Significant associations were established for 3 SNPs with VWF:Ag and 
VWF:RCo (rs9644133, SCARA5; rs687289, ABO; rs1063857, VWF), for 2 SNPs with 
VWF:Ag (rs9390459, STXBP5; rs12229292, STAB2), and for 2 SNPs with VWF:RCo 
(rs4981022, STAB2; rs10133762, TC2N). Three SNPs associated with VWF levels also 
demonstrated significant associations with FVIII:C: rs9644133 (SCARA5), rs687289 
(ABO), and rs12229292 (STAB2). ABO SNP rs687289 explained 24.6%, 20.6%, and 
20.0% of the heritability of VWF:Ag, VWF:RCo, and FVIII:C, respectively. VWF SNP 
rs1063857 explained 12.5% and 22.5% of the heritability of VWF:Ag and VWF:RCo,  
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Table 2.6: CHARGE and MARTHA meta-analyses SNPs evaluated for association 
with VWF and FVIII levels in the Amish pedigree 
Gene SNP Chr. Phenotype p-value %  GVC* Study 
EPB41L4A rs13361927 5q22.2 VWF:Ag 0.28  MARTHA
rs379440 5q22.2 VWF:Ag 0.30  MARTHA
STXBP5 rs9390459 6q24 VWF:Ag 0.03 3.5% CHARGE
SCARA5 rs2726953 8p21 VWF:Ag 0.22  CHARGE
rs9644133 8p21 FVIII:C 0.01 6.0% CHARGE
rs9644133 8p21 VWF:Ag 0.02 5.3% CHARGE
rs9644133 8p21 VWF:RCo 0.0047 7.8% CHARGE
ABO rs687289 9q34 FVIII:C 8.26x10-6 20.0% CHARGE
rs687289 9q34 VWF:Ag 1.34x10-5 24.6% CHARGE
rs687289 9q34 VWF:RCo 7.07x10-7 20.6% CHARGE
VWF rs1063857 12p13 VWF:Ag 0.01 12.5% CHARGE
rs1063857 12p13 VWF:RCo 3.62x10-5 22.5% CHARGE
STAB2 rs12229292 12q23 FVIII:C 0.021 6.0% CHARGE
rs12229292 12q23 VWF:Ag 0.001 8.9% CHARGE
rs4981022 12q23 VWF:Ag 0.09  CHARGE
rs4981022 12q23 VWF:RCo 0.04 3.9% CHARGE
STX2 rs7978987 12q24.3 VWF:Ag 0.16  CHARGE
TC2N rs10133762 14q32 VWF:RCo 0.048 7.8% CHARGE
ACCN1 rs1354492 17q11.2 FVIII:C 0.77  MARTHA
rs12941510 17q11.2 FVIII:C 0.59  MARTHA
CLEC4M rs868875 19p13.2 VWF:Ag 0.66  CHARGE
* Percent of trait genetic variance component explained by the test SNP 
respectively. All other SNPs explained less than 10% of trait heritability each. Exonic 
sequence analysis including exon/intron boundaries of STXBP5 and STAB2 identified 
only common variants (MAF ≥ 0.05) previously reported in dbSNP (data not shown). 
 
Two-point linkage analysis identifies regions of suggestive linkage to the bleeding 
score phenotype 
To evaluate modifier genes of the bleeding phenotype, we dichotomized the 
bleeding score at a threshold of ≥ 3 and ≥ 4. Nine regions showed suggestive LOD 
scores when the phenotype was defined as bleeding score ≥ 3: 7q32 (LOD = 2.52), 
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12p13.3 (LOD = 1.37), 12p12 (LOD = 1.27), 12q12 (LOD = 1.13), 16q12.2 (LOD = 
1.23), 16q23 (LOD = 1.65), 19p13.2 (LOD = 1.10), 21q22 (LOD = 1.38) and 22q13 
(LOD = 1.87). Eight regions with LOD scores > 1.0 were identified with the more 
stringent phenotype of BS ≥ 4: 6p23 (LOD = 1.09), 7q32 (LOD = 1.52), 8p23 (LOD= 
1.33), 8q11 (LOD = 1.82), 10q26.3 (LOD = 1.05), 12q12 (LOD = 1.26), 16q12.2 (LOD = 
1.48) and 18q12 (LOD = 1.33). Three regions suggested linkage with both bleeding 
score phenotypes: 7q32, 12q12, and 16q12. Perhaps even more interesting, two 
regions of suggestive linkage for bleeding overlapped with candidate QTL of VWF 
levels: 12p13.3 and 16q12.2. 
 
Discussion 
In this study we genetically and phenotypically characterized the largest single 
pedigree with VWD described to date and identified several candidate QTLs that affect 
VWF and FVIII levels. One of the advantages of this particular pedigree is the presence 
of a large number of individuals that exhibit a single unifying VWF mutation in the 
presence of a variable phenotype characterized by VWF levels and bleeding patterns. 
Over the last decade the phenotypes of prevalent human diseases such as cystic 
fibrosis and cleft lip and palate have been proven to be modulated at least in part by 
genetic modifiers139-141. Because of the complexity of the genetic and environmental 
etiologies, large families or populations are needed to identify genes of even modest 
impact257-259. A strategy that can circumvent the limitations of association analysis is to 
take advantage of more homogeneous groups, such as the Amish pedigree presented 
herein, to conduct genome-wide linkage analysis. Environmental factors such as 
physical activity, medications and diet are also known to modify VWF levels and 
bleeding tendency and are likely to play a role in the observed variability of VWD145,260. 
The environmental homogeneity of the Amish may also provide a distinct advantage in 
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our dissection of the genetic components of this variability261. Linkage analysis results 
can then be fine-mapped using association-based studies and candidate gene 
sequencing. This two-step approach has been successfully employed in Alzheimer 
disease (APOE) and Crohn’s disease (NOD2)257,262.    
The VWF c.4120C>T mutation, which exhibits high penetrance for VWF:RCo 
and VWF:Ag levels, was first described in a single individual from northern France with 
VWD type 2 and has been further identified in four individuals from the European Union 
study48,263. Based on previous reports and our own studies, it is clear that this mutation 
results in a qualitative defect of VWF. As shown in the model presented in Figure 2.1B 
and supported by the ristocetin binding experiments, the mutation affects the A1 
domain of VWF and appears to alter its binding to platelet GP1bα. When the mutated 
allele was co-expressed 1:1 with a WT allele in a mammalian cell line, we observed 
only a modest decrease in total VWF secretion. In contrast, pedigree members with the 
c.4120C>T mutation have substantially decreased plasma VWF:Ag levels and very low 
VWF:RCo activity, suggesting a dominant negative effect.  
While the c.4120C>T allele exhibits a significant effect on VWF:Ag, VWF:RCo, 
and FVIII:C levels, we also identified regions suggestive of linkage on several other 
chromosomes. The ABO gene, the only well-characterized QTL of VWF levels, maps to 
chromosome 9q33-34. We established evidence for ABO as a QTL of VWF levels by 
association and linkage. Furthermore, fine-mapping of the chromosome 9q34 QTL 
confirmed ABO is the primary gene contributing to variation in VWF levels whereas 
significant associations were not established between VWF levels and tagging SNPs in 
ADAMTS13. To the knowledge of the authors, this study represents the first report to 
fine-map the chromosome 9q34 QTL distinguishing ABO from ADAMTS13. 
Identification of ABO by linkage and association allows us to postulate that other 
signals identified in this study may have biological and clinical relevance. Interestingly, 
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the chromosome 6p22 candidate QTL is concomitant with the GAIT Project and 
Framingham Heart Study and also displays orthology with murine Vwf  modifiers264. The 
highest LOD score in the Amish pedigree outside of VWF and ABO maps to a new 
candidate QTL on chromosome 16q11.  Fine-mapping of the chromosome 6p22 and 
16q11 candidate QTL is ongoing. 
In addition to mapping QTL by genome-wide linkage analysis, we independently 
replicated previously reported associations with VWF and FVIII levels, confirming 
STXBP5, SCARA5, STAB2, and TC2N as candidate QTL. Significant associations of 
tagging SNPs in STXBP5, STAB2, and SCARA5 with VWF and FVIII levels were also 
reported by Antoni et al. within the MARTHA cohorts168. The role of these genes in VWF 
biosynthesis, processing, secretion, or clearance is unknown. 
Associations were reported between STXBP5 variants and VWF:Ag and VWF 
collagen binding activity (VWF:CB) in a case-control cohort with cardiovascular disease, 
though no significant association was established between STXBP5 and the prevalence 
of cardiovascular disease265. The association with VWF:Ag and with VWF:CB was more 
significant in the case cohort, indicating STXBP5 may modulate regulatory pathway 
VWF secretion. The majority of VWF detected by laboratory testing is released via the 
constitutive pathway. Thus, differences in VWF levels between cases and controls are 
likely mediated by the regulatory pathway. Furthermore, STXBP5 encodes tomosyn, a 
protein implicated in exocytosis266.  
In a cohort of VWD type 1 patients, genetic variation in STXBP5 was associated 
with the bleeding score among females267. Furthermore, significant associations 
between STXBP5 variants and the incidence of venous thromboembolism (VTE) have 
also been reported268. The CHARGE consortium study reported the TC2N SNP 
rs10133762 was associated with increased VWF levels. In the MARTHA and FARIVE 
cohort studies, the minor allele of rs1884841 (TC2N), which was highly correlated with 
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the rs10133762 (r2=0.961), was more common in cases with VTE than controls 
(combined OR = 1.28 [95% CI = 1.11-1.48; p=9.9x104)269.  
Interestingly, there are few individuals in the pedigree who exhibit bleeding 
scores greater than 3 and do not have the VWF c.4120C>T mutation. Amish 
communities have been reported to have hemophilia B and plasminogen activator (PAI-
1) deficiency270,271. However, initial screening laboratory analyses among unaffected 
relatives with bleeding scores greater than 3 have been negative for these deficiencies.  
In terms of bleeding, the analysis was complicated by several factors. Linkage 
analysis was limited by the subjective nature of the phenotype. Because the bleeding 
score is a Likert scale, we employed two-point linkage analyses and identified several 
regions suggestive of linkage. These regions are now being pursued for identification of 
modifiers of bleeding. One could argue that for the bleeding phenotype, the most 
informative analysis will compare those who bleed upon challenge with those who do 
not among individuals with the c.4120C>T mutation. In the era of next-generation 
sequencing, we have seen that rare variants, while at low minor allele frequencies 
(<0.01), are collectively common in the general population272. Linkage analyses will 
likely prove valuable in sorting through the massive amounts of data to identify causal 
variants with a large effect size. Thus, as sequencing costs continue to decrease, 
further analysis of the entire exome of pedigree members with VWD will likely yield rare 
variants that may affect their bleeding tendency and could potentially be tested in 
unrelated populations.  
In summary, we characterized a large Amish pedigree with VWD and identified 
several chromosomal regions of linkage to VWF levels and suggestive linkage for 
disease severity. These regions are actively being investigated at higher resolution. 
While genome-wide association studies are characterized by the identification of 
common variants of relatively modest effect, linkage studies such as the one we 
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present here may have the ability to identify rare variants as well as allelic 
heterogeneity, which may explain a large portion of the observed variability. These 
newly discovered regions that are likely to harbor modifier genes will provide new 
insights into the genetics of VWF and FVIII levels and could have important implications 
for understanding the genetic basis of bleeding and thrombosis. Fine-mapping of the 
chromosome 9q34 QTL confirms that common variants in ABO primarily modulate VWF 
levels as no significant SNP associations were established within ADAMTS13. 
Sequencing of ADAMTS13 is needed to evaluate the possibility of rare or private 
variants in ADAMTS13 that may contribute to linkage to the 9q34 QTL for VWF levels. 
We also replicated GWAS associations confirming STXBP5, STAB2, SCARA5, and 
TC2N as candidate QTL of VWF and FVIII levels. Consistent with previous genome-
wide QTL analyses, all candidate FVIII:C QTL loci identified by linkage analysis or 
replicated by association overlap with candidate VWF:Ag loci. Thus, all QTL effects on 






VWF SNP ANALYSIS IDENTIFIES MULTIPLE COMMON VARIANTS THAT OCCUR 
AT DIFFERENT FREQUENCIES IN VWD TYPE 1 PATIENTS 
 
Abstract 
Von Willebrand disease (VWD) type 1 is a complex diagnosis in which nearly half 
of patients do not have an identifiable mutation in the VWF gene. To date, the role of 
common variants that affect VWF levels is not understood in cases of VWD type 1. We 
genotyped 94 tagging SNPs through VWF in an Amish pedigree (n=445). Linkage 
disequilibrium (LD) patterns and pairwise correlations predict four haplotype blocks with 
evidence of long-range LD. Single SNP association tests established significant 
associations between VWF:RCo and twelve tagging SNPs: rs2362479 (telomeric to 
VWF), rs10849363 and rs7964554 (intron 4); rs216308 (intron 24); rs216310 and 
rs216311 (exon 28); rs11612370 and rs11612384 (intron 33); rs216330, rs11064003, 
and rs2239162 (intron 37); and rs216293 (intron 38).  rs216308 through rs216293 map 
to haplotype block 3, which encompasses exon 28 and the functional domains of the 
VWF polypeptide. To next evaluate the relevance of these SNPs in a broader Caucasian 
population, we conducted association analyses in three population-based cohorts. In 
total, rs11064003 and rs2239162 VWF associations were replicated in the ZPMCB-VWD 
control (n=150), GABC (n=934), and TSS (n=2,145) cohorts.  An additional four SNP 
associations were replicated in the ZPMCB-VWD control and TSS cohorts. Three SNP 
associations were replicated in ZPMCB-VWD control cohort. These findings confirm 
VWF SNPs identified in the Amish pedigree are relevant among Caucasians of Northern 
European ancestry. Multivariable logistic regression models predict different VWF SNPs 
are most important in explaining the variation of VWF:Ag, VWF:RCo, and the 
VWF:RCo/VWF:Ag ratio. We then compared the minor allele frequency (MAF) of the 
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tagging SNPs between the ZPMCB-VWD control cohort and the ZPMCB-VWD type 1 
index case cohort (n=310) and established that the minor allele of rs7964554 (lower 
VWF:Ag) was more common whereas the minor alleles of rs11612370, rs11612384, 
rs11064003, and rs2239162 (all higher VWF:Ag) were less common in VWD type 1 
index cases.  
 
Introduction 
Von Willebrand disease (VWD) is the most common inherited bleeding disorder 
and presents clinically with a pattern of mucocutaneous bleeding44. VWD is classified as 
quantitative (type 1 or 3) or qualitative (type 2) abnormalities of the glycoprotein von 
Willebrand factor (VWF)45. Conversely, elevated VWF levels are associated with acute 
myocardial infarction (MI) as well as reinfarction and mortality rates68-74. Elevated levels 
of VWF are also associated with lacunar infarct and ischemic stroke76-78. 
VWD type 1 encompasses mild quantitative deficiencies in VWF. Kindreds with 
familial VWD type 1 are characterized by incomplete penetrance, estimated at 60%, and 
variable expressivity. Despite being considered a “monogenic” disease, approximately 
37-45% of patients with VWD type 1 have no putative VWF mutation. Mutations in VWF 
are more likely to be identified in cases with VWF antigen (VWF:Ag) levels less than 30 
IU/dL48-50. Over 100 VWD type 1 mutations have been reported throughout VWF, the 
majority of which are inherited in an autosomal dominant pattern47. 
Von Willebrand Factor (VWF) is a large multimeric protein synthesized 
exclusively by endothelial cells and megakaryocytes that plays a prominent role in 
hemostasis and thrombosis27.  The VWF gene spans 178 kb on chromosome 12p13 and 
is composed of 52 exons, where exon 1 encodes the 5’-untranslated region (UTR) and a 
signal peptide, exons 2-17 encode the VWF propeptide, and exons 18-52 encode the 
VWF peptide monomer and 3’-UTR28-30. VWF is synthesized via constitutive and 
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secretory pathways, generating multimers ranging in size from 0.5 to 20 million 
daltons32. Within the endoplasmic reticulum, the signal peptide is cleaved and the VWF 
pre-propeptide undergoes initial glycosylation events and C-terminal disulfide-linked 
dimerization24. VWF is further processed in the Golgi apparatus, including glycosylation 
with H antigen carbohydrate moieties processed by the ABO blood system37. 
Glycosylated VWF dimers polymerize via N-terminal disulfide bonds within the trans-
Golgi and secretory granules to form multimers of variable size32.  High molecular weight 
multimers, the most biologically active multimers, are stored in endothelial Weibel 
Palade bodies and platelet α-granules36. VWF is also released through the constitutive 
pathway, which contributes 95% of plasma VWF levels measured by laboratory 
assays32,39. Endothelial stress induces storage granule release, increasing the local 
concentration of high molecular weight VWF multimers40-42.  
Among the general population, VWF levels exhibit a high degree of inter-person 
variability134-136. Significant determinants of VWF levels include ethnicity, age, gender, 
and body mass index144,146-149. Pedigree and twin studies estimate a genetic component 
of 0.25-0.75 with pedigree analyses providing consistently more conservative 
estimates150-153. The genetic variance component consists of allelic variation at VWF as 
well as other QTLs. VWF is a highly polymorphic gene with over 1,100 reported 
mutations and polymorphisms154. The impact of these changes remains unknown. To 
date, ABO is the best-characterized QTL that affects VWF levels, accounting for up to 
30% of the genetic variability of VWF levels37,136,150.   
  In this study we genotyped 94 tagging SNPs through VWF in a 
multigenerational Amish pedigree to evaluate the contribution of VWF variants to protein 
levels and activity. Replication in three independent population cohorts identified multiple 
VWF variants associated with VWF:Ag, VWF:RCo, and the VWF:RCo/VWF:Ag ratio. 
Evaluation of the minor allele frequency (MAF) identified significant differences in the 
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occurrence of five variants in VWD type 1 index cases compared to controls. Elucidation 
of the environmental and genetic etiology underlying VWF and FVIII variation may 
provide insight to improve the diagnosis of VWD as well as more accurate risk 





As described in Chapter II, the Amish pedigree studied is composed of over 
2,000 individuals, of whom 788 provided blood samples. Informed consent was obtained 
following institutional guidelines and according to the Declaration of Helsinki. Of the 
pedigree member samples available, 445 were included in this analysis.  
 
ZPMCB-VWD cohort 
 The ZPMCB-VWD cohort is a multicenter collection of smaller cohorts enrolled at 
eight primary clinical centers in Atlanta, Detroit, Houston, Indianapolis, Iowa City, 
Milwaukee, New Orleans, and Pittsburgh146. In this study, we utilized the control cohort 
and the VWD type 1 index case cohort. The control cohort consists of 231 unrelated 
individuals with no known family history of VWD. Of these individuals, 150 are 
Caucasian and 66 are African American. The remaining 10 individuals are of other 
ethnicities and were not included in this study. The VWD type 1 index case cohort 
consists of 361 patients, of whom 310 are Caucasian, 16 are African American, and 14 
are multiethnic. Ethnicity is not available on the remaining 20 individuals. Of the VWD 
type 1 index case cohort, we focused on Caucasian samples due to insufficient sample 
size for the other ethnicities. Informed consent was obtained following institutional 
guidelines at each primary site and according to the Declaration of Helsinki. 
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Genes and Blood-Clotting and Trinity Student cohorts 
 As previously described, the Genes and Blood-Clotting (GABC) study cohort 
consists of 1,152 healthy siblings between the ages of 14 and 35 years-old that were 
recruited from the University of Michigan (Ann Arbor, MI) between June 2006 and 
January 2009273. The Trinity Student Study (TSS) cohort consists of 2,524 healthy 
ethnically Irish Caucasian students attending Trinity College Dublin (Dublin, Ireland) 
during the academic year of 2003-2004273,274. Informed consent was obtained following 
institutional guidelines at each primary site and according to the Declaration of Helsinki. 
 
VWF:Ag and VWF:RCo levels  
As described in Chapter II, testing for VWF levels in the Amish pedigree was 
performed at the Blood Center of Wisconsin (Milwaukee, WI). VWF:Ag was measured by 
enzyme-linked immunosorbent assay (ELISA) and VWF:RCo was measured by 
automated analysis of formalin-fixed platelet agglutination. VWF:Ag levels in the GABC 
and TSS cohort were measured by ELISA as previously described 273. The 
VWF:RCo/VWF:Ag ratio is used to evaluate the potential of a qualitative deficiency in the 
VWF peptide. A ratio near 1 suggests a quantitative deficiency whereas a ratio ≤ 0.7 
suggests a qualitative deficiency. VWD type 1 is defined as a mild deficiency  in VWF 
levels characterized by moderately reduced VWF:Ag and VWF:RCo, a 
VWF:RCo/VWF:Ag ratio near 1, and with all species of multimers usually present by 
electrophoretic analysis36. 
 
SNP selection and genotyping in the Amish pedigree 
VWF tagging SNPs were selected using the Tagger algorithm as implemented in 
Haploview using pairwise tagging with an r2 threshold of 0.80242,243. As described in 
Chapter II, Centre d’Etude du Polymorphisme Humain from Utah (CEU) data 
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downloaded from the HapMap Genome Browser Release #28 was used to evaluate 
linkage disequilibrium and pairwise r2 of tagging SNPs. A total of 94 SNPs were required 
to tag an interval of 5,888,000-6,144,000 (NCBI36/hg18 coordinates) on chromosome 
12, capturing VWF plus 40 kb upstream and downstream of the gene. For a complete list 
of tagging SNPs genotyped, see Appendix F. Of the 94 SNPs, 14 map within exons 23-
34, a region with 97% homology to the VWF pseudogene on chromosome 2233. Primers 
were designed with at least 2 base pair differences between VWF and the corresponding 
pseudogene sequence (see Appendix G for primer sequences), and the 14 
corresponding SNPs were genotyped by Sanger Sequencing247. The remaining 80 SNPs 
were genotyped using an Illumina VeraCode assay by BodySync (Aurora, CO). All SNPs 
were filtered per manufacturer’s quality control recommendations using GenomeStudio. 
Mendelian inconsistencies were evaluated using PEDCHECK and inconsistent 
genotypes were resolved241. 
 
SNP genotyping in the ZPMCB-VWD control and VWD type 1 index case cohorts 
 SNPs rs216308, rs216310, rs216311, rs11612370, and rs11612384, which map 
between exons 23 and 34 (pseudogene region) were genotyped by Sanger sequencing 
as previously described in Chapter II. Primers were designed using Primer3 
(http://frodo.wi.mit.edu/) to amplify rs10849363, rs7964554, rs216330, rs11064003, 
rs2239162, and rs216293 (see Appendix G). 
 
Genotype imputation in the GABC and TSS cohorts 
The GABC and TSS cohorts were genotyped using the Illumina Human Omni 1M 
Quad v1_B SNP array. For the purposes of imputation in the GABC cohort, study SNPs 
were selected using a composite quality filter combined with a minor allele frequency 
(MAF) threshold of 0.01, with all founder samples included in the imputation. The 
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GENEVA (http://www.genevastudy.org) Coordinating Center (CC) performed genotype 
imputation of the GABC project using BEAGLE software 3 (http:// 
http://faculty.washington.edu/ browning/beagle/beagle.html). Imputation was performed 
for all autosomes as well as the X chromosome, with a reference panel selected from 
the 1000 Genomes Project (http://www.1000genomes.org). While the majority of GABC 
participants self-identified as Caucasian, a range of other racial groups were also 
represented. In order to allow imputation of all GABC participants simultaneously, the 
CC created a “cosmopolitan” 1000 Genomes reference panel comprising the unique 
intersection of BEAGLE-formatted haplotypes from the AFR, EUR, and ASN panels. 
Relatedness in GABC subjects was ignored here and all high quality samples were 
imputed together in one set. For a detailed description of genotype quality control 
analysis (QC) for the GABC project, please see the dbGAP report 
(http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000304.v1.p1). 
Within the TSS cohort, 757,533 autosomal SNPs were retained following 
standard QC for all 2,145 individuals to impute 2,512,420 SNPs based on HapMap II 
(release #22, n = 90) and 3,908,761 SNPs based on HapMap III (release #28, n = 90) in 
CEU phased haplotypes using MACH1.0. We used 200 randomly selected individuals 
from all 2,145 subjects for estimating model parameters with 100 iterations of rounds 
using the Monte Carlo procedure and all available haplotypes.   We then imputed all 
SNPs in the HapMap II and HapMap III reference panels to the 2,145 individuals’ 
genotypes in our dataset. We carried out single marker analysis using simple linear 
regression of the dosage of each imputed marker (scaled from 0 to 2) of high quality 




For all association analyses of VWF tagging SNPs with VWF:Ag or VWF:RCo, 
SNPs were modeled including age, gender, and rs687289 (ABO surrogate marker) as 
covariates.  As described in Chapter II, association analyses within the Amish pedigree 
were also conducted in SOLAR; gender was not found to be a significant covariate and 
was removed from the final analysis model.  Multiple testing corrections were 
implemented using the Holm-Bonferroni method246. In the ZPMBC-VWD control and 
VWD type 1 index case cohorts, SAS (9.2) PROC FREQ was used to evaluate the 
genotype and allele frequency distributions. Tests for associations between SNPs and 
VWF:Ag or VWF:RCo were conducted assuming an additive genetic model. The PROC 
LOGISTIC procedure in SAS was then used to fit a multivariable logistic regression 
model. In the GABC cohort, sibling relationships were adjusted for using EMMAX. For 
both the GABC and TSS cohorts, association analyses were conducted using PLINK. 
 
Results 
 VWF:Ag and VWF:RCo were measured in a multigenerational Amish pedigree. 
Of the 445 subjects included in this study, 83 were heterozygous for a familial 
c.4120C>T mutation in VWF that causes VWD type 2 that is inherited in an autosomal 
dominant pattern (see Chapter II). We analyzed VWF:Ag and VWF:RCo with respect to 
gender in individuals homozygous for the wild-type (WT) allele at position 4120 (Table 
3.1). 
Table 3.1: VWF levels by gender in Amish subjects with the CC4120 genotype 
 All Examined Females Males p-value* 
Number of subjects 362† 184 176  
Mean VWF:Ag IU/dL (Range) 107.0 (26, 483) 110.9 (26, 483) 102.9 (42, 262) 0.10 
Mean VWF:RCo IU/dL 
(Range) 
114.6 (43, 508) 118.2 (44, 508) 110.8 (43, 263 0.15 
* t Test, GraphPad Prism 
† Gender information was not available for two subjects 
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Figure 3.1: Haploview linkage disequilibrium and r2 patterns identify four 
haplotype blocks in VWF 
Linkage disequilibrium (LD; A) and r2 (B) patterns were visualized using Haploview. 
There is evidence of long-range LD within the pedigree. Based on LD and r2 patterns, we 
defined four haplotype blocks. Strong pairwise correlations are demonstrated within 
defined haplotype blocks. 
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 A total of 94 tagging SNPs were genotyped encompassing the VWF gene and 40 
kb upstream and downstream of the gene. Nine tagging SNPs genotyped were not 
informative in the Amish pedigree. An additional 4 SNPs in complete LD with other 
tagging SNPs were excluded from further analysis. One additional SNP was excluded 
because of Mendelian inconsistencies. As expected, visualization of haplotype block 
structure demonstrated extensive long-range LD within the Amish pedigree (Figure 
3.1A). Additionally, we identified several pockets of short-range LD, defining four 
haplotype blocks for further analysis. Tagging SNPs within haplotype blocks 
demonstrate high pairwise correlation with pockets of moderate to high long-range 
correlation (Figure 3.1B). Based on LD and r2 patterns, we defined four haplotype 
blocks. Block 1 encompasses the VWF promoter region through intron 4 and block 3 
encompasses exon 28 and the functional domains of the VWF peptide. Haplotype 
estimations within blocks 1-4 and association analyses with VWF:Ag and VWF:RCo are 
ongoing. 
 
Single SNP analysis in the Amish identifies 12 SNPs associated with VWF:RCo 
In addition to ongoing haplotype analysis, single SNP association analyses with 
VWF:Ag and VWF:RCo were conducted using SOLAR. The c.4120C>T mutation 
exhibits 100% penetrance for VWF:Ag and VWF:RCo and is subsequently included as a 
covariate. Previously, we demonstrated ABO and age are strong modifiers of VWF 
levels (see Chapter II), both of which were included as covariates in this study. After 
multiple testing corrections, 12 SNPs achieved study-wide significance for association 
with VWF:RCo (Table 3.2). Though tagging SNPs were distributed throughout the VWF 
gene, significant associations were concentrated in two regions of the gene: intron 4 and 
exon 28 through intron 38 (Figure 3.2). VWF exon 1 encodes a signal peptide, exons 2-
17 encode the propeptide, and exons 18-52 encode the VWF monomer28-30. 
65
                   Table 3.2: VWF tagging SNPs that achieved study-wide significance                             
                   for association with VWF:RCo 
SNP Position Location P-value 
rs2362479 6,026,354 Upstream 9.03 x10-5 
rs10849363 6,066,357 Intron 4 3.16x10-4 
rs7964554 6,067,152 Intron 4 4.17x10-7 
rs216308 6,124,666 Intron 24 5.08x10-5 
rs216310 6,127,943 Exon 28 5.32x10-5 
rs216311 6,128,443 Exon 28 9.17x10-5 
rs11612370 6,136,832 Intron 33 2.20x10-5 
rs11612384 6,136,846 Intron 33 6.72x10-5 
rs216330 6,146,630 Intron 37 1.65x10-4 
rs11064003 6,149,706 Intron 37 1.16x10-4 
rs2239162 6,151,670 Intron 37 3.78x10-4 
rs216293 6,153,659 Intron 38 1.80x10-4 
 
 
Figure 3.2: P-values of association between VWF:RCo and single SNPs in VWF 
Association between individual tagging SNPs in VWF and log-transformed VWF:RCo 
adjusting for age and ABO was evaluated using SOLAR. The data show two clusters of 
SNP associations that reach study-wide significance (dashed line) corresponding to 
haplotype blocks 1 and 3. The largest cluster of significant SNP associations maps to 
block 3, which includes exon 28 and the functional domains of the VWF peptide. 
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Two SNPs that map to intron 4 achieved study-wide significance for association 
with VWF:RCo. rs10849363 and rs7964554 are in moderate LD (r2=0.31). Neither SNP 
demonstrated high pairwise correlation with the remaining VWF tagging SNPs in Table 
3.2 (r2 range: 0.00-0.14). Only one SNP outside of VWF, rs2362479, achieved study-
wide significance. rs2362479 maps 31.7 kb telomeric to VWF and demonstrates 
moderate long-range LD with VWF  tag SNP rs7964554 (r2=0.53).  
We established significant associations with VWF:RCo for two SNPs in exon 28, 
the largest and most polymorphic exon: rs216310, a synonymous variant, and rs216311, 
a nonsynonymous variant. rs216311 encodes an A>G change at position 4391 of VWF, 
resulting in a threonine to alanine substitution at amino acid position 1381 (T1381A). 
PolyPhen-2 analysis predicts the T1381A variant is benign (score=0.00). rs216311 is in 
LD with several other significant SNPs, including rs216308, rs11612370, rs11612384, 
rs216330, rs11064003, rs2239162, and rs216293, which demonstrated  
moderate to high pairwise correlations (r2 range: 0.42-0.95). Interestingly, rs216310 is 
not correlated with the other significant SNPs reported herein (r2 range: 0.015-0.031).  
After multiple testing corrections, no SNP achieved study-wide significance for 
association with VWF:Ag. Table 3.3 lists the top six VWF tagging SNPs associated with 
VWF:Ag. For rs2362489, rs10849363, and rs7964554, we also established significant 
associations with VWF:RCo. rs1159993 is a less common variant with a MAF of 0.013 in 
the CEU population and does not demonstrate pairwise correlations with other reported  
                Table 3.3: Top six VWF SNPs associated with VWF:Ag 
SNP BP Location p-value 
rs2362479 6,026,354 Upstream 0.049 
rs10849363 6,066,357 Intron 4 0.017 
rs7964554 6,067,152 Intron 4 6.46x10-4 
rs1159993 6,083,564 Intron 9 0.0092 
rs216314 6,136,580 Intron 34 0.030 
rs216295 6,154,206 Intron 38 0.022 
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tagging SNPs. rs216314 and rs216295 are in almost complete LD and demonstrate 
strong correlation in the Amish pedigree (r2=0.99). Neither of these SNPs demonstrates 
pairwise correlations with VWF:RCo SNPs sufficient to be considered adequate 
substitutes. 
 
Replication of SNP associations in the ZPMCB-VWD, GABC, and TSS cohorts 
Eleven VWF tagging SNPs with established VWF:RCo associations were 
selected for analysis in three replication cohorts: rs10849363, rs7964554, rs216308, 
rs216310, rs216311, rs11612370, rs11612384, rs216330, rs11064003, rs2239162, and 
rs216293. The replication cohorts consisted of three distinct population cohorts, 
including the ZPMCB-VWD control cohort, the GABC sibling cohort, and the TSS cohort 
(Table 3.4).  
The ZPMCB-VWD control cohort includes 150 Caucasian subjects and 66 
African American samples. Variants associated with VWF levels in African-American 
control subjects within the cohort were previously reported146. We demonstrated using 
two-factor Analysis of Variance (ANOVA) that VWF:Ag was significantly higher in 
African-American control subjects compared to Caucasian subjects (p=0.016), which has 
a profound effect on the VWF:RCo/VWF:Ag ratio (p<0.0001), consistent with previous 
observations146. Based on ethnic differences in VWF:Ag, we anticipated significant 
distribution differences of allele frequencies between the Caucasian and African-
American control subjects. For 10 of the 11 candidate SNPs genotyped, the MAF was 
significantly different between the Caucasian and African-American control subjects 
(Table 3.5). 
Within the Caucasian control subjects, we replicated nine significant associations 
with VWF:RCo (Table 3.6). The most significant VWF:RCo associations were 
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     Table 3.4: VWF levels by population-based replication cohort 
Cohort VWF:Ag VWF:RCo 
ZPMCB-VWD Control (Caucasian)* 119.9 (41, 289) 120.2 (46, 301) 
ZPMCB-VWD Control (A. American) * 151.82 (67, 399) 130.0 (52, 290) 
GABC 108.8 (0, 350)† Not available 
TSS 108.4 (0, 265) † Not available 
        * VWF:Ag differs significantly between the Caucasian and African American control    
     subjects (p=0.016). 
        † VWF:Ag of 0 is suspected to be a failed test and corresponding individuals are 
     excluded from analysis 
 
            Table 3.5: MAF by ethnic group in the ZPMCB-VWD control cohort 
Minor Allele Frequency 
SNP Caucasian African American p-value 
rs10849363 0.43 0.18 2.0×10-12 
rs7964554 0.34 0.45 2.7×10-4 
rs216308 0.4 0.14 5.5×10-7 
rs216310 0.36 0.12 1.5×10-6 
rs216311 0.35 0.13 4.2×10-6 
rs11612370 0.26 0.41 0.0019 
rs11612384 0.26 0.42 9.3×10-4 
rs216330 0.33 0.3 0.6 
rs11064003 0.29 0.47 1.8×10-6 
rs2239162 0.33 0.44 1.9×10-4 
rs216293 0.42 0.2 1.2×10-12 
 
Table 3.6: P-values of association tests by ethnicity and phenotype 
 Caucasian African American 
SNP VWF:Ag VWF:RCo Ratio* VWF:Ag VWF:RCo Ratio* 
rs10849363 0.20 0.44 0.59 0.94 0.97 0.90 
rs7964554 0.25 0.55 0.51 0.29 0.28 0.99 
rs216308 0.28 0.01 0.0002 0.22 0.70 0.093 
rs216310 0.30 0.0024 2.5x10-6 0.071 0.41 0.050 
rs216311 0.17 0.0013 1.2x10-5 0.080 0.46 0.041 
rs11612370 0.0008 5.1x10-5 0.087 0.69 0.11 0.024 
rs11612384 0.0003 1.9x10-5 0.083 0.19 0.02 0.077 
rs216330 0.10 0.0025 0.0014 0.90 0.86 0.54 
rs11064003 0.0014 0.0002 0.098 0.50 0.62 0.060 
rs2239162 0.019 0.03 0.80 0.98 0.35 0.18 
rs216293 0.021 0.01 0.22 0.54 0.69 0.070 
* VWF:RCo/VWF:Ag ratio 
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established with rs11612370 and rs1162384, which are in almost complete LD (r2=0.91). 
We established five significant associations with VWF:Ag and four significant 
associations with the VWF:RCo/VWF:Ag ratio. Interestingly, the five SNPs with 
associations to both VWF:Ag and VWF:RCo (rs11612370, rs11612384, rs11064003, 
rs2239162, and rs216293) were not found to be associated with the VWF:RCo/VWF:Ag 
ratio. Conversely, the four SNPs associated with VWF:RCo but not VWF:Ag (rs216308, 
rs216310, rs216311, and rs216330) also established significant associations with the 
VWF:RCo/VWF:Ag ratio. In light of extensive LD within the VWF gene, these findings 
suggest that these nine tagging SNPs constitute two different haplotypes that contain 
unique variants modulating VWF levels. Multivariable logistic regression models predict 
rs11612384 is the most important SNP in explaining variation of VWF:Ag, rs216311 and 
rs11064003 are the most  important SNPs in explaining variation in VWF:RCo, and 
rs216310 is the most important SNPs in explaining the variation of the 
VWF:RCo/VWF:Ag ratio, respectively.  
As suspected, the SNP VWF:RCo associations established in the Amish 
pedigree, a Caucasian discovery cohort, were not replicated in the African-American 
control subjects (Table 3.6). The most significant p-value established corresponded to 
rs11612384 and VWF:RCo (p=0.02). At a threshold of α=0.05, significant associations 
were established between both rs216310 and rs216311 and the VWF:RCo/VWF:Ag ratio 
(p=0.050 and 0.041, respectively). 
To further analyze the 11 tagging SNPs identified in the Amish pedigree study, 
we imputed genotypes from the GABC and TSS population cohorts. In the GABC cohort, 
genotypes were available in 934 subjects. In the TSS cohort, we were able to impute 
genotypes for nine SNPs in 2,145 subjects. VWF:Ag was the only phenotype available in 
both cohorts for evaluation. The MAF and p-values for association tests with VWF:Ag 
are provided in Table 3.7.  
70
         Table 3.7: SNP MAF and p-values of association with VWF:Ag in the GABC  
         and TSS replication cohorts 
 GABC TSS 
SNP MAF(%) p-value MAF(%) p-value 
rs10849363 41.5 0.16 43.4 0.86 
rs7964554 35.8 0.97 36.4 0.95 
rs216308 37.2 0.76 Not available 
rs216310 36.5 0.52 Not available 
rs216311 35.4 0.60 38.7 0.42 
rs11612370 23.4 0.050 27.8 8.0x10-8 
rs11612384 23.4 0.050 27.8 8.0x10-8 
rs216330 32.6 0.59 35.1 0.0099 
rs11064003 26.1 0.0017 30.9 1.34x10-11 
rs2239162 30.3 9.6x10-6 33.3 7.35x10-15 
rs216293 43.5% 0.080 47.7% 2.59x10-8 
 
Within the GABC cohort, rs2239162 demonstrated the most significant 
association (p=9.6x10-6) with VWF:Ag. Three SNPs in moderate LD with rs2239162 
were also found to be associated with VWF:Ag: rs11612370 (r2=0.66, p=0.050), 
rs11612384 (r2=0.66, p=0.050), and rs11064003 (r2= 0.57, p=0.0017). 
We established significant associations with VWF:Ag for six of nine SNPs 
queried in the TSS cohort (Table 3.7). As in the GABC cohort, the most significant 
association with VWF:Ag was rs2239162 (p=7.35x10-15). Pairwise correlation data were 
not available in the TSS cohort to assess independence of the remaining four associated 
SNPs, but we anticipate that rs11612370 and rs11612384 are in complete or near 
complete LD, as demonstrated in the GABC cohort. 
 
Analysis of minor allele frequency in the ZPMCB-VWD Type 1 index case cohort 
 Within the ZPMCB-VWD cohort, we genotyped 11 candidate SNPs in 310 
Caucasian VWD type 1 index cases. We determined the MAF in the index cases and 
compared it to those established in the ZPMCB-VWD control cohort (Table 3.8).   
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Table 3.8: Comparison of MAF between the ZPMCB-VWD control and VWD type 1 
index case cohorts 
Minor Allele Frequency (%) 
SNP Control (n=150)* VWD Type 1 (n=310) p-value 
rs10849363 43.2 49.7 0.067 
rs7964554 34.0 46.2 0.0005 
rs216308 40.3 36.0 0.21 
rs216310 36.1 31.8 1.20 
rs216311 35.3 32.2 0.36 
rs11612370 25.0 18.3 0.018 
rs11612384 25.9 18.3 0.009 
rs216330 33.0 28.8 0.19 
rs11064003 29.5 21.8 0.012 
rs2239162 33.0 22.0 0.0004 
rs216293 41.6 38.1 0.31 
* Caucasian subjects from the ZPMCB-VWD control cohort  
The minor allele of rs7964554 was more common (p=0.0005), while the minor alleles of 
rs11612370, rs11612384, rs11064003, and rs2239162 were less common (p=0.018, 
0.009, 0.012, and 0.0004, respectively) in VWD type 1 index cases compared to 
controls. If the subject has VWD type 1, then the odds of being heterozygous for the 
minor allele of rs7964554 was 1.47 (95% CI: 1.08, 2.00; p=0.014; Table 3.9). Similarly, 
the odds of being heterozygous for the minor allele of rs216308 was 0.64 (95% CI: 0.45, 
0.91; p=0.014). The estimated odds ratios of a VWD type 1 index case being 
homozygous for the minor alleles of rs7964554 or rs216308 were 2.17 and 0.41, 
respectively. 
Sequencing of VWF exons and exon/intron boundaries was previously 
conducted, and suspected VWD type 1 mutations were reported by individual (data not 
shown). To date, molecular classification of VWD type 1 mutations has been lacking. 
Hence, we also compared MAF of VWD type 1 index cases with no identified mutations 
to index cases with reported mutations (Table 3.10). Interestingly, the minor alleles of 
exon 28 variants rs216310 and rs216311 were more common in VWD type 1 index  
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            Table 3.9: Odds ratio of having the minor allele in VWD type 1 index cases 
SNP Odds Ratio 95% CI p-value 
rs7964554 1.47 1.08, 2.00 0.014 
rs216308* 0.49 0.32, 0.74 0.0009 
rs2239162 0.64 0.45, 0.91 0.014 
             * Comparing VWD type 1 index cases with no mutation to index cases with a  
             reported VWF mutation 
 
           Table 3.10: MAF in VWD type 1 index cases by VWF mutation status 
Minor Allele Frequency (%) 
SNP No Mutation (n=180) Mutation (n=130) p-value 
rs10849363 51.4 47.2 0.3071 
rs7964554 48.3 43.4 0.231 
rs216308 41.3 28.7 0.0015 
rs216310 36.9 24.8 0.0016 
rs216311 36.7 26.0 0.0055 
rs11612370 19.6 16.4 0.3138 
rs11612384 19.7 16.4 0.3066 
rs216330 32.5 23.6 0.0173 
rs11064003 22.3 21.1 0.733 
rs2239162 21.9 22.3 0.9087 
rs216293 41.4 33.5 0.0501 
 
cases with no mutations than in index cases with a reported mutation (p=0.0016 and 
0.0055, respectively). The minor alleles of rs216308 and rs216330 were also more 
common in index cases with no mutation. Interestingly, the MAF of rs7964554, 
rs11612370, rs11612384, rs11064003, and rs2239162 were not significantly different 
with respect to VWD type 1 mutations. If the subject had a reported VWF mutation, then 
the odds of being heterozygous for the minor allele of rs2163308 was 0.49 (95% CI: 
0.32, 0.74; p=0.0009; Table 3.9), while the odds ratio for being homozygous was 0.24. 
 
Discussion 
We established significant associations of 12 VWF tagging SNPs with VWF:RCo 
in the Amish pedigree. Nine of the twelve SNPs identified in the Amish discovery cohort 
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map to haplotype block 3, which contains exon 28 and the functional domains of VWF, 
including the A1 domain that binds platelet receptor glycoprotein Ibα (GPIbα) to mediate 
platelet tethering and rolling at the site of endothelial damage12,13. The interaction of 
VWF with platelet GPIbα can be simulated using the antibiotic ristocetin which 
agglutinates formalin-fixed platelets in the presence of VWF (VWF:RCo). Haplotype 
analysis within the Amish pedigree is ongoing. 
 Of the 12 VWF:RCo SNPs identified in the Amish pedigree, two are exonic: 
rs216310 (synonymous variant) and rs216311 (T1381A). The T1381A variant maps to 
the A1 loop domain that binds GP1bα (data not shown). Interestingly, D1472H, an A1 
loop variant which was previously reported to be associated with a lower 
VWF:RCo/VWF:Ag ratio in the ZPMCB-VWD control cohort 146, is also predicted to be a 
benign variant (Polyphen-2 score = 0.00). Further characterization of D1472H 
determined the variant affected ristocetin binding but did not ultimately alter VWF-
platelet interactions. While T1381A may be a functional variant, it may also be in LD with 
other variants modulating VWF levels. Alternatively, as with D1472H, T1381A may 
represent an artificial variant that affect the binding of ristocetin but does not alter VWF-
platelet interactions. 
Nine VWF:RCo SNPs were intronic with one intergenic variant 31.7 kb telomeric 
to VWF. Recently, the Encyclopedia of DNA Elements (ENCODE) Project Consortium 
provided experimental and computational data to predict potential protein binding sites 
including transcription factor binding sites, DNA methylation sites, histone binding 
patterns, and other regulatory features275,276. Multiple components of the ENCODE 
dataset can be explored using the UCSC Genome Browser 
(http://genome.ucsc.edu/ENCODE/).  The region of intron 24 encompassing rs216308 
demonstrated DNase hypersensitivity in the ENCODE dataset, suggesting it may 
comprise a protein binding site (APPENDIX H). For all other variants analyzed, the 
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ENCODE data do not predict the SNPs coincide with protein binding sites or other 
regulatory features (data not shown).   
Providing further exploration of predicted functionality, GERP++ is an algorithm 
that allows genomic evolutionary rate profiling by estimating the evolutionary rates for 
individual alignment columns of multiple mammalian species to generate a rejected 
substitutions score277,278. The rejected substitution score ranges from -12.3 to 6.17 at the 
base-pair-level where positive rejection scores are calculated when fewer substitutions 
are observed than expected assuming a model of neutrality, which is suggestive of 
evolutionary constraint. The rejection score spectrum shifts toward neutral (0) as allele 
frequency increases such that approximately 75% of common variants (MAF between 
0.01 and 0.50) have rejection scores < 2.0. For rs216308, the rejection score is 2.28. 
Thus, rs216308 may represent a functional variant under evolutionary constraint.  
Previously, Van Hout et al. conducted a genome-wide survey of LD in the Old 
Order Amish and compared their findings to the CEU dataset from the International 
HapMap project256.  Allele frequencies were not significantly different for more than 99% 
of SNPs evaluated, though the authors report a slightly lower heterozygosity rate in the 
Amish reflecting the larger number of monomorphic SNPs in the Amish relative to the 
CEU dataset. LD patterns were also similar between the Amish and the CEU dataset 
with slightly less haplotype diversity and larger haplotype blocks in the Amish. The 
authors concluded the limited founder population of the Amish is not sufficient to 
significantly alter the MAF or LD patterns when compared to outbred populations. Thus, 
it is reasonable to assume association analyses and LD patterns established in the 
Amish may be applicable to other Caucasian populations. 
 All nine SNPs in haplotype block 3 were replicated in the ZPMCB-VWD control 
cohort. We established significant associations with VWF:Ag and VWF:RCo to four 
SNPs. Significant associations were established for the remaining five SNPs with 
75
VWF:RCo and the VWF:RCo/VWF:Ag ratio. Cogently, this observation suggests that 
variants altering both VWF:Ag and VWF:RCo do not ultimately significantly alter the 
VWF:RCo/VWF:Ag ratio whereas variants that alter only VWF:RCo also alter the 
VWF:RCo/VWF:Ag ratio. Multivariable logistic regression analysis established that 
different variants are most important for determining the variability of VWF:Ag, 
VWF:RCo, and the VWF:RCo/VWF:Ag ratio. Within the TSS cohort, we also established 
significant associations between six of nine SNPs available for analysis and VWF:Ag. 
Inconsistent replication in the GABC cohort may be due to population stratification. 
Though the majority of the GABC cohort self-reported as Caucasian, other ethnic groups 
were also represented. In total, of the 12 VWF tagging SNPs identified in the Amish 
pedigree, significant associations were established between VWF levels and 
rs11064003 and rs2239162 in the ZPMCB-VWD control, GABC, and TSS cohorts. 
Furthermore, significant associations were established between VWF levels and 
rs11612370, rs11612384, rs216330, and rs216293 in the ZPMCB-VWD control and TSS 
cohorts. We established a significant association for VWF levels with rs216311 in the 
ZPMCB-VWD control cohort as well as rs216308 and 216310, which were not available 
for analysis in the TSS cohort. 
 VWD type 1 is a complex diagnosis where symptoms and levels may overlap 
with the general population. Furthermore, 37-45% of patients do not have a “causal” 
mutation in VWF. The role of VWF variants that contribute to normal variation of levels 
remains unclear in VWD type 1. We report two SNPs with significantly different MAF in 
VWD type 1 index cases when compared to controls: rs7964554 (odds ratio=1.47) and 
rs2239162 (odds ratio=0.64). The minor allele of rs216308 was less common in VWD 
type 1 index cases with a reported VWF mutation than in VWD type 1 index cases with 
no mutation. For rs7964554, we established a significant association with VWF levels 
only in the Amish pedigree whereas significant associations for rs216308 and rs2239162 
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were established in multiple cohorts. Our results suggest that SNPs associated with 





QUANTITATIVE TRAIT LOCUS LINKAGE ANALYSIS IN A LARGE AMISH 
PEDIGREE IDENTIFIES NOVEL CANDIDATE LOCI FOR ERYTHROCYTE TRAITS 
 
Abstract 
We characterized a large Amish pedigree and, in 377 pedigree members, 
analyzed the genetic variance components with covariate screen as well as genome-
wide quantitative trait locus (QTL) linkage analysis of red blood cell count (RBCC), 
hemoglobin (HB), hematocrit (HCT), mean corpuscular volume (MCV), mean 
corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), 
red cell distribution width (RDW), platelet count (PLT), and white blood cell count 
(WBCC) using SOLAR. Age and gender were found to be significant covariates in many 
CBC traits. We obtained significant heritability estimates for RBCC, MCV, MCH, MCHC, 
RDW, PLT, and WBCC. We report four candidate loci with LOD scores above 2.0: 6q25 
(MCH), 9q33 (WBCC), 10p12 (RDW), and 20q13 (MCV). We also report eleven 
candidate loci with LOD scores between 1.50 and 1.99. Bivariate linkage analysis of 
MCV and MCH on chromosome 20 resulted in a higher maximum LOD score of 3.14. 
Linkage signals on chromosomes 4q28, 6p22, 6q25, and 20q13 are concurrent with 
previously reported QTL. All other linkage signals reported herein represent novel 
evidence of candidate QTL. Interestingly rs1800562, the most common causal variant of 




Complete blood counts (CBC) are one of the most commonly ordered laboratory 
tests to provide a rapid and inexpensive appraisal of a patient’s status. Standard CBC 
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analyses report several erythrocyte measures, including red blood cell count (RBCC), 
hemoglobin level (HB), hematocrit (HCT), mean corpuscular volume (MCV), mean 
corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), 
and red blood cell distribution width (RDW), as well as platelet count (PLT) and white 
blood cell count (WBCC). In addition to providing a cursory overall evaluation of current 
status, several associations have been reported between CBC traits and thrombotic 
disease. RBCC and HCT demonstrate association with increased risk of cardiovascular 
disease (CVD); HCT and HB are risk factors for ischemic heart disease; MCV is a risk 
factor for peripheral artery disease (PAD); and RDW is associated with increased risk of 
myocardial infarction (MI), heart failure, and stroke279-284. Furthermore, HCT is 
associated with morbidity and mortality in CVD and RDW is associated with higher 
mortality rates in cases of heart failure, pulmonary emboli, and PAD279,281,283-285. Platelets 
play an important role in acute MI pathogenesis; furthermore, baseline PLT at the time of 
diagnosis is a strong predictor of reocclusion, reinfarction, and mortality even one year 
post-MI205. WBCC is an independent risk factor for the development of new coronary 
heart disease and a prognostic marker in existing cardiovascular disease286. 
CBC traits are multifactorial phenotypes determined by complex etiologies that 
display significant inter-person variation as well as intra-person longitudinal 
stability212,287. Direct and inverse correlations have been well-documented among 
erythrocyte traits, including RBCC, HB, HCT, and MCV287. Intra-individual longitudinal 
stability and strong correlations among hematologic traits suggest these traits are 
subjected to homeostatic regulation, which is influenced by both environmental and 
genetic factors. Several co-morbidities of thrombotic disease are also independent 
environmental modifiers of CBC traits including smoking, alcohol consumption, and use 
of oral contraceptives288-290. Likewise, gender, age, and body mass index are 
documented modifiers of multiple CBC traits including RBCC, MCV, and WBCC287,288,291. 
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Multiple heritability and variance components analyses report genetic variance 
components ranging from 0.10 to 0.86 for RBCC, HB, HCT, MCV, MCH, MCHC, WBCC, 
and PLT216,217,292. Though heritability estimates have varied, there is evidence for both a 
significant genetic component and a significant environmental component for all 
standard CBC traits (with the exception of RDW which has not been previously 
evaluated)287.  
Several genes have been implicated in hematopoiesis due to the identification of 
rare mutations in patients with Mendelian phenotypes. However, common variants in 
these same and other genes are likely involved in modulating more mild variation in 
hematologic phenotypes. One approach to QTL that affect complex traits like the CBC 
traits is to focus on a single large, culturally isolated pedigree where it is reasonable to 
assume that the genetic component represents the common variation of an outbred 
population while being under the control of fewer QTL224,225. Thus, it is anticipated that 
related individuals with similar trait values will have a higher amount of sharing of genetic 
material identical by descent (IBD) near the gene or genes that contribute to the 
quantitative trait. Additionally, genetic isolates demonstrate a more homogenous 
environmental component than populations that are not socially or geographically 
isolated, whereas a collection of ancestrally unrelated smaller pedigrees tend to have 
more variable lifestyles than genetic isolates. We identified, characterized, and collected 
blood samples from a single Amish pedigree diagnosed with von Willebrand disease 
(VWD). CBC traits in this pedigree show variability that is representative of the normal 
population. QTL analysis of the pedigree identified several chromosomal regions that 
appear to harbor QTLs for CBC traits, as reported herein. In addition to identifying novel 




Amish pedigree and complete blood counts 
As described in Chapter II, the Amish pedigree is composed of more than 2,000 
individuals. Informed consent was obtained following institutional guidelines and 
according to the Declaration of Helsinki. Of the 395 pedigree members genotyped for 
genome-wide linkage analysis, eleven pedigree members were not included because of 
their uncertain position in the pedigree and seven others did not have CBC measures. 
Seventy-two individuals were heterozygous for a C>T missense mutation at position 
c.4120 (c.4120C>T) in VWF that results in an arginine to cysteine amino acid 
substitution at codon 1374 (R1374C), resulting in VWD type 2. CBC analyses were 
performed within 24 hours for all individuals and consisted of RBCC, HB, HCT, MCV, 
MCH, MCHC, RDW, PLT, and WBCC. RBCC, HB, and MCV that were measured 
directly, whereas HCT, MCH, and MCHC were mathematically derived from directly 
measured erythrocyte traits (MCVxRBC, HB/RBCC, and MCH/MCV, respectively)293. 
RDW is a measure of the variation of erythrocyte width as evaluated by MCV and is 
defined by an inverse relationship between the standard deviation of MCV and the mean 
MCV. Age-adjusted mean CBC measures were compared between males and females 
and between VWF c.4120C>T mutation carriers and non-carriers (wild-type sequence at 
position c.4120; CC4120) by fitting a two-factor analysis of variance model.  
 
Genome-wide scan 
As described in Chapter II, DNA was extracted with the Gentra Puregene Kit 
(Qiagen) and genotyping of pedigree members was completed by the NHLBI 
Mammalian Genotyping Service at Marshfield, WI using Screening Set 16 with 400 short 
tandem repeat polymorphic (STRP) markers at a 10 centiMorgan (cM) average interval. 
Data were processed and linkage analysis data files were created. Mendelian 
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inconsistencies were identified using the computer program PEDCHECK and 
resolved241.  
 
HFE rs1800562 and ABO rs687289 genotyping 
rs1800562 (HFE C282Y) and rs687289 (ABO) were genotyped in the Amish 
cohort using a commercially-available 5’ allelic discrimination high throughput 
fluorescent genotyping assay (TaqMan, Life Technologies).235 Hardy-Weinberg 
equilibrium was assessed using MENDEL. Assessment of an association of rs180562 
and rs687280 with CBC traits was conducted using SOLAR. 
 
Covariate, heritability, and linkage analyses 
Variance components analysis was conducted using the SOLAR (Sequential 
Oligogenic Linkage Analysis Routines, version 4.2.7) program and the significance of 
age, gender, rs687289 (an ABO blood group proxy), and the VWF c.4120C>T mutation 
as covariates for CBC traits RBCC, HB, HCT, MCV, MCH, MCHC, RDW, PLT, and 
WBCC was assessed244. The genetic variance component of the quantitative 
phenotypes was estimated using SOLAR assuming a polygenic model incorporating 
covariates found to be significantly associated with the analyzed trait. All individuals in 
the pedigree were included in the analysis. Multipoint variance component quantitative 
trait linkage analysis was also conducted using SOLAR. Because of the large size of this 
pedigree, the multipoint estimates of pairwise identity by descent (IBD) status that are 





Description of CBC traits and heritability estimates 
Standard CBC analyses were conducted for 384 Amish pedigree members; CBC 
data were available for 377 (Table 4.1). As gender is known to be associated with 
several erythrocyte traits, we described all CBC traits by gender and VWF mutation 
status. Males had a higher mean RBCC, HB, HCT, and MCHC and lower mean WBCC 
than females, which is consistent with previously reported findings217. Two-factor age-
adjusted Analysis of Variance (ANOVA) established males were younger than females 
and had a significantly higher mean RBCC, HB, HCT, and MCHC. Pedigree members 
who were heterozygous (C4120T, VWD) mutation carriers had significantly higher PLT, 
WBCC, and RDW than homozygous (CC4120, wild-type [WT]) members (Table 4.1).  
Additionally, previous studies reported that RBCC, HB, and HCT are highly 
correlated traits287. Within the Amish cohort, we demonstrated strong correlations 
(r2≥0.80) between RBCC, HB, and HCT as well as MCV and MCH (Table 4.2). 
Table 4.1: Comparison of CBC traits by gender and VWF mutation 
 Age RBCC HB HCT MCV MCH MCHC RDW PLT WBCC 
Mean 21.5 4.8 13.8 40.4 84.4 29.0 34.1 13.2 299.5 7.3 
Male 18.8* 4.9† 14.1† 41.3† 83.4 28.6 34.2* 13.3 298.0 7.3 
Female 24.2 4.6 13.4 39.6 85.4 29.3 33.9 13.2 301.1 7.4 
            
VWF C4120T 25.1 4.8 13.8 40.5 84.8 28.8 34.0 13.4‡ 310.8‡ 7.7‡ 
VWF WT 20.7 4.8 13.8 40.4 84.3 29.0 34.1 13.2 297.0 7.2 
            
Standard 
Deviation 
17.2 0.4 1.5 4.1 4.8 3.3 1.1 1.3 78.2 2.8 
Male 16.5 0.4 1.6 4.6 4.3 1.7 1.2 1.5 80.4 3.2 
Female 17.5 0.3 1.2 3.4 5.1 4.3 0.9 1.0 76.1 2.4 
            
VWF C4120T 19.6 0.4 1.6 4.6 5.4 2.1 1.1 1.0 77.7 3.5 
VWF WT 16.5 0.4 1.4 4.0 4.7 3.5 1.1 1.3 78.2 2.6 
* p<0.025 comparing males vs. females 
† p<0.0001 comparing males vs. females 
‡ p<0.05 comparing VWF C4120T vs. VWF WT 
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Table 4.2: Correlation of CBC traits 
RBCC HB HCT MCV MCH MCHC RDW PLT WBCC 
RBCC 1 0.80 0.82 0.04 0.05 0.06 -0.15 -0.18 -0.19 
HB 0.80 1 0.97 0.54 0.56 0.24 -0.42 -0.37 -0.30 
HCT 0.82 0.97 1 0.56 0.49 0.05 -0.41 -0.32 -0.22 
MCV 0.04 0.54 0.56 1 0.89 -0.03 -0.55 -0.32 -0.19 
MCH 0.05 0.56 0.49 0.89 1 0.34 -0.11 -0.23 -0.19 
MCHC 0.06 0.24 0.05 -0.03 0.34 1 -0.11 -0.23 -0.19 
RDW -0.15 -0.42 -0.41 -0.55 -0.52 -0.11 1 0.19 0.10 
PLT -0.18 -0.37 -0.32 -0.32 -0.37 -0.23 0.19 1 0.51 
WBCC -0.19 -0.30 -0.22 -0.19 -0.26 -0.19 0.10 0.51 1 
 
We also identified moderate correlations (r2 range: 0.49 to 0.56) of HB and HCT with 
MCV and MCH as well as moderate inverse correlations between RDW and HB, HCT, 
MCV, and MCH (r2 range: -0.41 to -0.55). 
In the variance components analysis, age was significantly associated with all 
CBC traits (Table 4.3). Gender was significantly associated with RBCC, HB, HCT, 
MCHC, and WBCC. The VWF c.4120C>T mutation was not associated with any CBC 
trait and was excluded as a covariate from all subsequent analyses. For RBCC, age-
squared was also significant. Significant genetic variance components estimates were 
obtained for RBCC, MCV, MCH, MCHC, RDW, PLT, and WBCC, with MCHC, RDW, 
PLT, and WBCC demonstrating the highest genetic variance components (0.48, 0.35,  











RBCC 7.005x10-14 2.478x10-21 0.119 0.258 0.23 0.00675 
HB 6.056x10-39 2.699x10-19 0.312 0.267 0.12 0.0792 
HCT 2.435x10-33 2.750x10-16 0.229 0.596 0.04 0.215 
MCV 5.482x10-31 0.153 0.553 0.716 0.20 0.00213 
MCH 6.135x10-25 0.841 0.789 0.840 0.22 0.00916 
MCHC 0.01881 1.056x10-4 0.813 0.663 0.48 1.060x10-9
RDW 1.773x10-13 0.411 0.134 0.462 0.35 5.103x10-9 
PLT 1.682x10-13 0.0972 0.994 0.348 0.57 3.140x10-12 
WBCC 1.238x10-7 7.601x10-3 0.427 0.258 0.41 2.360x10-11 
* VWF c.4120C>T mutation, VWD 
† rs687289 SNP in ABO, a surrogate marker of ABO blood type 
§ GVC: genetic variance components 
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0.57, and 0.41, respectively; Table 4.3).Within the Amish pedigree, the genetic variance 
components for HB and HCT were not significant. 
Previous studies reported evidence for the ABO gene on chromosome 9q33 as a 
candidate QTL for several erythrocyte traits223,294. We identified linkage of WBCC to 
chromosome 9q33 (Table 4.4), but we did not identify concomitant linkage for 
erythrocyte traits. In characterizing the Amish pedigree for VWD, ABO blood types were 
determined by sequencing (see Chapter II). Type O blood is over-represented within the 
Amish cohort and type B blood is under-represented. Analyses of blood types with CBC 
traits were limited to homozygous type A (A,A), heterozygous type A (A,O), and 
homozygous type O (O,O). No significant differences in CBC trait means were identified 
between blood group genotypes (data not shown). Additionally, rs687289, a surrogate 
genetic marker for ABO, was previously genotyped within the Amish cohort. With 
SOLAR, rs687289 was evaluated as a covariate of CBC traits, and no association was 
found with WBCC (p=0.258) or other erythrocyte traits (Table 4.3). 
 
Genome-wide QTL linkage analysis of CBC traits 
Genome-wide QTL linkage analysis was conducted using SOLAR for RBCC, 
MCV, MCH, MCHC, RDW, PLT, and WBCC (Figure 4.1). Age was included as a 
covariate for all CBC traits and gender was included as a covariate for RBCC, MCHC, 
and WBCC (Table 4.3). HB and HCT were excluded as there was no evidence for a 
significant genetic component in the Amish pedigree. Four candidate loci with logarithm 
of odds (LOD) scores above 2.0 were identified (Table 4.4; Figure 4.2): 6q25 (MCH), 
9q33 (WBCC), 10p12 (RDW), and 20q13 (MCV). We also identified eleven candidate 
loci on eight chromosomes with LOD scores between 1.5 and < 2.0 (Table 4.4): RBCC  
(2q37.3, 3p22, 4q28), MCV (4q35, 7p15), MCHC (6p22), RDW (13q32), WBCC (2q35, 
10p15, 13q14), and PLT (22q11). 
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Figure 4.1: Genome-wide SOLAR QTL linkage scans 
Quantitative trait locus linkage analysis was performed using SOLAR. The graphs 
represent the genome-wide scan results for RBCC (A), MCV (B), MCH (C), MCHC (D), 
RDW (E), PLT (F), and WBCC (G). Somatic chromosomes are represented along the x-
axis, and chromosome numbers are centered below the respective graph. LOD scores 
are represented along the y-axis with the scale relative to the maximum LOD score of 
the scan. As QTL analysis is a multipoint chromosome-wide analysis, the traces 
represent the LOD score as a continuous trace across the chromosome evaluated at 
each centiMorgan (cM). The maximum LOD score for single-trait analyses corresponds 
to MCH and maps to chromosome 6q25 (LOD=2.46) followed by WBCC on 9q33 
(LOD=2.18), MCV on 20q13 (LOD=2.17), and RDW on 10p12 (LOD=2.09). 
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Figure 4.2: Chromosome-specific SOLAR QTL linkage scans for LOD scores > 2.0 
Each panel represents a chromosome-wide scan for phenotypes where a candidate QTL 
was identified with a LOD score greater than 2.0. The map position along the 
chromosome is represented in cM along the X-axis and the LOD score is represented 
along the Y-axis. STRP marker names genotyped along each respective chromosome 
are imposed on the graphs vertically to represent the approximate coverage of each 
signal. Linkage traces are plotted continuously across a chromosome with an estimated 
LOD score at each cM. A) Chromosome 6, MCH (LOD=2.46). B) Chromosome 9, WBCC 






Table 4.4: Genome-wide QTL linkage analysis results LOD score > 1.5 
Chromosome Phenotype 1-LOD Interval (Mb)
Nearest 
Marker LOD p-value 
1q32 PLT 208.28-227.02 GATA48B01 1.77 p=0.003 
2q35 WBCC 222.70-235.96 GATA4G12 1.53 p=0.005 




3p22 RBCC 26.72-41.17 GATA27C08 1.71 p=0.001 
4q28 RBCC 112.12-136.85 GATA62A12 1.91 p=0.001 
4q35 MCV 190.78-191.15 165zf8ZP 1.76 p=0.001 
6q25 MCH 151.41-161.61 GATA184A08 2.46 p<0.001 
6p22 MCHC 16.00-38.78 GATA163B10 1.55 p=0.003 
7p15 MCV 18.03-26.97 GATA41G07 1.77 p=0.001 
9q33 WBCC 121.94-133.23 GATA64G07 2.18 p=0.002 
10p15 WBCC 0.00-4.93 GATA88F09 1.98 p=0.002 
10p12 RDW 18.41-38.59 GATA70E11 2.09 p=0.001 
13q32 RDW 102.10-109.72 ATA26D07 1.61 p=0.005 
13q14 WBCC 47.06-77.57 GATA11C08 1.61 p=0.005 
20p12.1-p11.23 MCV-MCH 11.14-48.64 GATA129B03 3.14 N.A. 
20q13 MCV 44.00-48.51 GATA47F05 2.17 p<0.001 
22q11 PLT 0.00-23.22 GATA198B05 1.69 p=0.004 
 
The chromosome 10p12 QTL for RDW represents one of the strongest linkage 
signals identified herein. Linkage between chromosome 9q33 and WBCC represents a 
novel finding. The candidate QTL for RBCC that maps to chromosome 4q28 is a novel 
finding, although linkage of RBCC to 4q31.2-q34.1 was reported in an Australian 
adolescent twin cohort (Table 4.5)295. Additionally, we identified a candidate QTL with a 
LOD score suggestive of linkage for MCV at 4q35 (Table 4.4, Figure 4.3). These three 
linkage intervals for RBCC and for MCV, which is inversely proportional to RBCC, 
suggest the presence of a QTL on the long arm of chromosome 4. The candidate 
linkage intervals for MCHC and MCH on chromosome 6p22 and 6p25, respectively, and 
MCV on chromosome 20q13 are consistent with previously reported QTL (Table 4.5). All 
other candidate linkage intervals in Table 4.4 are evidence of novel candidate QTL. 
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Table 4.5: Previously published candidate QTL concomitant with Amish pedigree 
Chromosome Phenotype SNP Gene Statistics Study 
4q31.2-q34.1 RBCC LOD=3.07 Iliadou295 
6p22.1 HB rs1800562 HFE p=5.74x10-19 Ganesh296 
6p22.1 HB rs1800562 HFE p=1.40x10-15 Lo223 
6p22.1 HCT rs1800562 HFE p=2.04x10-9 Ganesh296 
6p22.1 HCT rs1800562 HFE p=2.50x10-10 Lo223 
6p22.1 MCH rs1800562 HFE p=2.76x10-9 Kullo297 
6p22.1 MCV rs1800562 HFE p=1.40x10-23 Soranzo222 
6p22.1 MCV rs1800562 HFE p=1.01x10-46 Ganesh296 
6p22.1 MCV rs1800562 HFE p=6.80x10-16 Lo223 
6p22.2 MCH rs1408272 SLC17A3 p=3.87x10-39 Ganesh296 
6p22.2 MCH rs17342717 SLC17A1 p=4.66x10-8 Kullo297 
6q25.1 RBCC rs727979 TAB2 p=6.30x10-6 Yang166 
6q25.3-q27 RBCC rs2023048 LOD=2.9 Yang166 
20p12.3 RBCC rs6108011 p=5.8x10-6 Yang166 




Figure 4.3: SOLAR QTL linkage scans of chromosome 4 for RBCC and MCV 
The map position along the chromosome is represented in cM along the X-axis and the 
LOD score is represented along the Y-axis. STRP marker names genotyped along each 
respective chromosome are imposed on the graphs vertically to represent the 
approximate coverage of each signal. Linkage traces are plotted continuously across a 





Two candidate loci on chromosome 6, corresponding to 6p22 for MCHC and 
6q25 for MCH, were identified (Table 4.4). Ten associations with five erythrocyte 
measures were previously reported on chromosome 6p22, eight of which are with 
rs1800562, a nonsynonymous variant in the hemochromatosis gene, HFE (Table 4.5). 
rs1800562 has been associated with HB, HCT, and MCV in two meta-analyses of 
Caucasian cohorts223,296. Additionally, rs1800562 associations have been reported with 
serum iron as well as transferrin traits298. Fifty linkage and association signals of 
erythrocyte measures, including RBCC, HCT, HB, MCH, MCHC, and MCV, have been 
reported at multiple loci on the long arm of chromosome 6 in multiple Caucasian 
cohorts166,223,295,296. The Framingham Heart Study reported linkage and association of 
RBCC with 6q25.3-q27 and 6q25.1, respectively, which map within the 6q25 candidate 
linkage interval for MCH (Table 4.5)166. Additionally, for MCV, a LOD score weakly 
suggestive of linkage was identified on 6q25, overlapping with the MCH QTL (Appendix 
I). Due to the strong correlation between MCV and MCH, we conducted bivariate QTL 
linkage analysis for MCV-MCH on chromosome 6. Bivariate analysis lowered the 
maximum LOD score achieved with MCH, suggesting that 6q25 primarily impacts MCH. 
Multiple associations between erythrocyte traits and loci on chromosome 20 have 
been reported166,296. QTL analysis also identified weak evidence of linkage between 
chromosome 20q13 and MCH (Appendix I). We therefore conducted bivariate analysis 
for MCV-MCH on chromosome 20, which resulted in a higher maximum LOD score of 
3.14 (Table 4.4, Figure 4.4). When considered alone, the peak linkage region for MCV 
maps to 20q13 and the 1-LOD interval is restricted to the long arm of chromosome 20. 
Bivariate analysis of MCH-MCV shifted the peak linkage region to 20p12.1-p11.23. The 
1-LOD interval of the bivariate QTL encompasses the centromere and the entire MCV 
QTL reported herein. RBCC is inversely proportional to both MCV and MCH, and HB is 
proportional to MCH. In Caucasian populations, an association between RBCC and  
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Figure 4.4: SOLAR QTL linkage scan of chromosome 20 for MCV-MCH 
The map position along the chromosome is represented in cM along the X-axis and the 
LOD score is represented along the Y-axis. STRP marker names genotyped along each 
respective chromosome are imposed on the graphs vertically to represent the 
approximate coverage of each signal. Linkage traces are plotted continuously across a 
chromosome with an estimated LOD score at each cM. The maximum LOD score of 
3.14 maps to 20p12.1-p11.23 whereas the peak LOD score for the univariate analysis of 
MCV maps to the long arm of chromosome 20 (figure 4.2). Markers GATA29F06 and 
GATA42A03 flank the centromere, which corresponds to the trough within the 1-LOD 
candidate QTL interval. 
 
rs6108011 corresponds to the peak of the 20p12.1-p11.23 MCV-MCH linkage interval 
and an association between HB and rs6013509 (3 Mb telomeric to the 1-LOD linkage 
interval for MCV-MCH).166,296 
 
Proportion of variation attributable to candidate QTL 
To evaluate the proportion of variation accounted for by the candidate QTL 
reported herein, we employed an internal function of SOLAR that estimates the 
proportion of variance associated with a linkage element (denoted as H2q1) for each 
marker. Table 4.4 lists the short tandem repeat polymorphic (STRP) marker nearest the 
peak LOD score that was used to estimate H2q1 for the corresponding QTL. From this 
analysis, we determined that 6q25 (GATA184A08) accounted for 24.15% of the variation 
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in MCH, 9q33 (GATA64G07) accounted for 13.40% of the variation in WBCC, 10p12 
(GATA70E11) accounted for 26.67% of the variation in RDW, and 20q13 (GATA47F05) 
accounted for 37.41% of the variation in MCV in the Amish pedigree. Furthermore, on 
chromosome 4, 4q28 (GATA62A12Z) accounted for 24.15% of the variation in RBCC 
and 4q35 (165zf8ZP) accounted for 31.41% of the variation in MCV. 
 
HFE C282Y is associated with MCH and MCHC 
Interestingly, rs1800562, which has been associated erythrocyte traits in multiple 
studies (Table 4.5), corresponds to the amino acid change C282Y in HFE, the most 
common causal variant of hereditary hemochromatosis (MIM: 235200). Within the Amish 
pedigree, rs1800562 was found to be in Hardy-Weinberg equilibrium, with a minor allele 
frequency of 0.16. With adjustment for age and gender, there was significant 
associations of rs1800562 genotype with MCH (p=0.0036) and MCHC (p=0.0056), but 




CBC traits are multifactorial phenotypes determined by environmental and 
genetic components. Clinical assessment of CBC traits as risk factors and prognostic 
factors in thrombotic disease has been inconsistent due to the complex etiology of the 
phenotypes as well as a publication bias for small clinical studies that identify large 
effects299,300. Further elucidating environmental and genetic determinants of hematologic 
traits will allow for more accurate analyses and improve estimates of clinical significance.  
No genes within the 1-LOD interval for RBCC on chromosome 4q28 have been 
previously reported to affect erythropoiesis. Three genes involved in cellular replication 
and differentiation, though not directly implicated in erythropoiesis, demonstrate 
92
relatively high expression in hematopoietic cell linages, including early erythroid cells 
(GNF Expression Atlas 2 Data from U133A and GNF1H Chips, UCSC Genome Browser; 
http://www.genome.uscs.edu): MAD2L1, EXOSC9, and CCNA2. MAD2L1 encodes a 
component of the mitotic spindle assembly checkpoint and is homologous to MAD2, a 
checkpoint component that stabilizes kinetochore-microtubule attachments301. Cyclin A2 
(CCNA2) is a mammalian cell cycle regulator that promotes G1/S and G2/M transitions, 
and siRNA-mediated knockdown of CCNA2 in K562 cells resulted in a significant 
decrease in erythroid differentiation following doxorubicin administration302. In low doses 
doxorubicin induces erythroid differentiation of K562 cells (human leukemic cell lineage), 
suggesting that CCNA2 may play a role as a key regulator of erythropoiesis. 
Additionally, we identified a candidate QTL with a LOD score suggestive of 
linkage for MCV that maps to chromosome 4q35 (Table 4.4) and contains MLF1IP which 
encodes MDS/myeloid leukemia factor 1 (MLF1) interacting protein, a component of the 
kinetochore complex. Overexpression of Hls7, the mouse ortholog of MLF1, results in 
suppression of erythropoietin-induced differentiation of the J2E erythroleukemic cell line, 
suggesting MLF1 and its binding partners (including MLF1IP) may play a role in 
suppression of erythrocyte maturation303. While the causal gene on chromosome 4 
remains unclear, the two linkage intervals for RBCC and MCV reported herein and the 
previous report of linkage of RBCC strongly suggest the presence of a QTL for RBCC on 
the telomeric half of the long arm of chromosome 4. 
The short arm of chromosome 6 contains several gene clusters, including 
transfer RNA genes, histone cluster component genes, and the major histocompatibility 
complex gene cluster. Three candidate genes within the linkage interval for MCHC 
include MAD2L1BP, the binding partner of MAD2L1, a candidate gene for RBCC 
previously discussed; HFE, to which multiple MCH, HB, and HCT associations have 
been reported (Table 4.5); and FANCE, a Fanconi anemia gene.  
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HFE encodes an MCH class-I type gene that regulates serum iron levels by 
increasing the dissociation constant of transferrin from the transferrin receptor complex, 
reducing transferrin-mediated iron uptake within the gastrointestinal tract, and inhibiting 
iron efflux from monocyte and macrophage cells304,305. rs1800562, which has been 
associated with multiple erythrocyte traits as previously discussed, corresponds to a 
cysteine to tyrosine mutation at position 282 (C282Y), the most common mutation 
underlying the autosomal recessive disease hereditary hemochromatosis. 
Hemochromatosis is characterized by systemic iron overload but also anemia of chronic 
disease due to iron withholding from maturing erythrocytes306. 
C282Y is a common HFE variant, with an estimated prevalence of 5-10% among 
populations of northern European ancestry and rare among other ethnic groups.307 In the 
Amish pedigree, we identified a higher MAF, approximately 16%, which may be due to 
sampling bias or may reflect a higher prevalence of the C282Y variant among Anabaptist 
population isolates. Hfe -/- mice are resistant to Salmonella typhimurium septicemia, 
which may explain a selective pressure resulting in the prevalence of the C282Y among 
Caucasian populations308. Healthy cohorts screened for C282Y status and evaluated for 
evidence of hemochromatosis or iron overload-related disease demonstrate a range in 
the prevalence of clinically significant hemochromatosis from less than 1% to 28%, 
estimates that have been disputed as being too low and too high, respectively309,310. 
Thus, it is reasonable to hypothesize that C282Y, as well as other common variants 
within HFE, may also contribute to complex iron-dependent traits, such as the 
erythrocyte measures MCH and MCHC. 
The peak linkage region for MCV-MCH on chromosome 20 maps to 20p12.1-
20p11.23 and contains SEC23B, a COPII vesicle coat component involved in ER-to-
Golgi trafficking. Mutations in SEC23B have been identified in several familial cases of 
congenital dyserythropoietic anemia (CDA) type II, a form of anemia resulting from 
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ineffective erythropoiesis which is characterized by phenotypic variability311. Short 
hairpin RNA (shRNA)-mediated knock-down of sec23b in zebrafish results in aberrant 
erythropoiesis311. BMP2, which maps to 20p12.3 (telomeric of the 1-LOD linkage interval 
reported herein), encodes a bone morphogenetic protein that is part of the transforming 
growth factor-beta superfamily. In a study of hemochromatosis penetrance to identify 
genetic modifiers, significant association was demonstrated between rs235756 and 
ferritin levels; however, the role of the BMP pathway in modulating hemochromatosis 
penetrance remains unclear and BMP2 has not to date been implicated in 
erythropoiesis312. E2F1, which maps to 20q11.22, within the 1-LOD interval reported 
herein, encodes a component of cell cycle regulation that is mediated by BMP2, which 
suggests that HFE, BMP2, and E2F1 may encode components of a single pathway that 
affect erythrocyte traits313. XKR7, a Kell blood group complex subunit; EPB41L1, a 
neuronal variant of EPB41; and HCK (hemopoietic cell kinase), a member of the Src 
tyrosine kinase family primarily expressed in myeloid and B-lymphoid cell lineages, are 
also contained within the 1-LOD interval but seem less likely as modulators of 
erythrocyte traits. 
In summary, we characterized a large Amish pedigree and identified several 
chromosomal regions of linkage to CBC traits. We also demonstrated association 
between rs1800562 and MCH and MCHC, confirming HFE as a candidate QTL of 
erythrocyte traits. These newly discovered QTLs are likely to harbor genes that may 
provide insight into genetic components underlying hematopoiesis and could have 
important implications for understanding the genetic basis of bleeding and thrombosis. 
Furthermore, a more complete elucidation of the variation of CBC traits will allow a more 





DIFFERENTIAL VWF MUTANT MONOMER INCORPORATION DRIVES THE 
PHENOTYPE VARIABILITY OBSERVED IN A FAMILY WITH VWD TYPE 22 
 
Abstract 
Von Willebrand disease (VWD) is characterized by incomplete penetrance and 
variable expressivity. We characterized a 24-member pedigree with VWD type 2 due to 
a novel VWF T>G missense mutation at position c.3911 (c.3911T>G) that predicts a 
methionine to arginine change (M1304R) in the A1 domain of the von Willebrand factor 
(VWF) polypeptide.  The c.3911T>G mutation segregated with low VWF levels in an 
autosomal-dominant manner and resulted in clinical and biochemical phenotypic 
variability, including different VWF multimer patterns among VWD patients  
heterozygous for the c.3911T>G mutation. Sequencing of the complete coding regions 
of VWF in one patient and one unaffected relative did not identify additional mutations or 
VWF polymorphisms previously associated with VWF levels or activity. Evaluation of 
allele-specific mRNA levels by a novel primer extension assay demonstrated consistent 
mRNA ratios that cluster within unaffected relatives and VWD patients, ruling out a 
hypomorphic wild-type allele. In vitro expression of the c.3911T>G allele showed 
decreased VWF secretion and lack of storage granules. When co-expressed with the 
wild-type (WT) VWF allele, total VWF secretion was also decreased and no storage 
granules were formed, indicating that the M1304R substitution affects VWF trafficking. 
Gel electrophoresis analysis and immunostaining of VWF isolated form cell culture with 
                                                            
2 The Sandy Haberichter laboratory conducted all cell culture data. The in silico modeling 
of the M1304R mutation was completed by Donald Backos and Gianluca Interlandi. 
Nanobody binding experiments were conducted by the Jose Lopez laboratory. Jesse 
Hinckley designed and/or conducted all other experiments presented herein including 
pedigree characterization, VWF exon 28 and SNP sequencing, allele-specific mRNA 
quantification, and analysis and description of data provided by others. 
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demonstrated incorporation of the mutant monomer into VWF multimers. A llama 
nanobody (AU/VWFa-11), which detects the mutated A1 domain, bound with a wide 
range of variability among affected family members, indicating that VWF multimers 
contain different amounts of mutant monomers. These findings suggest that the 
observed variability in VWD phenotypes could in part be defined by the rate of mutant 
monomer incorporation into the mature VWF multimeric molecule. 
 
Introduction 
Von Willebrand disease (VWD) is the most common congenital bleeding disorder 
and is caused by quantitative or qualitative defects in von Willebrand factor (VWF).  The 
VWF gene is approximately 178 kilobases (kb) long and maps to chromosome 
12p13.328,29,314. Exons 1-17 encode the signal peptide and propeptide and exons 18-52 
encode the mature VWF polypeptide monomer. A pseudogene with homology to exons 
23-34 of VWF maps to chromosome 22 and contains several nonsense and splice site 
mutations, suggesting that it is unable to generate functional transcripts30,33.  
VWF is an adhesive glycoprotein that is necessary for the initial attachment of 
platelets to the blood vessel wall at sites of injury.  It is synthesized by endothelial cells 
and platelets where it is stored in the Weibel-Palade bodies and platelet α-granules, 
respectively, until released at the site of endothelial damage32,315,316.  VWF monomers 
homodimerize; undergo several posttranslational modifications in the endoplasmic 
reticulum and trans-Golgi network; and form large multimers through polymerization, 
ranging in size from 0.5 to 200 million daltons22,317. 
Mild and severe quantitative defects of VWF are classified as VWD types 1 and 
3, respectively, whereas qualitative defects of VWF are classified as VWD type 245. 
VWD type 2 can be the result of abnormal multimerization or dimerization; impaired 
secretion of VWF high molecular weight multimers (HMWM); increased ADAMTS13 
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cleavage; or abnormal interaction of VWF binding with platelet receptor glycoprotein 
(GP) 1b, collagen, or coagulation factor VIII318. The complexity of VWD is underscored 
by the variability observed in both the clinical phenotype (mucocutaneous bleeding) and 
the biochemical phenotype (represented by VWF levels, activity, and multimer pattern) 
among VWD patients. Though considered a monogenic disease, VWD is characterized 
by incomplete penetrance and variable expressivity, even in families with a single causal 
VWF mutation47,319. Variability may be explained in part by differences in VWF 
expression or incorporation of the mutant peptide monomer into VWF multimers. 
We identified a 24-member family including 11 individuals with VWD caused by a 
novel VWF mutation in exon 28. Interestingly, affected members of this family exhibit 
significant variability in VWF levels, multimer distribution, and bleeding severity. We 
thoroughly investigated the potential genetic and molecular mechanisms involved in this 
variability and demonstrated differential incorporation of the mutant subunit into plasma 




Twenty-four members of a single Caucasian multi-generational pedigree (11 
VWD patients and 13 unaffected relatives) were recruited at the bleeding disorders clinic 
of the University of Iowa. The study received institutional review board approval from the 
University of Iowa and the University of Colorado Anschutz Medical Campus, and 
informed consent was obtained following institutional guidelines and according to the 




VWF antigen and ristocetin cofactor levels (VWF:Ag and VWF:RCo, respectively) 
and factor VIII coagulant activity (FVIII:C) were measured for all recruited pedigree 
members who provided blood samples. VWF:Ag was measured by standard enzyme-
linked immunosorbent assay (ELISA) with a combination of two monoclonal antibodies 
as previously described146. Briefly, plasma samples were plated into duplicate wells at 
three different dilutions per sample. Captured VWF was detected with polyclonal rabbit 
antibody with an enzyme conjugate reaction. Agreement between dilutions was 
evaluated as a quality control measure. VWF:RCo was measured by automated analysis 
of formalin-fixed platelet agglutination on a Dade-Behring BCS analyzer (Dade Behring 
Inc. Newark, DE). Data were analyzed using the manufacturer’s end-point based 
software package. FVIII:C was determined by one-stage clotting assay in an MLA 900 
analyzer using a "lupus-anticoagulant" insensitive activator reagent (Actin FS, Dade 
Behring Inc.). Samples were measured at three dilutions and results were compared to a 
standard curve. FVIII:C was reported in relation to a population reference range. VWF 
multimer analysis was performed in all affected individuals. The VWF multimer pattern 
was evaluated by 1.5% agarose gel electrophoresis followed by Western blotting with a 
polyclonal VWF antibody, as previously described320. 
 
Bleeding score 
As described in Chapter II, to evaluate the bleeding phenotypes of pedigree 
members, a modified bleeding questionnaire that consisted of 10 questions that were 
selected on the basis of their positive predictive value was administered at study 
enrollment. Questions focused on nosebleeds, minor injury (cuts), bruising, gingival 
bleeding, bleeding after dental and surgical procedures, and transfusion requirements. 
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Questionnaires are graded on a Likert scale with the lowest (no clinical symptoms of 
bleeding) possible score being 0 and the highest (most severe) score being 7. 
 
Isolation of genomic DNA and VWF sequencing 
Genomic DNA was isolated from whole blood using a commercially available kit 
(Qiagen, Germantown, MD). Since VWF:RCo and VWF:Ag levels in several pedigree 
members suggested the diagnosis of VWD type 2, the sequencing strategy for VWF 
focused on exon 28, which harbors the majority of type 2 mutations. PCR and 
sequencing primers were designed to discriminate and selectively amplify VWF exon 28 
versus its corresponding pseudogene33. PCR was performed on genomic DNA using 
standard conditions, and Sanger sequencing was performed using BigDye V3.1 on an 
ABI3730xl DNA analyzer (Life Technologies, Carlsbad, CA). Analysis was conducted 
using Sequencher V4.9 (Gene Codes Corporation, Ann Arbor, MI). To rule out the 
presence of additional mutations in the VWF gene, full-length sequencing of genomic 
DNA for VWF, including introns, was performed in one VWD patient and one unaffected 
relative at the Partners Healthcare Center for Genetics and Genomics (Harvard Medical 
School, Boston, MA).  
 
In silico molecular modeling 
Molecular modeling studies were conducted using Accelrys Discovery Studio 3.0 
(Accelrys Software, Inc., San Diego, CA; http://accelrys.com).  The crystal structure 
coordinates of the human von Willebrand factor fragment (residues 1269-1466) in 
complex with GP1bα (PDB: 1SQ0) was obtained from the protein data bank 
(http://www.pdb.org).  Structures of the M1304R mutant were constructed by altering the 
wild-type (WT) residue to the mutant form.  Predicted mutation-induced changes in 
energy and/or protein conformation were determined by subjecting the WT and mutant 
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structures to the conjugate gradient minimization protocol using a CHARMM forcefield 
and the Generalized Born implicit solvent model321,322. Predicted protein-protein 
interactions between the minimized WT and/or mutant fibrinogen fragment D structures 
were calculated using the ZDock algorithm323.  The ZRank scoring function was used to 
calculate the interaction energies of the resulting predicted protein complexes and 
represents a combination of van der Waals attractive and repulsive energies, short and 
long range repulsive and attractive energies, and desolvation324.  Similarity of the 
predicted protein complexes to the crystal structure (1SQ0) was determined by 
calculating and the root mean square deviation (RMSD) using the crystal structure as 
the reference.  The four poses with the lowest RMSD values (i.e. the highest similarity to 
the crystal structure) were selected from each group for comparison. 
Molecular dynamics (MD) simulations were performed in order to investigate 
possible structural mechanisms by which the M1304R substitution may inhibit the 
function of the A1 domain. The simulation with the WT was started from the 
crystallographic structure with PDB code 1AUQ. The mutant M1304R was obtained per 
homology using the program CHARMM to construct missing atoms from internal 
coordinates. The coordinates of the mutated side chain were minimized with 100 steps 
of steepest descent325. The MD simulations were performed with the program NAMD 
using the CHARMM all-hydrogen force field (PARAM22) and the TIP3P model of 
water326,327. Electrostatic interactions were calculated within a cutoff of 10 Å, while long-
range electrostatic effects were taken into account by the Particle Mesh Ewald 
summation method328. Van der Waals interactions were treated with the use of a switch 
function starting at 8 Å and turning off at 10 Å.  The dynamics were integrated with a 
time step of 2 fs using SHAKE to rigidly constrain hydrogen atoms. Snapshots were 
saved every 10 ps for trajectory analysis. One simulation was performed with the WT 
and one with the M1304R mutant. The free energy perturbation calculations were 
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performed using the so-called "dual-topology" approach, where the initial and final states 
are defined329,330. MD simulation was performed where the atoms belonging to the initial 
state (M1304) slowly disappear while the atoms of the final state (R1304) slowly appear. 
For a complete description of MD simulations method, see Appendix J. 
 
Mammalian cell culture and transfection 
The human VWF expression vector, pCIneo-VWF-WT, has been previously 
described240. The c.3911T>G mutation was introduced into the full-length VWF 
expression vector to create pCIneo-VWF-M1304R. Human embryonic kidney cells 
(HEK293T, D. Ginsburg, University of Michigan, Ann Arbor, MI) and mouse pituitary 
tumor cells (AtT-20/D16v-F2, CRL 1795, American Type Culture Collection) were 
cultured at 37°C in an atmosphere of 5% CO2 as previously described
240. The variant 
pCIneo-VWF-M1304R was expressed alone or co-expressed with pCIneo-VWF-WT. 
AtT-20 and HEK293T cells were transiently transfected as previously described331. 
Conditioned media were harvested from the cells 72 hours after transfection and 
centrifuged to remove debris. Transfected HEK293T cells were washed twice with PBS 
(phosphate buffered saline) and lysed in Reporter Lysis Buffer (Promega, Madison, WI). 
VWF:Ag concentration in conditioned media and cell lysate was determined by ELISA.  
 
Confocal immunofluorescence microscopy  
The intracellular localization of VWF was examined by immunofluorescence 
antibody staining and confocal laser scanning microscopy in the Imaging Core of the 
Medical College of Wisconsin using a Leica TCS SP2 confocal laser imaging system as 
previously described240. Transfected HEK293T cells grown on 2-well chamber slides 
were fixed using 3.7% (vol/vol) buffered formalin, permeabilized in 1% Triton X-100 (in 
20 mM N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid, 300 mM sucrose, 50 mM 
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NaCl, 3 mM MgCl2·6 H2O, pH 7.0), and then blocked with 2% normal goat serum in 
Hanks balanced salt solution (HBSS). Cells were incubated at 4°C overnight in 2 to 5 
μg/mL primary antibodies diluted in HBSS containing 1% BSA. Cells were washed 3 
times and then incubated in secondary antibodies diluted 1:1000 in HBSS containing 1% 
BSA for 30 minutes at room temperature. Cells were washed 3 times with HBSS and 
mounted using Vectashield (Vector Laboratories). 
 
Allele-specific mRNA assay 
Allele-specific mRNA ratios were calculated as previously described264. Blood 
samples were collected and stored in RNA later per manufacturer recommendations 
(Ambion, Austin, TX). Total RNA isolations were performed using Ribopure Isolation kit 
(Ambion, Austin, TX), and quality was assessed using the RNA Nano chip on a 
Bioanalyzer 2100 (Agilent, Santa Clara, CA). First strand cDNA was synthesized from 
200 ng of total RNA using iScript cDNA kit (BioRad, Hercules, CA). Standard locus-
specific PCR using exon 28 primers (5-GAGCCCCACCACTCTGTATG-3 and 5-
TGCCCGCATACTTCACCT-3) was performed. Amplicons were treated with ExoSap-IT 
per manufacturer protocol (Affymetrix, Cleveland, OH). Allele-specific primer extension 
was performed with 0.15 uM of 6-FAM-labeled probe (5-
TGAAGTGCTGAAGGCCTTTGTGGTGGACAT-3), mixing with Qiagen PCR buffer at 1.5 
mM MgCl2 (Qiagen, Valencia, CA), 200 uM nucleotide mixture of dATP, dGTP, dCTP 
and ddTTP (GE Amersham, Piscataway, NJ), 2.5 U Taq polymerase (Epicentre 
Biotechnologies, Madison, WI), and 2 ul of ExoSap-treated PCR product and amplified 
via an initial denaturation at 94°C for 2 minutes; 30 cycles of 94°C for 30 seconds, 60°C 
for 30 seconds, and 72°C for 40 seconds; and a final extension of 72°C for 7 minutes. 
The resulting extension product(s) are differently sized (33 bp or 42 bp) because of the 
c.3911T>G mutation. Products were diluted 1:10 in Hi-Di formamide, separated by 
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capillary electrophoresis on an Applied Biosystems 3100-Avant Genetic Analyzer, and 
analyzed with GeneMapper 3.5 (Applied Biosystems, Carlsbad, CA). Relative allele-
specific mRNA accumulation was determined using the primer extension protocol with 
the fluorescently labeled probe and minigene plasmid constructs (Integrated DNA 
Technologies, Coralville, IA) containing each homozygous allele (T or G) of the c.3911 
T>G SNP. Each clone was quantitated with PicoGreen (Invitrogen, Carlsbad, CA) and 
mixed in specific ratios to generate a 10-point standard curve. All separations were 
completed in quadruplicate. The standards were fit to a line resulting in an r2 value of 
0.996, calculated by linear regression with Microsoft Excel. 
 
AU/VWFa-11 nanobody  
The llama nanobody AU/VWFa-11 detects an epitope in the VWF A1 domain that 
is exposed when VWF conformation is able to bind GPIbα332. Briefly, the nanobody was 
immobilized on an ELISA plate as a capture antibody, and oxidized or nonoxidized VWF 
in serial dilutions was then added to the coated wells. Bound VWF was detected by an 
HRP-conjugated polyclonal VWF antibody, was plotted against the concentration of 
VWF added to the wells, and the slopes of these plots were compared. 
 
Results 
We enrolled 11 patients with VWD type 2 and 13 unaffected relatives and 
evaluated VWF:Ag, VWF:RCo, and FVIII:C (Figure 5.1A, Table 5.1). The mode of 
transmission in this family was autosomal dominant. The bleeding scores, obtained from 
the bleeding questionnaire at the time of enrollment, differed significantly among family 
members with VWD. Interestingly, VWF levels also varied significantly among VWD 
patients within this family (Table 5.1). VWF multimer analysis showed decreased 
numbers of HMWM in some individuals (Figure 5.1B). However, other VWD patients in  
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Figure 5.1: Pedigree and VWF multimer analysis 
A) A three-generation pedigree with VWD type 2 due to the novel c.3911T>G mutation, 
which results in the M1304R amino acid substitution. Shaded individuals are 
heterozygous for the c.3911T>G and were diagnosed with VWD type 2 by VWF:Ag and 
VWF:RCo. B) Electrophoretic gel analysis of VWF multimers by bleeding score. 
Bleeding scores are labeled along the top x-axis and separated by vertical dashed lines. 
Pedigree members are labeled along the bottom x-axis. Individual III.4 is an infant and a 
bleeding survey was not completed for this subject. PNP: pooled normal plasma. 
 
 
the family exhibited multimer patterns that are almost indistinguishable from the 
unaffected relatives. The distribution of multimers did not correlate with the bleeding 
scores. All but two VWD patients had a VWF propeptide (VWFpp)/ VWF:Ag ratio greater 
than 2, indicating that the mutant confers increased clearance (Table 5.1). Additionally, 
VWD patients exhibited decreased binding to collagens type III and VI, likely due to the 
paucity of HMWM (Table 5.1). Biochemical characterization suggested a qualitative 
defect in VWF, resulting in classification as VWD type 2. 
 
VWD in this family is caused by a novel c.3911T>G mutation in VWF  
Sequencing of exon 28 revealed a novel T>G substitution at position c.3911 






















































































































































































































































































































































































































































































































































































































































































































































Figure 5.2: Mutation analysis and in silico modeling of M1304R 
A) Representative chromatograms of the c.3911T>G variant; homozygous WT 
chromatogram (top) and heterozygous c.3911T>G chromatogram (bottom). B) WT 
crystal structure of VWF (PDB: 1SQ0) with the location of M1304, the disulfide bonded 
C1272 and C1458, and the region of interaction with GP1bα indicated.  WT (C) and 
M1304R (D) mutant and the surrounding residues after energy minimization of the 
respective structures.  Predicted hydrogen bond interactions are represented as dashed 
green lines. 
 
1304 (M1304R) in the A1 domain of the VWF peptide (Figure 5.2A). The c.3911T>G 
mutation segregated to all VWD patients (defined by VWF:RCo < 20 IU/dL) in the family 
and was not present in the unaffected relatives. Complete VWF gene sequencing, 
including introns, in individual I.1 (VWD patient) and individual III.1 (unaffected relative) 
showed several sequence variants (Appendix K). There were 5 variants in individual I.1 
in addition to the c.3911T>G mutation, all of which were previously reported single-
nucleotide polymorphisms (SNPs). A total of 21 variants were identified in individual III.1, 
most of which were intronic variants or known SNPs.  Several exonic SNPs found in 
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these two individuals were sequenced in all members of the pedigree to assess their 
segregation status. No SNP segregated with the c.3911T>G mutation (data not shown).  
Mutations in the same region as the c.3911T>G mutation are known to cause VWD type 
2B.  
 
The M1304R variant results in defective VWF multimerization, trafficking, and 
platelet binding 
 Despite the larger side chain, introduction of the arginine residue in the 
substituted protein using Accelrys Discovery Studio did not substantially alter the 
predicted static conformation of the protein structure. The mutant also did not exhibit any 
energetic differences in the predicted association with GP1bα (Figure 5.2B-D). Molecular 
dynamics (MD) simulations were performed in order to investigate possible structural 
reasons why the M1304R substitution  inhibits function of the A1 domain in binding to 
GP1bα.  It is reasonable to speculate that a charged side chain introduced into an 
otherwise hydrophobic environment, such as the location of M1304 in the WT peptide, 
might thermodynamically destabilize the protein fold and alter functionality of the A1 
domain. We performed 50-ns long, room temperature simulations of the WT and the 
M1304R substituted peptide. Plots of the Cα root mean square fluctuations (RMSF) 
indicated that the α-helix containing the mutant arginine was more flexible than in the 
WT polypeptide (Figure 5.3A). Also, time series of the Cα root mean square deviation 
(RMSD) from the crystallographic structure indicated that the α-helix containing the 
arginine substitution deviated more from the starting configuration than the WT 
polypeptide and underwent larger fluctuations (Figure 5.3B). Furthermore, visual 
inspection of the trajectory demonstrated the arginine variant explored a larger space 
than the methionine residue in the WT polypeptide, indicating that an arginine side chain 
may kinetically destabilize peptide folding. Free energy perturbation calculations  
108
 
Figure 5.3: Flexibility of the M1304R variant vs. WT peptide in MD simulations 
A) RMSF of Cα atoms over the last 40 ns of the run with the mutant (M1304R; solid line) 
and WT (dashed line) peptides. Atoms in secondary structure elements are highlighted 
through solid circles for the mutant and hatched circles for the WT models. Red circles 
denote α-helices, green circles denote β-sheets, and violet circles denote 310 helices. 
The α-helix to which position 1304 maps is highlighted by a blue ellipse. The magenta 
line indicates RMSF values derived from crystallographic B-factors using the formula 
√(3/[8*PI2]*8Bi) where Bi is the B-factor of Cα of residue (i). The y-axis was truncated at 
2.5 Å in order to visually distinguish differences in the mutation site. The value 
accompanied by an up-arrow indicates that Cα atoms near the C-terminus have RMSF 
values up to 10 Å. B) Time series of the Cα RMSD from the initial conformation of the α-
helix containing residues 1290 to 1305. Grey and orange indicate the raw values for the 
M1304R mutant and WT, respectively, whereas black and red represent the respective 
averages over a 200 ps time window. 
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Figure 5.4: Expression and intracellular localization of recombinant M1304R VWF 
A) Left: Homozygous expression of WT (black) and M1304R (white) VWF in HEK293T 
cells. Right: Heterozygous expression of WT-MH tagged VWF with WT VWF (black) or 
M1304R VWF (white) at a 1:1 ratio in HEK293T cells. The concentration of recombinant 
VWF in conditioned media (supernatant) and cell lysate was assessed by ELISA and 
compared to WT VWF. WT VWF was normalized to 100% and M1304R VWF is 
presented as % of WT VWF. Each bar represents the mean ± standard deviation of at 
least three separate experiments. B) WT-MH tagged VWF (green) was co-expressed 
with WT (top, red) or M1304R (bottom, red) VWF at a 1:1 ratio in HEK293T, 
immunostained, and examined by confocal microscopy. Scale bars represent 10 μm. 
Top: WT-MH tagged and WT VWF demonstrate localization to Weibel-Palade body-like 
granules (WPBLG) indicated by punctate staining. Bottom: M1304R VWF demonstrates 
diffuse staining indicating loss of regulated storage. WT-MH tagged VWF colocalizes 
with M1304R in a diffuse staining pattern and localizes to WPBLG. 
 
indicated that the M1304R substitution was thermodynamically unfavorable and might 
lead to unfolding or misfolding of the A1 domain (ΔΔG=41kcal/mol, SEM ±3 kcal/mol). 
To assess the impact of the M1304R substitution on VWF synthesis, trafficking, 
and function, a VWF expression vector containing the c.3911T>G mutation (pCIneo-
VWF-M1304R) was constructed and expressed in HEK293T cells. The mutant VWF 
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vector was expressed alone (homozygous expression) and co-expressed with WT VWF 
(pClneo-VWF-WT; heterozygous expression). Homozygous expression of recombinant 
mutant full-length VWF resulted in an almost normal amount of VWF protein in cell 
lysates but a severe reduction of secretion into the medium (17% of WT; p<0.001; Figure 
5.4A).  Confocal images of M1304R VWF co-expressed with WT showed a diffuse fine-
granular pattern, whereas the WT control formed defined Weibel Palade body-like 
storage granules with little diffuse staining (Figure 5.4B).  The VWF multimer pattern of 
the 100% mutant transfection showed a more marked abnormality with high and 
intermediate multimers being barely detectable on low-resolution gel (Figure 5.5A). The 
ability of VWF to bind platelets in the presence of either ristocetin or botrocetin was  
 
Figure 5.5: Cell culture VWF multimer and platelet binding analyses 
A) Multimer analysis by gel electrophoresis demonstrates selective loss of HMWM in 
100% mutant expression assays with recovery as percent-WT construct increases. 
Ristocetin- (B) and botrocetin- (C) induced platelet binding demonstrate the M1304R 
mutation results in defective GPIbα binding which recovers with increasing percent-WT. 
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significantly impaired with increasing amounts of mutant expression compared to WT 
(Figure 5.5B and C).  These findings indicate that the degree of mutant monomer 
incorporation defines not only expression of the mature VWF but also its function.  
 
The phenotypic variability observed is not due to a hypomorphic VWF allele 
One potential source of variation in VWF multimers and activity may be due to 
allele-specific expression of VWF, especially if the WT allele harbor “common” variants 
that alter VWF levels. Several polymorphisms have been reported that modify VWF 
levels and may modify VWF activity47,154-156. Thus, differential expression of VWF alleles 
may drive phenotypic variability due to differences in the ratio of WT and mutant VWF 
polypeptide monomers available for multimerization. In pedigree members with the 
c.3911T>G mutation, the median percent WT allele of total VWF mRNA was 76.4% 




Figure 5.6: Allele-specific VWF mRNA levels 
Allele-specific mRNA levels are represented as percent T allele (WT allele at base 3911) 
along the y-axis. Individual pedigree members are represented along the x-axis. All 
samples were quantitated in quadruplicate, and each bar represents the mean percent 
WT with one-sided standard deviation bars. Samples are ordered by mean percent wild-
WT to demonstrate clustering of unaffected relatives around 95.2% WT and VWD 
patients around 76.4% WT.  
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76.4% and unaffected relatives around 95.3% indicate there is no significant variation in 
allele-specific expression of VWF in this pedigree (Figure 5.6).  
 
VWF M1304R multimerization depends on the wild-type/mutant monomer ratio 
As observed in Figure 5.5A, the transfection ratios of WT vs. M1304R expression 
constructs determined the degree of VWF multimerization. With increasing percentage 
of M1304R substitution construct, there was concomitant decrease in the HMWM with 
complete loss of HMWM when the M1304R substitution construct was transfected alone. 
However, the expression of M1304R at equal concentration with the WT did not appear 
to grossly affect multimerization. To explore the possibility that M1304R was 
incorporated in smaller multimeric forms (i.e. dimers, tetramers, etc.), we studied co-
expression of the WT and M1304R mutant alleles in a two-color multimer analysis. 
Antibodies with binding specificity for VWF or a Myc-His tag were used to visualize 
multimers generated from co-expression of the M1304R mutant construct and WT VWF-
Myc-His construct (Figure 5.7). Both WT and mutant monomers were readily detected, 
indicating that the M1304R mutant is incorporated into secreted multimers. 
 
The nanobody AU/VWFa-11 efficiently estimates mutant monomer incorporation in 
VWF multimers 
We then used the VWF AU/VWFa-11 nanobody to evaluate the amount of VWF 
mutant peptide incorporated in patient multimer structures. The AU/VWFa-11 nanobody 
detects an epitope within the A1 domain that is exposed when the A1 domain is 
activated and has been shown to bind at elevated levels to VWF multimers with causal 
VWD type 2B mutations332,333. We found that AU/VWFa-11 also binds at elevated levels 
to plasma from patients with the M1304R mutation. We tested multiple VWD patients 
with the M1304R variant, and inter-person AU/VWFa-11 binding to plasma VWF was  
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Figure 5.7: Two-color multimer analysis demonstrates M1304R mutant 
incorporation 
The M1304R mutant was expressed alone or co-expressed with WT VWF-mH (Myc-His 
tag) in 3:1, 1:1, and 1:3 ratios. Two antibodies were used to discriminate VWF without a 
mH tag (mutant or WT; red) from WT VWF-mH (green). Lane 1 demonstrates loss of 
HMWM due to the M1304R substitution. Lane 2 demonstrates M1304R mutant 
incorporation into multimers (yellow). As the ratio of M1304R/WT construct decreases, 
M1304R mutant incorporation also decreases. Lanes 7-12 are control experiments that 


















































































































































Figure 5.8: AU/VWFa-11 nanobody binding predicts differential mutant monomer 
incorporation into VWF multimers 
A) AU/VWFa-11 nanobody binding varies between patients, suggesting differential 
mutant monomer incorporation into VWF multimers. In most patients, nanobody binding 
was higher than pooled normal plasma (PNP, denoted by gray dashed line). This 
indicates the AU/VWFa-11 nanobody binds at elevated levels to VWF with the M1304R 
mutation. B) AU/VWFa-11 nanobody binding to VWF multimers derived from cell culture 
of VWF-M1304R expressed alone or co-expressed with VWF-WT at multiple ratios. 
Notice that with no ristocetin treatment (filled circles), nanobody binding decreases 
whereas ristocetin-induced nanobody epitope exposure increases with a decreased 
mutant/WT transfection ratio. 
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heterogeneous (Figure 5.8A). This indicates that incorporation of mutant VWF peptides 
into multimers was variable. 
The antibody ristocetin is a mimetic that simulates the ability of VWF to bind 
platelet GPIbα (VWF:RCo)334. Ristocetin also results in exposure of the AU/VWFa-11 
nanobody epitope. We expressed the VWF-M1304R mutant alone or co-expressed with 
the VWF-WT construct at multiple mutant/WT ratios. Analysis of ristocetin-induced 
exposure of the AU-VWFa-11 nanobody epitope demonstrated the increase with 
ristocetin was much less pronounced in VWF derived from the mutant construct 
compared to the WT construct (Figure 5.8B). This suggests that enhanced nanobody 
binding in the presence of ristocetin is a characteristic unique to WT monomers in the 
VWF multimer. Based on this observation, we devised an estimate of percent 
incorporation of mutant subunits into VWF multimers by examining nanobody indices 
(the slope of nanobody binding as a function of added VWF) in the absence and 
presence of ristocetin in VWF with various compositions of mutant dimers as estimated 
by transfections with different ratios of wild-type and mutant DNA. We found that a 
mutant/WT transfection ratio of 4:1 was sufficient to facilitate VWF multimerization. 
These findings are consistent with the hypothesis that the degree of mutant 
incorporation into VWF multimers is an important determinant of the synthetic and 
functional impairments observed.  
 
Discussion 
We thoroughly characterized the molecular pathogenesis of VWD in a family with 
VWD type 2 caused by a novel VWF c.3911T>G mutation that has not been previously 
reported. Interestingly, several other missense mutations that alter amino acids in the 
same region cause VWD type 2B. In this family, the platelet count was normal in all 
VWD patients and response to low-dose ristocetin was not enhanced, ruling out VWD 
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type 2B. Additionally, recombinant M1304R VWF did not bind platelets in the presence 
of ristocetin or botrocetin. Expression of a VWF construct containing the c.3911T>G 
mutation demonstrated that the M1304R substitution resulted in defective VWF 
multimerization and trafficking. In silico modeling suggested that the arginine amino acid 
may destabilize an α-helix in the A1-domain, resulting in defective GPIbα binding. 
One of the most remarkable features about this family is the phenotypic 
variability despite a unifying c.3911T>G mutation.  Potential explanations include the 
presence of a hypomorphic WT allele in addition to the c.3911T>G mutant allele335. We 
sequenced the VWF gene in two individuals of this family, one VWD patient and one 
unaffected relative. We subsequently sequenced all exonic variants and found that none 
co-segregated with disease status nor were any variants associated with VWF levels 
(data not shown). Allele-specific mRNA ratios ruled out the presence of a hypomorphic 
WT allele, as all c.3911T>G/WT ratios were comparable among VWD patients. 
 Another possible explanation for the observed variability in multimer distribution 
and ultimately in bleeding patterns is variable incorporation of mutant monomers into 
VWF multimers. In our studies of the mutant VWF M1304R peptide in cell culture, we 
found that the ability of VWF to multimerize greatly depended on the mutant/WT 
transfection ratio (Figure 5.5A). Interestingly, a 3:1 mutant-to-WT transfection ratio was 
sufficient to facilitate synthesis of HMWM. At this ratio expression of WT VWF decreased 
the percentage of protomers composed of two mutant monomers to 56%. Increasing the 
transfection ratio to 1:3 mutant-to-WT resulted in 6.25% of protomers containing two 
mutant monomers. Additionally, the VWF nanobody AU/VWFa-11, which preferentially 
recognizes the activated (exposed) A1 domain, exhibited heterogeneous binding to 
plasma from VWD patients in this family, suggesting a variable distribution of mutant 
monomer incorporation into VWF multimers.  
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Figure 5.9: Schematic representation VWF multimerization incorporating WT and 
1:1 WT/mutant protomers while excluding mutant promoters 
 
Our results suggest phenotypic variability is driven by the degree of mutant 
monomer incorporation into VWF multimers (Figure 5.9). In this model, we assume a  
VWD patient heterozygous for the causal mutation synthesizes the mutant and WT 
polypeptides in equal quantities. Dimeric protomers would consist of two WT 
polypeptides, one WT and one mutant polypeptide, and two mutant polypeptides in a 
ratio 1:2:1. The protomers containing two mutant polypeptides are either recognized as 
defective within the endoplasmic reticulum and sequestered for degradation, or evade 
detection and are trafficked to the Golgi network where they are unable to incorporate 
into growing multimers. Mutant dimers would subsequently be released into the plasma 
as C-terminal disulfide-bonded protomers. Multimers would form only from WT dimers 
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and from dimers containing one WT and one mutant monomer. Thus, multimers would 
consist of an average of two WT monomers to every one mutant monomer.  
Recently, Siguret et al. reported that when the VWF c.1458C>G mutation was 
expressed alone protomers consisted of only minor quantities of tetramers and 
hexamers336. Additionally, Rosenberg et al. reported that co-expression of WT VWF with 
a serine487 variant showed primarily WT homodimer formation with only 9% of the 
multimers containing heterodimers337. A similar observation was reported by Bodo et al. 
with the VWF C1149R mutation338.  
In summary, our findings suggest that the rate of mutant monomer incorporation 
into VWF protomers may underlie the efficiency of multimerization, resulting in the 
variable phenotype observed with some VWD type 2 mutations. Therefore, some 
mutations such as M1304R may alter VWF multimer biosynthesis in addition to resulting 
in a functional deficiency. Further studies are needed to directly quantify the amount of 
mutant protein incorporated into VWF multimers, which, to date, is limited by the 
complexity of VWF multimer structure and requires the development or adaptation of 









 Gray platelet syndrome (GPS) is a rare autosomal recessive bleeding disorder 
characterized by thrombocytopenia with large gray-appearing platelets and paucity of α-
granules. Genome-wide mapping analyses by our group and others mapped the GPS 
locus within a 8.73 MB region on chromosome 3p21. We employed homozygosity 
mapping in five patients with GPS from two related Native American families and one 
patient with GPS of Pakistani origin to redefine localization of the GPS locus to a 1.4 Mb 
region.  RNA isolated from platelets of a GPS patient was subjected to focused next-
generation RNA sequencing (RNA-Seq), which revealed abnormal transcript reads, 
including intron retention, mapping to NBEAL2 (Neurobeachin-like 2). DNA sequencing 
of genomic NBEAL2 identified compound heterozygosity for a canonical 3’ splice site 
mutation and a frameshift indel in this patient and a familial nonsense mutation and a 
frameshift indel in the Native American kindreds, supporting NBEAL2 as the genetic 
cause of GPS. NBEAL2 encodes a BEACH domain-containing protein predicted to be 
                                                            
3 This chapter contains previously published data as well as data that are not yet 
published. Figures adapted from publications are reproduced with permissions and will 
be cited within the figure legend. In this chapter, Jesse Hinckley and Shawn Jobe 
designed and conducted the initial homozygosity mapping experiments that originally 
mapped the GPS locus to chromosome 3p21 and defined an initial interval of 8.73 Mb. 
Jesse Hinckley conducted microsatellite genotyping to confirm the GPS locus by linkage 
analysis. Shay Fabbro and Jesse Hinckley conducted fine-mapping analysis of the 
Affymetrix 6.0 chip experiment to narrow the region of interest. Kai Wang performed the 
statistical genetics analysis. Jesse Hinckley analyzed genes in the interval to prioritize 
candidate genes for sequencing, sequenced NBEAL2 in all patients and controls 
identifying, and verifying the putative mutations. Andrew Weyrich’s laboratory performed 
the RNA-Seq experiments and provided results for analysis. John Patterson provided 
the evolutionary genetics analysis. James G. White provided the platelet electron 
microscopy images. 
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involved in vesicular trafficking, NBEAL2 arose through a recent gene duplication event 




Thrombocytopenia is a common clinical presentation. Thrombocytopenias are 
classified as microthrombocytic, normothrombocytic, or macrothrombocytic. In fewer 
than 5% of those with a chief complaint of thrombocytopenia is the finding congenital339. 
X-linked, autosomal dominant, and autosomal recessive inheritance patterns have been 
reported, as well as multisystem thrombocytopenic syndromes as part of chromosomal 
disorders.  
Gray platelet syndrome (GPS; OMIM: 13090) is a pure α-granule storage 
disorder characterized by large gray-appearing platelets when evaluated by stained 
peripheral blood smear340-344. Although familial clusters of GPS patients have been 
reported that are consistent with X-linked or autosomal dominant inheritance, most GPS 
patients and families autosomal recessive inheritance345-347. GPS is classified as a 
macrothrombocytopenia, though the mechanism of the thrombocytopenia is unclear. 
Patients with GPS have thrombocytopenia to varying degrees, mild to moderate 
bleeding, and splenomegaly342,348-350. Later in life, GPS patients also develop progressive 
bone marrow fibrosis due to abnormal reticulin deposition, thought to result from several 
of the proteins, including growth factors, normally stored in α-granules being “leaked” by 
megakaryocytes into the extracellular space340,342,351-353. 
Ultra-structural studies of GPS platelets show selective depletion of -granules 
and normal formation of -granules, lysosomes, mitochondria and peroxisomes by bone 
marrow-resident megakaryocytes, confirming GPS is a pure α-granule storage 
121
disorder341,342,344,354,355. To date, very little is known about α-granule biogenesis. Hence, 
though a rare disorder, the identification of the genetic cause of GPS will provide new 
insight into platelet physiology. The main objective of the study presented here is the 




 The study population consisted of two Native American kindreds and one 
Pakistani kindred, totaling six GPS patients, seven parents, and five control siblings.  
The mother of family 2 is from the same tribe as family 1 and the father is of Mexican 
ethnicity. The parents of family 3 are of Pakistani ethnicity and are not consanguineous. 
Informed consent was obtained from all participants according to institutional guidelines 
of the University of Iowa, University of Colorado, and the Research Ethics Board at The 
Hospital for Sick Children in Toronto. DNA was extracted from blood using the Gentra 
Puregene or QIAmp Blood Kit (Qiagen, Valencia, CA). 
 
Transmission electron microscopy 
Platelets were isolated using established methods356. Platelet-rich plasma was 
centrifuged at 800x g for 10 minutes and fixed with 2.5% glutaraldehyde in PBS pH 7.4 
at 4°C for 1 hour. Supernatants were discarded and platelets were washed with 0.1 M 
phosphate buffer (pH 7.4), followed by dH2O. Platelets were then post-fixed with 2% 
osmium tetroxide, dehydrated and embedded in Epon. Thin sections were examined 
with a JEOL JEM-1011 electron microscope after uranyl acetate and lead citrate 
staining. Digital images were captured with a side mounted Advantage HR CCD camera 
(Advanced Microscopy Techniques (AMT) Danvers, MA) saved in TIFF format, and 
trimmed for publication using Adobe Photoshop (CS3). 
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Homozygosity mapping and linkage analysis 
 DNAs from 3 affected GPS patients, 2 parents, and 1 control sibling from family 1 
were interrogated using the Affymetrix GeneChip Mapping 50K assay. The data were 
analyzed using Excel (Microsoft). Short-tandem repeat polymorphic (STRP) markers 
were selected corresponding to the candidate intervals, including 14 STRP markers in 
the 3p21 region, and genotyped according to manufacturer’s protocol (Applied 
Biosystems, Life Technologies). Two-point and multipoint non-parametric linkage 
analyses were performed using GeneHunter (http://linkage.rockefeller.edu/soft/gh/)357. 
Families 1 and 2 were analyzed individually and a combined logarithm of odds (LOD) 
score is reported herein.  
DNAs from each of eleven unaffected and five affected individuals were 
interrogated on the Genome-Wide Human SNP Array 6.0 (Affymetrix), which contains 
906,600 SNPs, using the Microarray Core facilities at the University of Colorado Denver 
as previously described 358. The data were analyzed using the Genotyping Console 
Software (Affymetrix). Homozygosity and copy number variation (CNV) analyses were 
performed on all samples using default parameters.  
 
Candidate gene sequencing and mutational analysis 
Candidate gene primers were designed covering all exons and exon/intron 
boundaries of the genomic sequence using Primer3 (see Appendix K). PCR was 
performed on genomic DNA and Sanger sequencing was performed using BigDye V3.1 
on an ABI3730xl DNA analyzer247. Sequence analysis was conducted using Sequencher 
V4.9 and Mutation Surveyor V3.97. All mutations identified in NBEAL2 were 
resequenced on both DNA strands. 
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Next generation RNA-sequencing 
Platelets were isolated from healthy volunteers and the Pakistani subject with 
GPS using established methods and protocols approved by the University of Utah and 
the Research Ethics Board at The Hospital for Sick Children in Toronto (Appendix 
L)356,359.  Leukocytes were removed by CD45+ selection followed by RNA isolation359. 
The integrity of the RNA was evaluated on an Agilent BioAnalyzer to ensure that each 
sample had an RNA integrity number (RIN) greater than 7.0.  Poly(A)-tailed RNA was 
subsequently prepared and used to create libraries for deep sequencing. Samples were 
sequenced for 50 cycles on an Illumina GAIIx sequencer and sequence reads were 
processed and aligned as previously described359. For visualization of actual read 
sequences in IGB, reads were re-aligned with Bowtie and processed into BAM format 
using Samtools360,361. 
 
Protein sequence data collection and analysis 
Protein sequences for the NBEAL-LYST family (NBEA, NBEAL1, NBEAL2 and 
LYST) were retrieved by the combination of two methods: Ensembl and PhyloPro 
searches362,363. Orthologous protein sequences were retrieved from the Ensembl 
database (version 62)362. These orthologs had been identified previously by performing a 
genome-wide reciprocal WUBlastp+SmithWaterman search of each gene across all 
completed genomes. Additional orthologous protein sequences were retrieved from 
PhyloPro. Representative sequences were selected for further analysis from the 
Vertebrata (H. sapiens, P. troglodytes, M. mulatta, M. muscuus, B. Taurus, G. gallus, M. 
domestica, X. tropicalis, T. rubripes and D. rerio), other Chordata (C. savignyi and C. 
intestinalis) and other eukaryotic species (D. melanogaster, C. elegans, N. vectensis, M. 
brevicollis and C. albicans). Pfam searches were performed to identify known domain 
architecture for each representative protein sequence364. 
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Multiple sequence alignment 
All representative protein sequences were aligned in MUSCLE v3.6 using default 
parameter settings365. In addition, NBEAL2 and its non-vertebrate orthologs (NBEAL2 
gene family) were also aligned as above. Protein multiple sequence alignments (MSAs) 
were manually edited by removing ambiguous regions from the alignment using the 
sequence alignment editor, Se-Al 2.0a11 (http://tree.bio.ed.ac.uk/software/seal/).  
 
Phylogeny reconstruction 
The model for amino acid substitution to be used for the NBEAL-LYST and 
NBEAL2 gene families MSAs were determined using ModelGenerator v0.85366. For the 
NBEAL-LYST family a neighbor joining (NJ) phylogeny was generated using MEGA5 
under the predetermined amino acid substitution model, JTT + G, and 1000 bootstrap 
replicates367. A maximum likelihood (ML) phylogeny of the NBEAL2 gene family was 
generated using PhyML with 1,000 bootstrap replicates368. The selected substitution 
model was JTT with invariable sites and a discrete gamma model of rate heterogeneity. 
 
Results 
The study cohort included two nuclear families from a Native American 
settlement (families 1 and 2) and a male patient of Pakistani origin and his parents 
(family 3; Figure 6.1A). The Native American families are part of the same settlement 
with limited outbreeding, suggesting the possibility of founder effect resulting in 
homozygosity for a causal familial mutation in the patients. The father of family 2 is of 
Mexican origin, which suggests compound heterozygosity in this family. The Pakistani 
family is not consanguineous. Platelet counts in patients ranged from 34-84 x109 
platelets/L (normal: 150-400 x109 platelets/L; Table 6.1). By transmission electron 
microscopy (EM), platelets showed complete absence of -granules (Figure 6.2). 
125
GPS locus maps to chromosome 3p21 
Homozygosity mapping is a proven method to elucidate candidate genes 
underlying Mendelian disorders in consanguineous families369,370. Due to founder effect 
among Native American tribes, we hypothesized GPS patients in family 1 would be 
homozygous for the familial mutation and the GPS patients in family 2 would be 
compound heterozygotes for the familial mutation. We therefore genotyped individuals 
II.11, III.2, III.6, III.87, III.9, and IV.5 of family 1 using the Affymetrix Gene Chip Mapping 
50K assay. Analysis of homozygosity among individuals III.6, III.7, and IV.5 while the 
control parents II.1 and III.2 were heterozygous and control sibling III.9 was 
heterozygous or homozygous for the major allele identified an 8.73 Mb region on 
chromosome 3p21 as the candidate GPS locus. 
 
Figure 6.1: GPS kindreds and NBEAL2 mutations 
A) The study population consists of three kindreds. Family 1 is a Native American family. 
The mother of family 2 is of the same tribe as family one and the father is of Mexican 
ethnicity. Family 3 is a nonconsanguenious Pakistani family. B) NBEAL2 is a 30 kb gene 
and consists of 54 exons. C) Four mutations were identified in NBEAL2, including 
c.1029+1G>A (Pakistani), c.1820G>A (W607X; Native American), 
c.4371_4375dupCGTGG (Pakistani), and c.5413dupG (Mexican). This material is 
adapted from Kahr and Hinckley et al. with permission of the Nature Publishing Group371. 
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Table 6.1: Three kindreds with Gray Platelet Syndrome. 
Subject Ethnicity* Gender PLT (K/μl) Hb (g/dL) WBCC (K/μl) 
1 (III-1) NA M 188 11.4 6.1 
1 (III-2) NA F 298 11.7 7.4 
1 (IV-1) NA F 345 13.4 5.9 
1 (IV-2) NA F 353 13.3 10.3 
1 (IV-4) NA F 360 10.7 7.2 
1 (IV-5) NA F 83 11.2 4.5 
1 (II-10) NA M 207 11.8 2.1 
1 (II-11) NA F 255 13.1 6.8 
1 (III-6) NA F 58 13.1 5.2 
1 (III-7) NA F 34 13.2 4.5 
1 (III-9) NA F 242 13.8 6.5 
2 (I-1) MEX M 247 15.1 4.5 
2 (I-2) NA F 311 13 8.6 
2 (II-1) MEX/NA M 407 14.8 8.1 
2 (II-2) MEX/NA M 84 11.8 7.4 
2 (II-3) MEX/NA F 68 12.6 4.8 
3 (I-1) PAK M 262 17.2 6.5 
3 (I-2) PAK F 168 12.9 7.4 
3 (II-1) PAK M 82 12.6 9.1 
* NA: Native American; MEX: Mexican; PAK: Pakistani 
 
 
Figure 6.2: GPS blood smear and platelet transmission electron microscopy 
A) Blood smear demonstrated macrocytic thrombocytopenia in a GPS patient (top left) 
compared to a unaffected relative (top right). B) Platelet transmission electron 
microscopy revealed platelets with a paucity of α-granules that are enlarged in the GPS 
patient (bottom left) compared to control (bottom right). This research was originally 
published in Blood. Fabbro, Kahr, and Hinckley et al. Homozygosity mapping with SNP 
arrays confirms 3p21 as a recessive locus for gray platelet syndrome and narrows the 




Figure 6.3: Linkage established to chromosome 3p21 
Focal linkage analysis of gray platelet syndrome established a maximum LOD score of 
2.7 at 70.6 cM (chromosome 3p21). This research was originally published in Blood. 
Fabbro, Kahr, and Hinckley et al. Homozygosity mapping with SNP arrays confirms 3p21 
as a recessive locus for gray platelet syndrome and narrows the interval 
significantly. Blood. 2011;117:3430-3434. © the American Society of Hematology372. 
 
Though the mother of family 2 is from the same tribe as family 1, we were unable 
to establish a direct relationship between the families. To validate 3p21 as the GPS 
locus, we genotyped 14 STRP microsatellite markers that map to the 8.73 Mb candidate 
interval. Linkage to 3p21 was evaluated and a cumulative LOD score of 2.7 was 
established to markers D3S3615, D3S648, and D3S1578 (70.6 cM) for GPS (Figure 
6.3). Our findings are consistent with a 9.4 Mb GPS locus reported by Gunay-Aygun et 
al., published after our initial mapping studies348.  
To narrow the candidate interval, we genotyped individuals I-10, I-11, II-3, II-4, II-
9, II-11, III-2, III-3, III-5, and III-6 from family 1; all individuals of family 2, and individual 
II-1 from family 3 using the Affymetrix 6.0 chip and identified 3 regions of homozygosity 
shared by the GPS patients of each family: 1q25.1 (171.8-172.3 Mb), 3p21 (48.4-50.1 
Mb), and a large centromeric region on chromosome 16. Based on our previous GPS 




Figure 6.4: High-density homozygosity mapping narrows the chromosome 3p21 
interval to 1.4 Mb 
Due to founder effect, we hypothesized family 1 GPS patients would be homozygous for 
a familial mutation whereas family 2 GPS patients would be heterozygous for the familial 
mutation. Homozygosity mapping using the Affymetrix Genome-wide Human SNP Array 
6.0 identified a 1.4 Mb interval (47.0-48.4 Mb) where family 1 patients II.9 and III.6 were 
homozygous and family 2 patients II.2 and II.3 were heterozygous. This research was 
originally published in Blood. Fabbro, Kahr, and Hinckley et al. Homozygosity mapping 
with SNP arrays confirms 3p21 as a recessive locus for gray platelet syndrome and 




and identified a 1.4 Mb region preceding the homozygosity block where GPS patients II-
9 and III-6 of family 1 were homozygous and GPS patients II-2 and II-3 of family 2 were 
heterozygous (Figure 6.4).  
Systematic review of candidate genes and coding region sequencing conducted 
by our lab and others did not identify any homozygous or compound heterozygous 
mutations. Gunay-Aygun et al. employed a nonbiased genome sequencing approach 
encompassing 69% of the coding region of 165 protein-coding genes within the 9.4 Mb 
interval which also did not identify any candidate mutations348. 
 
NBEAL2 identified as putative GPS gene 
 While platelets are anucleate cell fragments derived from megakaryocytes, they 
retain a diverse transcriptome360. To identify the putative GPS gene, we performed next-
generation genome-wide RNA sequencing (RNA-Seq) of platelet mRNA isolated from 
individual II-1 of family 3. We focused our analysis strategy on transcripts corresponding 
to genes within the 3p21 candidate interval. NBEAL2 transcripts from the GPS patient 
demonstrated intronic retention, suggesting abnormal mRNA splicing (Figure 6.5A). 
Sequencing of genomic DNA of individual II-1 identified a heterozygous c.1029+1G>A 
mutation resulting in disruption of the canonical 3’ splice site of exon 9, which predicts 
intron 9 would be abnormally retained within NBEAL2 transcripts derived from this allele 
(Figure 6.1C). Assuming intron 9 retention, three in-frame premature stop codons are 
introduced within 80 nucleotides of the putative splice site. The c.1029+1G>A mutation 
and intron 9 retention was confirmed by RNA-Seq analysis (Figure 6.5B). 
 Subsequent sequencing of NBEAL2 coding sequence and exon/intron 
boundaries identified compound heterozygosity for a five-base pair duplication in exon 
28 of bases 4,371-4,375 (c.4371_4375dupCGTGG; Figure 6.1C). Sequence analysis in 
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Figure 6.5: RNA-Seq reveals intron 9 retention in NBEAL2 
Platelets were isolated from individual II.1 of family 3 and an unrelated control and 
mRNA was extracted. A) RNA-Seq revealed intron 9 retention in NBEAL2 suggesting 
abnormal splicing. B) RNA-Seq sequence analysis confirms the c.1029+1G>A mutation 
disrupting the canonical exon 9 3’ splice site. This material is adapted from Kahr and 
Hinckley et al. with permission of the Nature Publishing Group371. 
 
individuals III-6, III-7, and IV-5 of family 1 identified the familial mutation as a 
homozygous G>A substitution at position 1820 (c.1820G>A), resulting in a premature 
stop codon (W607X; Figure 6.1C). An additional 55 unaffected relatives and 2 GPS 
patients where both parents are confirmed members of the Native American tribe were 
available for sequencing. Within this sample population, the c.1820G>A minor allele 
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frequency is 0.158 among tribe members evaluated with 100% penetrance homozygous 
individuals. In family 2, we identified single base pair duplication at position in 5413 
(c.5413dupG) for which the father and his three children are heterozygous (Figure  
6.1C). Position 5413 maps to exon 33, and a one-base duplication results in a frameshift 
that predicts the introduction of a premature TGA stop codon 172 bases downstream 
(bases 5,586-5,588).  
 
 
Figure 6.6: RNA-Seq reveals reduced NBEAL2 mRNA levels in GPS patients 
Platelets were isolated from family 1 patients III.7 and IV.5, obligate carrier III.1, and a 
control individual and mRNA was extracted. A) RNA-Seq analysis reveals the 
c.1820G>A mutation results in reduced NBEAL2 transcript levels. B). Relative quantity of 
NBEAL2 mRNA transcripts. 
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Following identification of the putative disease gene, we isolated platelet mRNA 
from individuals III.1, III.7 and IV.5 from family 1 and individual II.1 from family 3 and 
conducted quantitative RNA-Seq analysis of the platelet transcriptome. NBEAL2 
transcript levels were significantly lower (p=<0.05) in GPS patients III.7 and IV.5 than in 
individual III.1 (heterozygote) and a control individual (Figure 6.6). These findings 
suggest the familial c.1820G>A mutation results in nonsense-mediated decay. 
 
Homozygosity for NBEAL2 mutations alters the platelet transcriptome 
We also evaluated the RNA heat maps of the platelet transcriptome of GPS 
patients III.7 and IV.5 of family 1 and compared them between each other, to obligate 
carrier III.1 of family 1, and to an unrelated healthy control (Figure 6.7). Interestingly, we 
found a profound alteration of the GPS platelet transcriptome. GPS platelets exhibit a 
unique molecular signature with several differentially expressed transcripts when 
compared to normal platelets. Of the top 20 differentially expressed transcripts that were 
common to individuals III.7 and IV.5 (Table 6.2), some genes are over or under 
expressed by as much as 90-fold and 558-fold, respectively. Specifically, we found that 
ALAS2 and SELENBP1 were overexpressed by 94- and 61-fold respectively. Genes 
from the SLC superfamily such as SLC4A1 and SLC6A8, and SLC25A39 were also  
 
Figure 6.7: NBEAL2 mutations alter the platelet transcriptome heat map 
Platelets were isolated from family 1 patients III.7 and IV.5, family 1 obligate carrier III.1, 
and an unrelated control and platelet mRNA was extracted. The platelet transcriptome 
was evaluated by RNA-Seq and quantitated by reads per kilobase per million. The 
platelet transcriptome heat map revealed similar patterns of alteration between GPS 
patients III.7 and IV.5. 
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                Table 6.2: Platelet transcriptome top 20 fold changes 
Gene GPS RPKM* 
Control 
RPKM* Δ Fold 
ALAS2 400.43 4.25 94.28 ↑ 
CA1 122.02 1.87 65.40 ↑ 
SELENBP1 49.20 0.82 59.87 ↑ 
SLC4A1 51.45 1.14 45.16 ↑ 
AHSP 103.51 2.42 42.71 ↑ 
EPB42 19.76 0.48 40.99 ↑ 
IFIT1B 5.44 0.13 40.64 ↑ 
SLC6A8 3.86 0.14 27.99 ↑ 
HBE1 104.62 3.74 27.99 ↑ 
MYL4 25.78 1.19 21.72 ↑ 
HBM 86.41 3.99 21.63 ↑ 
HBA1 74993.67 3982.35 18.83 ↑ 
HBA2 81754.06 4522.02 18.08 ↑ 
SLC25A39 242.24 14.35 16.88 ↑ 
FGL2 0.13 7.56 58.21 ↓ 
VCAN 0.0706 5.84 82.77 ↓ 
MPEG1 0.10 9.14 89.65 ↓ 
FGD2 0.0610 6.92 113.44 ↓ 
RPS4Y1 0.0254 7.32 287.52 ↓ 
EIF1AY 0.0166 9.27 557.91 ↓ 
                * Reads per kilobase per million 
 
overexpressed by 45-, 28-, and 17-fold, respectively. SLC genes encode solute carrier 
proteins including passive transporters and ion-coupled cotransporters and 
exchangers373. The SLC superfamily is subdivided into 43 families that consist of 298 
genes. Families are defined by proteins that have at least 20-25% sequence homology. 
The SLC4 family encodes bicarbonate transporter proteins important in cellular pH 
homeostasis, the SLC6 family encodes sodium- and chloride-dependent 





 Nonsense mutations as well as frameshift mutations and splice site mutations 
are known to have deleterious effects on gene expression often constituting a null allele 
as a result of nonsense-mediated mRNA decay and other regulatory mechanisms374. We 
report a familial nonsense mutation (c.1820G>A) as well as a canonical splice site 
mutation (c.1029+1G>A) and 2 exonic duplications (c.4371_4375dupCGTGG and 
c.5413dupG), strongly suggesting that NBEAL2 mutations are the putative cause of 
autosomal recessive GPS. Platelet transcriptome analysis confirmed the c.1820G>A 
mutation results in decreased NBEAL2 mRNA levels, suggesting that the mutant 
transcript is subjected to nonsense-mediated decay. Heat map analysis of the platelet 
transcriptome also identified patterns of alteration in GPS patients. 
Additionally, mutations in NBEAL2 were reported as the cause of GPS by Albers 
et al. and Gunay-Aygun et al., whose articles were published in series with our own 
work371,375,376.  Gunay-Aygun et al. demonstrated NBEAL2 mRNA is present in platelets 
and cultured megakaryocytes376. NBEAL2 protein fragments were also identified by 
mass spectrometry in platelets isolated from control individuals. Albers et al. reported 
that silencing of nbeal2 by injection of antisense morpholino oligonucleotides in zebrafish 
embryos demonstrated complete loss of thrombocytes while erythropoiesis was 
unaffected375. Furthermore, 41% of nbeal2-depleted embryos developed spontaneous 
caudal bleeds whereas spontaneous bleeding was not observed in any control embryos. 
 NBEAL2 encodes a 2,574 amino acid polypeptide that shows homology to the 
protein product of LYST. Mutations in LYST underlie Chediak-Higashi syndrome (CHS; 
OMIM: 214500), a rare autosomal recessive disorder characterized by bleeding due to 
depletion of platelet dense granules377-381. LYST and NBEAL2 gene products contain a 
concavalin A-like lectin domain, a pleckstrin homology (PH) domain predicted to function 
in recruitment of proteins to cellular membranes, a Beige and CHS (BEACH) domain, 
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and numerous WD40 repeats382-385. BEACH proteins are implicated in vesicular 
trafficking by loss of platelet dense granules as well as abnormally large cytoplasmic 
granules in other cells in CHS386,387. BEACH proteins may also affect trafficking of 
endosomes, lysosomes, and lysosome-related organelles388. LYST orthologs and other 
BEACH proteins have been reported to participate in protein sorting, lysosome-
endosome fusion, and Rab11-dependent trafficking389-391. 
Phylogenetic analysis conducted by John Parkinson revealed that NBEAL2 and 
its close homolog NBEAL1 are members of a family of BEACH domain-containing 
proteins related to neurobeachin (expressed in neurons) and distinct from LYST (Figure 
6.8)371. During the emergence of metazoa the ancestral NBEAL gene underwent 
duplication, producing the neurobeachin and neurobeachin-like gene subfamilies. This 
event appears to have followed the divergence of protostomes from deuterostomes. A 
more recent duplication within the NBEAL lineage led to the formation of the NBEAL1 
and NBEAL2 subfamilies. A search of the cephalochordate Amphioxus genome 
identified only a single gene of the NBEAL1/NBEAL2 subfamily, suggesting the latter 
duplication is unique to the craniate (vertebrate) lineage. 
Our findings strongly suggest NBEAL2 mutations underlie GPS, identifying 
NBEAL2 as a key component required for platelet α-granule biogenesis. Phylogenetic 
analysis reported herein also indicates duplication of an ancestral cellular trafficking 
gene may have resulted in neofunctionalization of NBEAL2, accounting for the tissue-
specific phenotype of GPS. These results provide evidence of the first known gene in 
platelet α-granule biogenesis, which provides an anchor point for future studies to 




Figure 6.8: Phylogenetic analysis of NBEAL protein family members 
The maximum likelihood tree shows phylogenetic relationships between LYST and 
NBEAL family PH-BEACH domains. Numbers at nodes indicate bootstrap support for 
1000 samplings. From this tree it is apparent that NBEAL1 and NBEAL2 arose from a 
unique gene duplication event in the early vertebrate lineage. A search of the genome of 
the cephalochordate Amphioxus identified a single gene of the NBEAL1/NBEAL2 
subfamily (data not shown), suggesting the duplication is unique to the craniate 
(vertebrate) lineage and that LRBA and NBEA diverged prior to the emergence of 
Vertebrata. An initial neighbor joining tree of the complete NBEAL-LYST multiple 
sequence alignment produced the same overall topology. There were no topological 
changes to the overall PH-BEACH phylogeny on testing for the presence of long branch 
attraction, indicating that the analysis is not affected by this potential artifact (data not 
shown).This material is reproduced from Kahr and Hinckley et al. with permission of the 
Nature Publishing Group371. 
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CHAPTER VII 
AN ANKRD26 5’-UTR MUTATION IN LINKAGE DISEQUILIBRIUM WITH A MASTL 
MUTATION IN A FAMILY WITH AUTOSOMAL DOMINANT THROMBOCYTOPENIA 
 
Abstract 
 Autosomal dominant thrombocytopenia, THC2 is a familial nonsyndromic 
normocytic thrombocytopenia that demonstrates linkage to the THC2 locus on 
chromosome 10p11.2-12. Previous reports suggest causal mutations in ACBD5, 
MASTL, and ANKRD26. To date, six mutations in a 22-base pair segment of the 5’-
untranslated region (UTR) of ANKRD26 have been reported in 21 families. We report a 
new family with nonsyndromic thrombocytopenia inherited in an autosomal dominant 
pattern. Genome-wide linkage analysis was significant only for linkage to the THC2 
locus on chromosome 10 (LOD=3.29). Sequence analysis revealed all family members 
with thrombocytopenia were heterozygous for the previously reported MASTL c.506G>C 
variant as well as a novel ANKRD26 c.-126T>C variant that maps to the previously 
implicated 5’-UTR segment. Haplotype analysis established both variants are in linkage 
disequilibrium within the family, which is consistent with the extensive long-range linkage 
disequilibrium present in the CEU HapMap dataset. We also identified a non-penetrant 
ANKRD26 c.-113A>C variant previously reported as causal. Sequence analysis of two 
patients from the original MASTL kindred revealed they are also heterozygous for the 
ANKRD26 c.-126T>C variant. We also report a third unrelated kindred heterozygous for 
the ANKRD26 c.-126T>C variant in which no mutations in MASTL were present. 
Expression analysis by quantitative PCR demonstrated ANKRD26 is a widely expressed 
gene with low expression in hematopoietic tissues. Modeling of the ANKRD26 5’-UTR 
variants predicted the c.-126T>C and c.-134G>A (most common variant published to 
date) variants alter a stem structure within a very stable UTR structure. This results in 
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the introduction of a terminal stem loop. The c.-113A>C variant is not predicted to alter 
the stem structure, which is consistent with a nonpenetrant variant. Stem loop structures 
have previously been characterized as protein binding sites, suggesting that ANKRD26 
5’-UTR mutations that introduce this stem loop structure may alter protein binding 
resulting in a gain-of-function variant that causes nonsyndromic thrombocytopenia. 
 
Introduction 
Congenital platelet disorders are a heterogeneous array of diseases classified as 
thrombocytopenias with otherwise normal platelet function and thrombocytopenias with 
thrombocytopathy193-200. Thrombocytopenia may be the only laboratory finding or may 
present as part of a syndrome such as Chediak-Higashi syndrome, Fanconi anemia, 
Hermansky Pudlak syndrome, and Wiskott-Aldrich syndrome. Thrombocytopathies may 
also result from mutations in proteins that interact with platelets, including VWF54. 
Thrombocytopenias are caused by mutations in several genes that encode components 
of platelet structure and function200. Reported inheritance patterns include autosomal 
dominant and recessive and X-linked recessive. By platelet volume, nonsyndromic 
thrombocytopenias are classified as normocytic, macrocytic, and microcytic. 
Nonsyndromic autosomal dominant thrombocytopenias are typically moderate 
thrombocytopenias characterized by normocytic platelets with no detectable alterations 
of platelet morphology, normal megakaryocyte physiology, and a mild bleeding 
diathesis392-395. Linkage was established between autosomal dominant 
thrombocytopenia and chromosome 10p11.2-12 (THC2, OMIM: 188000) in two large 
unrelated Caucasian kindreds from Italy and the United States201,395. Candidate 
mutations were subsequently reported in ACBD5, encoding an acyl-CoA binding domain 
containing gene, and in MASTL (MIM: 608221), encoding a microtubule-associated 
serine/threonine kinase-like protein, respectively396,397. Further screening for MASTL and 
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ACBD5 mutations was negative in four Italian pedigrees in which linkage to the THC2 
locus was established398. Subsequently, DNA sequence analysis of 32 genes identified 
six mutations in a conserved 19-base pair (bp) region of the 5’-untranslated region 
(UTR) of ANKRD26 (MIM: 610855) in nine Italian families, including the original kindred 
with the putative ACBD5 mutation398. Further sequence analysis of ANKRD26 exon 1 
(encodes the 5’-UTR) identified a total of 12 candidate mutations confined to a 22-bp 
region of the 5’-UTR in 21 of 210 families with congenital thrombocytopenias of unknown 
cause399. 
Here we present a new kindred with nonsyndromic autosomal dominant 
thrombocytopenia in which linkage was established to the THC2 locus. Whole genome 
sequence analysis identified the previously reported candidate mutation in MASTL as 
well as a novel variant in the purported 22 bp region of ANKRD26. No other variants on 
chromosome 10 co-segregated among affected individuals. Subsequent haplotype 
analysis determined the MASTL and ANKRD26 variants were in linkage disequilibrium 
within the pedigree. Of note, a phenotypically normal founder who married into the 
kindred was heterozygous for an ANKRD26 variant previously reported as causal. We 
also report identification of an ANKRD26 5’-UTR mutation in the original MASTL kindred. 
Our findings suggest ANKRD26 is the most likely cause of nonsyndromic autosomal 




 The study population consists of three kindreds. The first kindred is a four-
generation pedigree, of whom 17 individuals have been diagnosed with nonsyndromic 
autosomal dominant thrombocytopenia. A total of 24 family members provided blood 
samples for DNA extraction. The second kindred consists of two cousins who are part of 
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the original MASTL pedigree reported by Drachman et al201,396. No known relationship 
was established between the first and second kindreds. The third kindred consists of a 
mother and two children diagnosed with nonsyndromic thrombocytopenia whose status 
was confirmed by platelet count at the time of enrollment. All patients and family 
members were enrolled according to institutional guidelines at the University of Iowa, the 
University of Colorado, and the Puget Sound Blood Center. DNA was extracted from 
blood using the Gentra Puregene Kit (Qiagen, Valencia, CA). 
 
Linkage analysis 
 In the first kindred, DNA from 24 pedigree members was genotyped using the 
Affymetrix Gene Chip Mapping 50K assay. Multipoint linkage analysis was conducted 
using GeneHunter (v2.1r5) as implemented in easyLINKAGE (v5.08)400. Significance of 
linkage results are reported as a logarithm of odds (LOD) score. Linkage results from the 
second kindred were previously published201. Linkage was not assessed in the third 
kindred. 
 
Whole genome sequencing and in silico modeling 
Ten samples were submitted to Illumina for whole genome sequencing using the 
Genome Analyzer IIx platform. Though a candidate interval was identified by linkage, 
whole genome sequencing was the most cost-effective technique to sequence the entire 
THC2 locus. Reads were mapped to the reference human genome sequence 
(GRCh37/hg19) with large-scale alignment software (ELAND).  Sequence calls for 
variants (single-nucleotide polymorphisms, insertions, and deletions) were 
performed using the Broad’s Genome Analysis Toolkit (GATK).  The resulting variants 
were input to the program ANNOVAR to annotate the variants by cross referencing 
various genetic variation databases (e.g., dbSNP, the 1,000 Genomes Project, AVSIFT, 
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etc.) to extract information about variant frequencies and location within genes if 
previously reported 401.   For non-synonymous changes, variants were cross-referenced 
to the dbSNP database to determine whether the changes to the protein would be 
considered tolerable or damaging, using prediction scores from SIFT, Polyphen2, LRT, 
and Mutation Taster, and conservation scores from PhyloP and GERP++. The 
ANKRD26  5’-UTR structure and variant structures were modeled using mfold402. 
 
Candidate mutation and THC2 tagging SNP sequencing 
 Primers to amplify candidate mutations were designed based on the 
GRCh37/hg19 build human genome sequence using Primer3 (http://frodo.wi.mit.edu/). 
As described in Chapter II, tagging SNPs were selected using the Tagger algorithm 
implemented in Haploview using pairwise tagging with an r2 threshold of 0.80242,243. 
Centre d’Etude du Polymorphisme Humain from Utah (CEU) data downloaded from the 
HapMap Genome Browser Release #28 was used to evaluate linkage disequilibrium and 
pairwise correlations of tagging SNPs for the candidate intervals indicated. Based on 
candidate mutation sequencing results, the THC2 locus was limited to chr10:27,330,000-
27,516,000 (GRCh36/hg18), encompassing ANKRD26 and MASTL. Primers to amplify 
tagging SNPs were designed using Primer3. For candidate mutation and tagging SNP 
primer sequences, see Appendix N. PCR was performed on genomic DNA and Sanger 
sequencing was performed using BigDye V3.1 on an ABI3730xl DNA analyzer247. 
Analysis of sequence was conducted using Sequencher V4.9. THC2 haplotype analysis 
was conducted using MERLIN (version 1.1.2) with command line option”—best”403. 
 
RNA isoform analysis 
Whole blood samples were collected from one patient and 3 unrelated control 
subjects directly into PAXgene blood RNA tubes (PreAnalytiX/Qiagen, Valencia, CA) 
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and total RNA isolation was performed using PAXgene Blood RNA kit per manufacturer 
protocol. RNA was treated with 2U DNase I digestion for 15 min at 37°C and purified 
with DNAse Inactivation Reagent (Ambion/Life Technologies AM1914, Grand Island, 
NY). RNA integrity was evaluated on a RNA Nano chip run on a BioAnalyzer 2100 
(Agilent Technologies, Santa Clara, CA). RNA integrity numbers (RIN) for all samples 
were 8.1-9.3. RNA for tissue panel was purchased from Ambion (FirstChoice Human 
Total RNA Survey Panel, AM600). Human bone marrow total RNA (636591) and 
peripheral leukocyte total RNA (636592) were purchased from Clontech (Mountain View, 
CA). Adult bone marrow CD33+ (RNA-BM006C) and CD36+ (RNA-BM013C) total RNA 
were purchased from AllCells (Emeryville, CA). cDNA first strand synthesis was 
performed in duplicate using 0.5 μg (whole blood) or 1μg (tissue panel) of total RNA with 
the iScript RT mix for RT-qPCR following manufacturer protocol (BioRad 170-8840, 
Hercules, CA). Primers were designed to amplify specific regions of sequence unique to 
each protein-coding ANKRD26 isoform as well as one region (exon 21) common to all 
isoforms using Primer3 (http://frodo.wi.mit.edu/) with a target amplicon length of 80-150 
bp (Appendix N). Primer sequences were evaluated for specificity and degeneracy by 
searching BLASTN (http://blast.ncbi.nlm.nih.gov/).  
Reference gene primers were designed and purchased from IDT [PrimeTime 
qPCR primers, Coralville, IA). Quantitative PCR was performed using a Roche 
LightCycler 480II Real Time PCR instrument, using Roche SYBR Green I Master (Roche 
04 707 516 001, Mannheim, Germany). All standard curve and validation reactions were 
performed in triplicate with no template control reactions for all primer sets; all samples 
were run in duplicate. Comparative quantitative analysis was performed using the 
LC480II data collection software (release 1.5.0.39 SP4). Seven log10 dilutions of 
plasmid template for all ANKRD26 isoforms and reference gene amplicon sequences 
were prepared and used for primer validation and standard curve reference. PCR 
143
efficiency for all target gene primer sets ranged from 90.1%-95.6% with all r2 values 
>0.99. To avoid confounding technical variation, one standard curve sample for all 
reference and target genes were included on every plate. Geometric averaging of five 
reference genes (ACTB, GAPDH, GUSB, HPRT, and TBP) were used normalize target 
gene transcripts. Melt curve analysis for all assays verify single product amplification and 
absence of primer dimers.  
 
Results 
A five year-old male, the index case of the first kindred, presented with a 
bleeding predisposition consistent with thrombocytopenia and a platelet count of 
58,000/mm3. Peripheral blood smear showed thrombocytopenia with normocytic 
platelets (Figure 7.1A). Bone marrow aspiration revealed normal numbers of 
megakaryocytes with numerous hypolobated forms (Figure 7.1B). Medical history was 
consistent with congenital nonsyndromic thrombocytopenia, and family history revealed 
extensive vertical transmission with multiple affected family members (Figure 7.2A).  
 
Figure 7.1: Index case blood smear and bone marrow aspirate 
A) The blood smear revealed normocytic thrombocytopenia. B) Bone marrow aspirate 
exhibited normal numbers of megakaryocytes at all stages of development that are 




Figure 7.2: ADT pedigree and candidate mutations 
A) We characterized three generations of a multigenerational kindred with nonsyndromic 
autosomal dominant thrombocytopenia. B) For candidate mutations, wild-type 
chromatograms are presented above heterozygous mutant chromatograms. 
 
Twenty-four pedigree members provided blood for DNA isolation including 10 
individuals with a diagnosis of nonsyndromic thrombocytopenia confirmed by platelet  
count at the time of enrollment (≤ 140,000/mm3; II.3, III.5, III.7, III.11, III.12, IV.5, IV.10, 
IV.12, IV.14, and IV.15) and 5 relatives with normal platelet counts confirmed at the time 
of enrollment (≥ 234,000/mm3; II.4, III.6, III.8, and IV.7). An additional 9 pedigree 
members provided samples, but platelet counts are not available to confirm their status. 
Two individuals (II.5 and II.7) self-reported a diagnosis of nonsyndromic 
thrombocytopenia. Four individuals (II.6, II.8, III.10, and III.13) are spouses of pedigree 
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members and self-report no bleeding diatheses. For three individuals (IV.11, IV.13, and 
IV.16), no phenotypic data was available. 
 Genome-wide analysis was undertaken by multipoint linkage analysis using 
easyLINKAGE. Linkage of the phenotype of thrombocytopenia was established to 
chromosome 10p11-12 with a maximum LOD score of 3.29. We observed no LOD 
scores greater than 2 in the genome-wide linkage analysis. Our findings are consistent 
with previously reported linkage of nonsyndromic autosomal dominant thrombocytopenia 
to the THC2 locus on chromosome 10201,395. 
 
Whole genome sequencing identifies an ANKRD26 and a MASTL mutation 
 Ten DNA samples were submitted to Illumina for whole genome sequencing 
including six pedigree members with thrombocytopenia (II.5, III.11, III.12, IV.10, IV.12, 
and IV.14) and four unaffected relatives (II.6, III.10, III.13, and IV.11). Chromosome 10 
variants were filtered by unaffected relatives, resulting in identification of nine exonic 
variants, 18 5’- and 3’-UTR variants, 1,438 intronic variants, 90 noncoding RNA variants, 
and 1,667 intergenic variants among individuals with thrombocytopenia. Of the nine 
exonic variants, eight were synonymous and one variant was nonsynonymous (MASTL 
c.506G>C, rs2894147). Based on the previously reported THC2 linkage intervals, we 
narrowed the candidate interval to a 5 Mb region (24,650,000-29,580,000). Within this 
interval when filtering by unaffected relatives, we retained one exonic variant, one 5’-
UTR variant, 210 intronic variants, seven noncoding RNA variants, and two intergenic 
variants (Appendix O). One insertion resulting in a frameshift was detected in PTCHD3. 
To allow for incomplete penetrance, we focused on exonic changes (UTR and 
amino acid coding regions) with the THC2 locus where patients were heterozygous and 
three or fewer of the unaffected relatives were heterozygous (Table 7.1). We then  
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Table 7.1: ADT candidate mutations allowing for incomplete penetrance 
  Amino   Heterozygous 
Gene Region  Acid Base rs# Patients Controls
ANKRD26 5' UTR N/A 27,389,381 6/6 0/4 
MASTL Exonic E167D 27,450,059 rs28941470 6/6 0/4 
ARHGAP21 3' UTR N/A 24,872,922 6/6 1/4 
PTCHD3 Exonic C407G 27,692,279 rs2484180 6/6 1/4 
GPR158 Exonic I>V 25,888,180 rs10828833 6/6 2/4 
MPP7 5' UTR N/A 28,543,716 rs11006956 6/6 2/4 
MPP7 5' UTR N/A 28,543,735 rs11006957 6/6 2/4 
PRTFDC1 3' UTR N/A 25,137,772 rs1045873 6/6 3/4 
ANKRD26 Exonic Q20R 27,389,197 rs7897309 6/6 3/4 
 
sequenced seven variants for which all six patients and two or fewer of  the unaffected 
relatives analyzed were heterozygous in 24 pedigree members including candidate 
mutations in ANKRD26, MASTL, ARHGAP21, PTCHD3, GPR158, and MPP7 (Appendix 
P). Only two variants were identified for which all patients were heterozygous for the 
minor allele and all unaffected relatives were homozygous for the wild-type allele: 
ANKRD26 c.-126T>C and MASTL c.506G>C (Figure 7.2B).  
The MASTL variant has been previously reported as causal396. The ANKRD26 
variant represents a novel variant within the 22-bp region of the 5’-UTR that has been 
previously reported to contain multiple causal variants, including a c.-126T>G variant399. 
No individuals, including the 10 samples analyzed by whole genome sequencing, were 
found to have the ARHGAP21 variant by Sanger sequencing. The remaining four 
variants in PTCHD3, GPR158, and MPP7 did not co-segregate with disease status 
within the pedigree. Interestingly, individual II.4, who married into the pedigree, carries 
an ANKRD26 variant previously reported as causal (ANKRD26 c.-113A>C; Figure 7.2B). 
Her platelet count is 246,000/mm3, and she does not exhibit any bleeding propensity. 
Her daughter, individual III.7, is heterozygous for both ANKRD26 c.-126T>C and c.-
113A>C variants as well as the MASTL c.506G>C variant and has a platelet count of 
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29,000/mm3. The ANKRD26 c.-126T>C and c.-113A>C and the MASTL c.506G>C 
variants are not present in the 1,000 Genomes Project. 
 The MASTL c.506G>C variant predicts a glutamic acid to aspartic acid 
substitution at amino acid position 167 (E167D). In silico analysis of the aspartic acid 
variant is discrepant. SIFT reports the site is not conserved among species with a score 
of 0.4 (< 0.05 is conserved), whereas GERP++ reports the site is conserved with a score 
of 5.58 (site is considered more conserved as the score approaches 6.17). Similarly, 
PolyPhen2 suggests the variant is possibly damaging in one isoform with a score of 
0.83, while being benign in two other reported isoforms (0.33, 0.39). In contrast, LRT 
and MutationTaster predict the MASTL variant is damaging, with scores of 8.2x10-5 and 
0.998, respectively. 
 Modeling using mfold predicted a stable structure for the ANKRD26 5’-UTR 
(ΔG=-74.1 kcal/mol). All reported mutations map to the distal half of a stem structure 
(bases 39-60, Figure 7.3A). This stem structure is present in five predicted models of the 
5’-UTR alone as well as five predicted models of exons 1-3, suggesting accurate 
modeling of the 5’-UTR when considered in isolation (data not shown).  Introduction of 
the ANKRD26 c.-126T>C variant alters the shape of the predicted stem structure, 
resulting in a smaller internal loop and a new terminal stem loop (base 47, Figure 7.3B). 
The c.-113A>C variant is not predicted to alter the 5’-UTR structure (base 60, ΔG=-74.1 
kcal/mol; Figure 7.3C). Modeling of the c.-134G>A variant, the most common variant 
reported by Noris et al. 399, predicted abolition of the internal loop of the stem structure 
with introduction of a new terminal loop (base 39, Figure 7.3D). The c.-126T>C and c.-




Figure 7.3: ANKRD26 5’-UTR structure predicted by mfold 
A) mfold simulation predicts a stable 5’-UTR structure. All reported ANKRD26 5’-UTR 
mutations map to a stem structure between model bases 39 and 60. Bases -134, -126, 
and -113 are shaded in gray and correspond to model bases 39, 47, and 60, 
respectively. Only the stem structure represented in the box is altered by the modeled 5’-
UTR mutations. The c.-126T>C (B) and c.-134G>A (D) variants alter the stem structure 
and are reported to be penetrant variants resulting in thrombocytopenia. The c.-113A>C 




ANKRD26 and MASTL variants are in linkage disequilibrium 
 ANKRD26 and MASTL are separated by approximately 55 kb. To determine if 
the ANKRD26 c.-126T>C and MASTL c.506G>C variants were in linkage disequilibrium, 
we selected tagging SNPs based on the HapMap project CEU dataset to capture an 
interval of 186 kb that contained both candidate genes (GRCh36/hg18: 27,330,000-
27,516,000). In the CEU dataset, this region demonstrates extensive linkage 
disequilibrium (Figure 7.4A). The majority of the interval is contained within one 
haplotype block, including most of ANKRD26 and MASTL. Thirty-two tagging SNPs were 
required to capture 100% of alleles in the interval. Phased haplotypes were generated 
via MERLIN including the sites of the two candidate mutations (Figure 7.4B). The 
ANKRD26 c.-126T>C and MASTL c.506G>C variants were found to be in linkage 
disequilibrium in haplotype 1. Haplotypes 2-6 represent wild-type founder haplotypes 
that did not contain either candidate mutation. Haplotype 2 differs from haplotype 1 at 
only the sites of the two candidate mutations. Haplotype 7 contains the wild-type 
sequence at both candidate mutation sites; however, this haplotype contains the 
ANKRD26 c.-113A>C variant.  
 
ANKRD26 c.-126T>C variant identified in the original MASTL kindred and a third 
unrelated kindred 
 In order to evaluate if the ANKRD26 c.-126T>C and MASTL c.506G>C variants 
are in linkage disequilibrium in an ancestral allele, we genotyped two cousins with ADT 
from the original MASTL kindred described by Drachman et al201,396. Both individuals 
were heterozygous for the previously reported MASTL c.506G>C variant as well as the 
ANKRD26 c.-126T>C. We did not have access to additional samples to generate 
phased haplotypes within this kindred. We also genotyped ANKRD26 exon 1 and all 
MASTL exons in a third unrelated kindred consisting of a mother and two children, all of  
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Figure 7.4: THC2 interval linkage disequilibrium and pedigree haplotype analysis 
A) In the CEU dataset, THC2 demonstrates significant linkage disequilibrium between 
ANKRD26 and MASTL (generated using Haploview). B) Phased haplotypes were 
generated using MERLIN. Haplotype 1 represents the ANKRD26 c.-126T>C and MASTL 
c.506G>C haplotype. Haplotypes 2-7 represent wild-type haplotypes. Haplotypes were 
imputed for individuals I.1, I.2, II.1, and III.10. 
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whom presented with nonsyndromic thrombocytopenia consistent with ADT. All three 
individuals were heterozygous for the ANKRD26 c.-126T>C variant. No mutations were 
identified in MASTL exonic regions including exon/intron boundaries. 
 
ANKRD26 is a widely expressed gene 
 Previous studies reported MASTL mRNA expression is restricted to 
hematopoietic cells and cancer cell lines404. Four protein coding ANKRD26 mRNA 
isoforms have been reported (http://www.ensembl.org). Isoform 001 
(ENST00000376087) is the only isoform that includes all 34 exons. Isoform 003 
(ENST00000445828) is the shortest isoform at 761 bp and is completely redundant with 
other isoforms. Isoform 201 (ENST00000376070) excludes the first 15 exons of 
ANKRD26, beginning with a 306 bp segment of intron 16 followed by exons 17-34. 
Isoform 202 (ENST00000436985) differs from isoform 001 by inclusion a 147 bp region 
from intron 6 and exclusion of exon 13. An additional three processed transcript isoforms 
have been reported (002, 004, and 005) that are less than 725 bp in length and do not 
encode a protein product. Exon 21 was selected to evaluate total ANKRD26 expression 
as it is present in all reported isoforms.  
ANKRD26 is a widely expressed gene with the highest levels of expression in 
cervix, heart, skeletal muscle, and small intestine total tissue mRNA (Figure 7.5). 
ANKRD26 expression was also detected in hematopoietic tissue including total bone 
marrow mRNA as well as CD33+ (myeloid progenitor) and CD36+ (erythroid progenitor) 
cells. ANKRD26 mRNA was not detected in thymus, thyroid, or trachea total mRNA. 
Isoforms 201 and 202 are the most commonly expressed ANKRD26 isoforms (Table 
7.2). Expression levels of isoform 001 were below the limit of quantitation for this assay, 
though the target product was confirmed by sequencing (data not shown).  
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Figure 7.5: Expression of ANKRD26 mRNA by tissue type 
ANKRD26 expression was assessed by qPCR of exon 21 (common to all reported 
isoforms) and quantitated for comparison to a standard curve. All mRNA samples except 
MEQ 01 and MEQ α (cell lines for future analyses of ANKRD26) are commercially 
available. X-axis: tissue or cell type. Y-axis: relative quantity of ANKRD26 exon 21 
mRNA based on quantitation to standard curve. A) Ambion FirstChoice human total RNA 
survey panel, Clontech human bone marrow and peripheral leukocyte total RNA, AllCells 
adult bone marrow CD33+ and CD36+ total RNA, and cell line Meq 01 and Meq α RNA. 
ANKRD26 is widely expressed with the highest expression levels cervix, heart, skeletal 
muscle, and small intestines. B) ANKRD26 is expressed in hematopoietic tissues at 





Table 7.2: ANKRD26 mRNA isoforms expression by tissue type 
  ANKRD26 001 201 202 
Tissue Exon 21 Exon 13 Intron 16 Intron 6 
Adipose + - + + 
Bladder + - + + 
Bone Marrow + - + + 
Brain + - + + 
CD33+ + - + + 
CD36+ + - + + 
Cervix + - + + 
Colon + - + + 
Esophagus + - + + 
Heart + - + + 
Kidney + - + + 
Liver + - + +/- 
Lung + - + + 
MEQ 01 + - + + 
MEQ α + - + + 
Ovary + - + + 
P. leukocytes + - + + 
Placenta + - + + 
Prostate + - + + 
Skeletal muscle + - + + 
Small intestine + - + + 
Spleen + - + + 
Testes + - + + 
Thymus - - - - 
Thyroid - - - - 




 To date, the MASTL c.506G>C mutation has been reported in two North 
American Caucasian kindreds with nonsyndromic autosomal dominant 
thrombocytopenia, THC2, including the new kindred reported herein. Whereas in silico 
analysis of the conservation of position 506 and the potential impact of the E167D 
substitution is discrepant, MASTL cannot be ruled out as a candidate gene. Previously 
published Northern blot analysis reported MASTL mRNA is expressed in hematopoietic 
cells404. Furthermore, transient knockdown of the MASTL ortholog in zebrafish resulted 
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in decreased expression of the thrombopoietin receptor (c-mpl) as well as platelet 
protein CD41 (GPIIb) and decreased circulating thrombocytes404. These findings suggest 
that MASTL may participate in hematopoiesis. Moreover, the zebrafish model indicates 
that the mechanism of disease may be haploinsufficiency. Though there is no known 
microdeletion syndrome that includes 10p12.1, at least six individuals have been 
reported with segmental duplications or deletions encompassing MASTL and ANKRD26 
(https://decipher.sanger.ac.uk/). Neither thrombocytopenia nor bleeding diathesis is 
listed as phenotypic traits in any of these six reports, suggesting that haploinsufficiency 
may not be the correct mechanism of disease. 
 In the study reporting identification of ANKRD26 5’-UTR mutations in 
nonsyndromic autosomal dominant thrombocytopenia, sequence analysis of MASTL 
revealed only variants previously reported in dbSNP, though no other details are 
provided about these sequence results398. It is worth noting the MASTL c.506G>C 
variant is listed in dbSNP (rs28941470). Subsequently, Pippucci et al., report five 
mutations confined to a 19-bp segment of the 5’-UTR of ANKRD26, which they propose 
is the causal gene underlying nonsyndromic autosomal dominant thrombocytopenia, 
THC2. A subsequent report by the same group increased the total number of ANKRD26 
variants to 12 confined to a 22-bp segment of the 5’-UTR399. The 1,000 Genomes 
Project did not reveal any variation in the candidate segment of ANKRD26 5’-UTR nor at 
position 506 of MASTL. Nearby SNPs are present within the 1,000 Genomes dataset, 
suggesting adequate coverage of these regions. 
Additionally, we identified the ANKRD26 c.-113A>C variant in two pedigree 
members: a mother who married into the kindred and a daughter with thrombocytopenia 
that is also heterozygous for the ANKRD26 c.126T>C and MASTL c.506G>C haplotype. 
The ANKRD26 c.-113A>C variant was previously reported as causal in an Italian family 
with three patients399. The previous report agnostically sequenced ANKRD26 exon 1 in 
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210 index cases of inherited thrombocytopenia of unknown cause. Thus, it is possible 
the family with the ANKRD26 c.-113A>C variant may not demonstrate linkage to THC2 
and thus be misclassified. 
Bone marrow examination of four Italian patients and the index case presented 
herein revealed normal numbers of megakaryocytes at all stages of maturity, though 
with hypolobated nuclei, suggesting that thrombocytopenia likely arises as a result of 
defective platelet release or decreased platelet lifespan. The proposed role of ANKRD26 
5’-UTR mutations resulting in increased apoptosis is mechanistically consistent with a 
gain-of-function mutation.  
The potential role of ANKRD26 in hematopoiesis and the pathogenesis of 
nonsyndromic thrombocytopenia are not well understood. ANKRD26 is believed to be 
the earliest known common ancestor to the POTE (prostate-, ovary-, testis-, and 
placenta-expressed ankyrin domain) family of genes based on sequence homology with 
POTE8, the earliest POTE gene by phylogeny405. Ankyrin is a conserved 33 amino-acid 
domain, and multiple ankyrin domains in a gene are thought to stack side-by-side to 
form specific protein-binding interfaces that mediate protein-protein interactions406. 
ANKRD26 also contains a coiled-coil region of α-helices thought to serve a mechanical 
role in forming stiff bundles of fibers. Sequence analysis predicts a strong nuclear 
localization signal near the amino terminal region of the polypeptide405. Previous reports 
suggest that the mouse ortholog peptide colocalizes with filamentous actin just beneath 
the plasma membrane when expressed in HeLa and 293T cells407. However, our 
sequence analysis of the Ankrd26-EGFP plasmid provided by Bera et al., reveals the 
expression construct contains a truncated Ankrd26 coding region (data not shown).  
To date, no data have been published demonstrating that ANKRD26  participates 
in apoptosis. POTE paralogs fused with actin cDNA have been reported, and 
overexpression in HeLa cells proved to be toxic to the cells408,409. Furthermore, 
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expression of a POTE-2α-actin fusion induced Fas ligand- and TRAIL-mediated 
apoptosis409. Autosomal dominant thrombocytopenia in which linkage to the THC4 locus 
was established is also hypothesized to be due to increased apoptotic activity410. Taken 
together, these reports establish apoptosis as a mechanism of thrombocytopenia, and 
these reports show genes with ancestral homology to ANKRD26 may encode apoptotic 
proteins. 
Interestingly, a mouse model in which Ankrd26 was disrupted by β-
galatctosidase insertion into intron 4, resulting in partial inactivation of Ankrd26, 
demonstrated that homozygous mutant mice develop obesity and insulin resistance due 
to hyperphagia.407 Heterozygous mice did not display an observable phenotype, and 
heterozygous and homozygous mice have a normal platelet count, supporting previous 
data to suggest that haploinsufficiency is not the disease mechanism underlying 
autosomal dominant thrombocytopenia, THC2398,407. 
When considering ANKRD26 as the putative gene underlying autosomal 
dominant thrombocytopenia, a key unanswered question is the role of the implicated 5’-
UTR mutations in mRNA biology. The 5’-UTR of mRNA is an important regulatory 
component of gene expression through diverse mechanisms that can include regulating 
translational efficiency411. The predicted ΔG of the ANKRD26 5’-UTR suggests that the 
folded 5’-UTR of ANKRD26 is a stable structure and would pose an obstacle to 
translation. While the predicted structural changes introduced by ANKRD26 5’-UTR 
variants are local, they may impact key protein binding domains within the 5’-UTR. The 
ANKRD26 c.-126T>C and c.-134G>A variants are predicted to alter a stem structure 
consistent in five mfold model simulations, introducing a novel terminal stem loop. 5’-
UTR stem loops have been implicated as protein binding sites that mediate translational 
efficiency412,413. Furthermore, gain-of-function 5’-UTR variants have been described that 
result in decreased binding of repressive proteins414. 
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 Alternatively, 5’-UTR mRNA folded structures are dynamic and can adopt 
multiple conformations415. The 5’-UTR mRNA stem structure in ANKRD26 implicated in 
nonsyndromic autosomal dominant thrombocytopenia, THC2, may undergo 
conformational changes under physiologic conditions that would result in the creation of 
a similar stem loop as that introduced by the c.-126T>C variant. Hence, it is possible 
ANKRD26 5’-UTR mutations may generate a more readily translated ANKRD26 
transcript. Recently, it has been demonstrated that the 5’-UTR folded structure is 
important to the formation and function of internal ribosome entry sites (IRES)416. 
Mutations within IRES domains may alter the efficiency of ribosome recruitment and 
assembly417. The c.-126T>C and c.-134G>A variants may result in the conformational 
changes necessary for recognition of an IRES within the ANKRD26 5’-UTR.  
Modeling the c.-113A>C variant results in no predicted structural changes of the 
5’-UTR stem structure implicated in nonsyndromic autosomal dominant 
thrombocytopenia, THC2. This is consistent with our observation that the c.-113A>C 
variant is non-penetrant, suggesting that it was previously misclassified as a causal 
variant. It is likely that ANKRD26 5’-UTR mutations underlying thrombocytopenia result 
in conformational changes of this stem structure and introduce a stem loop similar to that 
introduced by the c.-126T>C and c.-134 G>A variants. Thus, variants that do not disrupt 
the stem structure are likely nonpenetrant and may result in misclassification of the 
cause of thrombocytopenia if not further interrogated. 
Overexpression reporter assays of transfected K562 (undifferentiated myeloid) 
and Dami (megakaryoblastic) cells with wild-type or ANKRD26 c.-127A>T, c.-128G>A, 
or c.-134G>A demonstrated the ANKRD26 c.-128G>A and c.-134G>A constructs 
resulted in increased expression of the reporter gene398. When Dami cells were 
stimulated to mature toward a megakyarocytic linkage, all three ANKRD26 variant 
constructs resulted in increased expression of the reporter gene. Increased luciferase 
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activity is consistent with a gain-of-function mechanism, though the authors provide 
insufficient experimental details or results to differentiate transcript stability or levels from 
translational efficiency. 
It was previously reported that ANKRD26 transcripts were detected in 
megakaryocytes and erythroblasts cultured from cord blood418. We detected ANKRD26 
mRNA in multiple hematopoietic tissues and cell types including total bone marrow 
mRNA, CD33+ and CD36+ progenitor cells, and peripheral leukocytes. Preliminary 
experiments demonstrate slight elevation in total ANKRD26 expression in the one 
patient evaluated to date when compared to pooled unrelated control samples (1.51-fold 
increase in exon 21, 2.32-fold increase in isoform 201, and 2.25-fold increase in isoform 
202). Replication experiments are currently underway using mRNA isolated from a 
normalized number of platelets from patients and controls. 
In summary, we report the presence of the ANKRD26 c.-126T>C variant in 
linkage disequilibrium with the MASTL c.506G>C variant in a new kindred with 
autosomal dominant thrombocytopenia in which linkage to THC2 has been established. 
Furthermore, we report identification of the ANKRD26 c.-126T>C variant in the original 
MASTL kindred described by Drachman et al201,396. We also report a third kindred in 
which the ANKRD26 c.-126T>C variant was identified, but no exonic MASTL variants 
were present. Taken together with ANKRD26 5’-UTR variants reported in multiple Italian 
kindreds in which linkage to the THC2 locus has been established, these findings 
suggest that certain 5’-UTR mutations in ANKRD26 are the most likely cause of 




SUMMARY AND FUTURE DIRECTIONS 
 
Summary 
 The focus of this dissertation was to further elucidate the genetic etiology of the 
von Willebrand factor (VWF) – coagulation factor VIII (FVIII) – platelet axis of hemostasis 
and thrombosis through family-based studies. The multigenerational Amish pedigree, in 
which we diagnosed VWD type 2 with an underlying c.4120C>T mutation, was enrolled 
for the purpose of mapping quantitative trait loci (QTL) of VWF and FVIII levels, 
bleeding, and complete blood count (CBC) traits such as erythrocyte measures and 
platelet count. The candidate QTLs mapped within the Amish pedigree that may affect 
VWF and FVIII levels will provide new insights into the genetic etiology of these two 
continuous traits. Furthermore, our findings suggest that the effect of QTLs on FVIII may 
be mediated through its noncovalent relationship with VWF, which highlights the 
importance of VWF in determining FVIII levels. Additionally, the candidate QTLs that 
may affect CBC traits will provide new insights into erythropoiesis.  
By dichotomous multipoint linkage analysis, we established linkage between 
VWF:RCo and chromosome 6p22, a candidate QTL previously reported in multiple 
studies. With the implementation of SOLAR, genome-wide QTL linkage analysis 
identified candidate QTL of VWF:Ag and VWF:RCo mapping to chromosomes 3q28, 
9q34, and 16q11. Fine-mapping analysis of chromosome 9q34 established that ABO, 
and not ADAMTS13, contributes to variation in VWF levels in the Amish pedigree. To 
our knowledge, we are the first to specifically evaluate ADAMTS13 in light of linkage or 
association to chromosome 9q34. We also replicated previously reported associations 
with VWF and FVIII levels from the largest meta-analysis reported to date, confirming 
STXBP5, SCARA5, STAB2, and TC2N as candidate QTL. 
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 We also conducted genome-wide linkage analyses of CBC traits. Due to 
hemorheologic effect, larger blood components such as erythrocytes and leukocytes 
displace the circulating VWF-FVIII complex and platelets toward the endothelium. Thus, 
for all standard CBC traits, independent associations with pathologic thromboembolism 
have been reported. Within the Amish, we identified four candidate QTL with LOD 
scores greater than 2.0, replicating two previously reported QTL and identifying two 
novel QTL. To our knowledge, this study is also the first genome-wide evaluation of red 
blood cell distribution width (RDW), for which we identified candidate linkage to 
chromosome 10p12 (LOD=2.09). Interestingly, we demonstrated that rs1800562, the 
most common causal variant of the Mendelian disease hereditary hemochromatosis, is 
also associated with common variation in erythrocyte traits. 
 In addition to mapping QTL of VWF levels, we sought to further characterize 
variation as a result of the biology of the VWF gene and VWF polypeptide biosynthesis. 
We genotyped 94 tagging SNPs encompassing VWF in the Amish pedigree and 
established significant associations between 12 SNPs and VWF:RCo. Nine VWF:RCo 
SNPs map to a haplotype block within the pedigree that includes the functional domains 
of the VWF polypeptide. Of 11 SNPs selected for follow-up, we ultimately replicated 
significant associations for two SNPs in three different population-based cohorts 
(n=3,316). An additional four SNPs were replicated in two of three cohorts. Interestingly, 
we found that different VWF variants were most important in determining variation in 
VWF:Ag, VWF:RCo, and the VWF:RCo/VWF:Ag ratio. Furthermore, we identified a 
nonsynonymous variant (T1381A) as well as a potentially functional intronic variant 
(rs216308) that are associated with VWF levels. The ultimate goal of this project was to 
identify variants that may contribute to the complex etiology of VWD type 1. We 
established that one variant was overrepresented and four variants were 
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underrepresented in a VWD type 1 index case cohort compared to a control cohort, 
suggesting these variants may contribute to the complex etiology of VWD type 1. 
 As discussed, VWD is characterized by phenotypic variability. Management of 
mild cases of VWD is further complicated by the absence of a putative VWF mutation in 
nearly half of patients. In a cohort of VWD type 1 index cases, we established that the 
minor allele frequencies of five VWF SNPs were significantly different compared to 
unrelated control individuals. These findings suggest that common variants that affect 
VWF levels may also contribute to the genetic etiology of mild cases of VWD, particularly 
in the absence of a putative VWF mutation.  
 We identified the novel VWF c.3911T>G mutation and evaluated other VWF 
variants, allele-specific mRNA expression, and VWF multimer structure to characterize 
sources of phenotypic variation in a family with VWD type 2. Through cell expression 
assays we established that the c.3911T>G mutation results in defective VWF 
polypeptide synthesis and trafficking, though the mutant polypeptide is incorporated into 
VWF multimers. Using the AU/VWFa-11 nanobody we determined VWD patients had 
differential incorporation of the mutant polypeptide into VWF multimers. Thus, we 
proposed that the phenotypic variation in VWD type 2 may be due, in part, to differential 
mutant monomer incorporation. As better assays are developed to quantitate mutant 
monomer incorporation in VWF multimers, we may be able to establish a new biomarker 
of VWF function that may be more predictive of bleeding risk. 
 The final aim of this dissertation was to identify genes involved in platelet 
biogenesis through studying two families with congenital forms of thrombocytopenia. In 
three kindreds, including a large Native American pedigree, we identified multiple 
deleterious mutations in NBEAL2, ascertaining the first gene implicated in platelet α-
granule biogenesis. We also characterized a family with nonsyndromic autosomal 
dominant thrombocytopenia. Focused analysis of whole genome sequencing identified 
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two candidate mutations: c.506G>C in MASTL and c.-126T>C in ANKRD26. We 
established that both mutations are in complete linkage disequilibrium within the family 
and identified both mutations in a second kindred. However, in a third kindred, we 
identified only the ANKRD26 c.-126T>C mutation. This finding, in combination with 
recently published studies, suggests that 5’-untranslated region (UTR) mutations in 
ANKRD26 are the most likely cause of nonsyndromic autosomal dominant 
thrombocytopenia. In silico modeling determined the c.-126T>C mutation introduces a 
terminal stem loop, which may alter protein binding or ribosomal recruitment to the 
transcript, in turn affecting translational efficiency. 
 
Future directions 
 Analysis of the VWF gene and VWF multimerization provided unique insights into 
the genetic etiology of VWD type 1 as well as the phenotypic variability of VWD type 2. 
Ultimately, the interest in further characterizing common variation in VWF is to identify 
patients that are at high risk for excessive bleeding or pathologic thromboembolism due 
to chronically elevated or decreased VWF levels. Furthermore, recombinant protein 
manufacturing is expensive and manufacturers are interested interest in making the 
process more efficient by increasing protein expression or increasing product half-life115. 
VWF SNP analysis in the Amish pedigree identified four haplotype blocks that 
demonstrate strong linkage disequilibrium. Analyses are ongoing to identify haplotypes 
associated with VWF levels. Further biochemical characterization of the T1381A variant 
is needed to determine if it is an artifact altering ristocetin binding, a clinically relevant 
variant altering VWF levels or activity, or a marker of other functional variants. The most 
direct approach is to analyze blood plasma samples from individuals with and without 
the T1381A variant with respect to multiple laboratory evaluations of VWF-mediated 
binding including ristocetin-induced platelet aggregation and VWF collagen binding 
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assays.  Identification of variants that alter laboratory test results such as VWF:RCo but 
have no other clinical impact continue to provide clarification of a complex clinical 
challenge. Additionally, experiments are needed to determine if the intronic variant 
rs216308 is functional or is in linkage disequilibrium with functional variants. 
Electrophoretic mobility shift assay (EMSA) would allow one to determine if the DNA 
sequence containing the minor allele of rs216308 demonstrates altered protein binding 
when compared with the wild-type sequence. All other SNPs to which significant 
associations were established likely tag functional variants, which have yet to be 
elucidated. Based on haplotype structure within the Amish, we can conduct focused 
sequencing to elucidate variants for functional characterization. 
Within a smaller pedigree with VWD type 2, we identified and characterized the 
novel c.3911T>G mutation and proposed that differential mutant VWF monomer 
incorporation into multimers underlies phenotypic variability. Due to the complexity and 
size of VWF multimers, it remains a challenge to quantitate mutant and wild-type 
monomers in VWF multimers. Efforts are ongoing to optimize mass spectrometry 
protocols that would allow dissection of and allele-specific quantitation of VWF monomer 
subunits. This will provide a robust tool to validate our hypothesis and to further 
characterize the phenotypic variation of VWD type 2. 
While we did not identify differences in allele-specific mRNA expression within 
the VWF c.3911T>G family, we did optimize a novel assay for allele-specific mRNA 
quantitation in human subjects. Phenotypic variation in a larger family, such as the 
Amish pedigree, may be explained in part by differences in mRNA levels. Additional 
enrollment clinics will be required to collect samples for platelet isolation, and the allele-
specific quantitation protocol can then be adapted to the c.4120C>T mutation to 
evaluate the presence of a hypomorphic allele within the Amish pedigree. Furthermore, 
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the nanobody binding assay, and ultimately mass spectrometry, will be used to evaluate 
mutant monomer incorporation and phenotypic variability in the Amish pedigree. 
In terms of the bleeding phenotype of VWD, analyses are complicated due 
limitations in phenotype ascertainment. The bleeding survey is a subjective screening 
tool used to assess one’s risk to bleed. However, its usefulness as a measure of 
bleeding for research purposes has been poor. Arguably, the most informative 
individuals to study are those with a known causal VWF mutation that do not bleed upon 
clinical challenge such as tooth extraction, surgery, or parturition versus patients with the 
same mutation that demonstrate clinically significant bleeding. Limiting analysis of 
bleeding to a dichotomous trait will simplify the phenotype while simultaneously 
eliminating uninformative individuals from the study design. Within the Amish pedigree, 
work is ongoing to objectively define bleeding upon challenge and quality of life impacts 
that bleeding has upon this agrarian culture. Furthermore, as the cost of next generation 
sequencing continues to decline, it is becoming affordable to conduct whole genome 
sequencing or exome sequencing within the “bleeders” and “non-bleeders” with the 
c.4120C>T mutation to identify variants of the bleeding phenotype. Linkage analysis 
may prove valuable to sort through next generation sequencing data and detect variants 
with a large effect on the bleeding phenotype. 
 In addition to studying the phenotypic variability of VWD, we also sought to map 
candidate QTL of VWF and FVIII levels. Association analyses to fine-map the candidate 
QTL on chromosomes 6p22 and 16q11 are ongoing. Subsequently, we will increase 
fine-mapping resolution and sequence candidate genes to identify variants for replication 
in unrelated cohorts. Furthermore, we know that VWF:Ag and FVIII:C are highly 
correlated traits. All candidate QTL of FVIII:C identified are concomitant with VWF:Ag 
QTL, which suggests that variation is mediated through the noncovalent relationship of 
VWF and FVIII in circulation. Thus, we are currently conducting bivariate analysis of 
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VWF:Ag and FVIII:C to identify candidate QTL whose effect on VWF:Ag levels is 
sufficient to subsequently alter FVIII:C as well. 
 Identification of NBEAL2 in gray platelet syndrome provided the first gene 
implicated in α-granule biogenesis. We presented initial platelet transcriptome heat map 
analyses which are currently being replicated and further characterized within additional 
patients. Efforts are also ongoing to characterize the protein product of NBEAL2 in 
megakaryocytic cell lines to determine protein expression and localization as well as 
elucidate protein-protein interactions. By siRNA, we can knock down NBEAL2 
expression and evaluate the impact on α-granule and proplatelet formation within cell 
culture models. In addition, the nbeal2 null mouse is now available. We will conduct 
experiments to determine if the absence of murine nbeal2 expression triggers a similar 
disruption of the transcriptome as well as the role of nbeal2 in platelet biogenesis. 
 The elucidation of the gene in nonsyndromic autosomal dominant 
thrombocytopenia was complicated by the presence of two candidate mutations in 
complete linkage disequilibrium within the family. Identification of only the ANKRD26 5’-
UTR variant within an unrelated family in combination with other recently published 
reports suggests 5’-UTR mutations in ANKRD26 are the most likely cause of 
nonsyndromic autosomal dominant thrombocytopenia. Interestingly, we identified a 
nonpenetrant 5’-UTR variant (c.-113A>C) that has previously been reported as “causal.” 
In silico modeling analyses predicted the penetrant c.-126T>C variant introduces a novel 
terminal stem loop whereas the c.-113A>C variant does not alter the predicted wild-type 
5’-UTR structure. We will next evaluate the potential functionality of the ANKRD26 c.-
126 T>C and c.-113 A>C variants by EMSA and luciferase promoter assays. Based on 
clinical reports of microdeletions encompassing ANKRD26, we hypothesize the mutation 
functions through gain-of-function rather than haploinsufficiency. Increased luciferase 
activity would confirm a gain-of-function hypothesis. Furthermore, characterization of 
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mRNA and protein levels within the luciferase assay would allow differentiation of 
transcriptional stability versus translational efficiency.  
Pending luciferase assay results, we plan to evaluate the gain-of-function 
hypothesis by overexpressing ANKRD26 in megakaryocytic cell lines to determine the 
effect on megakaryopoiesis and proplatelet formation. We also plan to introduce gain-of-
function variants using the recently developed zinc finger nuclease methodology into a 
zebrafish model to evaluate thrombopoiesis419.  
Hemostasis and thrombosis represent a complex clinical spectrum. The research 
presented in this dissertation provided valuable insights and hypotheses regarding 
variation of common hemostatic traits as well as the phenotypic variability of VWD. 
Additionally, we identified genes implicated in platelet biogenesis. Additional studies will 
allow further elucidation of the complex etiology of hemostasis and thrombosis, providing 
new clinical insights for diagnosis and risk assessment. Furthermore, a better 
understanding of the molecular mechanisms of hemostasis and thrombosis may provide 
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VWF Gene and Pseudogene Alignment for Primer Design 
 
 




Query: VWF sequence 
Subject: Pseudogene sequence 
                                                         Sort alignments for this subject 
sequence by: 
                                                           E value  Score  Percent 
identity 
                                                           Query start position  Subject 
start position 
 Features flanking this part of subject sequence: 
   89813 bp at 5' side: putative T-complex protein 1 subunit theta-like 2 
   87433 bp at 3' side: XK-related protein 3 
 
 Score = 2.252e+04 bits (12193),  Expect = 0.0 
 Identities = 13368/13919 (96%), Gaps = 146/13919 (1%) 
 Strand=Plus/Minus 
Score = 1.562e+04 bits (8457),  Expect = 0.0 
 Identities = 9022/9293 (97%), Gaps = 45/9293 (0%) 
 Strand=Plus/Minus 
 
Query  98631   AGCAAGATAGAATACATTTTTTCTCTTTGTCTCAACATCAGGGCTCTAAGTATATTGTAA  98690 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  338498  AGCAAGATAGAATACATTTTTTCTCTTTGTCTCAACATCAGGGCTCTAAGTATATTGTAA  338439 
 
Query  98691   AAGTATAGCACCTTTTCTTCTCCAGGCCAAATATTTCCAGttttttctgtag---ttttt  98747 
               ||||||||||||||||||||||||||||||||||||||||||||||||||||   ||||| 
Sbjct  338438  AAGTATAGCACCTTTTCTTCTCCAGGCCAAATATTTCCAGTTTTTTCTGTAGTTTTTTTT  338379 
 
Query  98748   ttgttttattattatttttagttgacatttaactgtatgtatttactggtgacagtgtga  98807 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  338378  TTGTTTTATTATTATTTTTAGTTGACATTTAACTGTATGTATTTACTGGTGACAGTGTGA  338319 
 
Query  98808   tatttcagtacatgtatacagtgtgtagtgatcaaatcagggtagttactatatctgttc  98867 
               ||||||| ||||||||||||||||||| |||||||||||||||||||| ||||||| ||| 
Sbjct  338318  TATTTCAATACATGTATACAGTGTGTAATGATCAAATCAGGGTAGTTAGTATATCTCTTC  338259 
 
Query  98868   cctcaaacatttaccatttctttgtgttgggaacattcaaagtctgctcttccagctact  98927 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  338258  CCTCAAACATTTACCATTTCTTTGTGTTGGGAACATTCAAAGTCTGCTCTTCCAGCTACT  338199 
 
Query  98928   tgaaaatatacaataaactgttgataattatagtcaccctgtggtgctaccgaacactag  98987 
               |||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||| 
Sbjct  338198  TGAAAATATACAATAAACTGTTGATAATTATAGTCACCCTGTGGTGCTACAGAACACTAG  338139 
 
Query  98988   aacttatccctcctctttgtgtagttttCACTTGTTTCTCACTCATTCGTAACTACTTTT  99047 
               |||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||| 
Sbjct  338138  AACTTATCCCTCCTCTTTGTGTAGTTTTCACTTGTTTCTCACTCATTCATAACTACTTTT  338079 
 
Query  99048   TCAGAACTTGTTGCATGTTGCACTCCATGATGGGTGAACATGGAGACAGGTGAGACATAT  99107 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  338078  TCAGAACTTGTTGCATGTTGCACTCCATGATGGGTGAACATGGAGACAGGTGAGACATAT  338019 
 
Query  99108   CTTCCTGATTACATTTATGAGAGAGCAGAATTCTGCCCAGCCTACTCTGAACAGGCTGCA  99167 
               ||||||| |||||||||||| ||||||||||||||||||||||  ||||||||||||||  








Query  99168   CTTCTCCAGGCAAGGGGACTCACCTTCCCAGAGGCAGGCAGTTCTATAACTTTCCCTCCT  99227 
                |||||||||||||||||||||||| |||||||||||||||||||||||| ||||||||| 
Sbjct  337958  GTTCTCCAGGCAAGGGGACTCACCTGCCCAGAGGCAGGCAGTTCTATAACGTTCCCTCCT  337899 
 
Query  99228   TGGACCCCTACACCTCCATTGGTGGAGCAGTGTACCTGGCTCCTCTCTCTGCTTCTATGC  99287 
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| || 
Sbjct  337898  TGGACCCCTACACCTCCATTGGTGGAGCAGTGTACCTGGCTCCTCTCTCTGCTTCTACGC  337839 
 
Query  99288   TTGTTGGGGACAGTGATAGTTCCCACCAGTGATCTCAGGGCCAAGGCTGCCTGATTCCCA  99347 
               ||||||||||||| |||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  337838  TTGTTGGGGACAGCGATAGTTCCCACCAGTGATCTCAGGGCCAAGGCTGCCTGATTCCCA  337779 
 
Query  99348   CCTCTGCCCTTGGCTGACTATGTGACATGGGCATGTTGCCTCTC--TGTTTCCATAGCTT  99405 
               | ||||||||||||||||||||||||||||||||||||||||||  |||||||||||||| 
Sbjct  337778  CTTCTGCCCTTGGCTGACTATGTGACATGGGCATGTTGCCTCTCTTTGTTTCCATAGCTT  337719 
 
Query  99406   TAAATAAAATGGGGCCAGCAAGGAAGCTCAGGAAT-GGGTCTTGGCAATGGCAAGGCTTT  99464 
                |||||||||||||||||||||||||||||||||| ||| |||||||||||||||||||| 
Sbjct  337718  CAAATAAAATGGGGCCAGCAAGGAAGCTCAGGAATAGGG-CTTGGCAATGGCAAGGCTTT  337660 
 
Query  99465   GCTGCTCAcctcgggcctcctctgagtctctgtcccgctcctcctcctcttcctcgaatg  99524 
               |||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||| 
Sbjct  337659  GCTGCTCACCTCGGGCCTCCTCTGAGTCTCTGTCCCGCTCCTCCTCCTCTCCCTCGAATG  337600 
 
Query  99525   ccctctgcctccATTGCCGCCAGGAATGTTCCCCTTTCCCCTGAGCCGGAGAGCATGCTC  99584 
               |||||||||||||||||||||||||| |||||||||||||||||||| |||||||||| | 
Sbjct  337599  CCCTCTGCCTCCATTGCCGCCAGGAACGTTCCCCTTTCCCCTGAGCCAGAGAGCATGCCC  337540 
 
Query  99585   CTGGGCTTGACGGTGCTCATCCCTCAACTTGTCTCTCAAGGAGAAAGTGTGTGGCCTGTG  99644 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  337539  CTGGGCTTGACGGTGCTCATCCCTCAACTTGTCTCTCAAGGAGAAAGTGTGTGGCCTGTG  337480 
 
Query  99645   TGGGAATTTTGATGGCATCCAGAACAATGACCTCACCAGCAGCAACCTCCAAGTGGAGGA  99704 
               |||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||| 
Sbjct  337479  TGGGAATTTTGATGGCATCCAGAACAGTGACCTCACCAGCAGCAACCTCCAAGTGGAGGA  337420 
 
Query  99705   AGACCCTGTGGACTTTGGGAACTCCTGGAAAGTGAGCTCGCAGTGTGCTGACACCAGAAA  99764 
               |||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||| 
Sbjct  337419  AGACCCTGTGGACTTTGGGAACTCCTGGAAAGTGAGCTCGCAGTCTGCTGACACCAGAAA  337360 
 
Query  99765   AGTACGTCTGGGTCTCTGTGTGGACAGAGCCCTAGAGCTTGCTTCCTGGAATGTCCCTCT  99824 
               | |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||| 
Sbjct  337359  ACTACGTCTGGGTCTCTGTGTGGACAGAGCCCGAGAGCTTGCTTCCTGGAATGTCCCTCT  337300 
 
Query  99825   GTCCCCATTGTCATGGGGGCTGGAAGGGGGGTTGTGGGTGGTATGACCTCCAGGTGGCTG  99884 
               ||||||||| | ||||||||||||||||||||||||||||||||||||| |||||||||| 
Sbjct  337299  GTCCCCATTCTTATGGGGGCTGGAAGGGGGGTTGTGGGTGGTATGACCTTCAGGTGGCTG  337240 
 
Query  99885   CAGGGTGGGAAGGAGGGTCTCTTGGATCCTTCTGGGCTGAATAACCCCAGTTTGACCAGC  99944 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  337239  CAGGGTGGGAAGGAGGGTCTCTTGGATCCTTCTGGGCTGAATAACCCCAGTTTGACCAGC  337180 
 
Query  99945   TGACGGCTGGCCTATCTCTTGCCTGGTTCCCAGGTGCCTCTGGACTCATCCCCTGCCACC  100004 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  337179  TGACGGCTGGCCTATCTCTTGCCTGGTTCCCAGGTGCCTCTGGACTCATCCCCTGCCACC  337120 
 
Query  100005  TGCCATAACAACATCATGAAGCAGACGATGGTGGATTCCTCCTGTAGAATCCTTACCAGT  100064 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  337119  TGCCATAACAACATCATGAAGCAGACGATGGTGGATTCCTCCTGTAGAATCCTTACCAGT  337060 
 
Query  100065  GACGTCTTCCAGGACTGCAACAAGCTGGTGAGGACCTTGAGGGTAGTGGGAAGCAGACGG  100124 
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| || 
Sbjct  337059  GACGTCTTCCAGGACTGCAACAAGCTGGTGAGGACCTTGAGGGTAGTGGGAAGCAGATGG  337000 
 
Query  100125  TCCCAAGGCTTGGCCTGGTGGTATGGACACAGAGTGTGACCTTCTAACGTGGACACTACC  100184 
               |||||||||||||||  ||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  336999  TCCCAAGGCTTGGCCCAGTGGTATGGACACAGAGTGTGACCTTCTAACGTGGACACTACC  336940 
 
Query  100185  CTCGTGTCTTGACATGATCTGCACCAAGACACCACTTCGGC-tttttttCTTGGCTTTCA  100243 
               || ||||||||||||||||||||||||||||||||||  || |||||||||||||||||| 
Sbjct  336939  CTTGTGTCTTGACATGATCTGCACCAAGACACCACTTTAGCTTTTTTTTCTTGGCTTTCA  336880 
199
 
Query  100244  ATCTGGGAAACAAAAAGTAAAATCAACAGTTTCTAGGGGAAGCAATGCCTGGCAAAACAT  100303 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  336879  ATCTGGGAAACAAAAAGTAAAATCAACAGTTTCTAGGGGAAGCAATGCCTGGCAAAACAT  336820 
 
Query  100304  TTCCTTCTGCATGAGAAGTAACTCCCCTTGGCATGTGCCAATGCTTCTCTTTCAGCCCCA  100363 
               ||||||||||||||||||||||||||||||||||||||||| | ||||||||| |||||| 
Sbjct  336819  TTCCTTCTGCATGAGAAGTAACTCCCCTTGGCATGTGCCAACGTTTCTCTTTCGGCCCCA  336760 
 
Query  100364  GTCTTAGGATTTGTTCTCTTATTGAAGTATCTTGTTTTCAACACCAGAGCCAGAGATTTC  100423 
               |||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||| 
Sbjct  336759  GTCTTAGGATTTGTTCTCTTATGGAAGTATCTTGTTTTCAACACCAGAGCCAGAGATTTC  336700 
 
Query  100424  CTTTTCCTGTCACTGCTGCATTTGTCCAGACCAAAAGACCTTCCTCTCCCACCCCCT-AA  100482 
               |||||||||||||||||||||||||||||||||||||||| |||||||||| | ||| || 
Sbjct  336699  CTTTTCCTGTCACTGCTGCATTTGTCCAGACCAAAAGACCGTCCTCTCCCA-CTCCTCAA  336641 
 
Query  100483  AACCCCTTGGTGCCCATTTCTTGTCTCACAGAAATTCTTTTCTGGCCTTAATTTTGGTGA  100542 
               |||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||| 
Sbjct  336640  AACCCCTTGGTGCCCATTTCTTGTCTCACAGAAATTCTTTTCTGGCCTTACTTTTGGTGA  336581 
 
Query  100543  TTTTGAGTCCTCGTATTATGACTTATTTTTGTGTCTTCATCTCTAATGACAAGGAGGAAT  100602 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct  336580  TTTTGAGTCCTCGTATTATGACTTATTTTTGTGTCTTCATCTCTAATGACAAGGAGGAAC  336521 
 
Query  100603  TCCGCAAGGTTAAGTGCAGttgtctctctcttttttttttttttttgagacagagtctcg  100662 
               ||| || |||||||||||||||  ||||||    || ||||||||||||||||||||||| 
Sbjct  336520  TCCCCAGGGTTAAGTGCAGTTG--TCTCTC----TTCTTTTTTTTTGAGACAGAGTCTCG  336467 
 
Query  100663  ctctgtcacccaggctggagtgcaatggcatgatcttggcttagtgcagcctctgcctcc  100722 
               ||||||||| |||||||||||||||||||||||||||||||||||||||||||||| ||| 
Sbjct  336466  CTCTGTCACTCAGGCTGGAGTGCAATGGCATGATCTTGGCTTAGTGCAGCCTCTGCTTCC  336407 
 
Query  100723  tgggctcaagcgattctcctgcctcaacctcccgagtacctgggattacaggcacctgcc  100782 
                ||| ||||||||||||||||||||||||||||||||| ||||||||||||| ||| ||| 
Sbjct  336406  CGGGTTCAAGCGATTCTCCTGCCTCAACCTCCCGAGTAGCTGGGATTACAGGTACCCGCC  336347 
 
Query  100783  accacgcccagctaatttttgtatttttagtagagtcaaggtttcaccatgttggtcagg  100842 
               ||||| ||||||||||||||||||||||||||||| | ||||||||||| |||||||||| 
Sbjct  336346  ACCACACCCAGCTAATTTTTGTATTTTTAGTAGAGACGAGGTTTCACCACGTTGGTCAGG  336287 
 
Query  100843  ctggccttgaactcctga-ctcaggtgatctacccacctcg-gcctcccaaagtgctggg  100900 
               ||||||| |||||||||| |||||||||||||||||||| | |||||||||||||||||| 
Sbjct  336286  CTGGCCTCGAACTCCTGACCTCAGGTGATCTACCCACCT-GAGCCTCCCAAAGTGCTGGG  336228 
 
Query  100901  attacaggtgtgagccaccatgcccgaccATAGTGCAGTTGTCTCTTATCTGCTGCATGT  100960 
               ||||||||||| |||||||||||||||||||||||| ||||||||||||||||||||||| 
Sbjct  336227  ATTACAGGTGTAAGCCACCATGCCCGACCATAGTGCGGTTGTCTCTTATCTGCTGCATGT  336168 
 
Query  100961  ATGTGTGTACACACATGTGGACATGGGCTTGTACATGGACATATGTGACTACAGAAGTCT  101020 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  336167  ATGTGTGTACACACATGTGGACATGGGCTTGTACATGGACATATGTGACTACAGAAGTCT  336108 
 
Query  101021  GTGT--ACACACACAGCCATGCACACATACATGCTGCTGTGTAACACCACCAATGTGGGA  101078 
                |||  ||||||||||||||||||||||||||| ||||||||| |||||||||||||||| 
Sbjct  336107  ATGTACACACACACAGCCATGCACACATACATGTTGCTGTGTAGCACCACCAATGTGGGA  336048 
 
Query  101079  GAGACTGGTTGAAAACATGGATCTCAATTCTCTTTCTATCTATGCAGTGATTTTCGGTCT  101138 
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||| 
Sbjct  336047  GAGACTGGTTGAAAACATGGATCTCAATTCTCTTTCTATCTATGCAGTGATTTTCAGTCT  335988 
 
Query  101139  CTGAGGACTCCAAAGGATACTTACATTCCCTGGTTTGGTGGAAATCCTGGGCATCTGAGT  101198 
               |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||| 
Sbjct  335987  CTGAGGACTCCAAAGGATACTTACATTCCC-GGTTTGGTGGAAATCCTGGGCATCTGAGT  335929 
 
Query  101199  TGGAAGAGTGAGGACAGGGGAGGAGTTGGGGACATTGAGACTGTTGGAACGTCTTGGAAA  101258 
               ||||||||||||||||||||||||| ||||||||||| |||||||||||||||||||||| 
Sbjct  335928  TGGAAGAGTGAGGACAGGGGAGGAGCTGGGGACATTGGGACTGTTGGAACGTCTTGGAAA  335869 
 
Query  101259  CAATGACCCACTCAGTGTCTGAATTCATTTTCTGTCATAACTGCCCTGAAAAAGTCCAGT  101318 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  335868  CAATGACCCACTCAGTGTCTGAATTCATTTTCTGTCATAACTGCCCTGAAAAAGTCCAGT  335809 
200
 
Query  101319  GTGTTTAGAGGCGTGTTTTGGGGATGAGGAAGGGTTGGAACTGGTTGAACTGGATTTGGA  101378 
               ||||||||||||||||||| ||||||||||||||| |||||||||||||||||||||||| 
Sbjct  335808  GTGTTTAGAGGCGTGTTTT-GGGATGAGGAAGGGTGGGAACTGGTTGAACTGGATTTGGA  335750 
 
Query  101379  ATCAGAGTCTAGGCCCTATTGTCCTGCATACCTGCCCCATAGCACTGCAGTGAGGCAGCT  101438 
               |||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||| 
Sbjct  335749  ATCAGAGTCTAGGCCCTATTGTTCTGCATACCTGCCCCATAGCACTGCAGTGAGGCAGCT  335690 
 
Query  101439  GCAGGGCCTGATGTATTTCCCCATTCT-CTTTGCTGAATTGAGGCAAAGAAAGACAGTGA  101497 
               ||||||| ||||||||||||||||||| | |||||||||||||||||||||||||||||| 
Sbjct  335689  GCAGGGCTTGATGTATTTCCCCATTCTGC-TTGCTGAATTGAGGCAAAGAAAGACAGTGA  335631 
 
Query  101498  CCAGCACATATGTGTGTTTGTGTTTTTGTAAAAGCACCCACATGCTCATGAGGCTAAGAG  101557 
               ||||||||||||||||||||||||||||||||| |||||||||||||||||||| ||||| 
Sbjct  335630  CCAGCACATATGTGTGTTTGTGTTTTTGTAAAAACACCCACATGCTCATGAGGCCAAGAG  335571 
 
Query  101558  TGGGTTGTGAGGACAGATGGGTGGCTGAGCAGGGAGGTAGGCAGAGGGACAGAGGGAATG  101617 
               ||||||||||||||||||||||||||||||||||||| |||||||||||||||||||||| 
Sbjct  335570  TGGGTTGTGAGGACAGATGGGTGGCTGAGCAGGGAGGCAGGCAGAGGGACAGAGGGAATG  335511 
 
Query  101618  TTCTTCTGGAAAATCCTCAGGCTCATTGTGTTCTGCAGAAGGCCAGCAGCACTGCATTAT  101677 
               ||||||||||| |||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  335510  TTCTTCTGGAATATCCTCAGGCTCATTGTGTTCTGCAGAAGGCCAGCAGCACTGCATTAT  335451 
 
Query  101678  TCAACTCTTCTTGCTGGAATGCAGATTAGAAACTAAGAATCTTGCCTTCCCACTCATTCC  101737 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  335450  TCAACTCTTCTTGCTGGAATGCAGATTAGAAACTAAGAATCTTGCCTTCCCACTCATTCC  335391 
 
Query  101738  CTCTTTGAGACCATTGAGCTACATTTCTCCTTCTACCTGGA-CCCCCTTATCCTTAAATT  101796 
               ||||||||||||||||||||||||||||||||||||||||| |||||||||||||||||| 
Sbjct  335390  CTCTTTGAGACCATTGAGCTACATTTCTCCTTCTACCTGGACCCCCCTTATCCTTAAATT  335331 
 
Query  101797  GACCATCAGAACATTTGCACCCAGACTAAGAGCCAGAGTTCCTGACACCTGGCCATAGGC  101856 
               |||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||| 
Sbjct  335330  GACCATCAGAACATTTGCACCCAGACTAAGAGCCAGAGTTTCTGACACCTGGCCATAGGC  335271 
 
Query  101857  CTGGGCCACCTGAGGCTGCCTTTGCAGGTGGACCCCGAGCCATATCTGGATGTCTGCATT  101916 
               |||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||| 
Sbjct  335270  CTGGGCCACCTGAGGCTGCCTTTGCAGGTGGACCCCGAGCCATACCTGGATGTCTGCATT  335211 
 
Query  101917  TACGACACCTGCTCCTGTGAGTCCATTGGGGACTGCGCCTGCTTCTGCGACACCATTGCT  101976 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  335210  TACGACACCTGCTCCTGTGAGTCCATTGGGGACTGCGCCTGCTTCTGCGACACCATTGCT  335151 
 
Query  101977  GCCTATGCCCACGTGTGTGCCCAGCATGGCAAGGTGGTGACCTGGAGGACGGCCACATTG  102036 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  335150  GCCTATGCCCACGTGTGTGCCCAGCATGGCAAGGTGGTGACCTGGAGGACGGCCACATTG  335091 
 
Query  102037  TGCCGTGAGTACTGACGCCCTCATGTTCTCAGATGCCCTCCCTTCTTCCCATGTGTCTAT  102096 
               |||| ||||| ||||| ||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  335090  TGCCATGAGTCCTGACACCCTCATGTTCTCAGATGCCCTCCCTTCTTCCCATGTGTCTAT  335031 
 
Query  102097  GCTTGAAGACCTTGTGAGTGCAGGGGGATATCTTCATGGGCGAGAGAAGACAGAGTGTTA  102156 
               |||||||||||||||||||||||||||||||||||||||||||||||||||  |||| || 
Sbjct  335030  GCTTGAAGACCTTGTGAGTGCAGGGGGATATCTTCATGGGCGAGAGAAGAC--AGTGCTA  334973 
 
Query  102157  GTA-GGGACTGGATGGCCAAGGGCTAAGGAGGGTTAAGACATTGGCTGTGTAAGAAGTTT  102215 
               ||| ||||||||||||||||||||||| |||||||||||| ||||||| ||||||||||| 
Sbjct  334972  GTATGGGACTGGATGGCCAAGGGCTAACGAGGGTTAAGACGTTGGCTGAGTAAGAAGTTT  334913 
 
Query  102216  ATATTACGG---GTGAGGTGGGACATGGATTCAAGGCATGAACATGTGGAGACTTTTCTT  102272 
               |||||| ||    ||||| ||||||||||||||||||||||||||||||| ||||||||| 
Sbjct  334912  ATATTATGGACTTTGAGGCGGGACATGGATTCAAGGCATGAACATGTGGATACTTTTCTT  334853 
 
Query  102273  CTGGAGAGATTCTGGCAGGGGAGAAGAGGGAATACTGATGAAAAGAAGGAAGTCGATTTA  102332 
               |||||||||||||||||| |||||||||||||||||||||||||||||||||| |||||| 
Sbjct  334852  CTGGAGAGATTCTGGCAGAGGAGAAGAGGGAATACTGATGAAAAGAAGGAAGTTGATTTA  334793 
 
Query  102333  TGTCTTTAATTAGGCGTGATTATATTTGCCAATATGAGTGATCAACTCATACATTCATGT  102392 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  334792  TGTCTTTAATTAGGCGTGATTATATTTGCCAATATGAGTGATCAACTCATACATTCATGT  334733 
201
 
Query  102393  CTATAGAATCTTGCTTCTTTGGACAGAAGCAACTTAATGTTTTTATGtagaaaactgggc  102452 
               |||||||||||| |||||||||||| ||||||||||||| |||||||||||||||||||| 
Sbjct  334732  CTATAGAATCTTCCTTCTTTGGACATAAGCAACTTAATGCTTTTATGTAGAAAACTGGGC  334673 
 
Query  102453  cgggcacagtgactcatacctgtaatccctgtgttttgggaggctgaggccagaggattc  102512 
               | |||||||||||||| |||||| || ||||||||||||||||||||||||||||||||| 
Sbjct  334672  CAGGCACAGTGACTCACACCTGTGATACCTGTGTTTTGGGAGGCTGAGGCCAGAGGATTC  334613 
 
Query  102513  cttgagcccaggagttcaagaccagcctgggcaacatagcaagaccccatctgtacaaaa  102572 
               |||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||| 
Sbjct  334612  CTTGAGCCCAGGAGTTCAAGACCAGCCTGGGCAACATAGCAAGACCCCATCTCTACAAAA  334553 
 
Query  102573  attaaaaaaagaaaTGAATTCAGAACCAATAGATTCTGGTTTAGGTGCTTCAACAATCCA  102632 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  334552  ATTAAAAAAAGAAATGAATTCAGAACCAATAGATTCTGGTTTAGGTGCTTCAACAATCCA  334493 
 
Query  102633  GAAGTCTCTAATATTGGTGACGCCCATAGTCCCCTAGTTCCCCAACATTATCTCCAGATG  102692 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  334492  GAAGTCTCTAATATTGGTGACGCCCATAGTCCCCTAGTTCCCCAACATTATCTCCAGATG  334433 
 
Query  102693  GCGCAGGCCATCACCACATGGGTCTGCAGTCCTGGAGGCTTTGCCTGTTGTGGCCACAGC  102752 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  334432  GCGCAGGCCATCACCACATGGGTCTGCAGTCCTGGAGGCTTTGCCTGTTGTGGCCACAGC  334373 
 
Query  102753  CTTGTCTCCTGTCTACACAGCCCAGAGCTGCGAGGAGAGGAATCTCCGGGAGAACGGGTA  102812 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  334372  CTTGTCTCCTGTCTACACAGCCCAGAGCTGCGAGGAGAGGAATCTCCGGGAGAACGGGTA  334313 
 
Query  102813  TGAGTGTGAGTGGCGCTATAACAGCTGTGCACCTGCCTGTCAAGTCACGTGTCAGCACCC  102872 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  334312  TGAGTGTGAGTGGCGCTATAACAGCTGTGCACCTGCCTGTCAAGTCACGTGTCAGCACCC  334253 
 
Query  102873  TGAGCCACTGGCCTGCCCTGTGCAGTGTGTGGAGGGCTGCCATGCCCACTGCCCTCCAGG  102932 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  334252  TGAGCCACTGGCCTGCCCTGTGCAGTGTGTGGAGGGCTGCCATGCCCACTGCCCTCCAGG  334193 
 
Query  102933  TGAGGCCTCTATCCCTGGGGGTCAGGCTGGTGGGATGGGATAGGGATGGATGGAAAGGTG  102992 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  334192  TGAGGCCTCTATCCCTGGGGGTCAGGCTGGTGGGATGGGATAGGGATGGATGGAAAGGTG  334133 
 
Query  102993  CTTCTAGGTCTTGCTTCATCTCAGCCTCCACCTGCCACGTCCTATCTCTGACCTGCAAGG  103052 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  334132  CTTCTAGGTCTTGCTTCATCTCAGCCTCCACCTGCCACGTCCTATCTCTGACCTGCAAGG  334073 
 
Query  103053  CTGCTGCAGGTTCCGTGGGTTCTTTCATCAGAGTCAGGACAGTCGTGATTTTTCTCAAGT  103112 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  334072  CTGCTGCAGGTTCCGTGGGTTCTTTCATCAGAGTCAGGACAGTCGTGATTTTTCTCAAGT  334013 
 
Query  103113  CGAGCTCCTCCAAAATGCTTTTCTGTGCCTATTTATGGGATTCTCACCTAAAGCAGCCCC  103172 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  334012  CGAGCTCCTCCAAAATGCTTTTCTGTGCCTATTTATGGGATTCTCACCTAAAGCAGCCCC  333953 
 
Query  103173  TGCCGATAGAACTTTCTGCAGTGGGGGAATGTTGTATTGAATGTaactgtgacgagtgtg  103232 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  333952  TGCCGATAGAACTTTCTGCAGTGGGGGAATGTTGTATTGAATGTAACTGTGACGAGTGTG  333893 
 
Query  103233  tctgaggaactgaagttttgaattttattgaattttacttaatttaacgtaaatagccac  103292 
               |||||||||||||| ||||||||||||||||||||||||||||||||| ||||||||||| 
Sbjct  333892  TCTGAGGAACTGAATTTTTGAATTTTATTGAATTTTACTTAATTTAACTTAAATAGCCAC  333833 
 
Query  103293  acgcagtttgtgacgatcctatggtacagcacagCTCTAGAGTTACTGAAGGTGTTATTC  103352 
               | ||||||| |||| |||||||||||||||||||||| |||||||||||||||||||||| 
Sbjct  333832  ATGCAGTTTATGACTATCCTATGGTACAGCACAGCTCGAGAGTTACTGAAGGTGTTATTC  333773 
 
Query  103353  AGAAGAGCAGAAAGAGCCCCGGAGATAAGATTTCATTTGTCCTGAGGCTTGGGGAGGTGA  103412 
               ||||||||||||||||||| |||||||||||||||||||||||||||||||||||||||| 
Sbjct  333772  AGAAGAGCAGAAAGAGCCCTGGAGATAAGATTTCATTTGTCCTGAGGCTTGGGGAGGTGA  333713 
 
Query  103413  GGTAGGGTGAAGGAATCCCCGCTCCCAGTTTTGCAGAGGGATCAATCAAGGCACAAGCAG  103472 
               |||||| |||||||||||||||||||||||||||||||||||||||||||||||||| || 
Sbjct  333712  GGTAGGATGAAGGAATCCCCGCTCCCAGTTTTGCAGAGGGATCAATCAAGGCACAAGGAG  333653 
202
 
Query  103473  GAGAGATGCTCCTTGAGTGATGGGGTGACCCCT-GGGAGTGCAGGCAGGAGGAGTTGGCT  103531 
               |||||||||||||||||||   ||||||||||| ||| |||||||||||||||||||||| 
Sbjct  333652  GAGAGATGCTCCTTGAGTGGCAGGGTGACCCCTAGGG-GTGCAGGCAGGAGGAGTTGGCT  333594 
 
Query  103532  TCTAGGGCAGGAGGAGGAGTTGGCTCCTCCCTTTTAGTTAAAAATGAGGCTTCCTCGTGG  103591 
               |||||||||||||||||||||||||||||||||||||||||||||||| |||||| |||| 
Sbjct  333593  TCTAGGGCAGGAGGAGGAGTTGGCTCCTCCCTTTTAGTTAAAAATGAGACTTCCTTGTGG  333534 
 
Query  103592  GAAAGGGGAGCGTTTTGGTTCCTAATGAGAGCTTTCTTTTGCAGGGAAAATCCTGGATGA  103651 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  333533  GAAAGGGGAGCGTTTTGGTTCCTAATGAGAGCTTTCTTTTGCAGGGAAAATCCTGGATGA  333474 
 
Query  103652  GCTTTTGCAGACCTGCGTTGACCCTGAAGACTGTCCAGTGTGTGAGGTGGCTGGCCGGCG  103711 
               ||||||||||||||||||||||||||||||||| || |||||||||||||||||| |||| 
Sbjct  333473  GCTTTTGCAGACCTGCGTTGACCCTGAAGACTGCCCGGTGTGTGAGGTGGCTGGCTGGCG  333414 
 
Query  103712  TTTTGCCTCAGGAAAGAAAGTCACCTTGAATCCCAGTGACCCTGAGCACTGCCAGATTTG  103771 
               |||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  333413  TTTTGCCTCAAGAAAGAAAGTCACCTTGAATCCCAGTGACCCTGAGCACTGCCAGATTTG  333354 
 
Query  103772  GTAAAACAGATTCCTGGGTTGTTTGAAGTGATGAATCTTATTGCTTCTCCAGGGGCCAGC  103831 
               ||||||||||| ||||| ||||||||||||| |||||||||||||||||||||||||||| 
Sbjct  333353  GTAAAACAGATGCCTGGATTGTTTGAAGTGACGAATCTTATTGCTTCTCCAGGGGCCAGC  333294 
 
Query  103832  TTAGAGACTAGGTTTTGGGTAAAAAGTCCTAGCCACATGAGTTGAGAGACTGAgtttatt  103891 
               | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  333293  TCAGAGACTAGGTTTTGGGTAAAAAGTCCTAGCCACATGAGTTGAGAGACTGAGTTTATT  333234 
 
Query  103892  ttatttgtttatttatttaattcattatttaatgtagtttattgttttgtttgttCCTAG  103951 
               ||||||||||||||||||||||||||||||| |||||||||||||||||||||||||||| 
Sbjct  333233  TTATTTGTTTATTTATTTAATTCATTATTTAGTGTAGTTTATTGTTTTGTTTGTTCCTAG  333174 
 
Query  103952  GGTTTGCTTCTTTTTCTTTAGGGATGGACTAGACTGCTTCCTCCACATATATTCCTCCAC  104011 
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| || 
Sbjct  333173  GGTTTGCTTCTTTTTCTTTAGGGATGGACTAGACTGCTTCCTCCACATATATTCCTCTAC  333114 
 
Query  104012  AGTGTTTTTGCTCTTAATAGGTTTTTAAGTCCTAACAGGTTTTTGCTTTTCTCACTGAAG  104071 
               | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  333113  AATGTTTTTGCTCTTAATAGGTTTTTAAGTCCTAACAGGTTTTTGCTTTTCTCACTGAAG  333054 
 
Query  104072  GTGGGGGTATGGTCACTTATTGTCCTTGTAGGTCATGACTAGTCTGAGCACAGGTGTCCA  104131 
               ||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  333053  GTGAGGGTATGGTCACTTATTGTCCTTGTAGGTCATGACTAGTCTGAGCACAGGTGTCCA  332994 
 
Query  104132  TATACTGGAGGTGGGGACTCAGGAGAGGAAAGTGAGATGGAACCCAGGGCCCTCAGG-TA  104190 
               |||||||||||||| |||||||||||||||||||||||||||| | ||||||||||| || 
Sbjct  332993  TATACTGGAGGTGGCGACTCAGGAGAGGAAAGTGAGATGGAACGCGGGGCCCTCAGGGTA  332934 
 
Query  104191  ACATGAACGTCGTGGGGGCCATAGTCAAGGTGGCAGGGTGTGGCTGTCATAATGGGGAGG  104250 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  332933  ACATGAACGTCGTGGGGGCCATAGTCAAGGTGGCAGGGTGTGGCTGTCATAATGGGGAGG  332874 
 
Query  104251  GAAGGTGCTCGTTGCTCTCACCCTGGCTTCTCACTGGACTTGCCTCTGGGAAACTGGCCT  104310 
               |||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||| 
Sbjct  332873  GAAGGTGCTCGTTGCTCTCACCCTGGGTTCTCACTGGACTTGCCTCTGGGAAACTGGCCT  332814 
 
Query  104311  TTGGGGAGGTGAGAAGGAGTCCTCAGGGTGAGCTCTGAGCCCTCTGAAGTCCTGCTCATA  104370 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  332813  TTGGGGAGGTGAGAAGGAGTCCTCAGGGTGAGCTCTGAGCCCTCTGAAGTCCTGCTCATA  332754 
 
Query  104371  AGTAGGGAGCATTTATTAAAATCCAGATCTATTCAACACCACTCCCTGACACTAATCAAG  104430 
               |||||||| |||||||||||||||| ||||||||||||||||||||||||||| |||| | 
Sbjct  332753  AGTAGGGAACATTTATTAAAATCCACATCTATTCAACACCACTCCCTGACACTGATCAGG  332694 
 
Query  104431  CCTTCTGGGAGCTTAAACTTGAGAACGTAAATTCGCTGGGGAGGGGCTATGGTCACAGCT  104490 
               ||||||||||||||||||||||||| |||||||||||||||||||||||||||||||||| 
Sbjct  332693  CCTTCTGGGAGCTTAAACTTGAGAATGTAAATTCGCTGGGGAGGGGCTATGGTCACAGCT  332634 
 
Query  104491  GCTAGAGTCAGATCCTGCCGCCACCATCTGTACAAACAAGAATGAACACTGCCTGGGGTG  104550 
               || |||||||||||||||| |||||||||| ||||||||||| ||||||||||||||||| 
Sbjct  332633  GCCAGAGTCAGATCCTGCCACCACCATCTGCACAAACAAGAACGAACACTGCCTGGGGTG  332574 
203
 
Query  104551  AGTTTTCTAGCAAACACAGGAAACTAGAAAGTATGTCACTCATGCACTGTTAACCAAGGA  104610 
               |||||||||||||||||||||||||||||||||||||||||| |||| |||||||||||| 
Sbjct  332573  AGTTTTCTAGCAAACACAGGAAACTAGAAAGTATGTCACTCACGCACCGTTAACCAAGGA  332514 
 
Query  104611  TTGAAGCAATAAATCTTGTGGATCACGGGAAGGAGGAATTAACTTCCTAGTAAGACTCTA  104670 
               ||||||||||||||||  ||||||| |||||||||||||||||||||||||||||||||| 
Sbjct  332513  TTGAAGCAATAAATCTCATGGATCATGGGAAGGAGGAATTAACTTCCTAGTAAGACTCTA  332454 
 
Query  104671  CCTGCGCACACTCTTTATGCTGAAACAGAGACTGTAGGGAGCAAAGGACTGGGTGATTCT  104730 
               |||||||||||||||||||||||||||| ||||||||||||||||||| ||||||||||| 
Sbjct  332453  CCTGCGCACACTCTTTATGCTGAAACAGGGACTGTAGGGAGCAAAGGATTGGGTGATTCT  332394 
 
Query  104731  GATGCTGGCTTGGGGTTCTGTGCCAAAAGGGCATGAGAGCTTCGAGCCCTCTCCCCACCT  104790 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  332393  GATGCTGGCTTGGGGTTCTGTGCCAAAAGGGCATGAGAGCTTCGAGCCCTCTCCCCACCT  332334 
 
Query  104791  CCTTTGCTGGCACACGGGCAGGGGCAGCTGCCACGGTGCACGCTGAAGCTGCAAGCAGTG  104850 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  332333  CCTTTGCTGGCACACGGGCAGGGGCAGCTGCCACGGTGCACGCTGAAGCTGCAAGCAGTG  332274 
 
Query  104851  TGTGGACAGAAGTCCCACAGCAGGCTGGTGGCATCACCTGGTATCAAGCCGCAGGGGGAC  104910 
               |||||||||||||||||||||||||||| ||||||||||||||||||||| ||||||||| 
Sbjct  332273  TGTGGACAGAAGTCCCACAGCAGGCTGGGGGCATCACCTGGTATCAAGCCACAGGGGGAC  332214 
 
Query  104911  ACTTCCCAGGCTCAGGGCGCTGCCGCCTTGTCAGCTTTACTGGGAGTGCTGAAGGCCAGG  104970 
               |||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||| 
Sbjct  332213  ACTTCCCAGGCTCAGGGCACTGCCGCCTTGTCAGCTTTACTGGGAGTGCTGAAGGCCAGG  332154 
 
Query  104971  TGCCTCCAAGGCTGAGAGTCCAAAGAGGAGATGGTCCTGGCCCATATTGGTCTCCACCAC  105030 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  332153  TGCCTCCAAGGCTGAGAGTCCAAAGAGGAGATGGTCCTGGCCCATATTGGTCTCCACCAC  332094 
 
Query  105031  ACGGTCACTTGATTTCACCTGTGGGCTGGCAGGCCGTGCCACTTTCCGGGACACTGGCAA  105090 
               | || ||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  332093  ATGGCCACTTGATTTCACCTGTGGGCTGGCAGGCCGTGCCACTTTCCGGGACACTGGCAA  332034 
 
Query  105091  AAAGGTGATGTTACCAGCAGAGCCTGGAAATTTGGCATGGTAGTGTAGGAATTTGTGTGT  105150 
               ||||||||||||||||||||||||| |||||||||||| ||||||||||||||||||||| 
Sbjct  332033  AAAGGTGATGTTACCAGCAGAGCCTCGAAATTTGGCATAGTAGTGTAGGAATTTGTGTGT  331974 
 
Query  105151  GGGGGGCCACTGCTCTACTACAGACTTGTGGTGTGTGCTTGGGGCTGGGCACAGAGCCTG  105210 
               | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  331973  GTGGGGCCACTGCTCTACTACAGACTTGTGGTGTGTGCTTGGGGCTGGGCACAGAGCCTG  331914 
 
Query  105211  GCCAGTACCTGGCACATGAGAGGTGCTCACCCTATGTCTGCTGGAGGAATGAGTGAATGT  105270 
               |||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  331913  GCCAATACCTGGCACATGAGAGGTGCTCACCCTATGTCTGCTGGAGGAATGAGTGAATGT  331854 
 
Query  105271  CTTTTCCTAGGCCTGACACCGTGGAGACCCCTGTCTGCTACTCCCAAATAATTTGTTCTG  105330 
               |||||| ||||||| ||||| ||| ||||||||||||||||||||||||||||||||||| 
Sbjct  331853  CTTTTCTTAGGCCTAACACCTTGGGGACCCCTGTCTGCTACTCCCAAATAATTTGTTCTG  331794 
 
Query  105331  CTAGATAAAGCTGGGGTTTTGAATCTTTATTCATCTTTCTACAATGTTTTTGCTCCAATT  105390 
               ||||||||||||||||||||||||||||||||||||||| |||||||||||||||||||| 
Sbjct  331793  CTAGATAAAGCTGGGGTTTTGAATCTTTATTCATCTTTCCACAATGTTTTTGCTCCAATT  331734 
 
Query  105391  TTTTCTCTCTTCGTTAGGGCCCAACATATCAAACATGTTTTAAAACTCATGCAATTTACA  105450 
               ||||||||||||||||||||||||| ||| |||||||||||||||||||||||||||||| 
Sbjct  331733  TTTTCTCTCTTCGTTAGGGCCCAACGTATTAAACATGTTTTAAAACTCATGCAATTTACA  331674 
 
Query  105451  TTCTGTTAGAATATGTACTGTAAAGCATTTATCTTCAACAGAACATGTACAAACACAGGT  105510 
               |||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||| 
Sbjct  331673  TTCTGTTAGAATATGTACTGTAAAGCATTTATCTTCAACAGAACATGTACAAGCACAGGT  331614 
 
Query  105511  TAGCGTCTACATTTTAGTAACATTTGTTCTTGGAGACACTTGTAAGAAGGCTTGGATTAT  105570 
               ||||||||||||||||||||||||||||||||||||||||||||||||||||| |||||| 
Sbjct  331613  TAGCGTCTACATTTTAGTAACATTTGTTCTTGGAGACACTTGTAAGAAGGCTTAGATTAT  331554 
 
Query  105571  AATTAAGTATTCATGTTGCTAAAGATGTAGGTTGAAAAGAAATCAGCTTTGAGTGGTTGT  105630 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||| 
Sbjct  331553  AATTAAGTATTCATGTTGCTAAAGATGTAGGTTGAAAAGAAATCAGCTTTGAGTGGCTGT  331494 
204
 
Query  105631  GTGGATGGCCTAGAACAACGAGTATATTTTTTCATATCCTAGGATGGGCTAAAGCTTTGG  105690 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  331493  GTGGATGGCCTAGAACAACGAGTATATTTTTTCATATCCTAGGATGGGCTAAAGCTTTGG  331434 
 
Query  105691  TTTCTAGAATCAAAGGAAGTCGGCTATGTGTGTGTTTTGAAGGTGGGGGG-CATGCTATT  105749 
               |||||||||||||||||||||||||||||||||||||||||| ||||||| ||||||||| 
Sbjct  331433  TTTCTAGAATCAAAGGAAGTCGGCTATGTGTGTGTTTTGAAG-TGGGGGGGCATGCTATT  331375 
 
Query  105750  TGGGGACAGATGTTAAACAATGACATCTCACTTGGATGTGGAATGGTCCATGGGATCTCA  105809 
               ||||||||||||||||||| ||||||||||||||| ||||||||||||| |||||||||| 
Sbjct  331374  TGGGGACAGATGTTAAACAGTGACATCTCACTTGGGTGTGGAATGGTCCGTGGGATCTCA  331315 
 
Query  105810  AGTTCAGGTGGAACAGAGGAGATTCTGTGGGAATATGGAAGTCATTG-TACACTGTAGGG  105868 
               |||||||||||||||||||||||||||||||||||||||||| | |  |||||||||||| 
Sbjct  331314  AGTTCAGGTGGAACAGAGGAGATTCTGTGGGAATATGGAAGT-AGTCATACACTGTAGGG  331256 
 
Query  105869  CTCAGAAGTGTCCACAGGTTCTTCCTGAACCATTTTAATTTCTTCGCTCTTTTCTGCAGC  105928 
               |||||||||||||| |||||||| |||||||||||||||||||||||||||||||||||| 
Sbjct  331255  CTCAGAAGTGTCCATAGGTTCTTTCTGAACCATTTTAATTTCTTCGCTCTTTTCTGCAGC  331196 
 
Query  105929  CACTGTGATGTTGTCAACCTCACCTGTGAAGCCTGCCAGGAGCCGGGAGGCCTGGTGGTG  105988 
               |||||||||| ||||| ||||||||||||||||||||||||||||||||||||||||||  
Sbjct  331195  CACTGTGATGGTGTCACCCTCACCTGTGAAGCCTGCCAGGAGCCGGGAGGCCTGGTGGTA  331136 
 
Query  105989  CCTCCCACAGATGCCCCGGTGAGCCCCACCACTCTGTATGTGGAGGACATCTCGGAACCG  106048 
               ||||||||||||||||||||||||||||||||||||||||||||||||||||| |||||| 
Sbjct  331135  CCTCCCACAGATGCCCCGGTGAGCCCCACCACTCTGTATGTGGAGGACATCTCAGAACCG  331076 
 
Query  106049  CCGTTGCACGATTTCTACTGCAGCAGGCTACTGGACCTGGTCTTCCTGCTGGATGGCTCC  106108 
               | ||||||||||||||||||||||||||||||||||||| |||||||||||||||||||| 
Sbjct  331075  CTGTTGCACGATTTCTACTGCAGCAGGCTACTGGACCTGATCTTCCTGCTGGATGGCTCC  331016 
 
Query  106109  TCCAGGCTGTCCGAGGCTGAGTTTGAAGTGCTGAAGGCCTTTGTGGTGGACATGATGGAG  106168 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  331015  TCCAGGCTGTCCGAGGCTGAGTTTGAAGTGCTGAAGGCCTTTGTGGTGGACATGATGGAG  330956 
 
Query  106169  CGGCTGCGCATCTCCCAGAAGTGGGTCCGCGTGGCCGTGGTGGAGTACCACGACGGCTCC  106228 
               ||||||||||||||| ||||||||||||||||||| |||||||||||||||||||||||| 
Sbjct  330955  CGGCTGCGCATCTCCTAGAAGTGGGTCCGCGTGGCTGTGGTGGAGTACCACGACGGCTCC  330896 
 
Query  106229  CACGCCTACATCGGGCTCAAGGACCGGAAGCGACCGTCAGAGCTGCGGCGCATTGCCAGC  106288 
               ||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||| 
Sbjct  330895  CACGCCTACATCGGGCTCAAGGACCGGAAGCGACCGTCAGAGCTGCGGCGCGTTGCCAGC  330836 
 
Query  106289  CAGGTGAAGTATGCGGGCAGCCAGGTGGCCTCCACCAGCGAGGTCTTGAAATACACACTG  106348 
               ||||||||||||||||||||||||||||||||||||||||||| |||||||||||||||| 
Sbjct  330835  CAGGTGAAGTATGCGGGCAGCCAGGTGGCCTCCACCAGCGAGGCCTTGAAATACACACTG  330776 
 
Query  106349  TTCCAAATCTTCAGCAAGATCGACCGCCCTGAAGCCTCCCGCATCACCCTGCTCCTGATG  106408 
               ||||||||| ||||||||||||||||||||||||||| ||||||| |||||||||||||| 
Sbjct  330775  TTCCAAATCATCAGCAAGATCGACCGCCCTGAAGCCTTCCGCATCGCCCTGCTCCTGATG  330716 
 
Query  106409  GCCAGCCAGGAGCCCCAACGGATGTCCCGGAACTTTGTCCGCTACGTCCAGGGCCTGAAG  106468 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  330715  GCCAGCCAGGAGCCCCAACGGATGTCCCGGAACTTTGTCCGCTACGTCCAGGGCCTGAAG  330656 
 
Query  106469  AAGAAGAAGGTCATTGTGATCCCGGTGGGCATTGGGCCCCATGCCAACCTCAAGCAGATC  106528 
               |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  330655  AAGAAGAAGGTCATCGTGATCCCGGTGGGCATTGGGCCCCATGCCAACCTCAAGCAGATC  330596 
 
Query  106529  CGCCTCATCGAGAAGCAGGCCCCTGAGAACAAGGCCTTCGTGCTGAGCAGTGTGGATGAG  106588 
               |||||||| ||||||||||||||||||||||||||||||||||||||| ||||||||||| 
Sbjct  330595  CGCCTCATTGAGAAGCAGGCCCCTGAGAACAAGGCCTTCGTGCTGAGCGGTGTGGATGAG  330536 
 
Query  106589  CTGGAGCAGCAAAGGGACGAGATCGTTAGCTACCTCTGTGACCTTGCCCCTGAAGCCCCT  106648 
               ||||||||||||||||| ||||||||||||||||||||||||||||||||||| |||||| 
Sbjct  330535  CTGGAGCAGCAAAGGGAAGAGATCGTTAGCTACCTCTGTGACCTTGCCCCTGACGCCCCT  330476 
 
Query  106649  CCTCCTACTCTGCCCCCCGACATGGCACAAGTCACTGTGGGCCCGGGGCTCTTGGGGGTT  106708 
               |||||||||||||||||| |||||||||||||||||||||||||||||||||||||| || 
Sbjct  330475  CCTCCTACTCTGCCCCCCCACATGGCACAAGTCACTGTGGGCCCGGGGCTCTTGGGGCTT  330416 
205
 
Query  106709  TCGACCCTGGGGCCCAAGAGGAACTCCATGGTTCTGGATGTGGCGTTCGTCCTGGAAGGA  106768 
               |||||||||||||||||||||||||||||||||||||||||||| || |||||||||||| 
Sbjct  330415  TCGACCCTGGGGCCCAAGAGGAACTCCATGGTTCTGGATGTGGCATTTGTCCTGGAAGGA  330356 
 
Query  106769  TCGGACAAAATTGGTGAAGCCGACTTCAACAGGAGCAAGGAGTTCATGGAGGAGGTGATT  106828 
               ||||||||||||||||||||| |||||||||||||||||||||||||||||||||||||| 
Sbjct  330355  TCGGACAAAATTGGTGAAGCCAACTTCAACAGGAGCAAGGAGTTCATGGAGGAGGTGATT  330296 
 
Query  106829  CAGCGGATGGATGTGGGCCAGGACAGCATCCACGTCACGGTGCTGCAGTACTCCTACATG  106888 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  330295  CAGCGGATGGATGTGGGCCAGGACAGCATCCACGTCACGGTGCTGCAGTACTCCTACATG  330236 
 
Query  106889  GTGACTGTGGAGTACCCCTTCAGCGAGGCACAGTCCAAAGGGGACATCCTGCAGCGGGTG  106948 
               ||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  330235  GTGACCGTGGAGTACCCCTTCAGCGAGGCACAGTCCAAAGGGGACATCCTGCAGCGGGTG  330176 
 
Query  106949  CGAGAGATCCGCTACCAGGGCGGCAACAGGACCAACACTGGGCTGGCCCTGCGGTACCTC  107008 
               |||||||||||||||||||| ||||||||||||||||||||| ||||||||| ||||| | 
Sbjct  330175  CGAGAGATCCGCTACCAGGGTGGCAACAGGACCAACACTGGGGTGGCCCTGCTGTACCCC  330116 
 
Query  107009  TCTGACCACAGCTTCTTGGTCAGCCAGGGTGACCGGGAGCAGGCGCCCAACCTGGTCTAC  107068 
               || |||||||||||||||||||||||||||||||||||||||| |||||||||||||| | 
Sbjct  330115  TCCGACCACAGCTTCTTGGTCAGCCAGGGTGACCGGGAGCAGGTGCCCAACCTGGTCTCC  330056 
 
Query  107069  ATGGTCACCGGAAATCCTGCCTCTGATGAGATCAAGAGGCTGCCTGGAGACATCCAGGTG  107128 
               ||||||||| ||||||||||||||||| ||||||||||| |||||||||||||||||||| 
Sbjct  330055  ATGGTCACCAGAAATCCTGCCTCTGATAAGATCAAGAGGTTGCCTGGAGACATCCAGGTG  329996 
 
Query  107129  GTGCCCATTGGAGTGGGCCCTAATGCCAACGTGCAGGAGCTGGAGAGGATTGGCTGGCCC  107188 
               |||||||||||||||||||||||||||||||| ||||||||||||||||| ||||||||| 
Sbjct  329995  GTGCCCATTGGAGTGGGCCCTAATGCCAACGTTCAGGAGCTGGAGAGGATCGGCTGGCCC  329936 
 
Query  107189  AATGCCCCTATCCTCATCCAGGACTTTGAGACGCTCCCCCGAGAGGCTCCTGACCTGGTG  107248 
               |||||||| |||||||||||||||||||||||||||||| |||||||||||||||||||| 
Sbjct  329935  AATGCCCCCATCCTCATCCAGGACTTTGAGACGCTCCCCTGAGAGGCTCCTGACCTGGTG  329876 
 
Query  107249  CTGCAGAGGTGCTGCTCCGGAGAGGGGCTGCAGATCCCCACCCTCTCCCCTGCACCTGGT  107308 
               ||||||||||||||||||||||||||||||||||||||||||| ||||||||| |||||| 
Sbjct  329875  CTGCAGAGGTGCTGCTCCGGAGAGGGGCTGCAGATCCCCACCCGCTCCCCTGCCCCTGGT  329816 
 
Query  107309  ATGCTGGCACCTTGTGTGCAGGTGGGAGGGCTGGGCGAGGGCTGGCATGGCCTTGGTGCT  107368 
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| || 
Sbjct  329815  ATGCTGGCACCTTGTGTGCAGGTGGGAGGGCTGGGCGAGGGCTGGCATGGCCTTGGTACT  329756 
 
Query  107369  ACATGCATCTGCCAAGATACGACTCGGGTTCTAATCCTGGCTTCCCTGGTCTGTGTGGCC  107428 
               ||||||||||||||||||| |||| |||||||||||||||||||||||||||||||| || 
Sbjct  329755  ACATGCATCTGCCAAGATATGACTTGGGTTCTAATCCTGGCTTCCCTGGTCTGTGTGCCC  329696 
 
Query  107429  TTGGTTGAAACTTGCCTTCAAAGGGCCTGTGTTTCCTCACCTCCCTGGCAGGGAGACAAA  107488 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  329695  TTGGTTGAAACTTGCCTTCAAAGGGCCTGTGTTTCCTCACCTCCCTGGCAGGGAGACAAA  329636 
 
Query  107489  CTGTGATCCTTTTTCGGGGGAAGATCTTTTCTTATTGTGTGTGCTTCTATAAATTCAAAG  107548 
               ||||||||||||| |||||||||||||||||||||||||||||||||| ||||||||||| 
Sbjct  329635  CTGTGATCCTTTTGCGGGGGAAGATCTTTTCTTATTGTGTGTGCTTCTGTAAATTCAAAG  329576 
 
Query  107549  GTAATGGAAGCCTATTGTTAACATTTAAACAATGCCAATAAGGAGTaaaaaaaaaaaaaa  107608 
               ||||||||||||||||||||||||||||||||||||| ||||||||||||||||||| |  
Sbjct  329575  GTAATGGAAGCCTATTGTTAACATTTAAACAATGCCACTAAGGAGTAAAAAAAAAAATA-  329517 
 
Query  107609  aaTGCAAGTCTTACTTTATCACACAGCCTCTTCCCCACCCAATTCCACCCTCTGCCTTCA  107668 
                 |||||||||||||||||||||| |||||||||||||||||||||||||||  |||||| 
Sbjct  329516  --TGCAAGTCTTACTTTATCACACGGCCTCTTCCCCACCCAATTCCACCCTCCACCTTCA  329459 
 
Query  107669  AGGTAACCTCTGTTAAAGGTGGTGATGATAAGCTTCATTTTGACCACACTGGGTGGGTGA  107728 
               ||||||||||||||||||||| |||||||||||||| ||||||||||||||||||||||| 
Sbjct  329458  AGGTAACCTCTGTTAAAGGTGATGATGATAAGCTTCGTTTTGACCACACTGGGTGGGTGA  329399 
 
Query  107729  AATTATTCCGAGTAGCTGACATTCTTCAGGGCAAGACCAGGATGTCAGGTGTCAGGTAGC  107788 
               |||||||| ||||||||||||||||||||||| |||||||||||||||||| |||||||| 
Sbjct  329398  AATTATTCTGAGTAGCTGACATTCTTCAGGGCGAGACCAGGATGTCAGGTGCCAGGTAGC  329339 
206
 
Query  107789  AGGTGCAGTCTTCAGACACTGGAGTCAGA--CTGCCTTAGTTTGAATCTTATCTCTGCTA  107846 
               ||||||||||||||||||||||||||||   ||||||||||||||||||||||||||| | 
Sbjct  329338  AGGTGCAGTCTTCAGACACTGGAGTCAGTGTCTGCCTTAGTTTGAATCTTATCTCTGCCA  329279 
 
Query  107847  CTTGCTAGCTGGGTAATTTTGGGCAAATACTTAACCTCTTTGTATATC-GTCT  107898 
               |||||||||||||||||||||||||||||||||||||||||||||||| |||| 
Sbjct  329278  CTTGCTAGCTGGGTAATTTTGGGCAAATACTTAACCTCTTTGTATATCAGTCT  329226 
 
Query  107969  tcctcatctataaaatggggataataatagcacctacTTGCTTAAAATAGTATCTGGCAC  108028 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  329226  TCCTCATCTATAAAATGGGGATAATAATAGCACCTACTTGCTTAAAATAGTATCTGGCAC  329167 
 
Query  108029  ATGACAAGTGCTCaaaaaaaaaTGCTTGCTCCCACTGCTGTTACTACTACCTTTTACTGA  108088 
               ||||| ||||||| ||||||||||||||||||||||||||||| |||||||||||||||| 
Sbjct  329166  ATGAC-AGTGCTC-AAAAAAAATGCTTGCTCCCACTGCTGTTATTACTACCTTTTACTGA  329109 
 
Query  108089  CACTGGCGTCTAATCCATTCCTAGTTCCTGAACATCTTTATTCGGTGTGTTTGGGACCAT  108148 
               |||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  329108  CACTGGTGTCTAATCCATTCCTAGTTCCTGAACATCTTTATTCGGTGTGTTTGGGACCAT  329049 
 
Query  108149  CCCAGAATAATAAGCCTTCTTTTAGTATCTTTTGAGTCACACACTTGTCAGTACttttgt  108208 
               | |||||||||||||||||||||||||||||||||||| ||||||||||||||||||||| 
Sbjct  329048  CTCAGAATAATAAGCCTTCTTTTAGTATCTTTTGAGTCTCACACTTGTCAGTACTTTTGT  328989 
 
Query  108209  ttctttgtttttgtttttATTCACGGCCATAGATTTATTTAAATTCTTGTAATATTTCTG  108268 
               ||||||||||||||||||||||| |||||||||||||||||||||||||||||||||||| 
Sbjct  328988  TTCTTTGTTTTTGTTTTTATTCATGGCCATAGATTTATTTAAATTCTTGTAATATTTCTG  328929 
 
Query  108269  CTGAGGAAAACAACAATTACATCATTTCATCAAATCTCAGATGTGCTCAGACACTAACAG  108328 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  328928  CTGAGGAAAACAACAATTACATCATTTCATCAAATCTCAGATGTGCTCAGACACTAACAG  328869 
 
Query  108329  GAGCACTAGGCATTTATAGCTGGAAGAATCACAGTATGTTCACCTGCCCTGCAAGATCTG  108388 
               |||||||||||||||||||||||||||||||||||| ||||||||||| ||||||||||| 
Sbjct  328868  GAGCACTAGGCATTTATAGCTGGAAGAATCACAGTACGTTCACCTGCCTTGCAAGATCTG  328809 
 
Query  108389  AGGACACAGCAGCTCATTGTCCAGGGAGGGGCTGCCGCTCCATTTCCTTTTGCAGTCTCC  108448 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||  | | 
Sbjct  328808  AGGACACAGCAGCTCATTGTCCAGGGAGGGGCTGCCGCTCCATTTCCTTTTGCAG--T-C  328752 
 
Query  108449  TTGTATTGCCAGGCCAGTATTTTACTCATTTCTAGAAGAATGGTGGCCCCTTCTTACCGA  108508 
               ||||||||||||||||||||||||||||||||||||||| ||| |||||||||||||||| 
Sbjct  328751  TTGTATTGCCAGGCCAGTATTTTACTCATTTCTAGAAGAGTGGCGGCCCCTTCTTACCGA  328692 
 
Query  108509  GGAAGCCTATGCCTGCTGCTTTTATTTGTAGACATTTAAACTTCCTTTGGGTAGAATTGG  108568 
               ||||||| |||||| |||||||||||||||||||||||| |||||||||||||||| ||| 
Sbjct  328691  GGAAGCCCATGCCTACTGCTTTTATTTGTAGACATTTAAGCTTCCTTTGGGTAGAACTGG  328632 
 
Query  108569  AGTCTTCTCAGTGTCTCTAAATCTGAGGTAGTCCGGACCCAGGAACTCCATCTCCCC-AT  108627 
               || |||||||||||||| ||| |||||||||||| | |||||||||||||||||||| || 
Sbjct  328631  AGGCTTCTCAGTGTCTCCAAACCTGAGGTAGTCCAGCCCCAGGAACTCCATCTCCCCTAT  328572 
 
Query  108628  CCCCTCCTCCCTGGCCCACATTGCCCTTGTACTCACGAAGGCAccccccgccccccTTGG  108687 
               ||||||||||||||||||| ||||||||| |||||| |||||| |||||||||||||||| 
Sbjct  328571  CCCCTCCTCCCTGGCCCACGTTGCCCTTGCACTCACAAAGGCAGCCCCCGCCCCCCTTGG  328512 
 
Query  108688  TGGTGCCACGTGGTCAGCACGCCCTGCAGATCCTATTGGATGTCAGGTTGTAGGCCTGGT  108747 
               |||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||  
Sbjct  328511  TGGTGCCACGTGGTCAGCACGCCCTGCAGATCCTATGGGATGTCAGGTTGTAGGCCTGGC  328452 
 
Query  108748  GGCCATTGTCCCTGCTGGCACCTGTGTGCTCACCTTCCTGGTTGTCTTTGCAGACTGCAG  108807 
               ||||| || |||||||||||||||||||||||||||||||||| |||||||||||||||| 
Sbjct  328451  GGCCAGTGCCCCTGCTGGCACCTGTGTGCTCACCTTCCTGGTTATCTTTGCAGACTGCAG  328392 
 
Query  108808  CCAGCCCCTGGACGTGATCCTTCTCCTGGATGGCTCCTCCAGTTTCCCAGCTTCTTATTT  108867 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||| 
Sbjct  328391  CCAGCCCCTGGACGTGATCCTTCTCCTGGATGGCTCCTCCAGTTTCCCAGCTTCTTCTTT  328332 
 
Query  108868  TGATGAAATGAAGAGTTTCGCCAAGGCTTTCATTTCAAAAGCCAATATAGGTGGGTGAGC  108927 
               |||||||||||||||||| || ||||||||||||||||||||||||||||||| |||||  
Sbjct  328331  TGATGAAATGAAGAGTTTTGCTAAGGCTTTCATTTCAAAAGCCAATATAGGTGAGTGAGT  328272 
207
 
Query  108928  GAGGCACCTGAAGCAGCAGGTGACGAAGAGGCTCTTTTTGTGGCTCTACTTGATTCAAAA  108987 
               |||||||||||||||||||||||||||||||||||||||| ||||| |||||||||| || 
Sbjct  328271  GAGGCACCTGAAGCAGCAGGTGACGAAGAGGCTCTTTTTGGGGCTCCACTTGATTCAGAA  328212 
 
Query  108988  TAATCCGCATTTTCTCGTTCCGTTTAGGGCCTCGTCTCACTCAGGTGTCAGTGCTGCAGT  109047 
               |||||| |||||||| ||||||||||||||||| ||||||||||| ||||||||| |||| 
Sbjct  328211  TAATCCCCATTTTCTTGTTCCGTTTAGGGCCTCCTCTCACTCAGGGGTCAGTGCTCCAGT  328152 
 
Query  109048  ATGGAAGCATCACCACCATTGACGTGCCATGGAACGTGGTCCCGGAGAAAGCCCATTTGC  109107 
               ||||||||||||||||||||||||||||||||||||||| |||||||||||||||||||| 
Sbjct  328151  ATGGAAGCATCACCACCATTGACGTGCCATGGAACGTGGCCCCGGAGAAAGCCCATTTGC  328092 
 
Query  109108  TGAGCCTTGTGGACGTCATGCAGCGGGAGGGAGGCCCCAGCCAAATCGGTAACGTTGGTG  109167 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  328091  TGAGCCTTGTGGACGTCATGCAGCGGGAGGGAGGCCCCAGCCAAATCGGTAACGTTGGTG  328032 
 
Query  109168  CCACAGGCTGGATGCAGAAGCTGCATTCTGGTTCTTATTTTTGGCATAAGTGACTGTGTG  109227 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  328031  CCACAGGCTGGATGCAGAAGCTGCATTCTGGTTCTTATTTTTGGCATAAGTGACTGTGTG  327972 
 
Query  109228  ACCTCGGCCAGTCACTTTGCTCCTTGGCCTTAGTTTCTTCTCCTGGAAAGTGAGGGGCTA  109287 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  327971  ACCTCGGCCAGTCACTTTGCTCCTTGGCCTTAGTTTCTTCTCCTGGAAAGTGAGGGGCTA  327912 
 
Query  109288  GATGCTCTTCCACGTCTCTCCAGATCTCAACTGGGTGTTCCTTGGAGTTTCTGAATCATT  109347 
               |||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||| 
Sbjct  327911  GATGCTCTTCCACGTCTCTCCAGATCTCAACTGGGTGTTCCTTGGAGTCTCTGAATCATT  327852 
 
Query  109348  CAGCTTTTAAGTGACTTAAGGATCCACCGTTAAGACAGGGTGTCGAGCCGCAGTCAGTAC  109407 
               ||||||||||||||||||||||||||||| | |||||||||||| ||||||||||||||| 
Sbjct  327851  CAGCTTTTAAGTGACTTAAGGATCCACCG-TGAGACAGGGTGTCCAGCCGCAGTCAGTAC  327793 
 
Query  109408  TGACTTGGCGTGATCTGTTCTCCATCCTCAGGGGATGCCTTGGGCTTTGCTGTGCGATAC  109467 
               |||||||| |||||||||||||||||||||||||||||||||||||||||||||||| || 
Sbjct  327792  TGACTTGGTGTGATCTGTTCTCCATCCTCAGGGGATGCCTTGGGCTTTGCTGTGCGACAC  327733 
 
Query  109468  TTGACTTCAGAAATGCATGGTGCCAGGCCGGGAGCCTCAAAGGCGGTGGTCATCCTGGTC  109527 
               |||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||| 
Sbjct  327732  TTGACTTCAGAAATGCATGGTGCCAGGCCGGGAGCCTCGAAGGCGGTGGTCATCCTGGTC  327673 
 
Query  109528  ACGGACGTCTCTGTGGATTCAGTGGATGCAGCAGCTGATGCCGCCAGGTCCAACAGTAAG  109587 
               ||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  327672  ACGGATGTCTCTGTGGATTCAGTGGATGCAGCAGCTGATGCCGCCAGGTCCAACAGTAAG  327613 
 
Query  109588  AATCTGGTGTACAGTCCTCAATTCAGGAGAGCGAGACTTCAGAAATGATAGAGGATTAAA  109647 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  327612  AATCTGGTGTACAGTCCTCAATTCAGGAGAGCGAGACTTCAGAAATGATAGAGGATTAAA  327553 
 
Query  109648  AGTGGGCTGGGGTTACTTTTGGATGTTGTGGCTGATATTAAATATGCTCAATACCAACCT  109707 
               ||||| |||||||||||||||||||||||||||||||||||||||||||| ||||||||| 
Sbjct  327552  AGTGGCCTGGGGTTACTTTTGGATGTTGTGGCTGATATTAAATATGCTCAGTACCAACCT  327493 
 
Query  109708  CTGTCCTGGTTTCAAACAGCAGGAAATTATCCAACCACGATGTGATTAGGAAACCAAACA  109767 
               |||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||| 
Sbjct  327492  CTGTCCTGGTTTCAAACAGCAGGAAATTATCCAATCACGATGTGATTAGGAAACCAAACA  327433 
 
Query  109768  ATAAAAAGTGTGTATTGATCCTATATCTTTATAACTAATTATAA-TCTTTAATTTCTCCA  109826 
               |||| |||||||| ||||||||||||||||||||||||||||||  |||||||||||||| 
Sbjct  327432  ATAATAAGTGTGTGTTGATCCTATATCTTTATAACTAATTATAACCCTTTAATTTCTCCA  327373 
Query  109827  CATTTTCCCTTTGTGTCCAGGAGTGATCATACCTCTATGCCCTTTCTTTCTAAAGTAGGA  109886 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  327372  CATTTTCCCTTTGTGTCCAGGAGTGATCATACCTCTATGCCCTTTCTTTCTAAAGTAGGA  327313 
 
Query  109887  TTCGTGGTCTCTTACTAAAATGTCATGTCTGAGGCCAGAGTGATTCATTGTAGGGCCTTG  109946 
               ||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||| 
Sbjct  327312  TTCGTGGTCTCTTACTAAAATGTCATGTCTGAGGCCAGAGTGATTCATTGTGGGGCCTTG  327253 
 
Query  109947  AGAACCAATGGGGGCTTTCATGTATTTAGAGTCCTTTCCTGGTACCAGGTAATGGGCTTG  110006 
               ||||||||||||| |||||||||||||||||||||||||||||||||||||||||||||| 




Query  110007  GCAGGGTTGATGGATGAGAGACAAAGGATCATGCTGTAGGAAAGGGAAGGATCCAGATGT  110066 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  327192  GCAGGGTTGATGGATGAGAGACAAAGGATCATGCTGTAGGAAAGGGAAGGATCCAGATGT  327133 
 
Query  110067  CCAGCCTTGTGCTCCATAAGAACATGTGCTTATCATGTTCTTAATATCAACAGGATGTGA  110126 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  327132  CCAGCCTTGTGCTCCATAAGAACATGTGCTTATCATGTTCTTAATATCAACAGGATGTGA  327073 
 
Query  110127  GCTGGGACAGGTGGTAGAGTCT-AGGGACCACCTCCCAGCTGAAGAAGGTCTGGGTGAGT  110185 
               |||||||||||||||||||||| |||||||||||||||||||||| |||||||||||||| 
Sbjct  327072  GCTGGGACAGGTGGTAGAGTCTGAGGGACCACCTCCCAGCTGAAGGAGGTCTGGGTGAGT  327013 
 
Query  110186  GGAGTGACATTGAGTCCCCTCGTGGCCACCTGGAGAACTGTTCATCTTTCAGAACCCTGC  110245 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  327012  GGAGTGACATTGAGTCCCCTCGTGGCCACCTGGAGAACTGTTCATCTTTCAGAACCCTGC  326953 
 
Query  110246  CTAGGAGTGCTGTCAGAACCCTGTCTTTTCTCTGCTGTCTTCCTGATGTTCTTCCTGAGG  110305 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  326952  CTAGGAGTGCTGTCAGAACCCTGTCTTTTCTCTGCTGTCTTCCTGATGTTCTTCCTGAGG  326893 
 
Query  110306  AAGTTATTTGCTCCGTTCTCTATGTCACATATGAGCTACTCAAAATGTGCAAATCGTATT  110365 
               |||||||||||||||||||||||||||||||||||||||| ||||||||||||||      
Sbjct  326892  AAGTTATTTGCTCCGTTCTCTATGTCACATATGAGCTACTAAAAATGTGCAAATC-----  326838 
 
Query  110366  GTATTGTATTGTATTTGTAACATATCTATTCCTTGCAAAAAACTGGGAGTTCTTTGAAGG  110425 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  326837  GTATTGTATTGTATTTGTAACATATCTATTCCTTGCAAAAAACTGGGAGTTCTTTGAAGG  326778 
 
Query  110426  CAAGGGAAGATCTTGCTTATTTTTGTATCATCTGTGTATGATGCACAAAATAGGTGACCA  110485 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  326777  CAAGGGAAGATCTTGCTTATTTTTGTATCATCTGTGTATGATGCACAAAATAGGTGACCA  326718 
 
Query  110486  TTTAACGTTTGTTGAGTGAATGAATGTGACATGTTTATGAAATCTATGATTTTAGGGTAA  110545 
               ||||| ||||||||||||||||||||||||||||||||||||||||| |||||||||||| 
Sbjct  326717  TTTAATGTTTGTTGAGTGAATGAATGTGACATGTTTATGAAATCTATAATTTTAGGGTAA  326658 
 
Query  110546  AGGACACTAAAAGGGAAAGGATATATATTTGGATAATATAACGAACTTACAAGAGCTGAA  110605 
               |||||||||||||||||||||||||||||||||| |||||||||||||||||| |||||| 
Sbjct  326657  AGGACACTAAAAGGGAAAGGATATATATTTGGATGATATAACGAACTTACAAGGGCTGAA  326598 
 
Query  110606  AAGCTGCTAATAGAAAATCCGTTCCAACCTGAAGCACATTGCAAATTCCTAGAACTTTCT  110665 
               ||||||||| |||||||||| ||||||||||||||||||||||||||||||||||||||| 
Sbjct  326597  AAGCTGCTAGTAGAAAATCCATTCCAACCTGAAGCACATTGCAAATTCCTAGAACTTTCT  326538 
 
Query  110666  GGAGAGCTGAATTGAGGAATTTCAGGATGGAGATTTTTTCTCCTTCAGTATCAAGAATCC  110725 
               ||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||| 
Sbjct  326537  GGAGAGCTGAATTGAGGAATTTCAGGATGGAGATTTTTTCTCCTTTAGTATCAAGAATCC  326478 
 
Query  110726  AAAGAAAGATTTTCACTGGGAAAGAAAGCAGTTGTGGTCTT---GAAGCAGATATGATCC  110782 
               |||||||||||||||||||||||| ||||||||||||||||   |||||||||||||||| 
Sbjct  326477  AAAGAAAGATTTTCACTGGGAAAGGAAGCAGTTGTGGTCTTGAGGAAGCAGATATGATCC  326418 
 
Query  110783  AGAGCAAGTCATTTAACCGTCCAAAGCCTCGGTTTCTCATGTGTAAATGAGCATGCACAT  110842 
               |||||| ||||||||||| || |||||||||||||||||||||||||||||||||||||| 
Sbjct  326417  AGAGCACGTCATTTAACCATCTAAAGCCTCGGTTTCTCATGTGTAAATGAGCATGCACAT  326358 
 
Query  110843  TCTCTGGGCTCAGCCCTGTGATATTTTCTCTTCTCTTCTTACATATACCCCCTTGGTGGT  110902 
               ||||||||||||||||||||||||||||||||||||||||||||||||||  |||||||| 
Sbjct  326357  TCTCTGGGCTCAGCCCTGTGATATTTTCTCTTCTCTTCTTACATATACCCTGTTGGTGGT  326298 
 
Query  110903  CTAGTTCAGTGTCATGGGTCTAAATACATTTATACATCTTTGACTTTGAAATTCGTATCT  110962 
               ||||||||||||||||||||| |||| |||||||||||| |||||||||||||||||||| 
Sbjct  326297  CTAGTTCAGTGTCATGGGTCTGAATATATTTATACATCTCTGACTTTGAAATTCGTATCT  326238 
 
Query  110963  CCAGCCTCACCTCAACTCAGTTTGCATGCTCTAATAGGCAAAACTAAACTcctgattttc  111022 
               |||||||||||||||||||| ||||||||||||| ||||||||||||||||||||||||| 
Sbjct  326237  CCAGCCTCACCTCAACTCAGCTTGCATGCTCTAACAGGCAAAACTAAACTCCTGATTTTC  326178 
 
Query  111023  acatctgtctttcttatcttagaaaatggcaattccaaccttccagttgttcagttcaaa  111082 
               ||||| |||||||||||||||||||||||| ||||||||||||||||||||||||||||| 
Sbjct  326177  ACATCCGTCTTTCTTATCTTAGAAAATGGCGATTCCAACCTTCCAGTTGTTCAGTTCAAA  326118 
209
 
Query  111083  aagctcagcatccttgattcttcttccttttccctgatacctccatgcaagccacgaaca  111142 
               |||| |||||||||||||||||||||||||| |||||||||||||||||||||| ||||| 
Sbjct  326117  AAGCCCAGCATCCTTGATTCTTCTTCCTTTTTCCTGATACCTCCATGCAAGCCATGAACA  326058 
 
Query  111143  aactatagctccatcttcaaaatacttcgagagtcacacctccccacaccatgtccacta  111202 
               ||||||||||||||||||||||||||| ||||||  |||||| ||||||||||||||| | 
Sbjct  326057  AACTATAGCTCCATCTTCAAAATACTTTGAGAGTTGCACCTCTCCACACCATGTCCACCA  325998 
 
Query  111203  gggtcacctcaatccgagtccccatcatctctcacctggactattgaaatagctgtctaa  111262 
               |||||||||||||| ||||||||| ||||||||||||||||||||||||||||||||||| 
Sbjct  325997  GGGTCACCTCAATCTGAGTCCCCAGCATCTCTCACCTGGACTATTGAAATAGCTGTCTAA  325938 
 
Query  111263  ctggaaccccagcttccacctttgtcccctgcagatcattctcagcacagcagctgcagt  111322 
               |||||| ||||||||||||||||||||||||||| ||||||||||||||||||||||||| 
Sbjct  325937  CTGGAATCCCAGCTTCCACCTTTGTCCCCTGCAGCTCATTCTCAGCACAGCAGCTGCAGT  325878 
 
Query  111323  ggccctttaatatcaaaatcagctcctgtccctctgctctgtagtcttggctggctttgt  111382 
               ||||||||| ||||||| ||||| |||||||||||||||||||||||||||||| ||||| 
Sbjct  325877  GGCCCTTTACTATCAAAGTCAGCCCCTGTCCCTCTGCTCTGTAGTCTTGGCTGG-TTTGT  325819 
 
Query  111383  ttcattcacagaacatggtgagcccttactgtggccaatggagcattgcctgatccatgc  111442 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  325818  TTCATTCACAGAACATGGTGAGCCCTTACTGTGGCCAATGGAGCATTGCCTGATCCATGC  325759 
 
Query  111443  cctttccctctctTGCTTGTCCCTCTCTCCCCAGCCCCCGGGAGCATGcagtcacatttc  111502 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||| 
Sbjct  325758  CCTTTCCCTCTCTTGCTTGTCCCTCTCTCCCCAGCCCCCGGGAGCATGCAGTCACACTTC  325699 
 
Query  111503  tgctctggggcctttgcactcactcttctctctgcttgggatgtccctccctcagacatc  111562 
               | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  325698  TACTCTGGGGCCTTTGCACTCACTCTTCTCTCTGCTTGGGATGTCCCTCCCTCAGACATC  325639 
 
Query  111563  ctcttggctccttccatccttacatcaggtttctgctcagatgccatcttttcaccaaat  111622 
               ||||||||||||||| |||||||||||||| ||||||||||||||||||||||||||||| 
Sbjct  325638  CTCTTGGCTCCTTCCCTCCTTACATCAGGTCTCTGCTCAGATGCCATCTTTTCACCAAAT  325579 
 
Query  111623  gcttctccaactgccatatatgcaacgataacccacacctcagccctgggcattctcatc  111682 
               ||||||||||||||||||||| |||||||||||||||||||||||||||||||||||||| 
Sbjct  325578  GCTTCTCCAACTGCCATATATACAACGATAACCCACACCTCAGCCCTGGGCATTCTCATC  325519 
 
Query  111683  ccccttatctcattttgtttttttcctaagcatttatccacatctgaaattctatatatt  111742 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  325518  CCCCTTATCTCATTTTGTTTTTTTCCTAAGCATTTATCCACATCTGAAATTCTATATATT  325459 
 
Query  111743  tactttgtttgtgtgtttgttgtctatctctccatgaggacgggggacagggagggactt  111802 
               |||    ||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  325458  TAC----TTTGTGTGTTTGTTGTCTATCTCTCCATGAGGACGGGGGACAGGGAGGGACTT  325403 
 
Query  111803  tatgtgcttggttcactgctgtacccctattgcttacaatagtacctgacacagagtagc  111862 
               |||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||  
Sbjct  325402  TATGTGCTTGGTTCACTGCTGTACCCCTATTGCTGACAATAGTACCTGACACAGAGTAGG  325343 
 
Query  111863  agctcattaatatctgttgactgaaCATCTTCCTCATAGGGCTGATGTATGTGACCAGCC  111922 
               |||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||| 
Sbjct  325342  AGCTCATTAATATCTGTTGACTGAACATCTTCCTCATAGGGCTGGTGTATGTGACCAGCC  325283 
 
Query  111923  TGGAAAACATGAGGCTGTATTCAGATGCTGGATATAACGTCAGGCCAGTCCATTTTGAGC  111982 
               ||||||||| |||||||||||||||||||||||||||||||||||||||||||||||| | 
Sbjct  325282  TGGAAAACACGAGGCTGTATTCAGATGCTGGATATAACGTCAGGCCAGTCCATTTTGAAC  325223 
 
Query  111983  CTTCTTGCCCACAGATCCTTTCTTGTCTCTTTGCTAACTCTAGGAGTGACAGTGTTCCCT  112042 
               ||||||||||||||||||||||||||||||||||| |||||||||||||||||||||||| 
Sbjct  325222  CTTCTTGCCCACAGATCCTTTCTTGTCTCTTTGCTGACTCTAGGAGTGACAGTGTTCCCT  325163 
 
Query  112043  ATTGGAATTGGAGATCGCTACGATGCAGCCCAGCTACGGATCTTGGCAGGCCCAGCAGGC  112102 
                |||||||||||||||||||||||||||||||||||||||||||||| |||||||||||| 
Sbjct  325162  GTTGGAATTGGAGATCGCTACGATGCAGCCCAGCTACGGATCTTGGCCGGCCCAGCAGGC  325103 
 
Query  112103  GACTCCAACGTGGTGAAGCTCCAGCGAATCGAAGACCTCCCTACCATGGTCACCTTGGGC  112162 
               ||||||||| ||||||||||||||| |||||||||||||||||||||||||||||||||| 
Sbjct  325102  GACTCCAACATGGTGAAGCTCCAGCAAATCGAAGACCTCCCTACCATGGTCACCTTGGGC  325043 
210
 
Query  112163  AATTCCTTCCTCCACAAACTGTGCTCTGGTGAGTCTTATAATACCTTTCTTACTTCCCTC  112222 
               ||||||||||||||||||||||||||| |||||||||||||||||||||||||||||||| 
Sbjct  325042  AATTCCTTCCTCCACAAACTGTGCTCTCGTGAGTCTTATAATACCTTTCTTACTTCCCTC  324983 
 
Query  112223  aaaaaaaagttccaaaataaacccgccaaagaaacaaaaaTAGTATTCAAGAGACCCCAG  112282 
                |||||||||||||||| |||||||||||||||||||||||| ||||||||||||||||| 
Sbjct  324982  -AAAAAAAGTTCCAAAACAAACCCGCCAAAGAAACAAAAATACTATTCAAGAGACCCCAG  324924 
 
Query  112283  GGTGCCCATGCATAAGATTTGGCCTTGAATGAAGATTATTATATAGACCAGGACCTTTAA  112342 
               ||||||||||||||||||||||||||||| |||||||||||||||||||||||| || || 
Sbjct  324923  GGTGCCCATGCATAAGATTTGGCCTTGAAAGAAGATTATTATATAGACCAGGACATTCAA  324864 
 
Query  112343  GTTTCTGTTCATGGGAGGTGTATACCACAAGCCCCCATGGGGCCAGCAGAAAGCTTTCTG  112402 
               ||||||| |||||||||||||||||||||||||||| ||||||||||||||||||||||| 
Sbjct  324863  GTTTCTGCTCATGGGAGGTGTATACCACAAGCCCCCGTGGGGCCAGCAGAAAGCTTTCTG  324804 
 
Query  112403  TGTATGGTCCTATTTCCACTCTAATTGTCCATGTGAACTTGGCAGAGAGAGCCTAAGCTT  112462 
               ||||||||||||||||||||||||||| |||||||||||||||  ||||||||||||||| 
Sbjct  324803  TGTATGGTCCTATTTCCACTCTAATTGGCCATGTGAACTTGGC--AGAGAGCCTAAGCTT  324746 
 
Query  112463  ATTTGTGTAGAGGGATCTTGGACAAAAGAATCAGAAGACATAAGCAAGGAACCCCAGCGT  112522 
               |||||||||||||||||||||||||| |||||||||||||||||||||||||||||| || 
Sbjct  324745  ATTTGTGTAGAGGGATCTTGGACAAAGGAATCAGAAGACATAAGCAAGGAACCCCAGAGT  324686 
 
Query  112523  TCCGTAGGTATAGTCTTCTTCCCCATGGGCCTAGACTAACTCTCAACATGGGTATAAAGG  112582 
               |||  |  || |||||||||||||||||||||||||| |||||||||||||||||||||| 
Sbjct  324685  TCC--A--TAGAGTCTTCTTCCCCATGGGCCTAGACTCACTCTCAACATGGGTATAAAGG  324630 
 
Query  112583  GCTTTAGAAATACGATAACACGGAGACTCATATCAAAGTACCATAGTTTAAGTTGATTTT  112642 
               ||||||||||||| |||||| ||||||||||||||||||||||||||||||||||||||| 
Sbjct  324629  GCTTTAGAAATACAATAACATGGAGACTCATATCAAAGTACCATAGTTTAAGTTGATTTT  324570 
 
Query  112643  AGGTTAGAAacttaaaaaatatgcttttggccaggtgcagtggctcacgtctgtaatccc  112702 
               ||||||||||||||||||||| |||||||||||||  | |||||||| |||||||||||| 
Sbjct  324569  AGGTTAGAAACTTAAAAAATACGCTTTTGGCCAGGCACGGTGGCTCATGTCTGTAATCCC  324510 
 
Query  112703  agcactttgggaggccgaggcgggcggatcatgaggtcaggagatcgagaccatcttggc  112762 
               |||||||||||||||||||||||| |||||| |||||||||||||||||||| ||||||| 
Sbjct  324509  AGCACTTTGGGAGGCCGAGGCGGGTGGATCACGAGGTCAGGAGATCGAGACCGTCTTGGC  324450 
 
Query  112763  taacacagtgaaaccctgtctctactaaaaatacaaaaaattagccgggcgtggtggcgg  112822 
               |||||||||||| ||| | |||||||||| |||||||||||||||||||| ||||||||| 
Sbjct  324449  TAACACAGTGAATCCCCGCCTCTACTAAAGATACAAAAAATTAGCCGGGCATGGTGGCGG  324390 
 
Query  112823  gcacctgtagtaccagctacttgggaggctgaggcaggagaatggtgtgaacccgggagg  112882 
               ||||||||||||||||||||||||||||||||||||||||||||| |||||||| ||||| 
Sbjct  324389  GCACCTGTAGTACCAGCTACTTGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCAGGAGG  324330 
 
Query  112883  cagagcttgcagtgagccgagatcgcgccactgtactccagcctgggcaacagagtgaga  112942 
               | ||||||||||||||||||||||||| ||||| |||||||||||||| ||||||  ||| 
Sbjct  324329  CGGAGCTTGCAGTGAGCCGAGATCGCGTCACTGCACTCCAGCCTGGGCGACAGAGCAAGA  324270 
 
Query  112943  ctccatctc-aaa-a-a-a-a-a-a-a-a-a-a-a-a-atacacacacacacacacacac  112988 
               |||  |||| ||| | | | | | | | | | | | | | |||||||||||||||||||| 
Sbjct  324269  CTCTGTCTCAAAACACACACACACACACACACACACACACACACACACACACACACACAC  324210 
 
Query  112989  --gctttttttGTGGCGGG-GGCCTGGGTTTGTATATTTTCCCGTTACTAGATGTAAGTC  113045 
                 |||||||||| || ||| ||||||||||| |||||||||||||||||||||||||||| 
Sbjct  324209  ATGCTTTTTTTG-GG-GGGAGGCCTGGGTTTATATATTTTCCCGTTACTAGATGTAAGTC  324152 
 
Query  113046  AAAACCTGCATAAAGCTACTGTCCTTCGGGGGAATAAGTCAATGCAAGTTTGCCCTTAAA  113105 
               ||||||||||||||||||||||| ||| ||||||||||||| |||||||||||||||||| 
Sbjct  324151  AAAACCTGCATAAAGCTACTGTCTTTCAGGGGAATAAGTCAGTGCAAGTTTGCCCTTAAA  324092 
 
Query  113106  GGGCAATAACTCTATGCAAGTTTTGACTTATAGCTAATAACATTAGCTGTACAGAGAGAT  113165 
               ||||||||||||||  |||||||||||||||||| ||| ||||||||||||||||||||| 
Sbjct  324091  GGGCAATAACTCTACACAAGTTTTGACTTATAGCAAATCACATTAGCTGTACAGAGAGAT  324032 
 
Query  113166  GGCAGCTCTCCTGGTAGGAATCTTCAAGTAGATCTCTTTCAGGTTTCCAGGATCTTGCTT  113225 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  324031  GGCAGCTCTCCTGGTAGGAATCTTCAAGTAGATCTCTTTCAGGTTTCCAGGATCTTGCTT  323972 
211
 
Query  113226  CATCTCCCCACCTTCCCCATCCCTGGCGTGATCTACATGTGAACCAAGATAATGACAGCG  113285 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  323971  CATCTCCCCACCTTCCCCATCCCTGGCGTGATCTACATGTGAACCAAGATAATGACAGCG  323912 
 
Query  113286  TAAGCTGTAGTTATTGCCATATTATCGCTGTTGTTGGCATCATAATTATTAATAACTGCA  113345 
               |||||||||||||||||||||||||||||||||||||||||||||||||||| ||| ||| 
Sbjct  323911  TAAGCTGTAGTTATTGCCATATTATCGCTGTTGTTGGCATCATAATTATTAACAACCGCA  323852 
 
Query  113346  GAGCATGTCTGAAGAACCACAGGATGACCACCTCAGCCTCATGTCCCTATGTCTCCACTG  113405 
               |||||||||||||||||||||||||||||||||||||| |||||||||| |||||||||| 
Sbjct  323851  GAGCATGTCTGAAGAACCACAGGATGACCACCTCAGCCACATGTCCCTAGGTCTCCACTG  323792 
 
Query  113406  TTAACCTTGTTCAGATTCTTTTCAGAGTTGAGTTGACTTCAAAAACTAGACCAGGTTGCT  113465 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  323791  TTAACCTTGTTCAGATTCTTTTCAGAGTTGAGTTGACTTCAAAAACTAGACCAGGTTGCT  323732 
 
Query  113466  TAAGCAGACATTGTGAATGGTTCAGAATTTCTGGGTGAAAGATGGGAACTAAGGTCTTAT  113525 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  323731  TAAGCAGACATTGTGAATGGTTCAGAATTTCTGGGTGAAAGATGGGAACTAAGGTCTTAT  323672 
 
Query  113526  TTGTGTCTGTTGCAGGATTTGTTAGGATTTGCATGGATGAGGATGGGAATGAGAAGAGGG  113585 
               ||||||||||||||||||||||||||||| |||||||||||||||||||||||||||||| 
Sbjct  323671  TTGTGTCTGTTGCAGGATTTGTTAGGATTCGCATGGATGAGGATGGGAATGAGAAGAGGG  323612 
 
Query  113586  TAAGTTCCTTTCTGTTGACTTTGAAAGAAAGGTTAGAGATGTGTTTGGGGCTCTTGTTCC  113645 
               ||||||||||||||||||||||||||||||| |||||||||||||||||||||||||||| 
Sbjct  323611  TAAGTTCCTTTCTGTTGACTTTGAAAGAAAGATTAGAGATGTGTTTGGGGCTCTTGTTCC  323552 
 
Query  113646  CACTGGTTAATTTTTCCTCCTTTGGTCTTAGTCCAGTGCTTCCTTTTACTATTATCTTGT  113705 
               ||||| |||||||||||||||||||||||||||||| ||||||| ||||||||||||||| 
Sbjct  323551  CACTGTTTAATTTTTCCTCCTTTGGTCTTAGTCCAGCGCTTCCTCTTACTATTATCTTGT  323492 
 
Query  113706  TTTTGCGGGTCCATCTGTACATCTTGTGTTTTGCTTCCTGTCTCATGTACAGGGGGCCTC  113765 
               ||||| ||||||||||||||||||||||||||||||||||||||||||||||| |||||| 
Sbjct  323491  TTTTGAGGGTCCATCTGTACATCTTGTGTTTTGCTTCCTGTCTCATGTACAGGAGGCCTC  323432 
 
Query  113766  CTTGCTGTGTAGGCCTGTGTTCAATTCTAGGGGTCAGTTGTCTGGCAGATGGGCTTAGAG  113825 
               ||||||||||||||| |||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  323431  CTTGCTGTGTAGGCCCGTGTTCAATTCTAGGGGTCAGTTGTCTGGCAGATGGGCTTAGAG  323372 
 
Query  113826  TTGGAGTACCTCATCTTATTCCCTGCCTGAATCTGCTGTTTTCTTCTGCAGCCCGGGGAC  113885 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  323371  TTGGAGTACCTCATCTTATTCCCTGCCTGAATCTGCTGTTTTCTTCTGCAGCCCGGGGAC  323312 
 
Query  113886  GTCTGGACCTTGCCAGACCAGTGCCACACCGTGACTTGCCAGCCAGATGGCCAGACCTTG  113945 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  323311  GTCTGGACCTTGCCAGACCAGTGCCACACCGTGACTTGCCAGCCAGATGGCCAGACCTTG  323252 
 
Query  113946  CTGAAGAGTCATCGGGTCAACTGTGACCGGGGGCTGAGGCCTTCGTGCCCTAACAGCCAG  114005 
               |||||||||||||||||||||||||||||||||| ||||||||| ||||||||||||||| 
Sbjct  323251  CTGAAGAGTCATCGGGTCAACTGTGACCGGGGGCCGAGGCCTTCATGCCCTAACAGCCAG  323192 
 
Query  114006  TCCCCTGTTAAAGTGGAAGAGACCTGTGGCTGCCGCTGGACCTGCCCCTGTGAGTCCTTT  114065 
               |||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||| 
Sbjct  323191  TCCCCTGTTAAAGTGGAAGACACCTGTGGCTGCCGCTGGACCTGCCCCTGTGAGTCCTTT  323132 
 
Query  114066  GCTTCTCCAGCCAGGGCAGCGTCAAAGGGGCAGTGCTTTTAGCTTGGCTGTGCAGAAAAG  114125 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  323131  GCTTCTCCAGCCAGGGCAGCGTCAAAGGGGCAGTGCTTTTAGCTTGGCTGTGCAGAAAAG  323072 
 
Query  114126  TAGAGCAGGCACCCACCAGCCCAGAAGTACCCTTTCCCTCATCACCACATGCACAGTGCT  114185 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  323071  TAGAGCAGGCACCCACCAGCCCAGAAGTACCCTTTCCCTCATCACCACATGCACAGTGCT  323012 
 
Query  114186  ACCTTCACTCACCTTCCTTTCCTCCTGTGCTCTTTGGACATGCATGCAGCCAGTCTCAGG  114245 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  323011  ACCTTCACTCACCTTCCTTTCCTCCTGTGCTCTTTGGACATGCATGCAGCCAGTCTCAGG  322952 
 
Query  114246  GATCACTGCCCTCTTTCTCTGTCTTTGGAAGGCACTTCCCCAGATTATGCATAACTGGAA  114305 
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||| 
Sbjct  322951  GATCACTGCCCTCTTTCTCTGTCTTTGGAAGGCACTTCCCCAGATTATGCATAACCGGAA  322892 
212
 
Query  114306  GGAAGAATTGCTTTTCTGAGGTCAATGCTCAGCTTGGCTGTTGGCAAGTCAACCTTTAGG  114365 
               |||||||||||||||||||||||| ||||||||||||||||||||||||||||||||||| 
Sbjct  322891  GGAAGAATTGCTTTTCTGAGGTCAGTGCTCAGCTTGGCTGTTGGCAAGTCAACCTTTAGG  322832 
 
Query  114366  AATCTGTGTATTCAGGGTATAGCAGTGGAAGTATAGCAGTGAGAGAGACGCTTCCAGAAA  114425 
               ||||| |||||||||||||||||||||||||||||||||||||||||| ||||||||||| 
Sbjct  322831  AATCTATGTATTCAGGGTATAGCAGTGGAAGTATAGCAGTGAGAGAGATGCTTCCAGAAA  322772 
 
Query  114426  ACTCTCCAACCACACCTATAGCAACAGTACATCACCAAGGCGGCCTGGATTAAGAGGAGG  114485 
               |||||||||||||||||||||||| ||||||||||||||| |||||| |||||||||||| 
Sbjct  322771  ACTCTCCAACCACACCTATAGCAAGAGTACATCACCAAGGTGGCCTGAATTAAGAGGAGG  322712 
 
Query  114486  AAATATTTAAAGTCCATCTCATGTACACTTGTGGAGAGCATGTCATCCATGGGCTGGGTT  114545 
               ||||||||||||||||||||| ||||||||||||||||||| |||||||||||||||||| 
Sbjct  322711  AAATATTTAAAGTCCATCTCACGTACACTTGTGGAGAGCATTTCATCCATGGGCTGGGTT  322652 
 
Query  114546  AGCCTTCTGTCTCATGTTTGGGAGCAATGACTGCTTATGGTGACCATGACTCAGCAGTGG  114605 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  322651  AGCCTTCTGTCTCATGTTTGGGAGCAATGACTGCTTATGGTGACCATGACTCAGCAGTGG  322592 
 
Query  114606  ATtgtaacctttatgctgaacaggcataactggtgggatgcaatcaaaactgtat-ttat  114664 
               |||||||| |||||||||||||||||||||||||||||||||||||||||||||| |||| 
Sbjct  322591  ATTGTAAC-TTTATGCTGAACAGGCATAACTGGTGGGATGCAATCAAAACTGTATGTTAT  322533 
 
Query  114665  agctcattccccctttagaatttatttagtgagataaatttccctcttggtctaggtgaa  114724 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  322532  AGCTCATTCCCCCTTTAGAATTTATTTAGTGAGATAAATTTCCCTCTTGGTCTAGGTGAA  322473 
 
Query  114725  aactccaccagactttaggtttcttctgtttattcataaagaattctatagttactttgt  114784 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  322472  AACTCCACCAGACTTTAGGTTTCTTCTGTTTATTCATAAAGAATTCTATAGTTACTTTGT  322413 
 
Query  114785  cagaagacaaagtctcagttgataactagatacccactcttgcgtaataatcaaaacttt  114844 
               ||||||||||||||||||||||||| |||||||||||||||| ||||||||||||||||| 
Sbjct  322412  CAGAAGACAAAGTCTCAGTTGATAATTAGATACCCACTCTTGTGTAATAATCAAAACTTT  322353 
 
Query  114845  gaatttgattagagttaaaacacctcccAGTTCCAATTTAG-GCTGCCTGCCTCTGGGAA  114903 
               ||||||||||||||||||||||||||||||||||||||| | |||||||||||||||||| 
Sbjct  322352  GAATTTGATTAGAGTTAAAACACCTCCCAGTTCCAATTT-GCGCTGCCTGCCTCTGGGAA  322294 
 
Query  114904  GGAGGGTATGGTCAGCTTTCCTCTGTACAAAGAGCTttgccttttgtgattaaaagcata  114963 
               ||||||||||||||||||||||||||||||||||| |||||||||||||||||||||||| 
Sbjct  322293  GGAGGGTATGGTCAGCTTTCCTCTGTACAAAGAGCATTGCCTTTTGTGATTAAAAGCATA  322234 
 
Query  114964  tcctggaaattactcgatgtcatttcaaagagagcttcctaatacttcactgtgtaccat  115023 
               ||||||||||||| |||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  322233  TCCTGGAAATTACCCGATGTCATTTCAAAGAGAGCTTCCTAATACTTCACTGTGTACCAT  322174 
 
Query  115024  aggttacccaactgttcttctatggatgtgcgtttaggctgtttccagtgttttgtaatg  115083 
               ||||||||||||||||||||||||||||||| ||||||||||||||||||| |||||||| 
Sbjct  322173  AGGTTACCCAACTGTTCTTCTATGGATGTGCATTTAGGCTGTTTCCAGTGTCTTGTAATG  322114 
 
Query  115084  acaagcaatgctgcaatgagtaaacctgaacatacgaacgaattttcatatggttggagg  115143 
               |||||||||||||||||||||||||||| |||||||||    || ||||||||||||||| 
Sbjct  322113  ACAAGCAATGCTGCAATGAGTAAACCTGCACATACGAA----TTGTCATATGGTTGGAGG  322058 
 
Query  115144  tgtgtcttcagggtagattcctagaagtgagattcttgggtcaaaagataagtgcatatg  115203 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  322057  TGTGTCTTCAGGGTAGATTCCTAGAAGTGAGATTCTTGGGTCAAAAGATAAGTGCATATG  321998 
 
Query  115204  aagttccccttagacattcccagattctcctctaacaggtgagatgtggttgtgcaaaac  115263 
               |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  321997  AAGTTCCCCTTAGATATTCCCAGATTCTCCTCTAACAGGTGAGATGTGGTTGTGCAAAAC  321938 
 
Query  115264  tggaatgtccatcagtttggttttcgatcagcgaggtatgagagtgcatgcatctccacg  115323 
               ||||||||||||||||||| |||||||||||||||||||||||||||| || |||||||| 
Sbjct  321937  TGGAATGTCCATCAGTTTGCTTTTCGATCAGCGAGGTATGAGAGTGCAAGCTTCTCCACG  321878 
 
Query  115324  gccttgctgagtgtgttgttacagtttttatttattttttttgcaaatttcttacttttc  115383 
               |||||||| |||| ||||||||||| ||| ||| |||||||| ||||||||||||||||| 
Sbjct  321877  GCCTTGCTCAGTGCGTTGTTACAGTGTTT-TTT-TTTTTTTT-CAAATTTCTTACTTTTC  321821 
213
 
Query  115384  aggaaagaaatagtatctcagtgtacttgaaattcatttctctaatgatgagtgaggtta  115443 
               |||||||||||||||||| |||||||||||||||||||||| ||||||||||||||| || 
Sbjct  321820  AGGAAAGAAATAGTATCTGAGTGTACTTGAAATTCATTTCTGTAATGATGAGTGAGGGTA  321761 
 
Query  115444  aacattttatcatatgtttaattgccattttttggtctaattttgtgaattttctgctca  115503 
               |||||||| ||||||||||||||||||||||||||||||||||| ||||||||||||||| 
Sbjct  321760  AACATTTT-TCATATGTTTAATTGCCATTTTTTGGTCTAATTTTATGAATTTTCTGCTCA  321702 
 
Query  115504  tgcctttccccattttcccattagaaaagttgtgataagaaacacatgagatctacccta  115563 
               |||||||||||||||||||||||||| || |||||||| ||||||||||||||||||||| 
Sbjct  321701  TGCCTTTCCCCATTTTCCCATTAGAAGAGCTGTGATAAAAAACACATGAGATCTACCCTA  321642 
 
Query  115564  ttaataaattttccagtgtacaataccatattgttagctatttgcaagttgttgtacagc  115623 
               |||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||| 
Sbjct  321641  TTAATAAATTTTCCAGTGTACAATACAATATTGTTAGCTATTTGCAAGTTGTTGTACAGC  321582 
 
Query  115624  agatctctagaagtttttgttttgtgtgactgaaactatgcccactgaacagcaacttcc  115683 
               ||| || ||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  321581  AGACCTTTAGAAGTTTTTGTTTTGTGTGACTGAAACTATGCCCACTGAACAGCAACTTCC  321522 
 
Query  115684  cattttccccttcccctagcccccgcaaccaccattctgctttttgcttctatgaatttg  115743 
               |||||||||||||||||||||||| ||||||||||||||||||||||||||||||||||| 
Sbjct  321521  CATTTTCCCCTTCCCCTAGCCCCCACAACCACCATTCTGCTTTTTGCTTCTATGAATTTG  321462 
 
Query  115744  acgattttagatacctcctgtaagtggattcatgcagtagttatccttctgtgactggct  115803 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  321461  ACGATTTTAGATACCTCCTGTAAGTGGATTCATGCAGTAGTTATCCTTCTGTGACTGGCT  321402 
 
Query  115804  catttcacttagcttaacatcctccaagttcatctatgttgtggcatatgaaaggatttc  115863 
               |||||||||||||||||  ||||||||||||||||||||||||||||||||||||||||| 
Sbjct  321401  CATTTCACTTAGCTTAATGTCCTCCAAGTTCATCTATGTTGTGGCATATGAAAGGATTTC  321342 
 
Query  115864  cttctttctaaagactgaatagtattccattgcatgtatataccacattttctttatcca  115923 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  321341  CTTCTTTCTAAAGACTGAATAGTATTCCATTGCATGTATATACCACATTTTCTTTATCCA  321282 
 
Query  115924  tttgtccactgatgtgcatttggattatttctaactcttggctattgtgaataatgttgc  115983 
               |||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||| 
Sbjct  321281  TTTGTCCACTGATGTGCATTTGGATTGTTTCTAACTCTTGGCTATTGTGAATAATGTTGC  321222 
 
Query  115984  agtgaatgtggaagtgtataagtacctttttgagatcctgatttcaatgcttttggatga  116043 
               |||||| ||||||||||| | ||| ||||||||||||||||||||||||||||||||||| 
Sbjct  321221  AGTGAACGTGGAAGTGTA-A-GTATCTTTTTGAGATCCTGATTTCAATGCTTTTGGATGA  321164 
 
Query  116044  atacccagaagtgggattactgggtcatatgctaatactagttttaattttttgaggaac  116103 
               |||||||||||||||||| | ||||||||||||||||| |||||||||||| |||||||| 
Sbjct  321163  ATACCCAGAAGTGGGATTGCGGGGTCATATGCTAATACCAGTTTTAATTTTCTGAGGAAC  321104 
 
Query  116104  cttcttactgttttctgtagtcgcgacaccactttacattcctaccatcaatgcacaagg  116163 
               |||||||| |||||||||||| || ||||||||||||||||||||||||||||||||||| 
Sbjct  321103  CTTCTTACCGTTTTCTGTAGTGGCTACACCACTTTACATTCCTACCATCAATGCACAAGG  321044 
 
Query  116164  gtttcaatttcttcacattcttgttaacacgtggtatttcctggtgtgtgtgtgtgtgtg  116223 
               |||||| ||||||||||||||||||||||| ||||||||||||||||||||||||||||| 
Sbjct  321043  GTTTCAGTTTCTTCACATTCTTGTTAACACTTGGTATTTCCTGGTGTGTGTGTGTGTGTG  320984 
 
Query  116224  tgtgtgtgtgtgtgtgtgtgtttgataatggccattctagcacgtatgaggtgatacctc  116283 
               ||||||||||||||||| | |  ||||||||||||||||||||||||||||| ||||||| 
Sbjct  320983  TGTGTGTGTGTGTGTGT-T-T--GATAATGGCCATTCTAGCACGTATGAGGTAATACCTC  320928 
 
Query  116284  attatggttttgatttgcatttccctgatgatcagtaatgttggatattttttcatataa  116343 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  320927  ATTATGGTTTTGATTTGCATTTCCCTGATGATCAGTAATGTTGGATATTTTTTCATATAA  320868 
 
Query  116344  ttgagtttttggatgtctctttggaggaatgtcttttcaagtcctttgctcatttttaaa  116403 
               |||| ||||| ||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  320867  TTGACTTTTTAGATGTCTCTTTGGAGGAATGTCTTTTCAAGTCCTTTGCTCATTTTTAAA  320808 
 
Query  116404  ttgggttatttgcattttttttttttttgctattgagttgtatgagttcctaatatattt  116463 
               ||||||||||||||||||||||||||||||||||||||||| |||||||||||||||||| 
Sbjct  320807  TTGGGTTATTTGCATTTTTTTTTTTTTTGCTATTGAGTTGTGTGAGTTCCTAATATATTT  320748 
214
 
Query  116464  tggatattaaccctttatcaaatgtacggtttgcaaatattttcttccattctgtaggct  116523 
               |||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  320747  TGGATATTAACCTTTTATCAAATGTACGGTTTGCAAATATTTTCTTCCATTCTGTAGGCT  320688 
 
Query  116524  gcctttttattctgttgattgtttctttggctgcacagaagctttttggtttgctgtagt  116583 
               ||||||||||||||||||||||||||||||||||||||||||||||||||||| |||||| 
Sbjct  320687  GCCTTTTTATTCTGTTGATTGTTTCTTTGGCTGCACAGAAGCTTTTTGGTTTGATGTAGT  320628 
 
Query  116584  cccacttgtctatttttgcttttgttgccttgtttttggcaatgatatccaagaaatcgt  116643 
               ||||||||||||||||||||||||||||||||||||||| || ||||||||||||||||| 
Sbjct  320627  CCCACTTGTCTATTTTTGCTTTTGTTGCCTTGTTTTTGGTAACGATATCCAAGAAATCGT  320568 
 
Query  116644  cgccaagaccaatgttgcaaagttcttgtgttttcttttaggagttttataatttcaggt  116703 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  320567  CGCCAAGACCAATGTTGCAAAGTTCTTGTGTTTTCTTTTAGGAGTTTTATAATTTCAGGT  320508 
 
Query  116704  tttacgtatcagtgtttaagtttgattttgggttaactttgtgtatgatataaggtaagg  116763 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||| 
Sbjct  320507  TTTACGTATCAGTGTTTAAGTTTGATTTTGGGTTAACTTTGTGTATGATATAAGATAAGG  320448 
 
Query  116764  gtccaatttcattctttttcatgtggacaggttcattgttagtgtattgaaacaaatggt  116823 
               |||||| ||||||||||||||||||||||||| ||||||||||||||  ||||||||||| 
Sbjct  320447  GTCCAACTTCATTCTTTTTCATGTGGACAGGT-CATTGTTAGTGTATAAAAACAAATGGT  320389 
 
Query  116824  tttgtatgttgattttgtattctgcaactgaatttgttttaacttcgctgaatttgctaa  116883 
               ||| ||||||||||||||||||||||||||||||||||| ||||| |||||||||||||| 
Sbjct  320388  TTTCTATGTTGATTTTGTATTCTGCAACTGAATTTGTTTCAACTTTGCTGAATTTGCTAA  320329 
 
Query  116884  caaatttttggtgaaatctttagagttttctatgcatatgatcatgtcatctgcaaatgg  116943 
               ||||||||||||||||||||||||||||||||  |||| ||| ||||||||||||||| | 
Sbjct  320328  CAAATTTTTGGTGAAATCTTTAGAGTTTTCTACACATAAGATTATGTCATCTGCAAATTG  320269 
 
Query  116944  agataattttacttcttttttgatttgggtgatgttcatatcttcttgattcattgctct  117003 
               |||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||| 
Sbjct  320268  AGATAATTTTACTTCTTTTTTGATTTGGGTGATGTTTATATCTTCTTGATTCATTGCTCT  320209 
 
Query  117004  agctaagacttctcgtactatgttgaatagaagtggtgagagtgggcatctttgccgtct  117063 
               ||||||||||||| |||||||||||||||||||||||||||||||||||| |||| |||| 
Sbjct  320208  AGCTAAGACTTCTGGTACTATGTTGAATAGAAGTGGTGAGAGTGGGCATCCTTGCTGTCT  320149 
 
Query  117064  tcctgattagaggaaaagcttttagttttgcactattcggtgtgatgttagctgtggtat  117123 
               |||||||||||||||||||||||||||||||||||||| | ||||||||||||||||||| 
Sbjct  320148  TCCTGATTAGAGGAAAAGCTTTTAGTTTTGCACTATTCAG-GTGATGTTAGCTGTGGTAT  320090 
 
Query  117124  tttcattaatggcctttattttgttgaggtaattttcttctattcttagtttgttgaatg  117183 
               |||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  320089  TTTCATTAATGGCCTTAATTTTGTTGAGGTAATTTTCTTCTATTCTTAGTTTGTTGAATG  320030 
Query  117184  ttttaatcatgaaatggtgtttgaattatgacaaatgctttatctgtatctgttgacatg  117243 
               ||||||||||||||||||||||||||| |||||||||||||||||| |||| |||||||| 
Sbjct  320029  TTTTAATCATGAAATGGTGTTTGAATTTTGACAAATGCTTTATCTGCATCTATTGACATG  319970 
 
Query  117244  atagtatgatttttatcctttgttctgttaatgctatgtatcacctttattgatttttag  117303 
               | ||||||||||||||||||||| ||||||||||| |||||||| |||| |||||||||| 
Sbjct  319969  ACAGTATGATTTTTATCCTTTGTCCTGTTAATGCTGTGTATCACATTTACTGATTTTTAG  319910 
 
Query  117304  acgttgagccattctcctatctgagggataaatcccactccgtcagagtgtattatcctt  117363 
               | | ||||||||||||| ||||||||||||||||||||||    ||||||||| |||||| 
Sbjct  319909  ATGCTGAGCCATTCTCCCATCTGAGGGATAAATCCCACTC----AGAGTGTATGATCCTT  319854 
 
Query  117364  tgattgtgctgtttaattcagtttgctgtcattttgttgagaatttttgcatctgtgttc  117423 
               ||||||||||||| ||||||||||||| |||||||||||||||||||||||||| ||||| 
Sbjct  319853  TGATTGTGCTGTTGAATTCAGTTTGCTATCATTTTGTTGAGAATTTTTGCATCTATGTTC  319794 
 
Query  117424  atcaggaatattgacttgtagttttttttaatgtaaagtctttgactttggtatcagggt  117483 
               ||||||||||||||||||||||||| ||||| |||||||||||| ||||||||||||||| 
Sbjct  319793  ATCAGGAATATTGACTTGTAGTTTTCTTTAACGTAAAGTCTTTGGCTTTGGTATCAGGGT  319734 
 
Query  117484  aattctggcttcataaagtaggtttcccacttcagtgttttggaagagtgtgagaaagat  117543 
               |||||||||||||    |  | |||||||||||| |||||||||||||| |||||||||  




Query  117544  tggcattaattcttctttaaatctttggtagaattatccagtgaaagcatctgagctctt  117603 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  319680  TGGCATTAATTCTTCTTTAAATCTTTGGTAGAATTATCCAGTGAAAGCATCTGAGCTCTT  319621 
 
Query  117604  atttattgagagattatgattactaatttcatctccttactaat-gatggggctgttcag  117662 
                ||| ||| ||||||||||||| |||||| |||||||||||||| | ||||||||||||| 
Sbjct  319620  CTTTGTTGGGAGATTATGATTATTAATTTGATCTCCTTACTAATTG-TGGGGCTGTTCAG  319562 
 
Query  117663  attttctgtttattcatcattcaggcttggtaggttgtatgtttcagggatttattcatt  117722 
               |||||||||||||||||||||||| ||||||||||||||||||||||||||||||||||| 
Sbjct  319561  ATTTTCTGTTTATTCATCATTCAGTCTTGGTAGGTTGTATGTTTCAGGGATTTATTCATT  319502 
 
Query  117723  tctttaggttatccaatttgttagtgtgtagttgttcatagtagtctcttactaaccttt  117782 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||| 
Sbjct  319501  TCTTTAGGTTATCCAATTTGTTAGTGTGTAGTTGTTCATAGTAGTCTCTTACTAGCCTTT  319442 
 
Query  117783  ttatttctgcgctatcaattgtaatgtaagctcttctatttctgattttatttatttgag  117842 
               ||||||||| ||||||||||||||| ||| |||||||||||||||||||||||||||||| 
Sbjct  319441  TTATTTCTGTGCTATCAATTGTAATATAACCTCTTCTATTTCTGATTTTATTTATTTGAG  319382 
 
Query  117843  tcttctctttttgtcttggttaatctagctaaagctttgttaattttgttgacctttaaa  117902 
               |||| | |||| |||||||||||||||||||||| ||||||||||||||||||||||||| 
Sbjct  319381  TCTT-T-TTTT-GTCTTGGTTAATCTAGCTAAAGATTTGTTAATTTTGTTGACCTTTAAA  319325 
 
Query  117903  aaaccaattctaagttttattgatattttgtattctatatttcatttatttttcctcaaa  117962 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  319324  AAACCAATTCTAAGTTTTATTGATATTTTGTATTCTATATTTCATTTATTTTTCCTCAAA  319265 
 
Query  117963  tctttattatttccttccttctgctaacttacggcttagtttattcattttctagttc-t  118021 
               |||| |  ||||||||||||||||||||||| |||||||||||||||||||||||||| | 
Sbjct  319264  TCTT-A--ATTTCCTTCCTTCTGCTAACTTAGGGCTTAGTTTATTCATTTTCTAGTTCCT  319208 
 
Query  118022  tacattgtaaaattaggttatttgtttgagatctttcttactgtagacatttactgctgt  118081 
               ||  |||||||||||||||    ||||||||||||||||||||||||||||||||||||| 
Sbjct  319207  TATGTTGTAAAATTAGGTT----GTTTGAGATCTTTCTTACTGTAGACATTTACTGCTGT  319152 
 
Query  118082  aaactttccttttattgcttttgctgtttcccataagctttgctatgttgtgctttagtt  118141 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  319151  AAACTTTCCTTTTATTGCTTTTGCTGTTTCCCATAAGCTTTGCTATGTTGTGCTTTAGTT  319092 
 
Query  118142  tttgtttttctcaaaatattttctgatttttcttttgatttcttctttgactcattggtt  118201 
               ||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||| 
Sbjct  319091  TTTGTTTTTCTCAAAATATTTTCTGATTTTTCTTTTGATTTCTTCTTTGACCCATTGGTT  319032 
 
Query  118202  gttcaagagtgttttttaatttccacatatttgagaactttctgaaattatttctcttag  118261 
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||| 
Sbjct  319031  GTTCAAGAGTGTTTTTTAATTTCCACATATTTGAGAACTTTCTGAAATTATTTCTATTAG  318972 
 
Query  118262  caatgtctcattttattctgttgtcagaaaagatacttggtatgattttagcctccttaa  118321 
               ||||||||||||   || ||  ||||||||||||||||||||||||||||| |||||||| 
Sbjct  318971  CAATGTCTCATTCCGTTGTG--GTCAGAAAAGATACTTGGTATGATTTTAGTCTCCTTAA  318914 
 
Query  118322  atttgttaagatttgtttcgtgggctagcatgtgagctattctggagactgttctatgtg  118381 
               |||||||||||||||||| |||||||||||||||| |||||||||||||||||||||||| 
Sbjct  318913  ATTTGTTAAGATTTGTTTTGTGGGCTAGCATGTGAACTATTCTGGAGACTGTTCTATGTG  318854 
 
Query  118382  tgtttgagaagaatgtataatttgctgttgttgggtagaatgttctgtatttgtttgata  118441 
               |||||||| |||||||||||||||||||||||||||||||| |||||||||||||||||| 
Sbjct  318853  TGTTTGAGGAGAATGTATAATTTGCTGTTGTTGGGTAGAATATTCTGTATTTGTTTGATA  318794 
 
Query  118442  ggtccacttgggccatagtgttgtttgagttctctgtttccttattgatcttctatctgg  118501 
               ||||||||||||||||||||||||||||||| |||||||||||||||||||||| ||||| 
Sbjct  318793  GGTCCACTTGGGCCATAGTGTTGTTTGAGTTATCTGTTTCCTTATTGATCTTCTGTCTGG  318734 
 
Query  118502  attttttatccattattgaaagtgagatattaaaatctctcactattatgttgttctata  118561 
               |||||||||||||||||||||||||||||||| ||| ||||||||||||||||||||||| 
Sbjct  318733  ATTTTTTATCCATTATTGAAAGTGAGATATTACAATTTCTCACTATTATGTTGTTCTATA  318674 
 
Query  118562  tttatcatcacttctgtcaatatttgcttcttatatttgtgtgctttaatgttgggtgca  118621 
               |||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||| 
Sbjct  318673  TTTATCATCACTTCTGTCAACATTTGCTTCTTATATTTGTGTGCTTTAATGTTGGGTGCA  318614 
216
 
Query  118622  atgtacttata-t-----cttcctggtgaattgatgcatttatcactatataatgtccgt  118675 
               ||||| ||||| |     ||||||| |||||||||||||||||||||||||||||||||| 
Sbjct  318613  ATGTATTTATAATTATATCTTCCTGATGAATTGATGCATTTATCACTATATAATGTCCGT  318554 
 
Query  118676  ttttttgtctcttgtgaccatctttgacttgaagtttaatttctctaagtatggctacct  118735 
               |||||||||||||||||||||||||||||| ||||||||||| ||||||||||||||||| 
Sbjct  318553  TTTTTTGTCTCTTGTGACCATCTTTGACTTAAAGTTTAATTTGTCTAAGTATGGCTACCT  318494 
 
Query  118736  gtgctgtcttttagttaacattggcatgaaatatctttttccatcttctcactttaaacc  118795 
                  || | ||  ||||||||||||||||||||||||||||||||||||||||||| |||| 
Sbjct  318493  ---CT-T-TT--AGTTAACATTGGCATGAAATATCTTTTTCCATCTTCTCACTTTCAACC  318441 
 
Query  118796  tatgtgcattcttaaatctaaagtgagtctctctcttgtagacagcacatagttggatct  118855 
               |||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||| 
Sbjct  318440  TATGTGCATTCTTAAATCCAAAGTGAGTCTCTCTCTTGTAGACAGCACATAGTTGGATCT  318381 
 
Query  118856  tgttttatattt-t--atttatttatttactta---a-tttatttagatggagtcttgct  118908 
               |||||||||||| |  ||||||||||||| |||   | |||||||||||||||||| ||| 
Sbjct  318380  TGTTTTATATTTATTTATTTATTTATTTATTTATTTAATTTATTTAGATGGAGTCTGGCT  318321 
 
Query  118909  ctgttgcccaggctggagtgcaatggctcgatctcggctcactgcaacctctgcctcccg  118968 
               ||||||||||||||||||||||||||||||||||||||||||||||| || ||||||||| 
Sbjct  318320  CTGTTGCCCAGGCTGGAGTGCAATGGCTCGATCTCGGCTCACTGCAATCTATGCCTCCCG  318261 
 
Query  118969  ggttcaagtgattctcctccctcagcctcctaagtagctggaactacaagcacgtgccac  119028 
               |||||||||||||||||||||||||||||||||||||||||||||| |||| | |||||| 
Sbjct  318260  GGTTCAAGTGATTCTCCTCCCTCAGCCTCCTAAGTAGCTGGAACTAGAAGCGCATGCCAC  318201 
 
Query  119029  ca-tgcctggctaattttttgtatttttagtagagacggggtttcaccatgttagccagg  119087 
               || | ||||||||||||||||||||||||||||||||||||||||||  ||||||||||| 
Sbjct  318200  CACT-CCTGGCTAATTTTTTGTATTTTTAGTAGAGACGGGGTTTCACTGTGTTAGCCAGG  318142 
 
Query  119088  atggtctcgatctcctgatctctcatgatctgcctacctcagcctcccaaagtgctggga  119147 
               ||||||| ||||||||||||||||||||||||||||||||||| |||||||||||||||| 
Sbjct  318141  ATGGTCTTGATCTCCTGATCTCTCATGATCTGCCTACCTCAGCGTCCCAAAGTGCTGGGA  318082 
 
Query  119148  tcacagacatgagccaccgcacctggctgttttattttatttttaaaaattcatttcagc  119207 
               | |||||| ||||||||| ||||||||||||||||||||||||||||||||||||||||| 
Sbjct  318081  TTACAGACGTGAGCCACCACACCTGGCTGTTTTATTTTATTTTTAAAAATTCATTTCAGC  318022 
 
Query  119208  cacttcatagcttttgattggagagtttattctacttatacttaaagtaacta-tggata  119266 
               |||||||||||||||||||||||||||||||||| |||||||||||||||||| || ||| 
Sbjct  318021  CACTTCATAGCTTTTGATTGGAGAGTTTATTCTATTTATACTTAAAGTAACTACTG-ATA  317963 
 
Query  119267  gggaaggacttactgttgccattttg-taattattttcagtcagtcttgtagcttttttg  119325 
               |||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||| 
Sbjct  317962  GGGAAGGACTTACTGTTGCCATTTTGGTAATTATTTTCAGTCAGTCTTGTAGCTTTTTTG  317903 
 
Query  119326  tccctcttttctactcttactgcccttctttgtgtttcattgat-ttttttgggtaatga  119384 
               |||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||| 
Sbjct  317902  TCCCTCTTTTCTACTCTTACTGCCCTTCTTTGTGTTTCATTGATGTTTTTTGGGTAATGA  317843 
 
Query  119385  tgagatttgactccttcctcatttccttttgtgtatcttctatagatattttctttgtgg  119444 
               |||||||||| ||||| ||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  317842  TGAGATTTGATTCCTTTCTCATTTCCTTTTGTGTATCTTCTATAGATATTTTCTTTGTGG  317783 
 
Query  119445  ttaccatgaagcttacataaaacagcctatacttataacagtctattctaagcttataac  119504 
               |||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  317782  TTACCATGAAGCTTACTTAAAACAGCCTATACTTATAACAGTCTATTCTAAGCTTATAAC  317723 
 
Query  119505  aacttaatttcaattgctcacgaaaactctactcttttactgcctctcccccactttaca  119564 
               ||||||||||||||||| ||| ||||||||||| ||||||||||||||||||||||||   
Sbjct  317722  AACTTAATTTCAATTGCACACAAAAACTCTACTTTTTTACTGCCTCTCCCCCACTTTATG  317663 
 
Query  119565  ttattgatgtcacaaattatattttttaatgttgtgtattcattaactgatttttatagt  119624 
               ||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  317662  TTATTCATGTCACAAATTATATTTTTTAATGTTGTGTATTCATTAACTGATTTTTATAGT  317603 
 
Query  119625  gatagttatttttataagtttgtcttttaagtactataccagaattcaaagatttacaca  119684 
               ||  ||||||||||||| ||||||||||||||||||||||||||||| |||||||||||| 
Sbjct  317602  GA--GTTATTTTTATAACTTTGTCTTTTAAGTACTATACCAGAATTCCAAGATTTACACA  317545 
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Query  119685  ttgtcattatagtattaaaatattctatatttgtttatatatttacctttaccaggaatt  119744 
               ||||||||||||||||||||||| |||||||||||||||||||||||||||| ||||||| 
Sbjct  317544  TTGTCATTATAGTATTAAAATATCCTATATTTGTTTATATATTTACCTTTACAAGGAATT  317485 
 
Query  119745  ttacctttcatatgttttcatgttgctgcctagcattcttttatttcaacatgatggact  119804 
               |||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||| 
Sbjct  317484  TTACCTTTCATATGTTTTGATGTTGCTGCCTAGCATTCTTTTATTTCAACATGATGGACT  317425 
 
Query  119805  ccctttagcatttcttataaggcaggtatagtggtgatgaactctttcagcttttgtgca  119864 
               |||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||| 
Sbjct  317424  CCCTTTAGCATTTCTTATAAGGCAGGTATAGTGGCGATGAACTCTTTCAGCTTTTGTGCA  317365 
 
Query  119865  catgagaaagtctttatttcccctctatttttgaaagacagttttgctagacagagtatt  119924 
               |||||||||||||||||||||| || ||||||||||||||||||||||||| |||||||| 
Sbjct  317364  CATGAGAAAGTCTTTATTTCCCTTCCATTTTTGAAAGACAGTTTTGCTAGAGAGAGTATT  317305 
 
Query  119925  cttggctgcccgttgttttcttttgaatagatcatccatctcccttctggcctgcaaggt  119984 
               |||| |||||| ||||||||||||||||| ||||||||||||||||||||| || ||||| 
Sbjct  317304  CTTGACTGCCCATTGTTTTCTTTTGAATATATCATCCATCTCCCTTCTGGCTTGTAAGGT  317245 
 
Query  119985  ttctgctgagaaatttgttgatagtctcattgtggcccccttttatatgaaaagttgctt  120044 
               ||||||| ||||||||||| |||||||||| ||||||||||||||||||||||||||||| 
Sbjct  317244  TTCTGCTAAGAAATTTGTTAATAGTCTCATCGTGGCCCCCTTTTATATGAAAAGTTGCTT  317185 
 
Query  120045  ttctcttgctgctttcaaaattctgtttttgtctttgacttttgacaaattgattataat  120104 
               ||||||||||||||||||||||||||||||||||||||||| ||||||||| |||||||| 
Sbjct  317184  TTCTCTTGCTGCTTTCAAAATTCTGTTTTTGTCTTTGACTTCTGACAAATT-ATTATAAT  317126 
 
Query  120105  atatgttgtagcggacttctttaaattcattctagttggagtcttttgggcttcttgaag  120164 
               |||| |||||| ||||||||||||||| ||||||||||||||||||||| |||||||||| 
Sbjct  317125  ATATCTTGTAGTGGACTTCTTTAAATTAATTCTAGTTGGAGTCTTTTGGACTTCTTGAAG  317066 
 
Query  120165  ctggatgtctattttcttccctaaatttATTCATTATTTCTACTTTCCATTGGGTTTTAA  120224 
               |||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||| 
Sbjct  317065  CTGGATGTCTATTTTCTTCCCTAAATTTGTTCATTATTTCTACTTTCCATTGGGTTTTAA  317006 
 
Query  120225  TCTTATTCGTTATTTTAAATATTTGAACTATTAGCTCATTATCTGTGATATAGGTTGCAG  120284 
               |||||||| |||||||||||||| ||||||||||||||||||| |||||||||||||||| 
Sbjct  317005  TCTTATTCTTTATTTTAAATATTGGAACTATTAGCTCATTATCCGTGATATAGGTTGCAG  316946 
 
Query  120285  TACTATTTATTGACATGTTAATATTTGCCCCAGTGGTGTGAGATAAG--AATAATAATCA  120342 
               |||||||||||||||||| ||| |||||||||||| ||||||||||   ||||||||||| 
Sbjct  316945  TACTATTTATTGACATGTCAATGTTTGCCCCAGTGATGTGAGATAACTTAATAATAATCA  316886 
 
Query  120343  TAAACCAAATTTTCATATGTGCATGGGCTTATTTCTGAACtttttttCTGATTCCACTTG  120402 
               |||| ||||||||||| |||||||||||||||||||||| |||||||||||||||||||| 
Sbjct  316885  TAAATCAAATTTTCATGTGTGCATGGGCTTATTTCTGAA-TTTTTTTCTGATTCCACTTG  316827 
 
Query  120403  TTGTAAGCTATTCATATACCAAAACCACATTGTCTTAATTACCACACTGTCTTAATTAAG  120462 
               ||||||||||||||||||||||| |||||||||||||||||||||||||||||||||| | 
Sbjct  316826  TTGTAAGCTATTCATATACCAAAGCCACATTGTCTTAATTACCACACTGTCTTAATTA-G  316768 
 
Query  120463  AGGAaatacctctaatattttgtcattaaaggctttatggtatgttttattgtctggtag  120522 
               |||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||| 
Sbjct  316767  AGGAAATACCTCTAATATTTTGTCATTAAAGGCTTTATAGTATGTTTTATTGTCTGGTAG  316708 
 
Query  120523  cactagtacctccacatagctttattctaaagtgttttcctggctattcttttatgtttg  120582 
                |||||||||||| ||||||||||||||||| |||||||||||||||| ||| ||||||| 
Sbjct  316707  GACTAGTACCTCCGCATAGCTTTATTCTAAAATGTTTTCCTGGCTATTATTT-ATGTTTG  316649 
 
Query  120583  ttttttctgtatagactttagtgtcaacttgtttacctccataaaaagtttgttggtatt  120642 
               ||||||| |||||||||||||||||||||||||||||||||||| ||||||||||||||| 
Sbjct  316648  TTTTTTCCGTATAGACTTTAGTGTCAACTTGTTTACCTCCATAAGAAGTTTGTTGGTATT  316589 
 
Query  120643  tttattggaattgcattaaatttatacattaactttgggagaactggcatttttatgatg  120702 
               ||||||||||||||||||||||||||||||||||||||||||||| ||||||||||| || 
Sbjct  316588  TTTATTGGAATTGCATTAAATTTATACATTAACTTTGGGAGAACTAGCATTTTTATGGTG  316529 
 
Query  120703  ttaaatcatcctatccaagaacaagtttgtccacttattcaagctgacttgtctgtcttc  120762 
               |||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  316528  TTAAATGATCCTATCCAAGAACAAGTTTGTCCACTTATTCAAGCTGACTTGTCTGTCTTC  316469 
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Query  120763  tagaagtgttttcaggtttattcatttgggttttgcatatttcttgctaagtttattcca  120822 
               |||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  316468  TAGAAGTGTTTTAAGGTTTATTCATTTGGGTTTTGCATATTTCTTGCTAAGTTTATTCCA  316409 
 
Query  120823  agtattgaatcttccttgttgcaattgtaaatgagacttttttcttctccattatgttct  120882 
               |||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||| 
Sbjct  316408  AGTATTGAATCTTCCTTGTTGCTATTGTAAATGAGACTTTTTTCTTCTCCATTATGTTCT  316349 
 
Query  120883  ttaactacttattatttgtgtatataaagggtattgatatcaatatatataacatctata  120942 
               ||||||||||||| |||||||||||||||||||||| |||||||||||||||| | |||  
Sbjct  316348  TTAACTACTTATTGTTTGTGTATATAAAGGGTATTGGTATCAATATATATAACGTATATC  316289 
 
Query  120943  tatctatatataacctatatatatctgtatatgttaattccatatcctatagctttactg  121002 
               |||  |||| |||| ||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  316288  TAT--ATATCTAACATATATATATCTGTATATGTTAATTCCATATCCTATAGCTTTACTG  316231 
 
Query  121003  aattcttttattattgagttagttttatcatggattctctagggttttctgggtatgatg  121062 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  316230  AATTCTTTTATTATTGAGTTAGTTTTATCATGGATTCTCTAGGGTTTTCTGGGTATGATG  316171 
 
Query  121063  gtttgtcatttgcaaatagaattgtttttcttttttgtcaatttttgtgcctccaattaa  121122 
               || | ||||||||||||||||||||||||||| ||||||||||||||||||||||||||| 
Sbjct  316170  GTGTATCATTTGCAAATAGAATTGTTTTTCTTCTTTGTCAATTTTTGTGCCTCCAATTAA  316111 
 
Query  121123  tttctcttgtataattccattaataaactttttagtacaatgttgaatagcagtggagta  121182 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  316110  TTTCTCTTGTATAATTCCATTAATAAACTTTTTAGTACAATGTTGAATAGCAGTGGAGTA  316051 
 
Query  121183  tcttgcacacacacacacgcacacacacacgtgcacacacat-atcatgtattttat-at  121240 
               |||||||||||||||||||||||||||||  ||||||||||| ||||| |||||||| || 
Sbjct  316050  TCTTGCACACACACACACGCACACACACA--TGCACACACATTATCATATATTTTATCAT  315993 
 
Query  121241  -t-atgaaagtatccctcaattctcatttttgagtgtttttttgtcaagagtgattgtgg  121298 
                | ||||||||||||||| |||||||||||||||||||||||||| |||||||||||| | 
Sbjct  315992  ATTATGAAAGTATCCCTCGATTCTCATTTTTGAGTGTTTTTTTGTAAAGAGTGATTGTAG  315933 
 
Query  121299  aattttggtgttggtgaaggctttttcagcatctatggagataatctcttgatttttttt  121358 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  315932  AATTTTGGTGTTGGTGAAGGCTTTTTCAGCATCTATGGAGATAATCTCTTGATTTTTTTT  315873 
 
Query  121359  -ctttaaatatattgatatggtatattatttgaagaaatttcctaatgttgatcccactt  121417 
                ||||||||||||||||| |||||||||||||||| |||||||||||||||||||||||| 
Sbjct  315872  TCTTTAAATATATTGATACGGTATATTATTTGAAGGAATTTCCTAATGTTGATCCCACTT  315813 
 
Query  121418  ggctatgctttgttattttcataatgtggtgttggattctgtttggtaatattttattta  121477 
               ||||||| ||||||||||||||||||||||||||||||||||||||| |||||||||||| 
Sbjct  315812  GGCTATGGTTTGTTATTTTCATAATGTGGTGTTGGATTCTGTTTGGTTATATTTTATTTA  315753 
 
Query  121478  gtacgttggttttgacattcataagtatttttggtcagcaattttAACACTACttattta  121537 
               |||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||| 
Sbjct  315752  GTACGTTGGTTTTGACATTCATAAGTATTTTTGGTCTGCAATTTTAACACTACTTATTTA  315693 
 
Query  121538  aattttcagtaatatacatataacataaaatttatccttttaactatttttaagtatata  121597 
               ||||||||||||||||||||||||||    || ||||||||||||||||||||||||||| 
Sbjct  315692  AATTTTCAGTAATATACATATAACAT----TT-ATCCTTTTAACTATTTTTAAGTATATA  315638 
 
Query  121598  tccagtgacattatcatgaatgaggtcaggagattgagaccagcctggctaacacacggt  121657 
               |||||||||||||||| ||  | | || |||||| ||||||||| ||||||||||||||| 
Sbjct  315637  TCCAGTGACATTATCACGA--G-G-TCGGGAGATCGAGACCAGCATGGCTAACACACGGT  315582 
 
Query  121658  gaaaccccgtctctactaaaaatacaaaaaattagccgggcgtggtggcgggcgcctgta  121717 
               |||||||||||||||||||| |||||||||||||||||||||||||||| || ||||||| 
Sbjct  315581  GAAACCCCGTCTCTACTAAAGATACAAAAAATTAGCCGGGCGTGGTGGCAGGTGCCTGTA  315522 
 
Query  121718  gttccagttactcgggaggctgaggcaggagaatggcgtgaacccgggaggtggagcttg  121777 
               || |||| |||| |||||||||||||||||||||||||||||||||||||| |||||||| 
Sbjct  315521  GTCCCAGCTACTTGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTG  315462 
 
Query  121778  tagtgagccgagatcttgccactgcactccagcctgggcaacagagcgagactccgtct  121836 
                ||||||||||||||  |||||||||||||||||||||| ||||||||||||||||||| 




Reported CBC Candidate QTL 
Chromosome Trait Population Statistics Notes PMID 
1p34.2-p36.23 MCH-
MCHC 
Baboons LOD 2.5  17557178 
1p34.2-p36.23 MCH-
MPV 
Baboons LOD 1.5  17557178 
1p34.2-36.23 MCV Baboons LOD 3.5  17557178 
1p34.2-p36.23 MCV-HB Baboons LOD 3.2  17557178 
1p34.2-p36.23 MCV-
HCT 
Baboons LOD 3.2  17557178 
1p34.2-p36.23 MCV-
MCH 
Baboons LOD 2.5  17557178 
1p34.2-p36.23 MCV-
MCHC 
Baboons LOD 2.6  17557178 
1p34.2-p36.23 MCV-
MPV 
Baboons LOD 3.4  17557178 
1p34.2-p36.23 MCV-PLT Baboons LOD 3.1  17557178 
1p34.2-p36.23 MCV-
RBC 
Baboons LOD 3.2  17557178 
1p34.2-p36.23 MCV-
RDW 
Baboons LOD 2.8  17557178 
1p34.2-p36.23 MCV-
WBC 
Baboons LOD 3.0  17557178 
1p34.3 RBC Caucasian 4.20E-06 FLJ11730; BC016328 17903294 
1p34.2-p36.23 RBC-HCT Baboons LOD 3.5  17557178 
1q21 Hct Mice LOD 3.9 Locus named Hctq1, 
recesive model 
16596451 





1q23.2 HB Caucasian 1.60E-07 OR10J1; OR10J5 17903294 
1q23.1 MCHC Caucasian p=1.033E-10 SPTA1 19862010 
1q23.2 WBC African American LOD 96.8 DARC 18179887 
1q23.2 WBC African American 1.40E-103 DARC 21153663 
1q24.3 MPV Caucasian 2.10E-14 DNM3 19820697 
1q31.3 MCH Japanese 6.76E-10 ATP6V1G3-PTPRC 20139978 
1q32.1 MPV Caucasian 1.40E-20 TMCC2 19820697 
1q41-42 RBC Mice LOD 3.8 Locus named Rbcq3, 
dominant model, 
same signal as 17p11 
16596451 
1q44 HB Caucasian LOD 2.04  16950815 
1q44 HCT Caucasian LOD 2.72  16950815 
1q44 MCV Japanese 2.33E-08 TRIM58 20139978 
2p11.2-q11.2 MCV Caucasian LOD1.63  16950815 
2p16.2 HB Caucasian 1.00E-06  17903294 
2p16.1 MCV Caucasian p=1.125E-14 BCL11A 19862010 
2p21 HB Caucasian p=7.052E-13 PRKCE 19862010 
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2p21 HCT Caucasian p=3.748E-15 PRKCE 19862010 
2p21 MPV Caucasian 3.20E-11 EHD3 19820697 
2p21 RBC Japanese 3.81E-08 PRKCE 20139978 
2q11.1-q12.1 MCV-
RDW 
Baboons LOD 1.5  17557178 
2q32 MCHC Mice LOD 4.7 Locus named Chmq1, 
recessive model 
16596451 
3p14.2-p13 RBC Caucasian LOD 2.2  16950815 
3p21–p13 MPV Caucasian 5.50E-31 ARHGEF3 19820697 
3p23-p22.3 RDW-
PLT 
Baboons LOD 1.6  17557178 
3p24.2 MCH Japanese 3.52E-10 THRB 20139978 
3p24.2 MCV Japanese 3.33E-08 THRB 20139978 
3q12-13 Hgb Mice LOD 3.7 Locus named Hgbq1, 
dominant model 
16596451 
3q27.1 PLT Japanese 5.38E-11 THPO-CHRD 20139978 
3q29 MCH Japanese 4.46E-11 TFRC-ZDHHC19 20139978 
3q29 MCH Caucasian p=7.729E-13 TFRC 19862010 
3q29 MCV Japanese 1.66E-08 TFRC-ZDHHC19 20139978 
3q29 MCV Caucasian p=8.499E-14 TFRC 19862010 
3q29 MCV Caucasian 6.40E-04 TFRC-ZDHHC19 21153663 
4p12-q13.3 RBC Caucasian LOD 2.5  17903294 
4p15.1-p14 MCV Caucasian LOD 1.73  16950815 
4p15.33 RBC Caucasian 4.50E-06  17903294 
4q12 MCH Japanese 2.80E-25 PDGFRA-HK1 20139978 
4q12 MCV Japanese 2.19E-29 PDGFRA-HK1 20139978 
4q12 MCV Caucasian p=9.816E-10 KIT 19862010 
4q12 RBC Japanese 1.92E-17 PDGFRA-HK1 20139978 
4q31.2-q34.1 RBC Caucasian LOD 3.07  16950815 
4q34.3-q35.1 WBC-
MCHC 
Baboons LOD 2.0  17557178 
5p15.33 RBC Japanese 3.01E-08 TERT 20139978 
5q21.1 MCH Caucasian 5.80E-06  17903294 




6p21.1 MCH Japanese 1.80E-20 USP49-MED20-
BYSL-CCND3 
20139978 
6p21.1 MCH Caucasian p=8.198E-20 CCND3/BYSL 19862010 
6p21 MCV Australian, Dutch 1.20E-09 CCND3 19853236 
6p21.1 MCV Japanese 3.62E-27 USP49-MED20-
BYSL-CCND3 
20139978 
6p21.1 MCV Caucasian p=1.121E-31 CCND3/BYSL 19862010 
6p21.1 MCV Caucasian 7.00E-19 BYSL/ CCND3 19820697 
6p21.1 RBC Japanese 1.09E-10 USP49-MED20-
BYSL-CCND3 
20139978 
6p21 WBC Caucasian 1.90E-08  21153663 
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6p21.3 MCV Caucasian 1.40E-23 HFE 19820697 
6p21.31 PLT Japanese 6.66E-11 BAK1 20139978 
6p21.3 PLT Caucasian 3.70E-10 BAK1 19820697 
6p21.31 PLT African American 6.20E-08 BAK1 21153663 
6p21.31 PLT Caucasian 7.60E-73 BAK1 21153663 
6p21.33 WBC Japanese 6.76E-09 CDSN-PSORS1C1 20139978 
6p22 HB Caucasian p=5.737E-19 HFE 19862010 
6p22.1 HB Caucasian 1.40E-15 HFE 21153663 
6p22 HCT Caucasian p=2.035E-9 HFE 19862010 
6p22.1 HCT Caucasian 2.50E-10 HFE 21153663 
6p22.2 MCH Caucasian p=3.868E-39 SLC17A3 19862010 
6p22.1 MCH Emergency 
department 
2.76E-09 HFE 20927387 
6p22.2 MCH Emergency 
department 
4.66E-08 SLC17A1 20927387 
6p22.2 MCHC Japanese 5.00E-10 SLC12A7 20139978 
6p22 MCV Caucasian p=1.012E-46  HFE 19862010 
6p22.1 MCV Caucasian 6.80E-16 HFE 21153663 
6q21 MCH Japanese 1.49E-08 C6orf182-CD164 20139978 
6q21 MCV Japanese 2.51E-08 C6orf182-CD164 20139978 
6q21 MCV Caucasian p=4.198 CD164 19862010 
6q21 RBC Japanese 6.92E-09 C6orf182-CD164 20139978 
6q21 RBC Caucasian LOD 1.73  16950815 
6q23.1-q23.2 HB Caucasian LOD 3.03  16950815 
6q23.3 HCT Caucasian p=2.811E-15 HBS1L-MYB 19862010 
6q23-24 HCT Caucasian LOD 3.4 EBP41L2, HEBP2 
HPFH 
15635079 
6q23.3 HCT Caucasian 5.50E-04 MYB 21153663 
6q23.1-q23.2 HCT Caucasian LOD 2.95  16950815 
6q23.3 Ht Japanese 9.52E-11 HBS1L-MYB 20139978 
6q23.3 MCH Japanese 2.82E-66 HBS1L-MYB 20139978 
6q23.3 MCH Caucasian p=7.356E-69 HBS1L-MYB 19862010 
6q23.3 MCH Emergency 
department 
5.17E-16 HBS1L/MYB 20927387 
6q23.3 MCH Emergency 
department 
3.12E-14 HBS1L/MYB 20927387 
6q23.3 MCH Emergency 
department 
4.94E-14 HBS1L/MYB 20927387 
6q23.3 MCH Emergency 
department 
1.36E-15 HBS1L/MYB 20927387 
6q23.3 MCH Emergency 
department 
7.05E-11 HBS1L/MYB 20927387 
6q23.3 MCH Emergency 
department 
1.42E-08 HBS1L/MYB 20927387 
6q23.3 MCHC Japanese 6.22E-12 HBS1L-MYB 20139978 
6q23.3 MCHC Caucasian p=6.486E-10  HBS1L-MYB 19862010 
6q23.3 MCV Japanese 3.44E-56 HBS1L-MYB 20139978 
6q23.3 MCV Caucasian p=7.241E-86 HBS1L-MYB 19862010 
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6q23.3 MCV Emergency 
department 
1.37E-14 HBS1L/MYB 20927387 
6q23.3 MCV Emergency 
department 
5.03E-13 HBS1L/MYB 20927387 
6q23.3 MCV Emergency 
department 
7.94E-13 HBS1L/MYB 20927387 
6q23.3 MCV Emergency 
department 
2.82E-15 HBS1L/MYB 20927387 
6q23.3 MCV Emergency 
department 
2.50E-10 HBS1L/MYB 20927387 
6q23.3 MCV Emergency 
department 
3.49E-08 HBS1L/MYB 20927387 
6q23 –q24 MCV Caucasian 7.40E-42 HBS1L -MYB 19820697 
6q23.3 MCV Caucasian 3.90E-09 MYB 21153663 
6q23.3 PLT Japanese 2.54E-14 HBS1L-MYB 20139978 
6q23.3 RBC Japanese 7.31E-48 HBS1L-MYB 20139978 
6q23.3 RBC Caucasian p=1.148E-47 HBS1L-MYB 19862010 
6q23.3 RBC Emergency 
department 
1.11E-14 HBS1L/MYB 20927387 
6q23.3 RBC Emergency 
department 
2.46E-13 HBS1L/MYB 20927387 
6q23.3 RBC Emergency 
department 
2.85E-13 HBS1L/MYB 20927387 
6q23.3 RBC Emergency 
department 
7.18E-12 HBS1L/MYB 20927387 
6q23.3 RBC Emergency 
department 
5.57E-09 HBS1L/MYB 20927387 
6q23.3 RBC Caucasian 4.70E-04 MYB 21153663 
6q23.1-q23.2 RBC Caucasian LOD 1.88  16950815 
6q23.3 WBC Japanese 1.67E-09 HBS1L-MYB 20139978 
6q23.3 WBC Caucasian 4.40E-04 MYB 21153663 
6q24.1 MCH Japanese 1.42E-09 CITED2 20139978 
6q24.1 MCH Caucasian p=1.262E-17 CITED2 19862010 
6q24.1 MCV Australian, Dutch 5.30E-09  19853236 
6q24.1 MCV Japanese 1.08E-09 CITED2 20139978 
6q24.1 MCV Caucasian p=4.665E-25 CITED2 19862010 
6q25.1 RBC Caucasian 6.30E-06 MAP3K7IP2 17903294 
6q25.3-q27 RBC Caucasian LOD 2.9  17903294 
7p12.2 MCV Caucasian p=4.689E-13 IKZF1 19862010 
7p13-11 MCV Mice LOD 4.7 Locus named Mcvq2, 
heterozygotes low 
16596451 
7q11.21-q11.22 HB Caucasian LOD 1.55  16950815 
7q21.2 WBC Japanese 2.44E-08 CDK6 20139978 
7q21.2 WBC Caucasian 4.10E-04 CDK6 21153663 
7q22.1 HCT Caucasian p=4.45E-10 TFR2 19862010 
7q22 HCT Caucasian 4.30E-07 TFR2 21153663 
7q22.1 MCV Caucasian p=2.543E-11 TFR2 19862010 
7q22 MCV Caucasian 1.60E-07 TFR2 21153663 
7q22.3 MPV Caucasian 1.60E-33 PIK3CG 19820697 
223
 
7q22.1 RBC Caucasian p=1.123E-9 EPO 19862010 
7q22 RBC Caucasian 4.90E-10 TFR2 19820697 
7q22 RBC Caucasian 1.60E-05 TFR2 21153663 
7q22.1 RBC Caucasian 1.30E-06 EPO 21153663 
7q36.1 HB Caucasian p=3.025E-15 PRKAG2 19862010 
7q36.1 HB Caucasian 1.60E-10 PRKAG2 21153663 
7q36.1 HCT Caucasian p=6.045E-15 PRKAG2 19862010 
7q36.1 HCT Caucasian 5.00E-09 PRKAG2 21153663 
7q36.1-q36.2 MCV Caucasian LOD 2.2  17903294 
7q36.2 MCV Caucasian LOD 1.71  16950815 
7q36.2-q36.3 MCV Caucasian LOD 2.14  16950815 
8p12 RBC Caucasian LOD 1.52  16950815 
8p21.3 MCV Japanese 3.32E-08 DOK2-XPO7 20139978 
8p21.3-p22 RBC-
MPV 
Baboons LOD 1.6  17557178 
8q22.3-q24.11 RBC Caucasian LOD 1.99  16950815 
8q24.13 HB Caucasian 2.10E-06  17903294 
8q24.13-q24.11 HCT Caucasian LOD 2.02  16950815 
9p24.1 MCH Japanese 5.69E-11 RCL1 20139978 
9p24.1 MCH Caucasian p=2.166E-14 RCL1 19862010 
9p24.1 MCV Japanese 2.50E-14 RCL1 20139978 
9p24.1 MCV Caucasian p=3.184E-20 RCL1 19862010 
9p24.2 MCV Caucasian LOD 1.61  16950815 
9p24.1 PLT Japanese 2.95E-13 RCL1 20139978 
9p24.1 –p24.3 PLT Caucasian 8.50E-17 AK3 19820697 
9p24.2 RBC Caucasian LOD 1.62  16950815 
9q34.2 Hb Japanese 1.18E-11 ABO 20139978 
9q34.2 HB Caucasian 9.60E-04 ABO 21153663 
9q34 HCT-HB Caucasian LOD 3.1  15635079 
9q34.2 Ht Japanese 6.06E-10 ABO 20139978 
9q34.2 MCHC Japanese 4.32E-08 ABO 20139978 
9q34 MCV Korean 5.06E-05 ABO. Identified a 
CNV where deletion 




Baboons LOD 1.7  17557178 
9q34.2 RBC Japanese 3.33E-12 ABO 20139978 
9q34 RBC Korean 2.13E-06 ABO 22963146 
10p11.21 MCH Caucasian 5.90E-06 ANKRD30A 17903294 













10q11.23 MCV Japanese 6.73E-09 MSMB-NCOA4-
TIMM23 
20139978 
10q11.21 MCV Caucasian p=1.346E-10 Gene: MARCH8 19862010 




10q22.1 HB Caucasian p=2.116E-11 HK1 19862010 
10q22.1 HCT Caucasian p=9.636E-14 HK1 19862010 
10q21.2 –q21.3 MPV Caucasian 3.30E-21 JMJD1C 19820697 
10q26.3 PLT-MPV Baboons LOD 2.0  17557178 
10q26.3 RDW Baboons LOD 1.9  17557178 
10q26.3 RDW-
MPV 
Baboons LOD 2.0  17557178 
10q26.3 RDW-
PLT 
Baboons LOD 1.5  17557178 
11p15.4 MCH Caucasian LOD 3.6 Hemoglobin B gene 
cluster 
17211848 
11p15.3-p15.1 MCV Caucasian LOD 3.3  17903294 
11p15.4 MCV Caucasian LOD 3.8 Hemoglobin B gene 
cluster 
17211848 
11p15.4 MCV African American 2.90E-04 HBB 21153663 
11p15.4 MCV African American 4.90E-07 MMP26 21153663 
11p15.5 MPV Caucasian 1.30E-14 BET1L 19820697 
11p15.3-p15.2 RBC Caucasian LOD 3.2  17903294 
11q12.1 MCH Caucasian 6.90E-08 OR5AP2; OR5AR1; 
OR9G1; OR9G4 
17903294 
12p13.32 RBC Japanese 6.44E-09 CCND2 20139978 
12p13.2 RBC Caucasian LOD 3.0  17211848 
12p13.32-p13.31 RBC Caucasian LOD 2.8  17903294 
12q13.13 PLT African American 1.60E-06 NFE2-COPZI 21153663 
12q13.13 RBC Caucasian LOD 1.63  16950815 
12q15 WBC Japanese 2.85E-08 RAP1B-NUP107-
SLC35E3 
20139978 
12q21 MCH Mice LOD 4.4 Locus named Mchq1, 
recessive model 
16596451 
12q21 MCV Mice LOD 4.7 Locus named Mcvq3, 
recessive model 
16596451 
12q21 RBC Mice LOD 3.7 Locus named Rbcq4, 
dominant model 
16596451 
12q23.1 RBC Caucasian LOD 1.61  16950815 
12q24.13 HB Caucasian p=1.159E-11 TRAFD1 19862010 
12q24.12 HB Caucasian 3.20E-07 SH2B3 21153663 
12q24.12 HCT Caucasian p=1.363E-12 SH2B3-ATXN2 19862010 
12q24.12 HCT Caucasian 1.50E-06 SH2B3 21153663 
12q24.14 MCHC Japanese 7.25E-10 ALDH2 20139978 
225
 
12q24.31 MPV Caucasian 2.70E-44 WDR66 19820697 
12q24.12 PLT Japanese 4.75E-19 SH2B3 20139978 
12q24 PLT Caucasian 2.20E-13 ATXN2 19820697 
12q24 PLT Caucasian 7.70E-12 PTPN11 19820697 
13q22.1 MCV Caucasian LOD 1.74  16950815 
14q23.3 MCV Caucasian p=4.907E-8 FNTB 19862010 
14q24.3-q32.12 RBC Caucasian LOD 2.6  17903294 
15q14 MCV Mice LOD 9.8 Locus named Mcvq1, 
recessive model 
16596451 




15q22.1 MPV Caucasian 1.90E-08 TPM1 19820697 
15q26.3 RBC Caucasian LOD 2.3  17903294 
16p13.3 HB African American 6.10E-08 HBA2-HBA1 21153663 
16p13.3 HB African American 1.30E-06 MMP25 21153663 
16p13.3 MCH Japanese 2.83E-09 HBA2-HBA1-LUC7L-
ITFG3-RGS11 
20139978 
16p13.3 MCH Caucasian p=2.675E-10 ITFG3 19862010 
16p13.3 MCHC African American 7.40E-13 HBA2-HBA1 21153663 
16p13.3 MCV Caucasian p=1.819E-12 ITFG3 19862010 
16p13 MCV African American 5.00E-07  21153663 
16p13.3 MCV African American 1.40E-33 HBA2-HBA1 21153663 
16q23.2-q24.3 Hb Baboons LOD 1.6  17557178 
16q23.2-q24.3 HB-RDW Baboons LOD 2.2  17557178 
16q24.3 MCHC Japanese 3.55E-13 CDT1 20139978 
17p13.1-p12 MCV Caucasian LOD 1.95  16950815 
17p13.2 PLT Japanese 2.13E-12 GP1BA 20139978 
17p11 RBC Mice LOD 3.8 Locus named Rbcq3, 
dominant model, 
same signal as 1q41-
42 
16596451 
17p34-36 RBC Mice LOD 5.3 Locus named Rbcq2, 
recessive model 
16596451 
17q11.2-q22 HB Caucasian LOD 2.61  16950815 
17q11.2-q22 HCT Caucasian LOD 2.98  16950815 
17q11.2 MPV Caucasian 1.40E-22 TAOK1 19820697 
17q12 WBC Caucasian 9.40E-09 GSDMA/ ORMDL3 19820697 
17q21.32-q22 RBC Caucasian LOD 2.05  16950815 
17q21.1 WBC Japanese 2.94E-14 GSDMA-PSMD3-
CSF3-MED24 
20139978 
17q21.1 WBC Caucasian 1.80E-19 CSF3 21153663 
17q25.1-q25.3 RBC Caucasian LOD 2.3  17903294 
18p11.32-p11.31 RBC Caucasian LOD 3.3  17903294 
226
 
18q21 RBC Mice LOD 3.4 Locus named Rbcq1, 
recessive model 
16596451 
18q22.3 MPV Caucasian 1.40E-10 CD226 19820697 
19p13.12-q13.11 Hb Baboons LOD 1.9  17557178 
19p13.12-q13.41 HB-PLT Baboons LOD 2.0  17557178 
19p13.12-q13.41 Hct Baboons LOD 1.6  17557178 
19p13.2 MCH Caucasian p=1.415E-11 GCDH 19862010 
19p13.2 MCV Caucasian p=2.173E-12 RTBDN 19862010 
19q13.43 MCV Caucasian 8.30E-07 GALP 21153663 
19p13.12 PLT African American 3.00E-07 TPM4 21153663 
19p13.12 PLT Caucasian 3.00E-07 TPM4 21153663 
19p13.3 RBC Caucasian LOD 3.2 EPOR, EKLF 17211848 
20p12.3 RBC Caucasian 5.80E-06  17903294 
20p12.1-q11.2 RDW-
MPV 
Baboons LOD 2.4  17557178 
20p13 MPV Caucasian 7.70E-11 SIRPA 19820697 
20q13.2 HB Caucasian p=1.054E-10 TSHZ2 19862010 
20q13.31 MCV Japanese 1.37E-08 RBM38 20139978 
22q11.21 MCV Japanese 1.04E-08 HIC2-UBE2L3 20139978 
22q11.21-q11.22 MCV Caucasian LOD 1.7  16950815 
22q11.23-q13.2 RBC Caucasian LOD 2.2  17903294 
22q12 –q13 MCV Caucasian 4.30E-10 FBXO7 19820697 
22q12.1-q12.3 MCV Caucasian LOD 2.16  16950815 
22q12.3 HB Australian 5.30E-07 TMPRSS6, also 
associated with iron 
status (mechanism) 
19820699 
22q12.3 Hb Japanese 1.64E-10 TMPRSS6 20139978 
22q12.3 HB Caucasian p=3.25E-25 TMPRSS6 19862010 
22q12.3 HB Caucasian 1.60E-13 TMPRSS6, V736A 
substitution in serine 
protease domain 
reported w/ dose 
effect 
19820698 
22q12.3 HCT Caucasian p=1.846E-13 TMPRSS6 19862010 
22q12.3 MCH Japanese 4.84E-25 TMPRSS6 20139978 
22q12.3 MCH Caucasian p=8.77E-34 TMPRSS6 19862010 
22q12.3 MCH Emergency 
department 
1.10E-12 TMPRSS6 20927387 
22q12.3 MCH Emergency 
department 
3.73E-08 TMPRSS6 20927387 
22q12.3 MCH Emergency 
department 
2.41E-11 TMPRSS6 20927387 
22q12.3 MCH Caucasian 9.50E-10 TMPRSS6 19820697 
22q12.3 MCHC Japanese 7.73E-14 TMPRSS6 20139978 
22q12.3 MCHC Emergency 
department 
2.40E-11 TMPRSS6 20927387 
22q12.3 MCHC Emergency 
department 
1.13E-12 TMPRSS6 20927387 
227
 
22q12.3 MCV Australian 1.10E-10 TMPRSS6, also 
associated with iron 
status (mechanism) 
19820699 
22q12.3 MCV Japanese 1.22E-15 TMPRSS6 20139978 
22q12.3 MCV Caucasian p=2.772E-41 TMPRSS6 19862010 
22q12.3 MCV Emergency 
department 
5.41E-09 TMPRSS6 20927387 
22q13.33 MCH Japanese 4.37E-08 NCAPH2-SCO2-
TYMP-KLHDC7B 
20139978 
22q13.33 MCV Caucasian p=1.033E-15 ECGF1 19862010 
22q13.33 MCV Caucasian 1.00E-06 ECGF1 21153663 
Xp21.3-p11.4 MCV Caucasian LOD 2.3  17903294 
Xq25 HB African American 1.20E-15 G6PD 21153663 
Xq25 HCT African American 1.20E-13 G6PD 21153663 
Xq25 MCV African American 3.00E-18 G6PD 21153663 






Marshfield Map Screening Set 16 
Weber Lab Screening Set 16
MARKER LETTER DESIGNATIONS 
A = Amplify 2 polymorphic sites. 
N = Minor change in primer sequence with no change in primer position or allele size. 
Z = Primer moved from its initial position; the allele size changed. 
Y = Primer moved twice from its initial position; the allele size changed twice. 
P = A 7-base pigtail was added to the reverse primer.  The allele size has changed. 
M = An "Adenine" was added to the reverse primer.  The allele size has changed by one base. 
L = The reverse primer was shifted to a position which would accommodate a "Thymine" on 
the 
    5' of the primer. The allele size has changed. 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































VWF c.4120C>T Expression in Cell Culture 
 
Figure D.1: Functional characterization of the c.4120C>T (R1374C) mutation 
(A) Secretion of recombinant VWF from HEK293 cells transfected with the mutated allele 
alone, the wild-type allele alone and both alleles co-expressed at different 
concentrations. (B) Multimer patterns of the secreted VWF show “smeared” configuration 
when the 4120T mutation is expressed alone (left) and clearly defined bands when co-
expressed with wild type. (C) Ristocetin-induced platelet binding to recombinant wild- 
type VWF (), R1374C-VWF (■), and co-expressed alleles R1374C/WT (○). (D) 
Botrocetin-induced platelet binding to recombinant R1374C-VWF (■), wild-type VWF (), 





Chromosome 9q34 ABO-ADAMTS13 Tagging SNPs 
SNP Gene log.VWFAg log.VWFRCo log.FVIII 
rs8176749 ABO 0.1293463 0.0201647 0.1239331 
rs8176739 ABO 0.4596651 0.5589601 0.9932298 
rs2073824 ABO 0.000266 0.001971 0.0032395 
rs8176721 ABO 1 1 1 
rs512770 ABO 0.011546 0.0124137 0.087933 
rs8176707 ABO 0.0013131 0.004541 0.0235884 
rs8176704 ABO 0.5423531 0.7414893 0.5254834 
rs8176694 ABO 0.0001901 0.0019563 0.0002499 
rs657152 ABO 1.82E-07 9.89E-07 8.58E-06 
rs474279 ABO 6.65E-06 3.35E-05 0.0002325 
rs8176681 ABO 0.7520361 0.8533457 0.774533 
rs500498 ABO 0.0005473 0.0013157 0.0036143 
rs630014 ABO 2.38E-07 1.75E-06 1.42E-05 
rs8176630 Intergenic 0.0632992 0.045705 0.0861703 
rs579459 Intergenic 6.29E-06 4.34E-05 2.61E-05 
rs7030248 Intergenic 0.9807863 0.9429567 0.4159449 
rs558240 Intergenic 0.0005096 0.00285 0.001577 
rs7867739 Intergenic 0.7211956 0.463971 0.8908319 
rs7025162 Intergenic 0.6696191 0.6353766 0.6238697 
rs4962043 Intergenic 0.8012191 0.879608 0.7514891 
rs554710 Intergenic 0.0090429 0.0404194 0.0057972 
rs17150319 Intergenic 0.995778 0.3666132 0.2418583 
rs493014 Intergenic 0.2162935 0.3788538 0.4548992 
rs9411508 Intergenic 0.7660441 0.6006146 0.6238885 
rs10901263 Intergenic 0.0096928 0.0090574 0.0017128 
rs17150482 Intergenic 0.9849042 0.6556539 0.5885834 
rs10751505 Intergenic 0.0902177 0.0681751 0.0184148 
rs10793964 SURF6 0.0571819 0.0223046 0.0243949 
rs563666 SURF6 1 1 1 
rs11655 MED22 0.198296 0.2864716 0.1608362 
rs621907 MED22 0.738893 0.1767743 0.230251 
rs669056 MED22 1 1 1 
rs553877 MED22 0.4857907 0.2105227 0.1030687 
rs2021976 SURF1 1 1 1 
rs4962046 SURF4 0.5363695 0.334225 0.3163036 
rs1179037 SURF4 0.5317921 0.9531754 0.4657656 
rs28602591 c9orf96 0.6090107 0.5324088 0.2507892 
247
 
rs36091105 c9orf96 0.1599194 0.179287 0.1187587 
rs4549850 c9orf96 0.2432379 0.331567 0.1514483 
rs7038253 c9orf96 1 1 1 
rs3118667 ADAMTS13 0.4176771 0.4501604 0.6319319 
rs2073933 ADAMTS13 0.4734933 0.3742429 0.2121071 
rs2073932 ADAMTS13 0.5576623 0.491613 0.2321513 
rs603551 ADAMTS13 0.8884007 0.6814501 0.5190141 
rs652600 ADAMTS13 0.5030662 0.4851808 0.609375 
rs4962153 ADAMTS13 0.9816329 0.2478957 0.2755092 






VWF Tagging SNPs 
SNP Base SNP Base SNP Base 
rs10160866 6014627 rs17491334 6103844 rs980131 6169198 
rs10466913 6022495 rs12099542 6103998 rs7139057 6169323 
rs7306590 6023686 rs216904 6106018 rs4764482 6169733 
rs2362479 6026354 rs216905 6106255 rs12319392 6170486 
rs3825331 6030154 rs216800 6107946 rs1800378 6172202 
rs7958705 6044881 rs216805 6111476 rs1800387 6182828 
rs7398412 6046849 rs216811 6115274 rs3782711 6183181 
rs2362481 6049161 rs216812 6117211 rs10849380 6185309 
rs12367467 6049568 rs2363329 6119396 rs2109118 6194655 
rs7310736 6052265 rs542993 6120431 rs2239147 6195527 
rs2270151 6060960 rs9634155 6123777 rs2238101 6198231 
rs7961998 6061341 rs216308 6124666 rs2239142 6199078 
rs2286646 6061491 rs11613273 6126097 rs12317079 6202462 
rs12297370 6062777 rs216309 6126927 rs11836843 6202818 
rs3759321 6062878 rs1800385 6127891 rs41388848 6208618 
rs12317523 6063142 rs1800384 6127919 rs1579229 6223766 
rs10774387 6063429 rs216310 6127943 rs4764537 6225242 
rs10849363 6066357 rs216311 6128443 rs4764538 6248983 
rs7964554 6067152 rs216313 6129264 rs10849396 6265578 
rs12423243 6067240 rs2885752 6132784 rs12320321 6270739 
rs12369177 6073520 rs2854871 6133079 rs10849399 6271103 
rs11063961 6074016 rs216314 6136580 rs10774401 6272849 
rs12829220 6074650 rs11611917 6136634 
rs4764478 6078125 rs11612370 6136832 
rs12300917 6079058 rs11612384 6136846 
rs7301070 6080290 rs216330 6146630 
rs917857 6081824 rs11064003 6149706 
rs1159993 6083564 rs216340 6149799 
rs4764521 6084323 rs11064005 6150066 
rs216855 6085513 rs2239162 6151670 
rs216865 6090303 rs11064008 6153264 
rs216867 6091000 rs216293 6153659 
rs2058473 6093926 rs216295 6154206 
rs216873 6095274 rs7954351 6163705 
rs11063977 6097946 rs12304995 6164455 






VWF Tagging SNP Primers 
 
SNP Forward Reverse Size 
rs216811 TTGACTCCTTCCTCATTTCC CGGGCAGCCAAGAATAC 546 
rs216812 CTCCGTCAGAGTGTATTATCCT TACATTACAATTGATAGCGCAG 470 
rs2363329 GAGTGCATGCATCTCCAC CTTCTAGAGATCTGCTGTACAACA 332 
rs542993 GCTGAGGCCTTCGTG TCTTAATCCAGGCCGC 503 
rs9634155 GCAAGTCATTTAACCGTCC GGAGGTGTGACTCTCGAAG 400 
rs216308 GTTAAGACAGGGTGTCGAGC CAATACGATTTGCACATTTTG 991 
rs11613273 CTAAATCTGAGGTAGTCCGGAC ACTGACACCTGAGTGAGACG 455 
rs216309 TTGAGCACTTGTCATGTGC GGTGGTGATGATAAGCTTCAT 358 
rs1800385 GCGTTCGTCCTGGAAG TGTGGTCAGAGAGGTACCG 268 
rs1800384 rs1800385 captures N/A N/A 
rs216311 GTTGTCAACCTCACCTGTG CCTTCCAGGACGAACG 830 
rs216313 GCCCAACATATCAAACATG CATGGACCATTCCACATC 393 
rs2885752 CTGATGTATTTCCCCATTCTCT GCCAATGTCTTAACCCTCC 756 
rs2854871 rs2885752 captures N/A N/A 
rs216314 TGTTCCGTCTGCCTAAAC TCATATGGTTCTAGAGGTTGG 481 
rs11612370 rs216314 captures N/A N/A 
 
 
Primer Name Sequence Tm Size 
VWF_rs216311 F GATGTTGTCAACCTCACCTG 53.4 832 
VWF_rs216311 R CTTCCAGGACGAACGC 53.2 
    
VWF_rs10849363 F TCATTGTGTTACAGTTGCCTAC 55.44 210 
VWF_rs10849363 R TCACGTGTTGCTTAACAATG 55.77 
    
VWF_rs11064003 F TTTCCCACCACGAACTTAC 56.01 209 
VWF_rs11064003 R CACACTTCCAGGTTTGAATC 55.55 
    
VWF_rs216293 F GTACACTCGAGCCCTTCAG 55.92 295 
VWF_rs216293 R CAATGTAAGCCAGAGGTCAG 55.93 
    
VWF_rs7964554 F TAAATCACCACTTTCAGTTCAC 54.47 249 
VWF_rs7964554 R TGGCCTTTTCACTGTATTTC 55.38 
    
VWF_rs216310 F GCGTTCGTCCTGGAAG 56 268 
VWF_rs216310 R TGTGGTCAGAGAGGTACCG 57.1 
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VWF_rs216308 F GTTAAGACAGGGTGTCGAGC 57.4 991 
VWF_rs216308 R CAATACGATTTGCACATTTTG 56.8 
    
VWF_rs11612370 F agttcaaaaggtgctgtgac 55.35 213 
VWF_rs11612370 R ggttctagaggttggaaagc 55.61 
    
VWF_rs11612384 F acagacagaagcagaaaagg 54.72 385 
VWF_rs11612384 R TGTATGTGTCAAACGTGGTC 55.23 
    
VWF_rs10849363.1 F GGTAAGTGCCCTATACAGTATGTC 56.1 305 
VWF_rs10849363 R TCACGTGTTGCTTAACAATG 55.8 
    
VWF_rs216330 F TTAACACTCTGGAGGTGAGG 55.29 244 
VWF_rs216330 R TGGGGCTGGTAGTTCTTAG 55.41 
    
VWF_rs2239162 F CACTTGGATACCTGTCACG 54.85 249 
VWF_rs2239162 R CAGCTCCATTTTCTTTGTG 54.39 
    
VWF_rs1800383 F AGCAGTGTGGATGAGCTG 55.65 208 
VWF_rs1800383 R CAATTTTGTCCGATCCTTC 55.54 
    
VWF_rs216330.1 F TTGGGCATAAGTAGAAATCG 55.51 233 
VWF_rs216330.1 R GGTTTGGCTGACTCTTCTG 55.88 
    
VWF_rs216330.2 F CCAAGTGTTCTTCAATGAGC 55.89 346 
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 This screenshot was generated using the USCS genome browser 
(http://genome.ucsc.edu/) showing the Conservation (GERP++) and ENCODE tracks. 
rs216308 corresponds to the single black bar highlighted in red above. GERP rejection 
scores are displayed in full view as staggered bars to the right of the SNPs track. All 
subsequent tracks correspond to the ENCODE project dataset. Project track names are 
provided in the center of the track and species or cell lines are listed at the bottom of 
each track in this screenshot. Prediction strength of a regulatory element mapping to the 





CBC Genome-Wide QTL Linkage Analysis LOD Scores > 1.0 
 
Phenotype Chromosome Nearest Marker LOD 
PLT 1q31.3 GATA48B01 1.77 
PLT 2p25.1 GGAA20G10 1.20 
PLT 2p22 GATA86E02 1.20 
WBC 2q35 GATA4G12 1.53 
MCH 3q26 GATA3H01 1.39 
MCHC 3p14 AAC023 1.06 
PLT 4p16 GATA22G05 1.33 
WBC 4q13 GATA28F03 1.19 
MCV 4q35 165zf8ZP 1.76 
WBC 5q22 GATA68A03 1.45 
MCV 6q25 GATA165G02 1.23 
MCH 6q24 GATA184A08 2.46 
MCHC 6p22 GATA163B10 1.55 
MCV 7p21 GATA41G07 1.77 
MCH 7p21 GATA41G07 1.06 
WBC 8p23 ATT023 1.33 
WBC 8q24 GATA21C12 1.28 
PLT 9q22 ATA18A07 1.34 
WBC 9q33 GATA64G07 2.18 
WBC 10p15 GATA88F09 1.98 
RDW 10p12 GATA70E11 2.09 
WBC 13q14 GATA11C08 1.61 
MCV 13q32 ATA26D07 1.30 
RDW 13q32 ATA26D07 1.61 
MCV 14q24 GGAA4A12 1.35 
MCH 16q24 GATA11C06 1.13 
PLT 19p13 GATA21G05 1.42 
WBC 20p12 GATA129B03 1.16 
MCV 20q13 GATA47F05 2.17 










M1304R Molecular Dynamics Simulations Methods 
The simulation with the wild-type was started from the crystallographic structure 
with PDB code 1AUQ. The mutant M1304R was obtained per homology using the 
program CHARMM to construct missing atoms from internal coordinates. The 




The MD simulations were performed with the program NAMD using the 
CHARMM all-hydrogen force field (PARAM22) and the TIP3P model of water2,3. The 
protein was solvated in a cubic water box with side length of 84 Å.  Chloride and sodium 
ions were added to neutralize the system and approximate a salt concentration of 150 
mM. To avoid finite size effects, periodic boundary conditions were applied.  After 
solvation, the system underwent 500 steps of minimization while the coordinates of the 
heavy atoms of the protein were held fixed and subsequent 500 steps with no restraints. 
Electrostatic interactions were calculated within a cutoff of 10 Å, while long-range 
electrostatic effects were taken into account by the Particle Mesh Ewald summation 
method4. Van der Waals interactions were treated with the use of a switch function 
starting at 8 Å and turning off at 10 Å.  The dynamics were integrated with a time step of 
2 fs using SHAKE to rigidly constrain hydrogen atoms. Snapshots were saved every 10 
ps for trajectory analysis.  Before production runs, harmonic constraints were applied to 
the positions of all heavy atoms of the protein to equilibrate the system at 300 K during a 
time length of 0.2 ns. For the simulation with the mutant, harmonic constraints were kept 
on all heavy atoms except those of the mutated residue and of amino acids where any 
heavy atom is at least 4 Å from any heavy atom of the mutated residue, and equilibration 
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was continued for another 2 ns. After this equilibration phase, the harmonic constraints 
were released. One simulation was performed with the wild-type and one with the 
M1304R mutant. Each run lasted 50 ns.  During all runs, the temperature was kept 
constant at 300 K by using the Langevin thermostat with a damping coefficient of 1 ps-1, 
while the pressure was held constant at 1 atm by applying a pressure piston5,6. 
 
Free energy perturbation (FEP) calculations 
Using MD simulation to predict differences in folding ΔG due to mutations is 
challenging because an exhaustive sampling of the free energy landscape of a protein is 
computationally prohibitive.  By combining the thermodynamic cycle and free energy 
perturbation simulations, an estimate of the difference in folding ΔG (ΔΔG) can be 
calculated.  The free energy perturbation calculations were performed using the so 
called "dual-topology" approach, where the initial and final states are defined7,8. A MD 
simulation is performed where the atoms belonging to the initial state (M1304) slowly 
disappear while the atoms of the final state (R1304) slowly appear. This so called 
"alchemical transformation" gives an estimate of the free energy difference between the 
two states. An illustration of the method can be found here: 
http://www.ks.uiuc.edu/Research/namd/2.9/ug/node58.html A similar protocol was used 
here as in a previous study were FEP was used to study binding affinities9.  Each FEP 
run lasted in total 1 ns and contained 40 intermediate states. Each intermediate state 
consisted of 12.5 ps of equilibration and 12.5 ps of data collection. A soft-core term was 
used to avoid singularities in the van der Waals potential10.  In total, three FEP runs were 
performed with the folded state of the protein. They were started from snapshots 
collected after 10 ns, 20and 30 ns, respectively, during the 50-ns simulation with the 
wild-type. In order to perform FEP in the unfolded state, the assumption was made that 
when the protein is denatured the mutation site is completely solvent exposed and can 
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be approximated by a tri-peptide consisting of the mutated side-chain and the 
neighboring residues. The resulting tri-peptide Met1303-Met1304-Glu1305 was solvated 
in a cubic water box of 40 Å side length and one FEP run was performed. Using the 
thermodynamic cycle illustrated in Figure J.1, an estimate for ΔΔG was calculated. Since 
three runs with the folded state were performed, the average and standard error of the 
mean were calculated. 
 
Figure J.1: Illustration of the thermodynamic cycle. 
The thermodynamic cycle allows estimation of the folding DeltaDeltaG in the following 
way: ΔΔG = ΔGfold
2 – ΔGfold
1 = ΔGalch
2 – ΔG alch
1. ΔGfold
1 is calculated from the FEP run 
using the tri-peptide containing the mutated side chain, which mimics the unfolded state 
by completely exposing the mutation site to solvent. ΔGfold
2 is calculated from the FEP 



















































Table K.2: Individual III.1 VWF variants 
Genotype Variant 
Variant 
type Variant function 
C C IVS3+52T>C SNP INTRONIC 
G G c.4141A>G SNP NON SYNONYMOUS CODING 
G G c.4173A>G SNP SYNONYMOUS CODING 
A G c.1451A>G SNP NON SYNONYMOUS CODING 
CTT CTT IVS15-17_-16insCTT insertion INTRONIC 
A A IVS17-42C>A SNP INTRONIC 
G T IVS18+38G>T SNP INTRONIC 
T T IVS19+25C>T SNP INTRONIC 
G G c.2555A>G SNP NON SYNONYMOUS CODING 
T T IVS20+67G>T SNP INTRONIC 
C C c.4641T>C SNP SYNONYMOUS CODING 
        Table K.1: Individual I.1 VWF variants 
Variant  AA Change 
Variant 
class            Variant_function 
c.2365A>G T789A SNP NON_SYNONYMOUS_CODING
c.2555A>G Q852R SNP NON_SYNONYMOUS_CODING
c.3911T>G M1304R SNP NON_SYNONYMOUS_CODING
c.4141A>G T1381A SNP NON_SYNONYMOUS_CODING
c.4196G>A R1399H SNP NON_SYNONYMOUS_CODING
c.4751A>G Y1584C SNP NON_SYNONYMOUS_CODING




G G c.4751A>G SNP NON SYNONYMOUS CODING 
C T c.5844C>T SNP SYNONYMOUS CODING 
T T IVS38-14C>T SNP INTRONIC 
C T IVS41-7C>T SNP INTRONIC 
C C c.7239T>C SNP SYNONYMOUS CODING 
A C IVS44-59A>C SNP INTRONIC 
C T c.-2709C>T SNP UPSTREAM 
A G c.-2661A>G SNP UPSTREAM 
G A c.-2527G>A SNP UPSTREAM 
C T c.-64C>T SNP UPSTREAM 
















Amplicon 9  acaggcctgactttagcc GCAGATGTTGTTCTTACAAGC 
Amplicon 10  TCCTCCATTACTCACCTCAG caggaggttcttcatgactg 
Amplicon 11  AACCAAGAGAGCCTGGTG TGGACATGTACTGGATGTGAC 
Amplicon 12  CTGGACCCTCAGTGACTTC AGAAAGACAGCCAAGGACTC 
Amplicon 13  GTCTCTCAGCAGATGACGTG GCAGATCTGAGAGGTTCAGG 
Amplicon 14  GCCTCTACAAGCTGTTCCTG TAGGTGACTCTGGGGAAGAC 
Amplicon 15  CGTTCGCCTAGACATCTG acctttggagaggctacac 
Amplicon 16  ctgttagccaaatgctctgac GCTGCATACACCTTCAAAGAG 
Amplicon 17  TAACCAGGAACTGTGGAGTG GCATACGTGTCCATTTCG 
Amplicon 18  GTGCCACACCCGAATGG ACTTTGGCCTCTTTGGTC 
Amplicon 19  ATCACTTCGACCCTCACC cagaagaggacacactcagg 
Amplicon 20  catctctgggagtcatgagag GGATATCTCACGCTGTACCC 
Amplicon 21  CCCTCTCAAGGCTACCTAAG atctacccttgaccaagctc 
Amplicon 22  cctgtgacccctctaagtg GAAGTCCTCAGGAGAGCTG 
Amplicon 23  CCGGAATTCTTCTACTTTCC ttgattaggattcccatctg 
Amplicon 24  cttctcacccactttctgag AGATGAGGTAGATGCCACAG 
Amplicon 25  GCAGTGGTGTGAGTGGAC GACTGAATACAGGTGCAAGG 
Amplicon 26  CATTCCCTGGACCTATTTTC AGGGTTGTATTCCGTCTCTC 
Amplicon 27  AAGCTCATCGTGGTGGTC actgccgggtaaactgag 
Amplicon 28  ATGCTGGCATGTGAAGAC ATCGGGCTCAGTCAGTAAC 
Amplicon 29  CTACCCGGTTACTGACTGAG TAGAACCAGAAGAACCTTCG 




















PSG: (Pipes/Saline/Glucose)      2 L    4 L    6 L 
  5 mM PIPES (Sigma P‐3768)    3.464 g    6.928 g    10.392 g 
  145 mM NaCl (Fisher S‐271‐3)    17 g    34 g    51 g 
  4 mM KCl (Sigma P‐4504)      0.6 g    1.2 g    1.8 g 
  50 µM Na2HPO4 (Sigma S‐3264)    0.0142 g   0.0284 g   0.0426 g 
  1 mM MgCl2•6H2O (Fisher BP‐214‐500)  0.4g    0.8 g    1.2 g 





































































Autosomal Dominant Thrombocytopenia Candidate Mutation and THC2 Locus 
Sequencing Primers 
 
    Table N.1: ADT Candidate mutation sequencing primers. 
Primer Name Sequence Tm Size 
ADT ARHGAP21 F TTAAACTGGGGGTATGTCC 54.82 684 
ADT ARHGAP21 R CCATCCAGGATCCACTATC 55.14 
ADT PTCHD3 F CTCACCTAGAATAAGAAATGGTG 54.9 296 
ADT PTCHD3 R AGTCCCTGGGAATTAAAGG 55.65 
ADT GPR158 F TTCCAGCAACCTTTAACATC 55.38 270 
ADT GPR158 R TTTCCTTGATTGACAAATCC 55.1 
ADT MPP7 F AACAGAATTATCTTCGGTGTAAG 54.54 334 
ADT MPP7 R GGTCTGTAGCGATTATGTCC 54.73 
ADT ARHGAP21.A.1 F CCCCTTCTTTCCATACCAC 56.88 
587 ADT ARHGAP21.A.1 R CTGTTACCAATAAAACGCATTC 56.52 
ADT ARHGAP21.A.2 F TTGTCTCTTCATTGCAACAC 54.69 
691 ADT ARHGAP21.A.2 R GGAAGTTCTGTATCCACCTG 54.59 
ADT ARHGAP21.B.1 F CAGGTGGATACAGAACTTCC 54.59 
489 ADT ARHGAP21.B.1 R agtctctacccaccacagc 55.1 
ADT ARHGAP21.B.1 F CAGGTGGATACAGAACTTCC 54.59 
473 ADT ARHGAP21.B.2 R agcaagaaagaggagaagatg 55.5 
ADT ANKRD26.1 F acatttgtttgacaggaacg 56.1 
477 ADT ANKRD26.1 R GCAGCTTTGTGGATCTTG 55.24 
ADT ANKRD26.1 F acatttgtttgacaggaacg 56.1 
476 ADT ANKRD26.2 R CAGCTTTGTGGATCTTGC 55.24 
ADT ANKRD26.2 F catttgtttgacaggaacg 55.01 
476 ADT ANKRD26.1 R GCAGCTTTGTGGATCTTG 55.24 
ADT ANKRD26.2 F catttgtttgacaggaacg 55.01 
475 ADT ANKRD26.2 R CAGCTTTGTGGATCTTGC 55.24 
ADT ANKRD26.3 F accgacatttgtttgacag 54.35 






          Table N.2: THC2 Locus Tagging SNP Sequencing Primers 
Name Sequence Tm Size 
rs3824593 F ACTGCGATCCTATTCACG 54.55 289 
rs3824593 R GCCCACGAAGAGTGTAAG 54.14 
rs12572344 F GGAACGCTTCTGTTGTTG 55.15 260 
rs12572344 R GCAATTCACAGGACCTAAAG 54.96 
rs7911024 F TCCACAAAAGGGATAACAAC 55.05 295 
rs7911024 R caaagtgctgggattatagg 54.94 
rs11015498 F GTTTCTTGATCCACTCATGC 55.62 275 
rs11015498 R CGATAGCTGTTTCATAAAATCC 55.74 
rs3781099 F AAGCACCACCACATGAAC 55.07 236 
rs3781099 R CCACTGAAGAAATTGAGACAC 54.83 
rs9731310 F GGTTCGAGTGATTCTCCTG 55.62 395 
rs9731310 R GAGCCCTCCTGAACTAAATG 56.48 
rs11015574 F TGGAGTTTCACCATGTTAGC 56.19 236 
rs11015574 R AGTTTGCCATTGTTCTCAAC 55.28 
rs10159601 F  gcaacatcaagaagttaccc 54.78 234 
rs10159601 R aggcgagagagtctataaagtg 54.77 
rs10829165 F GGACTGAAAACACTGGACTC 54.6 250 
rs10829165 R AAATGCTCATGTTTTTCACC 55.2 
rs10764667 F CTGAACTTATTCCGGTTCG 55.83 295 
rs10764667 R TGCTTTCTCATTTTAGTCAACC 56.25 
rs9651377 F CTTAACCACAGTAGCCTAAAATG 55.17 388 
rs9651377 R CATGTCTGTCTCCATTTGC 54.88 
rs12411584 F CTCCTCAAACTCTGAACCAG 54.98 250 
rs12411584 R aaaattagccaggtgtgatg 55.25 
rs788221 F TTTGCTCACCTGGTACATAAC 55.34 236 
rs788221 R TGAGAGTTCCTACAGTTTTGC 54.76 
rs12772934 F  CAGAATCAAGTGAAATGTATGG 54.85 248 
rs12772934 R ACTGGTGAGGATTATCATTTG 54.16 
rs788208 F CTATGACAGCATCACTGCAC 55.21 234 
rs788208 R TCTCTGCCTTTGATCCTTAC 54.57 
rs10458707 F gcaatgggatatgtcctg 54.56 268 
rs10458707 R tcatgcagctatttgaacac 54.84 
rs3802526 F  AAAACTTCGAAAAGCAACAG 54.94 224 
rs3802526 R AAAGTCAGCCCTTAGATTCAG 55.38 
rs11015501 F GCTAAAGGATCAACATACTTCTG 55.04 495 
rs11015501 R CGCTGTACTATAGCAAGTGTATTC 55.34 
rs7907059 F TTATGAATACACCTGGCAAAG 55.44 227 
rs7907059 R tagagctagtcaggctcagg 55.02 
rs6482593 F ACCAGGCTCCTAAGAAAAAC 55.21 235 
rs6482593 R AACTGTGTGGTTCAGAGAGG 55.18 
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rs4749219 F AGACGGTAGGGGACAATC 54.79 243 
rs4749219 R tagtagacagggcatttcatc 54.49 
rs788222 F CTTCTTTCCATAACCACTGC 54.96 240 
rs788222 R AGGTTGGAGAAAAGACTTGAG 55.26 
rs11015506 F ACTTACAGATCCCTCTTCTGC 55.21 208 
rs11015506 R CAAATCATGGAGTTGGGTAG 55.51 
rs6482601 F CTGCTCTTCAGTTCCTTCC 55.04 231 
rs6482601 R CCCAACATTTGAAAGATCAG 55.65 
rs4749233 F GGGAAGATGGGATTATATGG 55.79 268 
rs4749233 R CAAAGTGTTTCCTAAGAAAAGG 55.09 
rs12266154 F tgacctcaggtggttcac 55.03 272 
rs12266154 R TCCAATAGCTTATCTGAAATCC 55.26 
rs3781101 F TCCCTTCACCCTAAAACAG 55.2 244 
rs3781101 R TTTCTCCAGCATTCTTTCTC 54.71 
rs12250031 F GGCCAATTAATCAACCTCTC 56.22 216 
rs12250031 R TGGATGAAAGCTCTGAAGAC 55.5 
rs11819631 F ACTCAAGTGTGGAGAACACTG 55.28 196 
rs11819631 R GGCCTAACATATAGTCCTTGG 55.47 
rs10829168 F GTACAGATGGGGTTTCACC 55.13 493 
rs10829168 R TGCACACACACAAGTTAAGG 55.68 
rs12770357 F ACAAATTGGAATTAGCAACG 55.42 247 
rs12770357 R ATTCTTGGTGACGATAGTGG 55.07 
rs2297144 F ACATTTACCTGCTTTGGATG 55.25 221 
rs2297144 R TCCCTTTTGGTTTTTAGAGTC 55.21 
    
rs10829168.1 F TTACGGTCTAAAAACATGCAC 55.51 363 
rs10829168 R TGCACACACACAAGTTAAGG 55.68 
rs10829168.1 F TTACGGTCTAAAAACATGCAC 55.51 362 
rs10829168.1 R GCACACACACAAGTTAAGGAC 55.75 
rs10829168.1 F TTACGGTCTAAAAACATGCAC 55.51 364 






ANKRD26 qPCR Primers and Melt Curve Gels 
Expanded protocol: 
 
Sample Collection, RNA isolation, Reverse Transcription 
Whole blood samples were collected from 4 patients (two control and two 
positive) directly into PAXgene blood RNA tubes [PreAnalytiX/Qiagen, Valencia CA, 
USA]. Tubes were stored at 4C overnight and total RNA isolation was performed using 
PAXgene Blood RNA kit per manufacturer protocol. RNA was treated with 2U DNAase I 
digestion for 15min at 37C and removed/purified with DNAse Inactivation Reagent 
[Ambion/Life Technologies AM1914, Grand Island NY, USA]. RNA integrity was 
evaluated on a RNA Nano chip run on a Bioanalyzer 2100 [Agilent Technologies, Santa 
Clara CA, USA]. RNA integrity numbers (RIN) for all samples were 8.1-9.3. RNA for 
tissue panel was purchased from Ambion [AM6000]. The cDNA first strand transcription 
was performed in duplicate using 0.5ug (patient) or 1ug (tissue panel) of total RNA with 
the iScript RT mix for RT-qPCR following manufacturer protocol [BioRad 170-8840, 
Hercules CA, USA]. The synthesized cDNA was stored at -20C until further use. 
 
qPCR: Primer design for SYBR green 
Design for primers that assay various isoforms of ANKRD26 were limited to 
specific regions of sequence unique to each isoform. Primers were selected using 
Primer3 (http://frodo.wi.mit.edu/) with a target amplicon length of 80-150bp. Primer 
sequences are provided in Table O.1. Primer sequences were evaluated for specificity 
and degeneracy by searching BLASTN and known SNPs (http://blast.ncbi.nlm.nih.gov/ 
and http://genome.ucsc.edu/index.html). Reference gene primers were designed and 




Quantification by qPCR 
Quantitative PCR was performed on a Roche LightCycler 480II Real Time PCR 
instrument, using Roche SYBR Green I Master [Roche 04 707 516 001, Mannheim 
Germany]. PCR was carried out in a 20ul volume and a final concentration of 1X 
reaction buffer, 200nM forward and reverse primers and 0.5ul cDNA reaction. All 
standard curve and validation reactions were performed in triplicate with NTC reactions 
for all primer sets, all samples were done in duplicate. PCR cycling parameters were as 
follows: hot-start at 95C for 5min, 45 cycles of 95C for 10sec, 60C for 15sec, 72C for 
30sec followed by a dissociation curve measurement from 65C to 97C. Comparative 
quantitative analysis was performed using the LC480II data collection software release 
1.5.0.39 SP4. Seven log10 dilutions of plasmid template for all ANKRD26 isoforms and 
reference gene amplicon sequences were prepared and used for primer validation and 
standard curve reference. PCR efficiency for all target gene primer sets ranged from 
90.1%-95.6% with all r-squared values >0.99. To avoid confounding technical variation, 
one standard curve sample for all reference and target genes were included on every 
plate. Geometric averaging of five reference genes (ACTB, GAPDH, GUSB, HPRT1 
andTBP) were used normalize target gene transcripts. Melt curve analysis for all assays 
verify single product amplification and absence of primer dimers. NTC reactions for all 





Table O.1: ANKRD26 qPCR primers 
 
 
Figure O.1: Intron 16 melt curve 
 
 
Figure O.2: Intron 6 melt curve 
 
Name Sequence Tm Size Notes 
ANKRD26 Intron 16 F TTCTGCTGGTACAGACGCTT 58.7 137 Amplifies intron 16, 
which is unique to 
isoform 201 
ANKRD26 Intron 16 R GTGGTGGAGAAGACCTCACA 58.6 
ANKRD26 Intron 6 F CAAAGTCTTGCACTGTTGCC 59.5 100 Amplifies intron 6, 
which is unique to 
isoform 202 
ANKRD26 Intron 6 R AGGTGGAGGCAGAAGAATTG 59.3 
ANKRD26 Exon 13 F GCTGCAGACGGAAAAGAAAA 60.5 138 Amplifies exons 12 
and 13. Exon 13 is 
unique to isoform 
001 
ANKRD26 Exon 13 R GGCTACTGGCATGCCTACAT 60.13
ANKRD26 Exon 21 F CCAGGATGCAGCTCTTTCAT 60.36 184 Amplifies exon 21, 
which is in all 
isoforms and is the 
control amplicon 




Figure O.3: Exon 13 melt curve 
 
 
Figure O.4: Exon 21 melt curve 
 
 





Variants Mapping to the THC2 Locus Where Autosomal Dominant 
Thrombocytopenia Patients Are Heterozygous 
 
Gene Position Type rs# Major Minor Genotype 
KIAA1217 24653841 intronic . C A het 
KIAA1217 24696474 intronic rs7911930 A T het 
KIAA1217 24696521 intronic rs7895880 C A het 
KIAA1217 24697579 intronic rs74122300 C T het 
KIAA1217 24699516 intronic . T G het 
KIAA1217 24700710 intronic . C A het 
KIAA1217 24704065 intronic . T G het 
KIAA1217 24707576 intronic . A G het 
KIAA1217 24708278 intronic rs74125404 A T het 
KIAA1217 24708422 intronic rs74125405 A C het 
KIAA1217 24711326 intronic rs74125407 G A het 
KIAA1217 24713241 intronic . C T het 
KIAA1217 24714839 intronic . A G het 
KIAA1217 24719505 intronic rs79641988 T C het 
KIAA1217 24754373 intronic . G A het 
KIAA1217 24757541 intronic . C T het 
KIAA1217 24824294 intronic . G C het 
ARHGAP21 24949517 intronic . G T het 
PRTFDC1 25139002 intronic . C T het 
PRTFDC1 25179724 intronic rs12572969 C G het 
PRTFDC1 25227898 intronic rs10764511 C T het 
PRTFDC1 25227988 intronic rs10828727 C T het 
ENKUR 25293765 intronic . G A het 
GPR158 25497651 intronic rs12762009 T C het 
GPR158 25584182 intronic . C T het 
GPR158 25606005 intronic rs71495423 C T het 
GPR158 25624290 intronic rs1340002 C T het 
GPR158 25646519 intronic rs12219956 A G het 
GPR158 25646974 intronic rs11014510 A C het 
GPR158 25655989 intronic rs80352191 A G het 
GPR158 25668778 intronic rs12762462 G A het 
GPR158 25669508 intronic rs10764539 A C het 
GPR158 25685872 intronic rs35663899 G T het 
GPR158 25685958 intronic rs35942963 A G het 
GPR158 25686900 intronic rs11818261 C T het 
GPR158 25687792 intronic rs10828791 G A het 
GPR158 25687835 intronic rs10828792 C T het 
GPR158 25690861 intronic rs11014527 G A het 
GPR158 25693677 intronic rs11014528 A G het 
GPR158 25693844 intronic rs12764320 G C het 
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GPR158 25693958 intronic rs12766749 A G het 
GPR158 25694041 intronic rs12258359 T C het 
GPR158 25694049 intronic rs12256778 A G het 
GPR158 25694156 intronic rs12256851 A G het 
GPR158 25694871 intronic rs12254479 G C het 
GPR158 25695278 intronic rs11014529 G A het 
GPR158 25695652 intronic rs12240665 C T het 
GPR158 25695936 intronic rs12249852 A G het 
GPR158 25696592 intronic rs12251917 T C het 
GPR158 25696712 intronic rs12251868 A G het 
GPR158 25697570 intronic rs12259043 G T het 
GPR158 25697921 intronic rs10764543 T C het 
GPR158 25698931 intronic rs10828793 A C het 
GPR158 25699152 intronic rs11014530 T C het 
GPR158 25699776 intronic rs12358447 T C het 
GPR158 25699841 intronic rs12259696 T C het 
GPR158 25700535 intronic rs7094439 T G het 
GPR158 25700603 intronic rs7090972 A G het 
GPR158 25700861 intronic rs11014533 A T het 
GPR158 25702280 intronic rs10508694 G A het 
GPR158 25714197 intronic rs7905216 C G het 
GPR158 25714311 intronic rs1958947 A C het 
GPR158 25714391 intronic rs1958948 A G het 
GPR158 25716511 intronic rs11014546 T G het 
GPR158 25717594 intronic rs11014547 C T het 
GPR158 25718331 intronic rs4431923 G A het 
GPR158 25720502 intronic rs10430566 G A het 
GPR158 25724277 intronic rs11014553 A G het 
GPR158 25724391 intronic rs11014554 C A het 
GPR158 25724744 intronic rs12773262 G A het 
GPR158 25725491 intronic rs16925850 G T het 
GPR158 25728288 intronic rs10764553 G A het 
GPR158 25728493 intronic rs11014558 G T het 
GPR158 25729644 intronic rs10741087 A C het 
GPR158 25730280 intronic rs10399962 C T het 
GPR158 25731702 intronic rs11014559 C T het 
GPR158 25731764 intronic rs11014560 C T het 
GPR158 25731770 intronic rs11014561 G A het 
GPR158 25731823 intronic rs10828807 C T het 
GPR158 25732083 intronic rs10828808 A G het 
GPR158 25762055 intronic . C T het 
GPR158 25787705 intronic rs4747522 G C het 
GPR158 25787906 intronic rs4749041 C G het 
GPR158 25788668 intronic rs10828810 C T het 
GPR158 25790197 intronic rs11014580 G A het 
GPR158 25791017 intronic rs4749042 A G het 
GPR158 25792709 intronic rs1887925 T C het 
GPR158 25793569 intronic rs943984 G C het 
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GPR158 25803024 intronic rs4623781 A T het 
GPR158 25803988 intronic rs4747525 A G het 
GPR158 25810258 intronic rs11014589 G A het 
GPR158 25810281 intronic rs11014591 G A het 
GPR158 25811764 intronic rs10828815 T C het 
GPR158 25814295 intronic rs1932150 G A het 
GPR158 25814527 intronic rs80074459 G T het 
GPR158 25817558 intronic rs1932149 A C het 
GPR158 25817666 intronic rs1932148 C T het 
GPR158 25818777 intronic rs4459183 G A het 
GPR158 25822360 intronic rs4749043 A G het 
GPR158 25825929 intronic . A T het 
GPR158 25836299 intronic rs4747529 G C het 
GPR158 25846158 intronic . T C het 
GPR158 25864381 intronic rs12359026 G T het 
GPR158 25865777 intronic rs4749050 C A het 
GPR158 25867000 intronic rs17557638 T G het 
GPR158 25867088 intronic rs11014622 A T het 
GPR158 25867106 intronic rs11014623 T C het 
GPR158 25867301 intronic rs4237372 G A het 
GPR158 25867510 intronic rs4237374 T C het 
GPR158 25867733 intronic rs4747533 G A het 
GPR158 25868377 intronic rs12355530 C T het 
GPR158 25869543 intronic rs11014625 T G het 
GPR158 25872099 intronic rs11014630 C A het 
GPR158 25874222 intronic rs1932147 A C het 
GPR158 25874515 intronic rs11014631 A G het 
GPR158 25874581 intronic rs10764563 G A het 
GPR158 25874863 intronic rs10764564 G A het 
GPR158 25875012 intronic rs10764565 C G het 
GPR158 25875892 intronic rs58254885 G A het 
GPR158 25877060 intronic rs10458686 T C het 
MYO3A 26226598 intronic . C T het 
MYO3A 26234176 intronic rs76951627 C T het 
MYO3A 26274559 intronic . C G het 
MYO3A 26363300 intronic . T C het 
MYO3A 26395920 intronic . T C het 
MYO3A 26424614 intronic . A C het 
MYO3A 26426444 intronic . C T het 
MYO3A 26453823 intronic rs11014980 C T het 
GAD2 26514047 intronic rs8190617 A T het 
GAD2 26518749 intronic . A G het 
GAD2 26527590 intronic rs11015008 G A het 
GAD2 26545425 intronic . G A het 
GAD2 26556560 intronic rs59147413 G A het 
GAD2 26566456 intronic rs11015025 C T het 
GAD2 26594192 downstream . C T het 
APBB1IP 26759447 intronic . G A het 
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APBB1IP 26790109 intronic rs787039 T C het 
APBB1IP 26790824 intronic . C A het 
APBB1IP 26797343 intronic rs787032 C A het 
APBB1IP 26810937 intronic . C A het 
APBB1IP 26842099 intronic rs2040027 C T het 
NCRNA00264 26881968 ncRNA rs72788603 T C het 
NCRNA00264 26884079 downstream rs73594379 A C het 
ABI1 27127607 intronic . A C het 
NCRNA00202 27221728 ncRNA . C T het 
NCRNA00202 27222874 ncRNA rs2477937 A G het 
NCRNA00202 27226655 ncRNA . T G het 
NCRNA00202 27226684 ncRNA rs36188550 T C het 
ANKRD26 27348615 intronic . G A het 
ANKRD26 27389381 UTR5 . A G het 
YME1L1 27402315 intronic . T C het 
YME1L1 27438066 intronic . A G het 
MASTL 27450059 exonic rs28941470 G C het 
MASTL 27455431 intronic . G T het 
RAB18 27812465 intronic rs76443154 G A het 
MKX 27980516 intronic rs11015947 A C het 
MKX 27999164 intronic rs79185604 T A het 
ARMC4 28112002 intronic . G A het 
ARMC4 28170243 intronic rs79110720 G C het 
ARMC4 28258247 intronic . G C het 
MPP7 28343645 intronic . A T het 
MPP7 28351855 intronic rs11006819 T C het 
MPP7 28355450 intronic rs11006828 C T het 
MPP7 28355817 intronic rs11006829 T C het 
MPP7 28356187 intronic rs11006831 C G het 
MPP7 28358540 intronic . A C het 
MPP7 28363867 intronic rs11006842 G C het 
MPP7 28370133 intronic . A T het 
MPP7 28370770 intronic . C T het 
MPP7 28372497 intronic rs72801882 G A het 
MPP7 28376999 intronic rs11006848 T A het 
MPP7 28380196 intronic rs72801897 C G het 
MPP7 28381071 intronic rs11006856 T C het 
MPP7 28383385 intronic rs72801902 C A het 
MPP7 28385737 intronic rs11006860 G C het 
MPP7 28387958 intronic rs11006864 T C het 
MPP7 28388750 intronic rs11006865 T A het 
MPP7 28393809 intronic rs72803614 T C het 
MPP7 28395460 intronic rs11006872 A G het 
MPP7 28414791 intronic rs7080796 C T het 
MPP7 28414954 intronic rs7098896 T G het 
MPP7 28416388 intronic rs66764206 G A het 
MPP7 28417828 intronic rs12411923 A G het 
MPP7 28428205 intronic rs76812798 T A het 
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MPP7 28428240 intronic rs72803630 G A het 
MPP7 28430418 intronic rs72803634 A G het 
MPP7 28430572 intronic rs78131314 C T hom 
MPP7 28434569 intronic rs72803636 T C het 
MPP7 28435081 intronic rs58193497 A C het 
MPP7 28441519 intronic . C T het 
MPP7 28451221 intronic rs78477008 T C het 
MPP7 28452477 intronic rs76009353 A G het 
MPP7 28453215 intronic rs78236200 C G het 
MPP7 28455686 intronic rs76826800 G A het 
MPP7 28456021 intronic rs75818413 C T het 
MPP7 28457035 intronic . G A het 
MPP7 28458567 intronic rs74835530 T C het 
MPP7 28467599 intronic rs79041263 G A het 
MPP7 28479036 intronic rs75243964 A G het 
MPP7 28484696 intronic rs76528336 G A het 
MPP7 28490983 intronic . T C het 
MPP7 28493391 intronic rs80053794 T A het 
MPP7 28504944 intronic rs11006923 T C hom 
MPP7 28513112 intronic rs11006927 T G hom 
MPP7 28514249 intronic rs11006928 A T hom 
MPP7 28515799 intronic rs17831816 G A hom 
MPP7 28519598 intronic rs11006933 T C hom 
MPP7 28523598 intronic rs11006937 C A hom 
MPP7 28525378 intronic rs11006938 G A hom 
MPP7 28525523 intronic rs11006939 C T hom 
MPP7 28536445 intronic rs11006945 T C hom 
MPP7 28538289 intronic rs78086976 G C hom 
MPP7 28539175 intronic rs11006947 C A hom 
MPP7 28544070 intronic rs11006958 A C hom 
MPP7 28546620 intronic rs11006960 C A hom 
MPP7 28549726 intronic rs11006964 T C hom 
MPP7 28557741 intronic rs77457054 G A hom 
WAC 28858846 ncRNA . A G het 
WAC 28908889 ncRNA rs80068643 T A het 
BAMBI 28967570 intronic rs78860727 C T het 






Autosomal Dominant Thrombocytopenia Candidate Mutation Sequencing Results 
in Full Pedigree 
   PLT MASTL ANKRD26 ARHGAP21 PTCHD3 GPR158 MPP7 
 ID (K) 27450059 27389381 24872922 27692279 25888180 28543716 28543735 
D9 303 G,G T,T G,G A,C G,G C,C G,G 
D10 285 G,G T,T G,G A,A G,G C,T G,T 
D11 33 G,C T,C G,G A,C G,G C,T G,T 
D13 285 G,G T,T G,G A,A A,G C,C G,G 
D14 29 G,C T,C G,G C,C A,G C,T G,T 
D15 246 G,G T,T G,G A,C A,A C,C G,G 
D16   G,C T,C G,G A,C A,G T,T T,T 
D17   G,G T,T G,G A,A A,A C,C G,G 
D18   G,C T,C G,G A,C A,G T,T T,T 
D19 G,G T,T G,G C,C A,A C,C G,G 
D20 81 G,C T,C G,G A,C A,G C,T G,T 
D21 G,G T,T G,G A,C A,G C,T G,T 
D22 94 G,C T,C G,G C,C A,G C,T G,T 
D23 105 G,C T,C G,G A,C G,G T,T T,T 
D24   G,C T,C G,G C,C A,G C,C G,G 
D25 G,G T,T G,G A,A A,G C,T G,T 
D26 140 G,C T,C G,G A,C A,G C,T G,T 
D27 108 G,C T,C G,G A,C A,G C,T G,T 
D28 G,G T,T G,G A,A A,A C,C G,G 
D29 119 G,C T,C G,G A,C G,G T,T T,T 
D30 G,C T,C G,G A,C A,G C,T G,T 
D31 74 G,C T,C G,G C,C A,G C,T G,T 
D32 234 G,G T,T G,G A,C A,G C,C G,G 
D33 55 G,C T,C G,G A,C A,G C,T G,T 
F1P1 70 G,C T,C G,G C,C A,G C,T G,T 
F1P2 30 G,C T,C G,G A,C G,G C,T G,T 
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